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Abstract  
Primary cutaneous melanoma is a highly heterogeneous tumour. My hypothesis is that 
the histopathological heterogeneity reflects biological variation, which is likely to have 
prognostic and predictive significance.  
A histopathological review of 798 primary melanomas from the Leeds Melanoma 
Cohort Study was recorded using virtual pathology. The tumour blocks had previously 
been sampled using a tissue microarray needle, yielding a core from which RNA was 
extracted and assayed using Illumina® WG-DASL. This provided the opportunity to 
compare histopathological characteristics with gene expression data derived from 
consistently sampled regions. RandomSpot© was used to estimate the percentage of 
stroma (POS) within cored regions. Statistical analyses were performed using STATA 
v14.2. Inter- and intraobserver agreement were analysed and robust measures were 
retained.  
Histopathological characteristics were analysed with respect to germline BAP1 
mutation status to assess whether they could predict germline BAP1 mutation status. 
BAP-like histopathology was not significantly associated with germline BAP1 mutation 
status (deleterious versus none, Fisher’s exact test, p=0.1). A personal history of 
mesothelioma (Fisher’s exact test, p=0.005), or a family history of meningioma 
(Fisher’s exact test, p=0.005) or BCC (Fisher’s exact test, p=0.02) was associated with 
deleterious, germline BAP1 mutations. Cancer history appeared to be a better indicator 
of germline BAP1 mutation status than BAP-like histopathology. 
Several histopathological factors were predictive of melanoma-specific survival, 
including the POS. The area under the curve increased by 3% when the POS and 
AJCC stage were combined in ROC curve analysis. The POS was an independent 
predictor of melanoma-specific survival (HR 0.99, 95% CI 0.98-0.99, Cox proportional 
hazards model, p=0.005), even adjusting for known prognostic factors. SDF1 gene 
expression was significantly associated with the POS and was independently 
protective for melanoma-specific death (HR 0.8, 95% CI 0.68-0.94, Cox proportional 
hazards model, p=0.005) in adjusted analyses. The POS and SDF1 could represent 
novel predictive and prognostic biomarkers. 
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A table providing additional information regarding the complex histological and 
statistical definitions used throughout the thesis is given in Appendix A. 
 
1 
Chapter 1 Introduction  
1.1 Cutaneous melanoma 
Cutaneous melanoma is a form of skin cancer that develops from melanocytes, the 
pigment-producing cells of the skin. Normal melanocytes predominantly reside in the 
basal layer of the epidermis [1]. Skin cancer prevention is a considerable public health 
concern, with 15419 new cases of melanoma diagnosed in 2014 in the United Kingdom 
(UK) and a rising incidence, especially in people over the age of 60 [2, 3]. Cancer 
among young people is unusual but melanoma is indiscriminate of age after puberty. 
Between 2012 and 2014, an estimated 50% of cases were diagnosed in those aged 65 
years and older in the UK [2]. 
Melanoma is a complex and diverse condition. There is remarkable variability in its 
clinical presentation: some being pigmented and flat while others are amelanotic and 
exophytic. It stands to reason that the biology of these tumours could be different. 
 
1.2 The clinical diversity of melanoma 
The most frequent presentation of primary cutaneous melanoma is of a changing mole 
(naevus) with one or more of the following features: asymmetry, change of colour, 
shape or size, bleeding or itch. Indeed, this is the basis of the Asymmetry Border 
Colour Diameter Evolution (ABCDE) public health awareness campaign [4]. These 
characteristics most closely relate to the commonest melanoma subtype: superficial 
spreading melanoma rather than nodular and amelanotic melanomas. It is the 
tendency of melanoma to “stand out from the crowd” (relative to benign naevi) that 
facilitates its clinical diagnosis.  
Multiple factors lead a pathologist to suspect melanoma upon microscopic 
examination, including the relative absence of benign features, e.g. lack of uniform 
nuclei and maturation [5]. Atypical features are also variably present: asymmetrical 
architecture, abnormal melanocytes spreading upwards through the epidermis 
(“pagetoid spread”), variability of the size and shape of nuclei (“pleomorphism”) and 
nuclear cell division (“mitoses”) [5].  
  
2 
1.3 Melanoma survival/prognosis 
1.3.1 Factors associated with melanoma-specific survival 
In terms of survival, age, sex and tumour site predict survival as well as 
histopathological characteristics of the tumour. 
1.3.2 Age at diagnosis and melanoma 
Melanoma onset before 20 years of age has a favourable outcome despite aggressive 
histopathological features and a diathesis to sentinel node metastasis [6, 7]. The worse 
prognosis in those aged >70 years has been attributed to a tendency to have 
melanomas with poor prognostic features but a lower rate of sentinel lymph node 
positivity and higher mortality which might imply a greater likelihood of haematogenous 
spread [6, 7]. Moreover, Weiss et al. reported that older patients were significantly 
more likely to be male and to have an increased risk of death due to melanoma, 
compared with their younger counterparts [8]. A rising incidence in melanoma has 
been reported, which is most marked in men aged 70 years and older [9, 10]. 
Advancing age has also been linked to decreased self-detection [11] and 
immunosenescence [12]. Furthermore, older patients are significantly less likely to 
have a dense immune cell infiltrate, consisting of brisk tumour-infiltrating lymphocytes, 
within their primary melanomas [8], suggesting a decreased ability to mount an 
appropriate anti-tumour response. In essence, there is evidence that older people have 
a worse prognosis, partly due to later presentation, although age is an independent 
predictor of melanoma death. Some have reported evidence that relative immune 
insufficiency is seen with age and that could be causal. 
1.3.3 Sex disparity and melanoma 
Men have been shown to be at greater risk of death from melanoma [13]. Biological 
differences in the type of tumour could account for some of this increased risk, e.g. 
men are prone to ulcerated primaries with a worse prognosis [14-16]. Conversely, 
mitotic count does not appear to predict sex-based differences in survival [17]. 
Variation in care-seeking behaviour might explain some of the sex disparity [18] but 
Joosse et al. have identified sex as an independent risk factor for melanoma death, 
even after lymph node metastasis [19]. Men have an increased propensity to visceral 
metastases [19] and a higher mutation burden in their metastases, compared with 
women [20]. It is well recognised that men are less likely to use sun protection [21], 
however, the observed differences in mutation burden cannot be attributed to 
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ultraviolet radiation (UVR) [20], which supports the view that genuine biological 
differences exist in melanomas between the sexes. 
Several studies have confirmed the independent, protective effect of female sex [22-
24], while others have not substantiated this finding [22, 25-27]. In a study of 1998 
melanoma cases with negative sentinel lymph node biopsies, sex was not 
independently predictive of outcome [28]. Furthermore, Mandala et al. evaluated 1524 
cases of localised melanoma and did not find sex to be independently predictive of 
either relapse or death [26]. 
The underlying basis for the apparent sex disparity has not been fully elucidated, 
although several hypotheses have been proffered. Hormonal influences, including the 
effect of exogenous oestrogens, in the form of the oral contraceptive pill (OCP) or 
hormone replacement therapy (HRT), have been explored but there are conflicting 
results. In a retrospective study, MacKie et al. noted a survival advantage for female 
melanoma patients who received HRT, compared with those who did not, however, 
ulceration was more frequent in the latter group [29]. Conversely, a meta-analysis of 
case-control studies of OCP use and melanoma, showed no significant difference in 
outcome between women who did and did not receive the OCP [30]. However, there is 
some evidence to suggest that the protective effect of female sex reduces after the 
menopause [14]. Alternative hypotheses for the sex disparity in mortality include 
differences in immune function, response to oxidative stress and the expression of X-
linked genes but none of these studies has been conclusive [31]. 
1.3.4 Body site and melanoma 
Historically, the most common site for melanoma has been the trunk for men and the 
lower limb for women [2]. Truncal primaries are becoming more common among 
younger females, possibly reflecting changes in fashion (and, hence, uncovered skin) 
or sun exposure [32]. The site of primary melanoma has been shown to be an 
independent predictor of outcome, with melanomas located at an axial site (trunk, head 
and neck) having a significantly increased risk of sentinel lymph node positivity [33] 
and death, compared with melanomas on the extremities [28, 34]. This is not as yet 
biologically understood, although it is possible that biological differences could exist 
between tumours located at different sites. For example, mutation status is influenced 
by body site, with BRAF mutations more frequently associated with sites of intermittent 
sun-exposure, NRAS with sites that are continuously exposed [35] and KIT in acral and 
mucosal melanomas, and some melanomas occurring on chronically-sun damaged 
skin [36]. However, there is little evidence that driver mutation status per se is a 
determinant of outcome [37]. Furthermore, melanomas located at acral sites tend to 
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have a poor prognosis [38, 39], which most likely reflects late detection, at least in part. 
Similarly, melanomas that occur in locations that are not readily visualised, including 
genital and rectal melanomas, tend to have low survival rates [40, 41]. 
1.3.5 Histopathological classification of melanoma 
Melanoma is classified after surgical resection, by histopathological examination. Light 
microscopy is used to identify characteristic cellular features from cross-sectional 
profiles of the tumour. The distinction between radial and vertical growth phases and of 
in situ from invasive disease is of paramount importance. The established view is that 
the radial growth phase (RGP) precedes the vertical growth phase (VGP) in most 
melanomas. Vertical growth phase melanomas carry the risk of metastasis, possibly 
due to their proximity to blood and lymphatic vessels. Advancing thickness is also likely 
to reflect a more biologically aggressive tumour. 
Multiple subtypes of invasive melanoma have been described, each with characteristic 
(and somewhat subjective) histopathological features. In addition, each subtype may 
well demonstrate distinct biological behaviour. For example, nodular melanoma is 
regarded as a more foreboding tumour, often lacking classical clinical features as 
discussed and tending to present thicker [42]. Superficial spreading melanomas may 
contain a nodular component, making subtype distinctions less clear. 
1.3.6 Histopathological factors associated with prognosis 
Here I describe the recognised histopathological factors impacting on survival from 
melanoma, some of which are incorporated into the 7th edition American Joint 
Committee on Cancer (AJCC) staging system (see Table 1.1) [43]. There are 
additional well-recognised features, e.g. cellular morphology, of unknown biological 
and prognostic significance.  
1.3.7 Breslow thickness 
Breslow thickness is a well-established, independent prognostic factor [23, 25, 26, 43, 
44] and is superior to Clark’s level of invasion in predicting outcome from melanoma 
[23]. Breslow compared the depth of invasion, tumour diameter and cross-sectional 
area in a cohort of 98 melanomas and established that thickness was the best 
predictor of outcome, with metastases developing only after a depth of 0.76mm [45]. 
The Breslow thickness cut-off point for stage IA (T1a N0 M0, Table 1.1) in the AJCC 7th 
edition staging is 1.0mm [43], however, a cut-off point of 0.8mm will be used in the 
forthcoming AJCC 8th edition (in press). 
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1.3.8 Microscopic ulceration 
Microscopic ulceration is a key prognostic variable in the AJCC staging of cutaneous 
melanoma [43]. Although ulceration occurs more frequently in thicker tumours, it is an 
independent predictor of outcome and confers an increased risk of metastasis 
compared to non-ulcerated melanomas of equivalent thicknesses [46-49]. Higher 
mitotic counts have been recorded in ulcerated tumours, suggesting intrinsically 
aggressive behaviour [48, 49]. Recent evidence suggests an association between 
ulcerated primaries and sun-protected sites, nodular subtype, lymphovascular invasion, 
microvessel density and macrophage infiltration [49, 50]. 
The presence of microscopic ulceration is clearly important for prognosis; however, its 
detection is somewhat challenging. The Royal College of Pathologists define ulceration 
as “a full-thickness epidermal defect”, associated with “reactive changes” (e.g. fibrin, 
neutrophils) and “thinning, effacement or reactive hyperplasia of the surrounding 
epidermis” in the absence of trauma or surgery [51]. Yet, the distinction of true from 
artefactual ulceration is subject to interobserver variation [52]. 
In addition to its presence, the extent of ulceration appears to provide additional 
prognostic information but there is no consensus about the optimal cut-off point. In a 
study of 4661 cases, ulceration alone conferred a HR of 1.55 for melanoma-specific 
death, whereas for ≤5mm ulceration and >5mm ulceration, the HRs were 1.39 and 
2.03, respectively [53]. By contrast, a study of 235 melanoma patients reported that 
ulceration of as little as 5% of the lesional diameter was hazardous [54]. Day et al. 
suggested using a cut-off point of 3mm for ulceration width, as their study of 596 
patients showed no significant difference in survival between cases with ≤3mm 
ulceration and without ulceration [55]. In a study of 365 melanomas, the extent of the 
largest ulcer, type of ulceration and involvement of adjacent epidermis were recorded 
[56]. The extent of ulceration was expressed as a percentage of the lesional diameter 
and a cut-off point of 70% was used to define “minimal/moderate” and “excessive” 
ulceration groups [56]. Using a previously published classification, ulceration was 
deemed to be infiltrative when the epidermis was infiltrated and eroded by melanoma 
cells and as attenuative when a melanoma nodule expanded the epidermis resulting in 
a defect with minimal infiltration [57]. Excessive ulceration (≥70%) and attenuative type 
were independent risk factors for melanoma death (HR 3.57, 95%CI 2.01 - 6.36, 
p<0.0001; and HR 3.02, 95%CI 1.82 - 5.01, p<0.0001, respectively) and an ulceration 
width >3mm was significantly hazardous [56]. 
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Table 1.1: TNM staging of melanoma (on which the 7th edition AJCC staging 
system is based). 
Adapted from reference [43]. 
Primary tumor (T) Melanoma 
T1 
T1a: ≤ 1.0 mm in thickness without ulceration, mitoses < 1/mm2 
T1b: ≤ 1.0 mm in thickness with ulceration or mitoses ≥ 1/mm2 
T2 
T2a: 1.01-2.0 mm in thickness without ulceration 
T2b: 1.01-2.0 mm in thickness with ulceration 
T3 
T3a: 2.01-4.0 mm in thickness without ulceration 
T3b: 2.01-4.0 mm in thickness with ulceration 
T4 
T4a: >4.0 mm in thickness without ulceration 
T4b: >4.0 mm in thickness with ulceration 
Regional lymph nodes (N) 
N0 No regional metastases detected 
N1 
N1a: Micrometastases in one lymph node 
N1b: Macrometastases in one lymph node 
N2 
N2a: Micrometastases in 2-3 lymph nodes 
N2b: Macrometastases in 2-3 lymph nodes 
N2c: In-transit metastases/satellites without metastatic lymph nodes 
N3 ≥ 4 metastatic lymph nodes, or matted lymph nodes, or in-transit 
metastases/satellites with metastatic lymph node(s) 
Distant metastasis (M) 
M0 No evidence of distant metastases 
M1a Metastases to the skin, subcutaneous tissue, or distant lymph nodes, 
normal serum lactate dehydrogenase (LDH) level 
M1b Lung metastases, normal LDH level 
M1c Metastases to all other visceral sites or distant metastases to any site 
combined with an elevated serum LDH level 
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1.3.9 Mitotic count 
For primary melanomas, a mitotic count (as measured by counting the presence of 
mitotic figures within tumour nuclei) of ≥1/mm2 has been found to be an independent, 
poor prognostic factor for stage I melanoma (T1b N0 M0, Table 1.1) [43]. This forms 
part of the AJCC 7th edition staging, to stratify tumours with a thickness of ≤1mm (Table 
1.1) [43], although no longer a criterion to define stage IB (T1b N0 M0, Table 1.1), in 
the forthcoming AJCC 8th edition (in press).  
Several studies have explored the optimum cut-off point for mitotic count and whether it 
might also provide additional prognostic information for thicker melanomas. Roach et 
al. analysed mitotic count in 551 melanomas >1mm thick and found that the presence 
≥6 mitoses was associated with an increased risk of relapse and death, although it was 
not an independent predictor [58]. In a study of 313 T2 melanomas with negative 
sentinel lymph node biopsies, Baker et al. reported that a mitotic count ≥1 was 
significantly hazardous for melanoma relapse and death [59]. However, Speijers et al. 
explored various cut-off points and analysed mitotic count as a continuous variable for 
453 cases with a Breslow thickness >1mm and failed to show an independent effect for 
mitotic count [22]. Conversely, in a study of 13,296 stage I and II patients (T1a-T4b N0 
M0), Thompson et al. reported mitotic count to be the most significant prognostic 
factor, after Breslow thickness, with an increasing mitotic count being significantly 
inversely associated with survival [23]. Recently, Mandala et al. reported that a mitotic 
count ≥3 was an independent predictor of relapse and death, compared to <3 mitoses, 
for melanomas >1mm in thickness (n=1524) [26]. Moreover, mitotically active tumours 
are less likely to have brisk tumour-infiltrating lymphocytes [26] and are more likely to 
be thicker and ulcerated [22, 58, 59]. The presence of mitoses is regarded to be a 
marker of a proliferating, aggressive tumour that is more likely to metastasise [23]. 
1.3.10 Tumour-infiltrating lymphocytes 
Standard histopathology reporting of melanoma includes a description of tumour-
infiltrating lymphocytes (TILs), derived from a classification developed by Clark et al. as 
absent, non-brisk or brisk [60] (Figure 1.1). This classification has been shown to 
correlate with disease-free and overall survival in some studies; brisk TILs having the 
best prognosis [27, 60-63]. Others have not confirmed an independent survival 
advantage [25, 64-67]. TILs have not been incorporated into AJCC staging [43]. Absent 
TILs may increase the likelihood of a positive sentinel node biopsy [24, 64] but there 
are conflicting results [68]. The reason for this variation is unclear but may reflect the 
subjective nature of the current classification. This has led to the development of 
alternative grading systems for TILs. In 1996, Clemente et al. proposed a modified 
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version of Clark’s classification, showing a prognostic significance [61]. The Melanoma 
Institute of Australia (MIA) proposed a modified classification of TILs, with grades 
ranging from 0 to 3, incorporating the distribution and density of the infiltrate [24]. This 
correlated with melanoma-specific survival [24]. 
 
Figure 1.1: Clark’s classification of tumour-infiltrating lymphocytes (TILs) 
Lymphocytes involving the radial growth phase do not have prognostic 
significance; therefore, to qualify as TILs, lymphocytes must surround and disrupt 
tumour cells in the vertical growth phase [60] 
TILs have also been reported to vary according to Breslow thickness [24, 27, 33, 61, 
69]. Clemente et al. noted that brisk TILs were most frequent in melanomas ≤2mm 
thick [61]. In a study of 3,330 primary melanomas from the Genes, Environment and 
Melanoma Study, there was an inverse association between brisk TILs and Breslow 
thickness [27]. Similarly, Azimi et al. reviewed 1865 melanomas from the MIA database 
and reported that a higher TIL grade was inversely associated with Breslow thickness, 
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ulceration and mitoses [24]. Moreover, a study of melanomas with a thickness ≥4mm or 
regional nodal metastases at diagnosis, did not replicate the association between TILs 
and survival [70]. 
Immunohistochemistry (IHC) is an alternative approach that can be used to quantify 
TILs [69]. Weiss et al. assessed whether or not IHC could improve the predictive power 
of TILs, by evaluating the immunohistochemical expression of the lymphocyte markers, 
CD3, CD45 and FOXP3, in 184 primary melanomas [69]. They enumerated 
intratumoural and peritumoural lymphocytes within one high power field of the highest 
regions of expression of CD3, CD45 or FOXP3 [69]. There was no independent 
predictive power for IHC-quantified TILs [69]. Furthermore, there was no significant 
difference in either the pattern of lymphocytes (absent, non-brisk and brisk) or in 
survival by the expression of FOXP3, a marker of inhibitory T-regulatory lymphocytes 
(Tregs) [69]. Moreover, the authors evaluated the transcriptomic expression of 579 
immune genes in 67 melanomas and found that brisk TILs appeared to be biologically 
distinct, with a greater number of differentially expressed genes, compared with non-
brisk and absent TILs [69]. The top biological pathways associated with brisk TILs were 
related to immune cell activation and cytokine signalling [69]. Therefore, the grading of 
the pattern of TILs by histopathologists using H&E-stained sections appears to be of 
superior prognostic value to IHC, although transcriptomic studies could provide further 
insight into the biological basis for such patterns. 
1.3.11 Regression 
Regression, that is the replacement of tumour cells by fibrosis and/or an immune cell 
infiltrate, is thought to result from host-mediated immune responses to melanoma [71, 
72]. An alternative hypothesis is that regression represents a type of tumour 
remodelling, triggered by the accumulation of a critical burden of chromosomal 
abnormalities and resulting in apoptosis [73]. Although regression is reported to occur 
more frequently in thin melanomas, an association with poor prognostic factors, 
including male sex, older age at diagnosis and an axial site of primary melanoma, has 
also been noted [74]. 
The histopathological definition is variable [72, 75] and includes the presence of a 
mixed immune cell infiltrate composed of lymphocytes and melanophages, which may 
be accompanied by epidermal atrophy [76]. Kaur et al. described regression as a 
segment of melanoma that is lost and replaced by fibrosis, with evidence of increased 
vascularity and infiltration by melanophages and lymphocytes [77]. Zurac et al. 
classified regression as: segmentary, partial and mixed [75]. Segmentary regression 
was defined by the complete loss of tumour within a segment of the melanoma, while 
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partial regression was characterised by patchy loss of tumour cells [75]. The authors 
also reported a trend for regressing tumours to lack ulceration and to have a lower 
tumour mitotic count [75]. Furthermore, different phases of regression have been 
described, including an early “inflammatory” phase, which may be difficult to distinguish 
from TILs, and a later phase associated with dense fibrosis [76]. Moreover, others have 
classified regression as partial (involving <50% of the melanoma) or extensive (≥50%) 
[78]. 
The prognostic effect of regression is an area of intense debate. Regression is 
considered to be favourable by some, reflecting anti-tumour immunity [74, 79]. Kaur et 
al. studied the association between regression and sentinel lymph node status [77]. 
They noted a trend towards decreased nodal disease among regressing tumours [77]. 
Other studies have shown no association between regression and survival [80, 81]. A 
recent meta-analysis showed that the presence of regression was associated with a 
reduced risk of sentinel lymph node positivity [72]. 
Conversely, some authors report a worse prognosis and an increased propensity to 
metastasise [82-86] and it has been speculated that regression could have led to 
underestimation of the true Breslow thickness and, thereby erroneous down-staging of 
the tumour [71, 80]. Rubenstein et al. reported that 16% of 252 primary melanomas 
≤1mm showed evidence of regression and although it was not predictive of nodal 
metastases, the presence of regression was significantly associated with a false-
negative sentinel lymph node biopsy and subsequent nodal recurrence [71]. The 
authors proposed that similar mechanisms underlying regression in the primary might 
have led to regression in the lymph node [71]. In a study of 2243 melanomas, Maurichi 
et al. reported that the presence of ≥50% regression was associated with a significantly 
increased risk of death, again thought to be due to underestimation of the original 
Breslow thickness [78]. 
1.3.12 Lymphovascular invasion 
The presence of tumour cells in vessel lumina predicts the likelihood of sentinel node 
metastasis [87] and drainage to multiple sentinel lymph nodes [88]. Furthermore, 
lymphovascular invasion is associated with a higher Breslow thickness, ulceration, 
mitoses and a nodular subtype [89]. Detection is improved by the use of 
immunohistochemical stains to more clearly delineate vessel walls, including the 
vascular marker CD34 and the lymphatic endothelial marker D2-40, and this has 
prognostic significance in some studies [89-91]. Others have not found an association 
with survival [87]. 
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1.3.13 Perineural invasion 
The majority of melanomas with evidence of perineural invasion are located in the 
head and neck region, typically occurring in older men and composed of spindle cells 
[92-95]. Cases with perineural invasion may be more likely to recur, which could be 
related to the mode of spread and, therefore, adequate margins of excision are 
required to reduce the risk of recurrence [95].  
1.3.14 Microsatellites 
A microsatellite is deemed to be present if there is a “discontinuous nest of metastatic 
cells” >0.05mm, beneath the invasive melanoma and separated from it by ≥0.3mm of 
normal tissue [43]. The current Cancer Outcomes and Services Data set (COSD) 
minimum requirements for the reporting of primary melanomas includes microsatellites, 
as their presence indicates stage III melanoma and a worse prognosis [96]. The 
current approach is to exclude microsatellites from the Breslow thickness 
measurement [51].  
 
1.4 Histopathological factors of uncertain biological 
significance 
1.4.1 Melanoma cell shape 
Histopathologists have long noticed and reported differences in cellular shape between 
primary melanomas. Epithelioid cells are one of these distinct cell types, consisting of 
large, round cells with abundant, often eosinophilic cytoplasm and conspicuous 
eosinophilic nucleoli [97]. Spindle cells have an elongated or fusiform appearance and 
are often seen in lentigo maligna, acral and mucosal melanomas [98]. 
Cellular shape has been reported to impact on survival. Desmoplastic melanomas, 
which are ill-defined spindle cell tumours characterised by the presence of an 
abundance of collagen-rich stroma [5], are reported to recur locally but to metastasise 
less frequently than tumours of other cell types [99, 100]. In a study of 212 melanoma 
cases with a Breslow thickness <1mm, 86.6% of recurrences were in patients with 
melanomas of epithelioid cell-type [101]. Epithelioid cell melanomas have been shown 
to have more DNA ploidy abnormalities [102]. A study of 669 melanomas revealed 
spindle cells, marked pigmentation and a low mitotic count were indicative of a better 
prognosis [103]. Melanomas of mixed cell type and low mitotic count were the most 
frequent finding [103]. 
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Cellular shape might predict response to treatment. In a trial of 44 patients with 
advanced melanoma, who received a polyvalent vaccine plus Bacillus-Calmette Guerin 
(BCG) or BCG plus placebo, 9/11 (81.8%) patients who died within 6 months had 
epithelioid cell-type melanomas [101]. Ascierto et al. performed retrospective studies of 
low or intermediate dose interferon among a small cohort of melanoma patients and 
showed that the majority of relapsers, 73.1% and 87.5% respectively, had tumours of 
an epithelioid cell-type [101]. 
In the process of metastasis, melanoma cells physically migrate from the skin, and it 
has been postulated that motility varies according to cell shape. Two patterns of 
melanoma cell migration, influenced by alterations in the cytoskeleton and actomyosin 
contractility, have been demonstrated in vitro: a rounded or “amoeboid” type and an 
elongated or “mesenchymal” type [104-106]. Melanoma cells are considered to be 
highly plastic, with a propensity to alternate in a switch-like fashion between the two 
patterns [104]. In cell migration assays, the amoeboid mode of movement was faster 
and these cells have been noted at the invasive front of some melanomas [106, 107]. 
A number of groups have reported the biological basis of differences in cellular shape 
between melanomas. Viros et al. performed an analysis of 302 melanomas and 
defined 4 shapes: round, ovoid, elongated and spindle [108]. They showed that BRAF-
mutated melanomas consist of larger, rounder, pigmented cells [108]. Research in 
melanoma cell lines demonstrated that PTEN loss was associated with elongated cells 
[109]. 
1.4.2 Primary tumour architecture 
The way in which primary melanoma cells are organised in the skin contributes to the 
histopathological subtyping: nesting being typical of superficial spreading melanoma 
whilst junctional clefts are often seen in Spitzoid lesions [110]. There is evidence that 
the nature of the driver mutations (Section 1.6.1) is reflected in tumour morphology: 
BRAF-mutated melanomas are associated with epidermal hyperkeratosis, pagetoid 
spread and intraepidermal nesting [108]. Spindle cells tend to arrange in fascicles [98]. 
This might reflect differences in the pliability of the stroma or intrinsic factors related to 
cell shape, as elongated cells degrade collagen I less efficiently than rounded cells 
[105].  
1.4.3 Melanoma cell pigmentation 
Melanin pigment production (“melanogenesis”) is a hallmark of melanocytes and this 
occurs within structures called melanosomes [1]. Melanin protects the skin from UVR 
and is a marker of melanocyte differentiation [111]. One of the most striking clinical 
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characteristics of melanoma is irregularity of pigmentation [112], and the lack thereof 
contributes to difficulty in diagnosing amelanotic melanomas [113]. It is possible that 
differences in the degree of melanocyte differentiation might contribute to variation in 
melanoma cell pigmentation. Furthermore, heterogeneity in melanoma cell 
pigmentation is a prominent histopathological feature of cutaneous melanoma [108]. 
This curious phenomenon might reflect biological variation. Viros et al. performed a 
detailed histopathological assessment of melanoma cell pigmentation within 298 
primary melanomas and showed that pigmented melanomas were more likely to 
harbour BRAF mutations [108]. 
Moreover, pigmentation might affect the ability of melanoma cells to invade. Sarna et 
al. showed an inverse association between pigmentation and both melanoma cell 
elasticity and transmigration in vitro [114]. They concluded that melanosomes 
contributed to the rigidity of pigmented melanoma cells [114]. These findings suggest 
that the loss of pigmentation could promote melanoma cell invasion.  
The prognostic implications of pigmentation have been reported in small studies. 
Brozyna et al. studied the melanin content of 73 primary melanomas and 42 matched 
lymph node metastases and did not find any overall difference in survival, based on the 
presence or absence of pigmentation [111]. In a subset analysis of cases that 
developed metastases, there was a reduced interval to relapse and death in cases with 
pigmented, compared with amelanotic, primaries [111]. In a subsequent study, Brozyna 
et al. assessed the pigmentation of 57 melanoma metastases and 84 primary 
melanomas and noted that there was less pigment in thicker primaries [115]. Yet, they 
noted a higher level of pigmentation among the thick melanomas that metastasised, 
compared with primary melanomas that did not metastasise [115]. Furthermore, they 
reported that cases with amelanotic metastases, treated with radiotherapy, tended to 
survive longer compared to cases with pigmented metastases [115]. However, the 
radioprotective effect of melanin might have been contributory. 
The relationship between primary and metastatic melanoma cell pigmentation appears 
to be complex. Pinner et al. reported that melanoma cells undergo reversible 
“switching” between levels of high and low pigmentation, adopting a less pigmented, 
less differentiated phenotype in the process of metastasis [116]. These motile, less 
pigmented cells adopted a rounded morphology and moved rapidly [116]. Therefore, 
the classification of melanoma cell pigmentation within primary melanomas is of 
interest, however, the corresponding metastatic potential is uncertain. 
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1.4.4 Melanoma heterogeneity 
Primary cutaneous melanoma displays remarkable variation in its clinical appearance, 
both within and between tumours [1]. Just as features of the ABCDE [112] prompt a 
dermatologist to recognise melanoma, asymmetry, the lack of melanocyte maturation 
and the presence of mitoses assist a pathologist in diagnosing melanoma [5]. At a 
histopathological level, heterogeneity reflects diversity in cellular size, shape, 
pigmentation [117] and differences in the pattern of immune cell infiltration [60]. Even 
within the same tumour, some melanocytes elicit a lymphocytic response, while others 
lack an inflammatory infiltrate, so-called “non-brisk” TILs [60]. Some melanomas arise 
within pre-existing naevi, while others do not [5]. 
At a biological level, heterogeneity might result from genetic variation both within and 
between tumours, with heterogeneous primary tumours having multiple subpopulations 
or subclones [118]. Harbst et al. examined intra-tumoural heterogeneity within 41 
melanoma biopsies from 8 cases and reported that a higher level of mutational 
heterogeneity was associated with a worse prognosis [119]. Mutational heterogeneity 
was not associated with recognisable morphological characteristics and just 12% of 
driver mutations displayed intra-tumoural heterogeneity [119]. Furthermore, in a study 
of 63 melanomas from 28 cases, discordant gene-expression profiles were reported 
within different tumours from the same patient in half of cases [120]. Despite such 
variation, BRAF and NRAS mutations appeared to be conserved in subsequent 
metastases, when identified in the first metastasis [120]. Sanborn et al. reported that in 
6/8 (75%) cases, melanoma metastases within the same patient were derived from 
different subclones within the primary tumour and that the metastases developed at 
various anatomic sites in a parallel fashion [121]. Intra-tumoural heterogeneity has also 
been shown to contribute to the development of resistance to targeted therapy, via 
selection for resistant subclones [118]. An integrated taxonomy of melanoma is in 
evolution, combining descriptive terminology, related to morphology, with the molecular 
inferences of such traits [122], which could help to inform therapeutic decisions. 
1.4.5 Dominant nodule 
As previously discussed, histological subtypes are defined by somewhat subjective 
characteristics. For instance, a nodular component can occur within a superficial 
spreading melanoma, which could reflect the positive selection of a clone of tumour 
cells during melanoma evolution. Rao et al. performed a histopathological review of 
293 primary melanomas >4mm in thickness and noted the presence of a “dominant 
nodule” in 18% (53/293) of cases [70]. They defined a dominant nodule as an 
expansile nodule, consisting of homogeneous cells with either a naevoid or 
15 
pleomorphic appearance, and proposed that it might represent a clonal expansion of 
tumour cells [70]. Furthermore, the presence of a dominant nodule was significantly 
associated with an increased risk of relapse, with almost 40% of cases with a dominant 
nodule having lymph node metastases, however, there was no significant difference in 
survival [70]. 
 
1.5 Host immunity 
In addition to tumour-specific features, there is strong evidence for the role of the 
immune system in melanoma. Spontaneous regression has been reported [123], and 
the immune-mediated damage to normal melanocytes (vitiligo) is a good prognostic 
factor in patients being treated with chemotherapy [124]. A case report by MacKie et al. 
is an anecdotal record of the importance of immunosuppression in host responses to 
melanoma [125]. In this report, two renal transplant recipients developed melanoma, 
one metastatic and the other locally at the donor kidney site [125]. The donor, who had 
a history of melanoma 16 years before, was common to both cases [125]. The 
implication is that metastases had survived for 16 years within the kidneys of the 
donor, only to grow and metastasise under the influence of immunosuppression of the 
recipient. 
Successful responses to immune-checkpoint blockade, e.g. ipilimumab [126], anti-PD1 
[127] and anti-PDL1 [128] agents, highlight the importance of the immune system in 
suppressing melanoma. Melanomas with an immune-related gene expression 
signature pre-treatment with the anti-CTLA4 agent, ipilimumab, appear to exhibit better 
clinical responses [129]. 
1.5.1 The melanoma microenvironment 
The overall histopathological appearance of a melanoma embodies features intrinsic to 
its constituent melanoma cells, including cell shape, nuclear size, the distribution of 
chromatin and the degree of pigmentation. The blueprint formed by each melanoma is 
also a representation of its complex interaction with and integration of different 
components of its surrounding microenvironment. Therefore, melanoma stands, not 
alone, but within a framework of supportive infrastructure. This non-tumour component 
is often referred to as the stroma; yet, it is a variably defined entity. In breast cancer, 
Criscitiello et al. describe stroma as a composition of endothelial cells, fibroblasts, 
immune cells and extracellular matrix [130], whilst Moorman et al. define stroma as “the 
connective tissue that supports the deeper layer of breast tissue” [131]. Ruiter et al. 
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tabulated the various constituents of the melanoma stroma in detail, which included 
microvessels, inflammatory cells, fibroblast-like cells and extracellular matrix [132]. 
A complex, physical inter-relationship exists between the tumour and stroma, which 
suggests that it is an active rather than a passive process. Desmoplastic melanoma is 
a rare melanoma subtype, characterised by a dense collagenous stroma and 
paucicellular, spindle-shaped melanoma cells [133]. Notably, although prone to local 
recurrence, it rarely metastasises [99]. It provides anecdotal evidence of a favourable 
role for the stroma in melanoma. The significance of the tumour/stroma interaction can 
also be summarised by quantifying their respective amounts. Their relative proportions 
have been shown to provide prognostic information in several cancers [134-141]. In 
addition, increased expression of stromal genes has been shown to predict outcome in 
gastric cancer and was significantly associated with the estimated stromal content 
[142].  
Previous work in cutaneous melanoma has demonstrated some interesting findings, for 
instance, the density and thickness of collagen have been shown to differ between 
melanomas and naevi [143]. In a small study, histopathological sections of 12 
melanomas (>1mm thick) and 12 melanocytic naevi were stained with azan trichrome 
and analysed using automated imaging software [143]. Naevi contained more collagen 
than melanomas, whilst the latter tended to have thicker collagen bundles [143]. In a 
subsequent study of 267 Clark level III-IV melanomas, Smolle et al. measured the 
area, perimeter and diameter of pre-existing collagen bundles, which had been 
assimilated into the body of the tumours [144]. To ascertain these dimensions, a typical 
collagen fibre was marked and automated imaging applied to the H&E-stained sections 
[144]. Thicker melanomas had integrated more pre-existing collagen [144]. 
Interestingly, there was a significant inverse relationship between the area of collagen 
and both metastasis-free and overall survival in a univariable model [144]. The 
prognostic effect of collagen was lost after incorporating Breslow thickness in a 
multivariable analysis; however, the median follow-up was only 31 months [144]. 
Limitations of this study were that fine collagen, that was considered to represent the 
tumour stroma itself, was excluded from the measurements and the relative area 
occupied by melanoma cells was not recorded, thus it was not possible to infer the 
proportion of stroma [144]. The melanomas in this study were also restricted to the 
trunk and limbs, so that these results could not readily be applied to melanomas at 
other body sites [144]. 
Webster et al. utilised automated imaging software to determine the areas and 
percentages of tumour and stroma in lymphomas, melanomas and osteosarcomas 
[145]. For melanomas, muscle, connective tissue, epithelium, haemorrhage and 
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necrosis were counted as stroma [145]. The median percentage of stroma was 26% 
(range 0.21 – 93.24%) [145]. Algorithms had to be readjusted for melanomas due to 
their heterogeneity, yet measurements for 10/70 (24.3%) melanomas could not be 
computed [145]. Important histopathological and clinical parameters, e.g. Breslow 
thickness and ulceration, and survival data were not reported in this study [145]. During 
my PhD, I evaluated the percentage of stroma within primary melanomas and I 
analysed its effect on melanoma-specific survival. This work, on the nature and extent 
of the stroma within primary melanomas, is described in detail in Chapter 5. 
 
1.6 The molecular biology of melanoma 
1.6.1  Key pathways and genes implicated in melanoma 
Altered signalling through the mitogen-activated protein kinase (MAPK) and 
phosphatidylinositol-3-kinase (PI3K) pathways frequently occurs in melanoma [146]. 
Two common “driver” mutations drive this signalling, in the v-raf murine sarcoma viral 
oncogene homolog B1 (BRAF) and neuroblastoma RAS viral gene homolog (NRAS) 
genes (Figure 1.2) and these mutations are usually mutually exclusive [147]. Rarely 
mutations in mast/stem cell growth factor receptor (KIT) drive melanoma, usually in a 
small proportion of mucosal or acral subtypes. 
1.6.2 Molecular profiles of melanoma 
The AJCC staging is a powerful predictor of outcome [43] but unexplained variance of 
between 26% and 32% in survival exists [148][151], which researchers hope to reduce 
by better understanding the molecular diversity among tumours.  
Due to difficulties in acquiring sufficient volumes of fresh primary melanomas, most 
studies relate to metastases. The melanoma transcriptome, i.e. the transcripts of all 
messenger RNA, can be divided into meaningful prognostic groups by statistical 
analysis. One such method is unsupervised hierarchical clustering. This agnostic 
approach produces a dendrogram that can be used to assign individuals to different 
groups, based on the degree of similarity of their gene expression profiles. Jönsson et 
al. applied this technique to stratify the transcriptomic profile of 57 metastatic 
melanomas into 4 categories, referred to as “high-immune”, “proliferative”, 
“pigmentation” and “normal-like”, with the high-immune subtype having the best 
prognosis [149]. The names of the groups summarise the corresponding genes 
enriched within each category, e.g. MITF and other pigmentation genes in the 
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“pigmentation” subtype. These subtypes were replicated in 2 further data sets, which 
included 39 stage III melanomas. 
 
 
Figure 1.2: The mitogen-activated protein kinase (MAPK) pathway. 
AKT: protein kinase B. α-MSH: alpha-melanocyte stimulating hormone. BAD: 
Bcl2 associated death promoter. BRAF: V-raf murine sarcoma viral oncogene 
homolog B1. cAMP: cyclic adenosine monophosphate. cFos: Fos proto-
oncogene. cJun: Jun proto-oncogene. E2F: E2F family of transcription factors. 
EGFR: epidermal growth factor receptor. ERK: extracellular signal-related kinase. 
IL-6: interleukin 6. KIT: Mast/stem cell growth factor receptor. MEK: mitogen-
activated protein kinase kinase. MITF: microphthalmia-associated transcription 
factor. mTOR: mammalian target of rapamycin. NF-κb: nuclear factor kappa-light-
chain-enhancer of activated B cells. NRAS: Neuroblastoma RAS viral gene 
homolog. PI3K: phosphatidylinositol-3-kinase. PIP2: phosphatidylinositol 
biphosphate. PTEN: phosphatase and tensin homolog. TERT: Telomerase 
reverse transcriptase. 
Using a similar approach, Harbst et al. validated these 4 subtypes in 223 primary 
melanoma tumours and 2 distinct prognostic subclasses evolved: high- and low-grade 
[150]. The pigmentation and proliferative subgroups were merged to form the high-
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grade subclass whilst the low-grade subclass consisted of melanomas originally 
classified as high-immune and normal-like [150]. Melanomas with a high-grade 
signature tended to be thicker and nodular, to have a higher mitotic count and stage 
and displayed upregulation of cell cycle genes [150]. Conversely, melanomas with a 
low-grade signature were more likely to have brisk infiltration of TILs, BRAF mutations 
and were enriched for the expression of immune genes [150]. These two subclasses 
were validated in 29 stage III and 79 primary melanomas [150]. These subclasses 
were predictors of outcome, independent of stage [150]. This suggests that the 
transcriptome can provide additional prognostic information, both in early and 
advanced melanoma. In 2015, the Leeds group reported that these Jönsson subtypes 
could also be detected in samples from the Leeds Melanoma Cohort study and that 
96% and 81% of the primaries could be classified using the 4-grade and 2-grade 
signatures, respectively [151]. 
Previous transcriptomic studies have largely focused on advanced and metastatic 
melanomas due to the limited availability of tumour tissue, particularly from thin 
melanomas. However, Gerami et al. sought to identify patients at risk of progression at 
an earlier stage of disease (stages I and II) [152]. They developed a binary 
classification, based on the expression of 28 genes that had previously been reported 
to be associated with metastasis [152]. Gene ontology software also predicted these 
genes to be involved in processes of epithelial differentiation and cell-cell junction, 
which were considered to be pertinent to the metastatic process [152]. This 
classification had a negative and positive predictive value for metastasis of 93% and 
72%, respectively [152]. 
Clearly, a number of methods can be used to define subgroups within the 
transcriptome that have clinical and/or prognostic relevance. Selecting how to utilise 
this potentially powerful tool is in itself a challenge, as the transcriptome can potentially 
be interrogated in several ways to satisfy different aims. In my thesis, I will explore 
different techniques that I have adopted to address my aims, which are outlined at the 
beginning of each chapter. 
1.6.3 Driver mutation status and melanoma 
In addition to stratifying patients based on their transcriptomic profiles, recent evidence 
suggests that it is possible to make meaningful distinctions based on the principle 
driver mutation status. The Cancer Genome Atlas (TCGA) Network described a 
classification composed of 4 melanoma subtypes based upon these mutations: BRAF, 
RAS, neurofibromin 1 (NF1) mutant and triple wild type [153]. However, this framework, 
based on 67 primary and 266 metastatic melanomas, failed to demonstrate an 
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association with outcome [153], indicating that although these cases were genetically 
distinct, they were not significantly different in their behaviour. Nonetheless, these 
molecular entities might have histopathological correlates. 
Three-quarters of primary melanomas and, interestingly, 84% of metastases had a UV 
signature, i.e. a distinct set of somatic mutations attributable to ultraviolet radiation 
[153]. The mean mutation rate was high at 16.8/MB [153], relative to other cancers 
assessed within the TCGA data set [154]. Therefore, statistical algorithms were used to 
identify the most significantly mutated genes among the samples [153]. Patients with 
BRAF-mutated melanomas tended to be younger, while patients with NF1-mutated 
melanoma were older [153]. The triple wild type subgroup had a lower frequency of UV 
signatures (30%) and a diathesis to complex structural rearrangements [153]. 
Although there was no significant association between driver mutation status and 
survival, using unsupervised hierarchical clustering, it was possible to define 3 
prognostic groups within the transcriptome: “immune”, “keratin” and “MITF-low” [153]. 
The immune group had increased expression of immune cell subsets, cytokines and 
chemokines and within this group, patients with regional metastases had a better 
outcome than those in the other 2 groups [153].  
 
1.7 Histopathological consequences of variation in the 
molecular biology of melanoma 
1.7.1 The presence of BRAF mutation and implications for 
histopathological appearance 
Although diversity is typical of primary melanomas, it may be possible to sub-classify 
them by categorising their histopathological characteristics and there is some evidence 
for a relationship between biological and histopathological variation. Previous studies 
suggest a relationship between such features and the presence of a driver mutation. 
Viros et al. performed a histopathological review of 302 primary melanomas and found 
that BRAF-mutant melanomas tended to display more intra-epidermal scatter and 
nesting of melanocytes, which had a round, pigmented appearance [108]. Patients with 
a BRAF mutation also tended to be younger. The reproducibility of this scoring system 
was investigated by Broekaert et al., who reported an accuracy in prediction of BRAF 
status of up to 65.5%, with the best inter-observer agreement for pigmentation, 
intraepidermal scatter and solar elastosis [155]. BRAF-mutations have been reported in 
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superficial spreading melanomas, particularly on sites of intermittent sun exposure 
[156]. 
 
1.7.2 Kinase fusions and histopathological appearance 
Apart from predicting the driver mutation status, Yeh et al. described characteristic 
histopathological appearances associated with kinase fusions involving ALK in a series 
of 32 Spitz tumours: plump, spindle-shaped melanocytes arranged in elongated nests, 
often with a wedge-shaped base [157]. In a further series of 17 cases with ALK fusions, 
a plexiform growth pattern was noted [158]. This suggests that recognising such 
features could be helpful in the identification of appropriate lesions for future molecular 
testing and the potential for more targeted treatment. This will be explored further in 
Chapter 6. 
1.7.3 BAP1 and histopathological appearance 
An area of current speculation is whether or not germline mutations could be predicted 
based on the histopathological appearances of tumours. Wiesner et al. reported an 
autosomal dominant tumour predisposition syndrome associated with mutations in the 
BAP1 gene in 2 families with uveal and cutaneous melanoma [159]. Cases had 
multiple pink naevi, which had a bland appearance clinically but had an unusual 
histopathological appearance; composed of pleomorphic, epithelioid melanocytes and 
lacking an epidermal component [159]. Multinucleated melanocytes and intranuclear 
pseudoinclusions have also been described in melanocytic lesions among cases [160, 
161]. Various terms have been proposed for these lesions, including “Melanocytic 
BAP1-mutated Atypical Intradermal Tumours” (MBAITs) [162] and “NEvoid Melanoma-
like Melanocytic Proliferations” (NEMMPs) [163]. The types of cancer to which these 
families are prone continue to expand but include mesothelioma [162], renal cell 
cancer and meningioma [164-166]. This will be discussed further in Chapter 6. 
1.7.4 Ulceration and gene expression profiles 
As mentioned, microscopic ulceration is one of the key prognostic indicators in 
melanoma, included in the current AJCC staging system and here I describe the 
evidence that ulceration reflects important biological differences [43]. Although the 
presence of ulceration strongly predicts melanoma death, somewhat paradoxically, a 
subgroup analysis of data from a trial of intermediate dose interferon-alpha-2b as 
adjuvant therapy for resected stage IIB and III melanoma suggested that ulceration 
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predicted benefit from interferon [167]. Patients with ulcerated melanomas who 
received the 25-month schedule were significantly less likely to die than those with 
non-ulcerated primaries (HR 0.59, p=0.0007) [167]. 
The mechanisms underlying ulceration are not fully understood. Rakosy et al. analysed 
the gene expression patterns of 36 primary melanomas and discovered that 1,080 
genes distinguished ulcerated from non-ulcerated cases, 93 of which were upregulated 
[168]. The top pathways identified in ulcerated melanomas included p53, NFκB and 
Wnt/β-catenin [168]. Jewell et al. from the Leeds group explored this further by 
comparing the gene expression profiles of ulcerated and non-ulcerated melanomas in 
multiple data sets [49]. Ulceration occurred more frequently with advancing age, male 
sex and in melanomas on sun-protected sites [49]. The expression of 56 genes was 
significantly different between ulcerated and non-ulcerated cases in the test data set; 
the most prominent differences included downregulation of genes involved in cell 
adhesion and the upregulation of Interleukin-6 (IL-6) and Interleukin-8 (IL-8) [49]. 
These observations were confirmed in 2 validation sets [49]. When hierarchical 
clustering was applied, 2 distinct clusters were identified, the first of which had a higher 
proportion of ulcerated melanomas [49]. Differential expression of genes involved in 
wound healing discriminated between the non-ulcerated melanomas of clusters 1 and 
2 and gene ontology revealed cell cycle and cell proliferation pathways to be enriched 
among ulcerated cases [49]. This suggests that ulceration is associated with a 
proliferative melanoma phenotype and that it appears to be associated with a pro-
tumourigenic type of inflammation, which might be amenable to interferon therapy. 
 
1.8 Molecular techniques for imputing stromal composition 
1.8.1 ESTIMATE and tumour purity 
Establishing the proportion of tumour present within a sample is important: it informs 
decisions about the contribution of the tumour to the transcriptomic profile. For 
example, one might infer that if RNA is extracted from a melanoma sample with a high 
tumour purity, then most of the resultant transcriptome is likely to have been derived 
from the melanoma cells themselves, whereas, the opposite could be true in cases of 
low tumour purity. Estimation of STromal and Immune cells in MAlignant Tumours 
using Expression data, is a method of quantifying the contribution of stromal and 
immune cells within a sample, based on the expression of a stromal and an immune 
gene signature [169]. Genes from the Cancer Genome Atlas and publicly available 
databases were filtered in order to construct these signatures [169]. The immune score 
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included genes that were both enriched in haematopoietic cells (relative to normal 
cells) and were associated with high immune cell infiltration in ovarian carcinoma [169]. 
Genes that were enriched in stromal tissue isolated by laser-capture microdissection 
from breast, ovarian and colorectal cancers were filtered to generate the stromal score: 
removing genes that had decreased expression in glioma stem cell-like cells and 
genes that showed little variability among cancer cell lines [169]. The tumour purity was 
subsequently derived from these scores [169]. The comparability of these 
transcriptomically-derived estimates of tumour purity, immune and stromal content with 
a histopathological assessment will be investigated in Chapter 5.  
 
1.9 The “immunome”  
The immune cell infiltrate within primary melanomas is an integral part of the 
melanoma microenvironment and is thought to represent a snapshot of the host 
response to foreign tumour tissue at a certain point in time. Several cell types 
contribute to this immune infiltrate, including T-lymphocytes, plasma cells, neutrophils, 
eosinophils and phagocytic cells, e.g. melanophages [170]. The immune cell response 
is complex: extensive discussion is beyond the scope of this thesis. Suffice it to say 
that there is considerable variation in the cell configuration and intensity of the immune 
cell infiltrate within primary melanomas: TILs being completely absent in some, whilst 
others display brisk TILs [60]. This is informative of the communication between 
melanoma and immune cells: potentially, the efficiency of the host immune response in 
eradicating the tumour and also escape mechanisms exploited by melanoma cells, in 
order to continue to proliferate and invade. Visual inspection of H&E-stained sections 
does not permit precise definition of the cellular composition, e.g. the pattern of TILs 
can be recorded but it is not possible to distinguish between cytotoxic- and T-helper 
cells, without ancillary tests, e.g. immunohistochemistry or multispectral imaging [171-
173]. In order to better understand the key immune cell players and their respective 
numbers, it would therefore be helpful to be able to identify these features without 
sacrificing several sections of clinical tissue. Furthermore, it seems likely that much 
more detailed categorisation of the immune cell infiltrates into tumours would tell us 
much more about the nature of host/tumour interactions and the determinants of those 
interactions. As an approach to this, Bindea et al. developed a resource, consisting of 
577 genes compiled from published literature, which could be used to map the 
presence of 28 immune cell subtypes [174]. This was initially applied to colorectal 
cancer but has since been validated in melanomas by the Leeds group. I am in receipt 
of these data, which I will implement to further interpret immune cell responses within 
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primary melanomas and the relationship between their histopathological and 
transcriptomic profiles. 
 
1.10 Hypotheses 
 Histopathological heterogeneity could be indicative of biological variation 
 The presence of a dominant nodule could be indicative of the positive selection 
of a clone of melanoma cells and might represent a more aggressive 
melanoma, which could be reflected in increased risk of relapse or death from 
melanoma 
 The immune system is important in determining outcome from melanoma and 
this can be measured histopathologically 
 The percentage of stroma might be predictive of melanoma-specific survival 
 BAP-like histopathology could help to predict germline BAP1 mutation status 
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Chapter 2 Methods 
My thesis was based on samples from the Leeds Melanoma Cohort, which is a long-
term study; already mature at the beginning of my time in Leeds. Although 2184 
participants were studied, my work focused on 798 tumour samples for which matching 
transcriptomes were ultimately available in 676 cases. I had access to the anonymized 
clinical and exposure data collected from participants, e.g. relapse data, etc. 
At the beginning of my thesis, I trained in melanoma histopathology. I accomplished 
this by studying the literature and through regular one-to-one training with Dr Will 
Merchant, consultant dermatopathologist, using light microscopy. A protocol that had 
previously been developed by Prof. Martin Cook was initially utilised. In the process, I 
developed a list of key histopathological variables of putative prognostic and/or 
biological significance to be measured, based upon the literature. I worked under Dr 
Merchant’s tutelage to define robust definitions for those variables. I carried out inter 
and intraobserver comparisons which are reported in Chapter 3. 
During the first year, it became possible to use digitised images. I moved to this virtual 
pathology approach because of its advantages in annotating and digitally extracting 
specific regions of tumour. Additionally, images of the measurements could be 
captured, for future reference, e.g. for clarification with a consultant dermatopathologist 
or in my subsequent research. 
 
2.1 Generation of H&E-stained sections, tumour mutation 
status, TMA core biopsies and whole-genome 
transcriptomes 
By the time I started my PhD, ethical approval had already been granted for the Leeds 
Melanoma Cohort (LMC) Study (MREC 01/3/057), which began recruiting in 2000 and 
upon which my thesis is based. Participants were asked to consent to sampling of their 
stored primary tumour blocks. Histology sections (each 5 μm thick) were taken from 
their primary melanoma formalin-fixed, paraffin-embedded (FFPE) tumour blocks. 
Histology sections and staining with H&E were performed by staff in the Section of 
Epidemiology and Biostatistics. The H&E slide was examined by Prof. Julia Newton-
Bishop and laboratory staff. A 0.6mm diameter circle of tumour was identified which 
was towards the advancing edge but was not so near the edge that sampling using a 
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tissue microarray (TMA) needle horizontally would miss the bulk of the tumour. The 
area selected contained the least inflammatory cell infiltrate and the least amount of 
stroma, so that the samples would be comparable. The site was marked with a marker 
pen and, subsequently, laboratory staff used this to guide sampling of the block using 
the TMA needle. For large tumours, the protocol allowed sampling twice. Where the 
tumour was judged too small to sample without destruction of the block (which might be 
needed subsequently by the patient for clinical testing) then no core was taken. 
DNA and RNA were extracted from the TMA cores according to a previously published 
protocol [175, 176]. BRAF and NRAS mutation status were established from extracted 
DNA using pyrosequencing by section staff. The mRNA was assayed by an external 
service provider using the Whole-Genome DASL HT12v4 assay (Illumina®). This array 
was developed by Illumina® for use particularly in degraded RNA extracted from FFPE 
tissue. The use of archival FFPE tissue for RNA extraction can yield cross-linked, 
degraded fragments [177]. The Whole-Genome DASL® assay utilises random primers, 
which can bind small fragments of RNA (~50 nucleotides) [178]. The Whole-Genome 
DASL® assay has previously been shown to produce high quality transcriptomic data 
from RNA extracted from FFPE tissue [175, 178]. Data were extracted using 
GenomeStudio© software. The whole-genome gene expression data were quantile-
normalised using Lumi R by Dr Jeremie Nsengimana [179]. Singular value 
decomposition (SVD) was used to assess the relationship between the top principal 
components of gene expression and technical variables, such as the batch, plate, chip, 
age of the tumour block and the date of RNA extraction using ‘swamp’ package [180]. 
Technical variables, found to significantly affect the data, were adjusted out. Significant 
variation disappeared when the data were adjusted for the chip used for each sample. 
 
2.2 Histopathological review of H&E-stained sections using a 
light microscope 
During the first ten months of the PhD, I used a Leica® DMLB2 light microscope to 
learn about melanoma histopathology and to grade 158 primary melanomas for key 
prognostic factors. I utilised a protocol that had previously been developed by Prof. 
Cook for this analysis (please see Appendix B). I learned melanoma pathology through 
reading dermatopathology textbooks, to which Dr Merchant kindly provided access, 
and by reading the literature about melanoma pathology. Dr Merchant provided regular 
one-to-one histopathology training. In order to be able to use the detailed protocol that 
had been developed by Prof. Cook, it was necessary to learn about melanoma 
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pathology. I reviewed melanoma cases with Dr Merchant using a multi-headed light 
microscope. I learned how to record measurements, correcting for the appropriate 
magnification. I gained an appreciation of the criteria used to define histopathological 
factors, e.g. distinguishing artefactual from true ulceration. The Royal College of 
Pathology guidelines were used as a reference for histopathological definitions [51]. An 
approach was developed for measures that were not already defined, through 
discussion and review of cases with Dr Merchant. I gradually became more familiar 
with melanoma pathology, by reviewing melanoma H&E sections that had been made 
for research purposes (results for the histopathological assessment using the Prof. 
Cook protocol are provided in the Appendix B). Dr Merchant reviewed cases where 
queries arose or where verification was required. 
The aims of the thesis were such that I needed to describe features of a whole slide, 
representative of the thickest part of the tumour, and features of the particular area 
within the tumour from which the TMA core was taken. Below, I describe how I 
identified the area of the tumour sampled for examination. 
After training using the light microscope, I worked with digitized images of the histology 
slides (virtual pathology) and hence some of the definitions used relate to screen 
dimensions rather than fields. It is notable that at this time of transition, I adopted a 
different classification to define certain factors, e.g. tumour-infiltrating lymphocytes 
(TILs). A decision was also made to discontinue the recording of other factors, e.g. 
microsatellites due to limited interobserver reproducibility and to allow sufficient time to 
record novel measures introduced in the virtual pathology protocol. 
The scoring variables outlined in Table 2.1 were applied for the protocol using the light 
microscope. The protocol was modified after discussion with my supervisor, Prof. Julia 
Newton-Bishop, and particularly with Dr Merchant, to derive definitions as seen in 
Table 2.3, which were used for the virtual pathology protocol.  
 
 Table 2.1: Properties of the Histopathological Scoring Variables for Whole-Tumour Measures using the Light Microscopy Protocol. 
Microscopic diameter, ulceration width, Breslow thickness, thickness of regression and distance to the peripheral and deep margins were 
calculated using the measurement on the eyepiece graticule, multiplied by the relevant calibration factor for the microscope. In cases where the 
maximum microscopic diameter, ulceration width, Breslow thickness or distances to the peripheral and deep margins were outside of the field of 
view, even at the lowest magnification (2x on the microscope used), a ruler was used, however, this was a crude estimate and would give a 
value to the nearest millimetre only. 
Scoring variable Detail of Scoring Schema 
Acral lentiginous melanoma 
Melanoma occurring in the volar or subungual skin. The intraepidermal component is usually lentiginous in 
pattern with a “moth eaten” appearance. 
Breslow thickness 
Measured from the top of the granular layer of the epidermis to the deepest invading melanoma cell, 
ignoring melanoma cells that were apposed to adnexal structures or within vessels. In ulcerated cases, 
where the thickest part of the melanoma was beneath the ulcer, the Breslow thickness was measured from 
the ulcer base. 
Clark level I Melanoma confined to the epidermis. 
Clark level II Melanoma begins to encroach on but does not fill the papillary dermis. 
Clark level III Melanoma fills and expands the papillary dermis. 
Clark level IV Melanoma invades the reticular dermis. 
Clark level V Melanoma invades the subcutaneous fat. 
Desmoplastic melanoma 
Ill-defined and variably cellular melanoma composed of spindle cells associated with dense collagen and 
usually occurring on sun-damaged skin. Lentigo maligna may be seen in association. 
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 Scoring variable Detail of Scoring Schema 
Epithelioid cells 
Cells with a round nucleus, a prominent, pink nucleolus and variably eosinophilic and often abundant 
cytoplasm [97]. 
Histological subtype As per definitions listed in Appendix A.  
Lentiginous intraepidermal proliferation Proliferation of melanoma cells along the basal layer of the epidermis. 
Lentigo maligna 
The in situ phase of lentigo maligna melanoma (i.e. radial growth phase; peri-adnexal involvement is 
frequent). 
Lentigo maligna melanoma 
Melanoma characterised by epidermal atrophy, a prominent intraepidermal lentiginous component, 
accompanied by evidence of actinic damage or solar elastosis and frequently involving adnexal structures. 
Lymphovascular invasion The presence of melanoma cells within lymphatic or blood vessels. 
Maximum microscopic diameter 
(in mm) 
The distance between the most lateral epidermal nest at either side of the melanoma, or where nests are 
absent, the distance between the furthest edges of the invasive component of the tumour. (This definition 
was developed following discussion with Dr Merchant).  
Melanocytic lesion of unknown 
malignant potential 
A melanocytic lesion where uncertainty exists regarding its biological behaviour and its propensity to 
metastasise is unclear. The behaviour may follow either a benign or a malignant course. Histopathological 
assessment tends to reflect a combination of features that can be seen in melanocytic naevi and in 
melanoma but fall short of a diagnosis of melanoma. 
Microsatellites 
The presence of melanoma nests >0.05mm in diameter, lying in the reticular dermis, panniculus or vessels, 
deep to the invasive melanoma and separated by normal tissue of at least 0.3mm on the section in which 
the Breslow thickness was measured [51, 181]. 
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 Scoring variable Detail of Scoring Schema 
Mitotic count 
(per mm2) 
The number of dermal mitoses within 1mm2  region of the “hot spot” (or area of apparently most numerous 
dermal mitoses), or in the absence of a hot spot, the number of dermal mitoses within 1mm2 of a 
representative dermal mitosis [43]. 
Naevoid melanoma minimal deviation 
A subtype of melanoma characterised by the presence of a nodule composed of uniform melanocytes, with 
rare or absent mitoses and tending to lack a host response or necrosis [182]. 
Nested intraepidermal proliferation The proliferation of melanocytes in nests within the epidermis. 
Nodular melanoma 
Melanoma characterised by a predominant vertical growth phase, with the lateral intraepidermal component 
extending no more than 3 rete ridges beyond the vertical growth phase component. 
Pagetoid intraepidermal proliferation Proliferation of melanocytes following a pagetoid spread pattern.  
Pagetoid spread Upward spread of atypical melanocytes into the epidermis. 
Percentage regression 
Calculated by dividing the horizontal diameter of regression by the maximum microscopic diameter of the 
lesion and multiplying by 100. 
Perineural invasion The presence of melanoma cells around a nerve. 
Pigmentation 
Initially graded as absent, mild, moderate and severe but subsequently modified and graded according to a 
protocol developed by Viros et al. as absent, faint, moderate, high and very high [108]. Later amended to 
record both the main and highest degree of pigmentation within the tumour as pigmentation was noted to 
vary significantly across the whole tumour. 
Radial growth phase melanoma 
Predominantly intraepidermal melanoma or if present, dermal nests consist of <15 cells, are no larger than 
intraepidermal nests and dermal mitoses are absent. 
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 Scoring variable Detail of Scoring Schema 
Radial growth phase (in situ) The presence of intraepidermal melanoma cells, singly or in nests [98]. 
Radial growth phase (microinvasive) The presence of intraepidermal melanoma with involvement of the papillary dermis [98]. 
Regression 
Replacement of melanoma cells by a variable lymphocytic infiltrate, melanophages, telangiectasia and 
fibrosis and often accompanied by epidermal atrophy [77]. 
 Stage 1 regression: some loss of dermal melanoma but preservation of the epidermal component [77]. 
 Stage 2 regression: loss of all dermal melanoma but a residual junctional component remains [77]. 
 Stage 3 regression: loss of junctional and dermal components of melanoma, with resultant dermal 
scarring [77]. 
Partial regression: loss of part of the tumour mass without complete replacement of tumour by inflammatory 
cells and fibrosis [75]. 
Segmentary regression: complete regression of a segment of melanoma [75]. 
Regression thickness 
Measured from the top of the granular layer of the epidermis to the nearest melanoma cell (if present) lying 
deep to the regression. If no melanoma cells remained, the thickness was measured to the deepest 
estimated edge of regression. 
Small/naevoid cells 
Melanoma cells which have prominent nuclear hyperchromasia, sparse cytoplasm and resemble benign 
naevus cells. 
Solar elastosis 
The presence of elastotic fibres in the dermis, which may occur singly or may form clumps or amorphous 
masses [183]. Graded as follows: mild if single, scattered, elastotic fibres were present, moderate if there 
were clumped, elastotic fibres with normal intervening dermis and severe if amorphous masses of elastotic 
fibres were present or if the papillary dermis was replaced by clumped elastotic fibres [183]. 
Spindle cells Cells with an elongated or fusiform appearance and a long axis proportionally larger than the short axis. 
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 Scoring variable Detail of Scoring Schema 
Spitzoid cells Melanoma cells within a spitzoid melanoma, which may be spindled and/or epithelioid in appearance [184]. 
Spitzoid melanoma 
A melanoma that has features of a Spitz naevus, i.e. dome-shaped and consisting of spindle and/or 
epithelioid melanoma cells [184]. 
Subungual melanoma Melanoma occurring underneath or in close proximity to a fingernail or toenail. 
Superficial spreading melanoma 
Characterised by a predominant nested pattern of melanoma but may contain a dermal nodule with a lateral 
intraepidermal component extending more than 3 rete ridges beyond the vertical growth phase melanoma. 
Pagetoid spread is common in this subtype. 
Tumour-infiltrating lymphocytes (TILs) 
Lymphocytes in the vertical growth phase that surround and disrupt melanoma cells [51]. 
 Absent TILs: no lymphocytes or if present, they do not infiltrate the vertical growth phase melanoma [60]. 
 Non-brisk TILs: lymphocytes infiltrate the invasive melanoma but only focally [60]. 
 Brisk TILs: lymphocytes diffusely infiltrate the entire base or the entire invasive component [60]. 
TILs pattern 
The pattern of TILs was recorded as peripheral if present at the edge of the tumour only, central if present 
anywhere within the body of the vertical growth phase (VGP) of the tumour except the edge, and both if 
present in a combined pattern. 
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2.3 Preparation for the transition to virtual pathology 
2.3.1 Ethical approval for virtual pathology 
The opportunity arose to make virtual pathology images of H&E sections from the 
Leeds Melanoma Cohort (LMC) Study for analysis. This would permit digital 
measurements and annotations to be made on the virtual pathology images. These 
digital measurements and annotated images could then be saved for future reference. 
Thus, facilitating learning and interobserver studies, by enabling the review of 
differences in the measurements recorded between observers. Clarification was sought 
from the Ethics Committee, who permitted this. An official amendment was also 
submitted, detailing the storage of images, both on the secure Genetic-Epidemiology 
server and anonymised images on the Leeds virtual pathology website. 
2.3.2 Recording the locations of TMA core biopsies 
H&E sections of primary melanomas from the LMC study had already been assessed 
by Prof. Newton-Bishop and Dr Jon Laye (senior histology technician) for suitability for 
sampling using a TMA core biopsy needle. TMA core biopsies were extracted from 
tumours where sufficient melanoma would remain in the event that the specimen might 
be required for subsequent clinical testing. Therefore, there was a bias to sampling 
thicker tumours. Overall, more than 2000 slides were reviewed, in excess of 900 
tumour blocks were sampled and RNA extracted. Unfortunately two plates of RNA 
samples were sent to the service provider and failed analysis due to reagent 
degradation. In total, 703 tumour transcriptomes were generated from the 2184 
participants. 
Glass slides containing H&E sections that had previously been marked for TMA coring 
using a black felt-tip pen, were scanned using a flatbed scanner (Canon® Canoscan 
LIDE 60) to retain a record of the markings that corresponded to the sites of TMA cores 
before cleaning (Figure 2.1A). JPEG images of the scanned slides were saved by 
study number on the secure Genetic-Epidemiology server.  
  
34 
 
Figure 2.1: (A) Flatbed-scanned and (B) virtual pathology images showing cored 
regions 
(A) The image on the left shows the sites that had been marked with a black felt-
tip pen for sampling using a TMA biopsy needle. (B) The virtual pathology image 
on the right shows the corresponding annotated regions. 
2.3.3 Slide scanning 
Glass slides containing H&E sections of primary melanomas from the LMC study were 
cleaned using 100% ethanol and paper towel, with assistance from laboratory staff 
(Minttu Polso and Tracey Mell). Slides were then submitted for scanning using the 
Aperio AT2®  slide scanner (performed by Michael Hale). 
 
2.4 Pilot work using virtual pathology 
Dr Darren Treanor, consultant histopathologist, provided initial virtual pathology training 
on the first scanned images, which were viewed on a large screen, known as the mini-
wall (Figure 2.2). The cored regions were annotated as follows: the JPEG image from 
the flatbed scanner and the corresponding virtual pathology image were opened on 
parallel screens on the mini-wall. The images were adjusted to the same scale. A 
600μm square (the same diameter as a TMA core needle) was overlaid onto the virtual 
pathology image in the cored region. This was repeated for subsequent cores from the 
same case (Figure 2.1B). After marking, an image of 2,426 pixels, at a resolution of 
0.2473μm per pixel, was extracted (corresponding to a width of 600μm). Each virtual 
pathology image was assigned a unique SVS number and each case was saved on the 
secure Genetic-Epidemiology server as an .xml file. 
Pilot work on measuring stromal content within the estimated cored regions and a 
representative area of the expansile vertical growth phase (VGP) of the tumour was 
performed on 10 cases. An outline of the representative tumour from which the core 
had been obtained was created, and the file was exported as an .xml file (Figure 2.3A). 
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Only the dermal, invasive component of the melanoma from which the core had been 
taken was incorporated into the outline, ignoring in situ components. I used a 
programme called RandomSpot© to estimate stromal content. This approach has 
previously been applied to other cancers, including colorectal [141] and breast cancer 
[136] for this purpose. A series of arrowheads or ‘spots’ are generated by the software. 
The observer then uploads the output onto the virtual slide, where the tissue identified 
by each arrowhead can be viewed at high magnification and the relevant cell or 
structure recorded (Figure 2.3B). 
 
Figure 2.2 Photograph of the mini-wall used to perform the virtual pathology 
review 
The mini-wall consists of 3 parallel screens connected to a single computer. The 
first screen was used to access files and to input information into the FileMaker 
Pro© database. The second screen was used to assess and to annotate the 
virtual pathology images. The third screen was used to visualise flatbed-scanned 
images of the glass slides, which contained black markings that corresponded to 
the sites of TMA core biopsies. 
To superimpose a set of arrows onto the virtual images, RandomSpot©, bespoke virtual 
pathology software was used (http://129.11.65.182/RandomSpot/, developed by Alex 
Wright, Virtual Pathology Department, University of Leeds) [185]. 
The .xml files were uploaded separately: 50 spots (arrowheads) were selected for each 
estimated cored region and 300 spots for each of the representative tumour areas 
(Figure 2.3C).  
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Figure 2.3: Virtual pathology images showing (A) the outline of the vertical 
growth phase melanoma, (B) spots imported from RandomSpot© onto the 
digital image within the vertical growth phase melanoma and (C) spots 
imported from RandomSpot© onto the cored region 
(A) The outline of a representative region of the vertical growth phase melanoma 
is shown (x4 magnification), (B) 305 spots imported from RandomSpot© onto the 
digital image within the representative region of melanoma (x8 magnification). 
Please note that although 300 spots were selected, RandomSpot© allocates the 
approximate number of spots requested, and (C) 48 spots imported from 
RandomSpot© onto the 600 micron square which corresponded to the TMA 
biopsy site (50 spots had been requested). 
Sections were scored with a “t” or “s” for each arrowhead that landed on tumour and 
stroma, respectively. Anything that was not tumour was recorded as stroma, i.e. 
immune cells, connective tissue, vascular structures. If an arrowhead landed on a non-
informative area, “▪” was recorded. Similarly, squamous epithelium (including rete 
ridges and hair follicles) was excluded from the calculation by recording as “▪”. 
Results were exported both as .xml and .xls/.xlsx files. Proportions of tumour and 
stroma were calculated using pivot tables in Microsoft Excel (2007) and the data were 
imported into the statistical software package STATA v.12.1 [186]. 
Regions on the virtual image that had been estimated to correspond to cored regions 
were analysed for the proportion of stroma. The percentage of stroma (POS) was 
C 
38 
calculated for each core and was subsequently categorised into percentage groupings 
as follows: 0, 1-24, 25-49, 50-74, ≥75%. This was then compared with an eyeballed 
measure of the POS and the extent of agreement was calculated. 
In order to assess the variance across the arrow count and the number of arrows 
required to accurately record the proportion of stroma in each estimated core, the 
moving average of the 50-arrow count was calculated for each estimated core. Line 
graphs were plotted of the moving average versus the arrow number (Appendix C). 
Lines for multiple cores within the same case were superimposed and, for patients with 
two cores, the frequency distributions of the moving average for each core were 
compared using a two-tailed T-test. Line graphs of the moving average for the 300-
arrow count over the representative tumour region were plotted using the same 
method. 
2.5 Virtual pathology protocol: whole tumour measures 
Virtual pathology opened up new possibilities to record measurements hitherto 
infeasible using a light microscope, such as the use of a technology to facilitate the 
estimation of stromal content called RandomSpot©. The histopathology review was 
restricted to all available primary melanomas that had been sampled using a TMA 
needle to generate whole-genome transcriptomes. An iterative process ensued to 
develop a suitable protocol that would account for features of the primary melanoma as 
a whole and also characteristics particular to the locations selected for TMA sampling.  
Slides were accessed from a personal folder within the Leeds virtual pathology 
website, using Internet Explorer version 9. The relevant batch was selected and the 
SVS of interest was opened in ImageScope© v12.2.1.5005. Separate files linking the 
study number, batch and SVS numbers and files containing details of which cases met 
the inclusion criteria (i.e. had been sampled using a TMA needle) were stored on the 
secure Genetic-Epidemiology server. These were consulted each time a case was 
assessed. 
With respect to the whole tumour, Breslow thickness, microscopic ulceration, TILs and 
regression were retained as measures to be recorded. There were multiple H&E 
sections available for several cases. Each section was assessed. The method I applied 
to each parameter is described below. Briefly, a maximum of three measurements per 
section and a total of up to six measurements per case were recorded for Breslow 
thickness. The highest value for Breslow thickness on any section was recorded as the 
maximum Breslow thickness. Microscopic ulceration was deemed to be present if it 
was present on any section. A maximum of six measurements were recorded for the 
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extent (width) of ulceration in millimetres. These measurements could be distributed 
between different sections or could be recorded on a single section. The maximum 
value for the extent of ulceration was used as the value for the maximum extent of 
ulceration. Tumour-infiltrating lymphocytes (TILs) were assessed on the thickest 
section (i.e. the section where the maximum value for Breslow thickness had been 
recorded). TILs were recorded as non-evaluable if the base of the section was partially 
or entirely missing (e.g. due to a shave biopsy). If regression was present on any 
section, it was recorded as being present for that case. Up to six measurements were 
permitted for the depth of regression and the maximum value was recorded as the 
maximum depth of regression. The ruler icon in Aperio® ImageScope© was selected to 
record measurements in millimetres. 
Whole-tumour measures were recorded in a FileMaker Pro© database, specifically 
designed for the study. A photograph was taken of the measurements made using the 
camera icon in ImageScope©. Annotations for each slide were exported as separate 
.xml files. These and the corresponding JPEG images were saved on the Genetic-
Epidemiology server. 
Several variables were dropped due to limited reproducibility (Chapter 3) and in an 
effort to utilise time as effectively as possible, while introducing new, detailed measures 
for the cored regions. These dropped variables included the histological subtype, the 
maximum microscopic diameter, percentage of ulceration, the growth phase, Clark’s 
level, lymphovascular and perineural invasion, percentage and stage of regression, 
microsatellites, co-existent naevus, solar elastosis, distances to the deep and 
peripheral margins and the type of intraepidermal melanocytic proliferation. The 
recording of TILs was modified (please see below) and the mitotic count, predominant 
cell type and pigmentation of melanoma cells were recorded in the cored regions rather 
than within the whole tumour. I elected to enumerate mitoses within the cored region in 
preference to the whole tumour because this would permit subsequent comparisons 
with the transcriptomic data. These dropped measures had already been recorded from 
histology reports on the Section of Epidemiology and Biostatistics database.  
Details of the scoring variables used and the scoring schema adopted are given in 
Table 2.2. 
 
 Table 2.2: Properties of the Histopathological Scoring Variables for Whole-Tumour Measures using the Virtual Pathology Protocol 
Details of histopathological variables that were measured for cases reviewed using the virtual pathology protocol.  
Scoring variable Detail of Scoring Schema 
Absent tumour-infiltrating lymphocytes 
(TILs) with a perifibrotic/regression 
pattern  
TILs located mainly in a region of fibrosis or regression (with or without melanophages). 
Absent tumour-infiltrating 
macrophages/melanophages (TIMs) 
with a perifibrotic/regression pattern 
TIMs located mainly in a region of fibrosis. 
Absent tumour-infiltrating lymphocytes 
(TILs) with a perivascular pattern 
TILs situated predominantly around vascular structures. 
Absent tumour-infiltrating 
macrophages/melanophages (TIMs) 
with a perivascular pattern  
TIMs situated predominantly around vascular structures. 
Breslow thickness (in mm) 
The measurement between the top of the granular layer of the epidermis and the deepest point of invasion 
of melanoma, or where epidermal ulceration is present (and involves the thickest region of tumour), the 
measurement between the base of the ulcer and the deepest point of melanoma invasion. Melanoma cells 
apposed to adnexal structures or within vessels or microsatellites were excluded from the measurement. 
Brisk diffuse TILs 
TILs situated throughout the base of the vertical growth phase (VGP) melanoma and additionally infiltrating 
the body of the VGP to the extent that the majority of the VGP appears to be consumed by TILs. 
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Brisk diffuse TIMs 
TIMs situated throughout the base of the VGP melanoma and additionally infiltrating the body of the VGP to 
the extent that the majority of the VGP appears to be consumed by TILs. 
Brisk peripheral TILs 
TILs situated throughout the base of the VGP melanoma, which may infiltrate some of the body of the VGP 
to an extent that is less that of brisk diffuse TILs. 
Brisk peripheral TIMs 
TIMs situated throughout the base of the VGP melanoma that may infiltrate some of the body of the VGP to 
an extent that is less that of brisk diffuse TIMs. 
Cumulative extent of ulceration The sum total of width measurements for discontiguous ulcers on the same section of melanoma. 
Deep tumour loss 
A deficit within the melanoma VGP whose proximal aspect begins within the dermis but is not in direct 
contact with the dermo-epidermal junction. 
Depth of tumour loss (mm) 
Measured from the top of the granular layer of the epidermis to the deepest estimated edge of tumour loss, 
i.e. fibrosis or lymphohistiocytic infiltrate. 
Dominant nodule 
The presence of a nodule of melanoma, characterised by an abundance of melanoma cells accounting for 
an entire screen of the mini-wall at 10x magnification which may contain immune cells or blood vessels but 
not perceptible collagen or the following structures: nests, fascicles or dispersed. 
Extent of ulceration (mm) The distance between the most lateral points of the epidermal defect and associated reactive changes. 
Focally absent biphasic VGP TILs 
TILs present to some extent within one VGP component of the melanoma but lacking in another VGP 
component. 
Focally absent biphasic VGP TIMs 
TIMs present to some extent within one VGP component of the melanoma but lacking in another VGP 
component.  
Microscopic ulceration 
Full thickness epidermal defect, accompanied by reactive changes (including neutrophils and fibrin) and 
surrounding epidermal thinning or hyperplasia, in the absence of trauma or surgery. 
Non-brisk sparse TILs TILs that infiltrate the upper half of the VGP melanoma. 
Non-brisk sparse TIMs TIMs that infiltrate the body of the VGP melanoma in the absence of TIMs along the base of the VGP. 
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Non-brisk peripheral TILs 
TILs that infiltrate the VGP melanoma focally or subtotally and are absent from the upper half of the VGP 
melanoma. 
Non-brisk peripheral TIMs TIMs that infiltrate the VGP melanoma along the base in a focal or subtotal fashion. 
Regression thickness (in mm) 
Measured from the top of the granular layer of the epidermis to the nearest melanoma cell (if present) lying 
deep to the regression. If no melanoma cells remained, the thickness was measured to the deepest 
estimated edge of regression. 
Superficial tumour loss  
A deficit in the melanoma, detectable at 4x magnification, whose proximal aspect is situated in the dermis 
that is immediately in contact with the dermo-epidermal junction. This must not underlie a region of 
melanoma in situ without perceptible VGP melanoma beneath it or a region of microscopic ulceration. 
Totally absent TILs TILs that are not detectable at 10x magnification or do not infiltrate the VGP melanoma. 
Totally absent TIMs TIMs that are not detectable at 10x magnification or are not closely apposed to the VGP melanoma. 
Tumour-infiltrating 
macrophages/melanophages (TIMs) 
Macrophages/melanophages that infiltrate or are closely apposed to the VGP melanoma. 
Tumour loss 
A clear deficit within the silhouette of the melanoma at 4x magnification and composed of a variable 
presence of lymphocytes, melanophages and/or fibrous tissue. 
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2.5.1 Breslow thickness measurement 
For non-ulcerated cases, Breslow thickness was calculated by selecting the ruler icon 
in Aperio® ImageScope© and drawing a line from the top of the granular cell layer of the 
epidermis to the deepest point of melanoma invasion (excluding adnexal or 
lymphovascular involvement or microsatellites) (Figure 2.4). A maximum of three 
measurements were permitted on one section and a maximum of six measurements 
were recorded in total per slide (i.e. some slides contained multiple sections). 
 
Figure 2.4 Virtual pathology image showing a melanoma with annotated Breslow 
thickness measurements 
Histopathological findings (low power view) show a melanoma with 3 annotated 
Breslow thickness measurements. The greatest tumour thickness on any section 
for a single case was taken to be the definitive Breslow thickness.  
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2.5.2 Dominant nodule 
Superficial spreading melanoma is characterised by the presence of a nested 
arrangement of melanoma cells; however, some of these may have a prominent 
nodular component. In contrast, nodular melanoma adopts a nodular configuration and 
is said to lack a radial growth phase [182]. The histological definition, however, permits 
the presence of intraepidermal melanoma cells lateral to the nodule for up to 3 rete 
ridges [187]. If melanoma cells extend laterally beyond this limit, then superficial 
spreading melanoma is recorded. Therefore, there is a degree of overlap between 
these two categories, the cut-off point for which is somewhat arbitrary.  
Rao et al. noted that a “dominant nodule” was present in some thick melanomas [70]. 
They defined a dominant nodule as “an expansile nodule composed of morphologically 
homogeneous cells of naevoid or pleomorphic morphologic features” and considered 
that it might reflect a clonal expansion of melanoma cells [70]. Its presence was shown 
to influence relapse-free survival [70]. Therefore, the presence of a prominent nodular 
component, regardless of its histological subtype appeared to be noteworthy. 
Accordingly, I opted to record the presence or absence of a dominant nodule (recorded 
as yes or no). This initially appeared to be a simple measure, however, it became clear 
that its interpretation could be altered by the magnification used. Although Rao et al. 
recommended that low-power magnification be used to determine the presence of a 
dominant nodule, it became clear that melanomas with significant nesting could be still 
be captured by this definition (as nesting might not be fully appreciable at low-power). 
The definition was adapted in order to record the presence of a confluent nodule, which 
I considered most likely to represent the positive selection of a clonal expansion of 
melanoma cells, dominating over other subpopulations. The final definition 
necessitated that each section of melanoma be assessed at 10x magnification. A 
dominant nodule was deemed to be present if melanoma cells occupied the entirety of 
a single computer screen of the mini-wall. The presence of lymphocytes, macrophages, 
plasma cells, neutrophils, eosinophils, vascular or lymphatic vessels was permitted 
within the dominant nodule of the melanoma. Squamous epithelium, rete ridges, 
normal dermis or subcutaneous fat had to be excluded from the field of vision. A 
dominant nodule was absent if these elements could not be excluded from the screen, 
if the melanoma was too small to fill the entire screen, if collagen or a clear structural 
pattern of melanoma, other than sheets (Table 2.1 and Table 2.2), could be 
appreciated at this magnification. Whether or not the TMA biopsy was taken from the 
dominant nodule was also recorded as yes, no or not applicable. 
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Figure 2.5: Virtual pathology images (A) and (B) of a melanoma containing a 
dominant nodule 
The histopathological appearance (A) at low power (x2 magnification) is suggestive of 
the presence of a dominant nodule, however, the findings (B) at x10 magnification 
confirm that this meets the criteria for a dominant nodule. One entire screen of the 
mini-wall was occupied by melanoma at this magnification and the appearance was 
relatively structureless with minimal connective tissue.  
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2.5.3 Microscopic ulceration and measurement of its extent 
If ulceration was present on any section, it was deemed to be present. Where present, 
the extent of ulceration was measured by drawing a line (using the ruler icon) between 
the two most lateral points of ulceration with the computer cursor (Figure 2.6A). A total 
of six separate measurements could be made, on either the same or different sections. 
The largest value recorded on any slide for the same case was the maximum extent of 
ulceration for that case. For melanomas with multiple, discontiguous ulcers, the 
cumulative extent of ulceration was also calculated, by the addition of measurements 
for up to six ulcers on the same section (Figure 2.6B). The maximum cumulative extent 
of ulceration for a case was the maximum value for the sum of these discontinuous 
ulcers within the same section. 
2.5.4 Grading tumour-infiltrating lymphocytes 
TILs were graded at 10x magnification on the thickest section of melanoma. A modified 
version of Clemente et al.’s approach was employed [61] (Figure 2.7). 
 
 
 
 
 
 
Figure 2.6 (on following page): Virtual pathology images (A) and (B) showing 
melanomas with annotated measurements for the extent of microscopic 
ulceration 
Histopathological findings (low power view) show (A) a continuous ulcer 
measuring 10.99mm (annotated in yellow). Measurements for Breslow thickness 
are annotated in green. The maximum thickness was used for the definitive 
Breslow thickness. (B) Four discontiguous, focal ulcers (annotated in yellow). The 
largest ulcer (340 microns) was used for the definitive extent of ulceration, while 
the cumulative extent of ulceration was calculated by summing the 
measurements of all four ulcers on this section (to give a cumulative extent of 
ulceration of 0.965mm). The extent of ulceration was used for statistical analyses, 
as the cumulative extent of ulceration was present in a minority of cases.  
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Figure 2.7: Clemente’s classification of TILs [61], modelled on Clark’s original 
classification.  
Brisk TILs were subclassified as diffuse and peripheral. Non-brisk TILs were 
subclassified as sparse and peripheral. TILs were considered to be “totally” 
absent if lymphocytes were present but did not infiltrate the vertical growth phase 
(VGP). TILs were “focally” absent if they infiltrated only one part of a biphasic 
VGP melanoma. TILs occurring in a perivascular pattern or associated with a 
region of fibrosis were regarded as being absent. 
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Examples of TIL infiltration patterns are shown in (Figure 2.8 A-G). “Brisk peripheral” 
was assigned if TILs infiltrated the entire base of the vertical growth phase (VGP) 
melanoma. TILs were deemed to be “brisk diffuse” if they met the criteria for “brisk 
peripheral” and additionally infiltrated the VGP melanoma centrally, to the extent that 
the VGP melanoma appeared to be consumed or heavily infiltrated by TILs. If TILs 
were located within the upper half of the VGP and were not distributed in a brisk 
pattern, then they were regarded as “non-brisk sparse” TILs, irrespective of focal 
infiltration of the VGP base. Even small clusters of TILs in the upper half of the VGP 
were sufficient to be categorised in this way. “Non-brisk peripheral” was recorded if 
TILs infiltrated the base of the VGP focally or in an incomplete manner. TILs were 
considered to be “totally absent” if there was no lymphocytic infiltrate noted at 10x 
magnification or if lymphocytes were located elsewhere in the skin, including near but 
separate to the base, i.e. not infiltrating the VGP. TILs were graded as “absent with a 
perivascular pattern” if they did not meet the criteria for brisk or non-brisk but instead 
congregated in clusters surrounding blood vessels within the VGP. TILs were graded 
as “absent with a perifibrotic/regression pattern” if they did not meet the criteria for brisk 
or non-brisk and were located predominantly within a region demonstrating fibrosis or 
regression (with or without a variable infiltrate of melanophages). “Focally absent 
biphasic VGP” was selected if the melanoma had more than one VGP component and 
if TILs infiltrated only one of these VGPs, regardless of the pattern of TILs in the 
infiltrated VGP component. A series of sequenced questions was developed to 
determine the categorisation in a systematic way (Figure 2.9). 
 
Figure 2.8 Virtual pathology images (A-G) showing melanomas with different 
patterns of tumour-infiltrating lymphocytes (TILs) 
Histopathological findings (x10 magnification) show (A) TILs extensively 
infiltrating the base and the body of the melanoma. TILs were classified as brisk 
diffuse. (B) A brisk lymphocytic infiltrate at the invasive margin of the melanoma. 
TILs were classified as brisk peripheral. The superficial part of the melanoma was 
not heavily infiltrated by TILs (not shown). (C) Small clusters of lymphocytes can 
be seen focally infiltrating the superficial aspect and the invasive margin of the 
melanoma. TILs were classified as non-brisk sparse. (D) Focal infiltration of the 
invasive margin of the melanoma but sparing of the superficial aspect of the 
melanoma. TILs were classified as non-brisk peripheral. (E) TILs are not 
apparent within this melanoma and were classified as totally absent. (F) Absent 
TILs with a perivascular pattern. (G) TILs within a region of fibrosis, classified as 
absent TILs with a perifibrotic/regression pattern. 
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Figure 2.9: Flow chart for determining the category for tumour-infiltrating 
lymphocytes (TILs)  
A series of questions was used to determine the pattern of TILs within the 
thickest section of melanoma. VGP=Vertical growth phase.  
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2.5.5 Regression and tumour loss 
During interim analysis, it became clear that the regression variable was ill-defined and 
could have represented multiple, different features: an immune response consisting of 
lymphocytes or melanophages, in isolation or combined; a fibrous tissue reaction, a 
region of tumour destruction or even a skip lesion (i.e. a region lacking in melanoma 
due to architectural arrangement rather than destruction). An attempt was made to 
solidify this measure and to apply this both to melanomas already reviewed and to 
further cases. Different aspects of regression were recorded together and separately 
as follows: tumour loss, the maximum depth of tumour loss in millimetres, the presence 
of melanophages and their intensity and pattern within the thickest section of 
melanoma. Tumour loss was defined as a clear deficit within the silhouette of the 
melanoma at 4x magnification and composed of a variable presence of lymphocytes, 
melanophages and/or fibrous tissue. Verification of constituents was permissible at a 
higher magnification but the overall impression of tumour loss had to be gauged at 4x.  
2.5.5.1 Type of tumour loss 
Tumour loss was also categorised as superficial, deep or both (Figure 2.10). Superficial 
tumour loss was deemed to be present if there was a deficit within the melanoma 
underlying the dermo-epidermal junction and its immediately adjacent dermis, without 
overlying microscopic ulceration or melanoma in situ. This was to distinguish from a 
dyscohesive response that could be seen underlying a region of ulceration and from a 
lymphocytic response that could be seen in response to a region of in situ disease: not 
considered to represent tumour loss for the purpose of this study. Tumour loss was 
described as deep if the proximal aspect of the deficit began at a deeper level of the 
dermis or subcutis than that described in superficial. “Both” was assigned if there was a 
combination of superficial and deep types of tumour loss.  
Figure 2.10 (on following page): Classification of tumour loss 
Tumour loss was deemed to be present if there was a deficit within the 
melanoma, detectable at 4x magnification. The region of tumour loss could be 
composed of an infiltrate of melanophages alone, a mixture of fibrosis and an 
infiltrate of melanophages and/or lymphocytes, or fibrosis alone. Tumour loss was 
classified as superficial if the deficit was situated in the dermis, immediately 
underlying the dermo-epidermal junction, without overlying melanoma in situ or 
ulceration. Tumour loss was classified as deep if the deficit was within the dermis 
but without direct contact with the dermo-epidermal junction. Tumour loss was 
classified as both if both superficial and deep tumour loss were present. 
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2.5.5.2 The maximum depth of tumour loss 
The maximum depth was measured from the top of the granular cell layer to the lowest 
pole of the immune infiltrate within the region of loss, where present or the most inferior 
aspect of the perceived deficit. 
2.5.6 Grading the intensity of melanophages 
 The intensity of melanophages was adjudged at 2x magnification on the thickest 
section of melanoma and was categorised as follows: none, very few, moderate or lots 
(Figure 2.12). 
2.5.7 Grading the pattern of tumour-infiltrating melanophages 
The pattern of infiltration by melanophages was summarised in a similar way to the 
method used to define TILs at 10x magnification on the thickest section, with a few 
exceptions (Figure 2.13 and Figure 2.14). Firstly, melanophages had to be in close 
proximity, but did not need to be in direct apposition, to melanoma cells. Secondly, if 
melanophages were present along part of the tumour base, the non-brisk peripheral 
category was assigned in preference to non-brisk sparse, regardless of whether or not 
some melanophages were present within the upper half of the melanoma. 
 
 
 
 
Figure 2.11 (on following page): Virtual pathology images (A-C) showing 
melanomas with different types of tumour loss 
Histopathological findings (x4 magnification) show (A) fibrosis and melanophages 
within a region of tumour loss in the superficial dermis, just inferior to the dermo-
epidermal junction. This was classified as superficial tumour loss. (B) A dense 
infiltrate composed of melanophages at the deep aspect of the melanoma. The 
red line highlights the annotation for the depth of tumour loss. This was classified 
as deep tumour loss. Breslow thickness is annotated with green lines. (C) A focal, 
dense infiltrate of melanophages extends from the superficial dermis to the 
invasive margin of the melanoma. This was classified as “both” types of tumour 
loss. 
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Figure 2.12: Virtual pathology images (A-D) varying intensities of melanophages 
Histopathological findings (x2 magnification) show (A) none, (B) very few, (C) moderate and (D) lots of melanophages within the melanomas. 
A B C D 
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Figure 2.13: Virtual pathology images (A-D) of melanomas showing different patterns of tumour-infiltrating melanophages (TIMs) 
Histopathological findings (x10 magnification) show (A) brisk diffuse TIMs, (B) brisk peripheral TIMs, (C) non-brisk sparse TIMs and (D) non-
brisk peripheral TIMs. 
A B D C 
5
9
 
60 
 
Figure 2.14: Flow chart for determining the category of tumour-infiltrating 
melanophages (TIMs) 
A series of questions was used to determine the pattern of TIMs within the 
thickest section of melanoma. VGP=Vertical growth phase.  
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2.6 Virtual pathology protocol: cored region measures 
Details of the scoring variables and schema for cored regions using the virtual 
pathology protocol are given in Table 2.3. 
2.6.1 Calculating the proportion and the percentage of stroma 
The cored regions were extracted in association with the flatbed-scanned image and 
the proportion of stroma was calculated using RandomSpot© as previously described in 
the “Pilot work using virtual pathology” section. On the basis of the pilot work, 50 spots 
were selected per core. The percentage of stroma (POS) was calculated by multiplying 
the proportion of stroma by 100. Several cut-off points were explored for the POS and 
the continuous measure was also divided into quintiles. The continuous measure for 
POS was used in multivariable survival analyses (Chapter 4), as it was the strongest 
prognostic factor. 
2.6.2 The quality of the stroma 
The quality of the stroma was used to describe the appearance of the connective 
tissue/collagen within the cored region (Figure 2.15). “Compact” was recorded if the 
connective tissue had a pink colour and adopted an organised, regular structure. 
“Loose” was recorded if the connective tissue appeared to be disorganised, with 
frequent gaps. “Mixed” was recorded if both compact and loose connective tissue was 
present within the cored region. 
 
 Table 2.3: Properties of the Histopathological Scoring Variables for Cored Region Measures using the Virtual Pathology Protocol 
Details of variables recorded within the cored regions using the virtual pathology protocol.  
Scoring variable Detail of Scoring Schema 
Absent pigmentation The cytoplasm of melanoma cells lacking melanin. 
Barely perceptible infiltrate An immune cell infiltrate within the cored region that is very faint but just visible at 20x magnification. 
Balloon cell shape A melanoma cell shape that is round and contains abundant, nonstaining, vacuolated cytoplasm. 
Blood vessel A structure whose lumen contains red cells. 
Compact stroma Pink connective tissue that has a uniform structure and lacks significant gaps. 
Dispersed 
A type of melanoma structure characterised by individual melanoma cells separated from each other by 
strands of connective tissue. 
Distribution of immune cell infiltrate The location of the immune cell infiltrate within the cored regions. 
Epithelioid cell shape 
A melanoma cell shape consisting of a round nucleus, a prominent, pink nucleolus and variably eosinophilic 
and often abundant cytoplasm [97]. 
Location of the immune cell infiltrate 
The location of the immune cell infiltrate within the cored regions: classified as follows: at the tumour/stroma 
interface, dispersed between tumour cells or both. 
Faint pigmentation 
Pigmentation of the melanoma cell cytoplasm that is slight, just detectable and significantly lighter than the 
melanoma cell nucleus. 
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 Scoring variable Detail of Scoring Schema 
Fascicles A melanoma cell structure consisting of elongated bundles of cells. 
High pigmentation Pigmentation of the melanoma cell cytoplasm such that it is darker than the melanoma cell nucleus. 
Loose stroma Connective tissue that has several gaps within it and does not form an orderly structure. 
Lots of infiltrate The most abundant amount of immune cell infiltrate within the cored region. 
Melanoma cell structure The way in which individual or small groups of melanoma cells tend to be arranged. 
Mixed stroma Connective tissue that has features of both compact and loose stroma. 
Moderate infiltrate An immune cell infiltrate within the cored region that is intermediate between some and lots. 
Moderate pigmentation Pigmentation of the melanoma cell cytoplasm that is intermediate between faint and high. 
Naevoid cell shape 
A melanoma cell shape that resembles a benign naevus cell and has prominent nuclear hyperchromasia 
and sparse cytoplasm. 
Nests A melanoma cell structure characterised by round/ovoid groups of melanoma cells. 
Plasmacytoid cell shape A melanoma cell shape that resembles a plasma cell and has an eccentric nucleus. 
Round/ovoid cell shape A melanoma cell shape consisting of a round to oval nucleus and lacking an eosinophilic nucleolus.  
Sheets 
A melanoma cell structure characterised by individual melanoma cells in close apposition to one another 
and relative absence of connective tissue between individual melanoma cells. 
6
3
 
 Scoring variable Detail of Scoring Schema 
Some infiltrate 
An immune cell infiltrate within the cored region that is readily detectable at 20x magnification but the extent 
of which is mild. 
Stroma 
The part of the cored region that remains after subtracting the melanoma cells, i.e. the non-tumour 
compartment. This consists of collagen, vascular or lymphatic structures and immune cells. Squamous 
epithelium or rete ridges or non-informative regions are excluded. 
Stroma quality The appearance of the connective tissue within the cored region, i.e. loose, compact or mixed. 
Spindle cell shape 
A melanoma cell shape with an elongated or fusiform appearance and a long axis proportionally larger than 
the short axis. 
Super spindle cell shape A melanoma cell shape with a markedly elongated spindle cell shape and a narrow, long nucleus. 
Very high pigmentation Dark pigmentation of the melanoma cell cytoplasm, to the extent that the nucleus cannot be perceived.  
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Figure 2.15: Virtual pathology images of cored regions from melanomas showing 
(A) compact and (B) loose stroma 
Histopathological findings (x20 magnification) show digitally extracted cored 
regions containing (A) compact stroma (black arrows) with nests of epithelioid 
cells and (B) loose stroma (black arrows).  
A 
B 
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2.6.3 Melanoma cell shape 
The digitally extracted cored regions were then opened as separated images in 
ImageScope© and each cored region was assessed separately (Figure 2.16). 
Melanoma cell shape categories were as follows: “epithelioid”, “round/ovoid”, “spindle”, 
“super spindle”, “naevoid”, “plasmacytoid” and “balloon”. Epithelioid cells were 
characterised by the presence of round nuclei containing prominent, eosinophilic 
nucleoli and often abundant eosinophilic cytoplasm. Round/ovoid cells were defined by 
the presence of round to oval nuclei and the absence of eosinophilic nucleoli. Spindle 
cells consisted of cells with cigar-shaped or fusiform nuclei. Super spindle cells were 
distinguished from spindle cells by their elongated, thinner nuclei. Naevoid cells 
contained nuclei with marked hyperchromasia and sparse amounts of cytoplasm and 
resembled benign melanocytes. Plasmacytoid cells had eccentric nuclei and resembled 
plasma cells. Balloon cells were round with abundant, nonstaining, vacuolated 
cytoplasm. The most abundant cell shape present (in approximately ≥80% melanoma 
cells by eyeball) within the cored region, was assigned to that core. If it was not 
possible to assign one of these choices, “other” was selected and further details were 
recorded. Where a mixture of melanoma cell shapes were present and no cell 
represented 80% of the cored region, up to two cell shapes were recorded: as “mixed-” 
followed by details of the most dominant cell shape and then the second most 
dominant cell shape. If two melanoma cell shapes accounted for approximately 50% of 
melanoma cells each, then “equal-” followed by the names of the categories was 
recorded. 
 
 
 
 
 
 
 
Figure 2.16 (following page): Virtual pathology images (A-G) showing different 
melanoma cell shapes within the cored regions 
Histopathological findings (x20 magnification) show digitally extracted cored regions 
containing (A) round/ovoid, (B) epithelioid, (C) spindle, (D) “super spindle”, (E) naevoid, 
(F) plasmacytoid and (G) balloon melanoma cell shapes. 
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2.6.4 Melanoma cell structure 
The structural arrangement of melanoma cells was termed “melanoma cell structure” 
and was defined by the following categories: nests, sheets, fascicles and dispersed 
(Figure 2.17). Nests defined the presence of melanoma cells in round/ovoid 
aggregates. Sheets referred to the presence of melanoma cells in close apposition to 
one another. Fascicles referred to the presence of melanoma cells in elongated 
bundles. Dispersed was used to define a sparse arrangement of melanoma cells, 
where individual cells were segregated by strands of collagen. The predominant 
structural arrangement was recorded and the option of “mixed-” followed by the two 
most dominant structural arrangements was allowed when no single type dominated. If 
two types of structural arrangement accounted for approximately 50% of melanoma 
cells each, then “equal-” followed by the names of the two structural arrangement 
categories was recorded. 
2.6.5 Melanoma cell pigmentation 
Melanoma cell pigmentation was graded according to a modified version of the Viros et 
al. method [108] (Figure 2.18). The level of pigmentation in at least 80% of melanoma 
cells (by eyeball) within the cored region was recorded. Melanophages were not 
included in the grading. “Absent” meant that the cytoplasm of the melanoma cells 
lacked any evidence of pigmentation. “Faint” meant that the cytoplasm was lightly 
pigmented, to the extent that it was just perceptible and was significantly lighter than 
the nucleus. “Moderate” meant that the melanoma cell cytoplasm was moderately 
pigmented, i.e. intermediate between faint and high. “High” meant that the melanoma 
cell cytoplasm was heavily pigmented, so that the cytoplasm was approximating or 
darker than the nucleus but the nucleus was still detectable. “Very high” was the 
highest grade of pigmentation, to the extent that the nucleus appeared to be obliterated 
and was not possible to distinguish from the surrounding cytoplasm. If one grade of 
pigmentation could not be ascribed to at least 80% of the melanoma cells, then “mixed” 
was recorded and the two most dominant pigmentation grades were assigned, with the 
most predominant grade listed first. If two grades of pigmentation accounted for 
approximately 50% of melanoma cells each, then “equal-” followed by the names of the 
two pigmentation grades was recorded. 
  
69 
 
 
 
 
Figure 2.17: Virtual pathology images (A-D) showing different melanoma cell 
structures within the cored regions 
Histopathological findings (x20 magnification) show digitally extracted cored 
regions with the following melanoma cell structures: (A) nests, (B) sheets, (C) 
fascicles and (D) dispersed. 
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Figure 2.18: Virtual pathology images (A-E) of melanoma cored regions showing 
varying degrees of melanoma cell pigmentation 
Histopathological findings (x20 magnification) show digitally extracted cored 
regions with (A) absent, (B) faint, (C) moderate, (D) high and (E) very high 
melanoma cell pigmentation.  
D 
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2.6.6 The core immune cell infiltrate 
The presence or absence of an immune cell infiltrate within each cored region was 
recorded as either “yes” or “no”. The immune cell infiltrate had to be readily seen at 20x 
magnification to be recorded as “yes”. If immune cells were too sparse to be visualised 
at 20x, the immune cell infiltrate was recorded as absent. 
2.6.7 The extent of the core immune cell infiltrate 
The extent of the core immune cell infiltrate was graded as follows: barely perceptible, 
some, moderate or lots (Figure 2.19). “Barely perceptible” was assigned if the immune 
cell infiltrate was just perceptible at 20x magnification. “Some” was recorded if the 
immune cell infiltrate was limited or minimal but easily visualised. “Lots” was recorded if 
there was a dense immune cell infiltrate. “Moderate” was recorded if the immune cell 
infiltrate was intermediate between some and lots. Where more than one type of 
immune cell was present, the overall abundance of immune cells, as a composite 
grade, was recorded. 
2.6.8 The location of the core immune cell infiltrate 
The location of the core immune cell infiltrate was recorded as follows: at the 
tumour/stroma interface, dispersed between tumour cells or both (Figure 2.20). If 
immune cells were mainly restricted to the boundary between the melanoma cells and 
the connective tissue/collagen, then “at the tumour/stroma interface” was selected. If 
the immune cells were predominantly lying between individual melanoma cells, 
“dispersed between tumour cells” was selected. “Both” was selected if the core immune 
cell infiltrate adopted both patterns. 
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Figure 2.19 Virtual pathology images (A-E) showing melanoma cored regions 
with varying extents of immune cell infiltration 
Histopathological findings (x20 magnification) show digitally extracted cored 
regions with (A) none, (B) barely perceptible, (C) some, (D) moderate and (E) lots 
of immune cell infiltrate within the core.  
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Figure 2.20: Virtual pathology images (A-C) of melanoma cored regions showing 
different locations of the core immune cell infiltrate 
Histopathological findings (x20 magnification) show digitally extracted cored 
regions with immune cells (A) at the tumour/stroma interface, (B) dispersed 
between tumour cells and (C) both (at the tumour/stroma interface and dispersed 
between tumour cells). 
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2.6.9 The composition and extent of the constituents of the core 
immune cell infiltrate 
The presence or absence of each of the following immune cells was recorded (if the 
extent of core immune cell infiltrate was graded as some, moderate or lots): 
lymphocytes, plasma cells, macrophages or melanophages, neutrophils and 
eosinophils (Figure 2.21). Where present, the extent of each of these immune cells was 
recorded as some, moderate or lots, using a similar approach to the grading of the 
overall immune cell infiltrate as previously discussed. The grading was adjudged at 20x 
magnification but it was permissible to view the immune cells briefly at 40x 
magnification if it was not possible to clearly distinguish between immune cell types at 
20x. It is important to note that if the overall core immune cell infiltrate was recorded as 
either absent or barely perceptible, the presence or absence and the extent of the 
various immune cell subtypes was not further assessed. 
2.6.10 The number of mitoses within the cored region 
Each cored region was assessed at 40x magnification throughout, beginning at the top 
left corner of the extracted image, for the presence of nuclear mitoses. The arrow icon 
was selected in ImageScope© to annotate each mitosis separately, thus allowing the 
total number of mitoses to be accurately counted (Figure 2.22A). 
2.6.11 The number of blood vessels within the cored region 
The cored regions were assessed for the number of blood vessels using a similar 
method to that used to count mitoses (Figure 2.22B). As blood vessels were not always 
sectioned horizontally, it was not always possible to clearly visualise a lumen or to 
distinguish the boundaries of each blood vessel, where there appeared to be 
interconnecting vessels. Therefore, the decision was made to count a blood vessel only 
if there was a lumen containing red cells. If two lumina were in direct apposition and not 
separated by strands of connective tissue/collagen and interposing melanoma cells, 
then only one blood vessel was counted. Where the presence of red cells was clearly 
due to extravasation or artefactual haemorrhage, it was not counted. 
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Figure 2.21 Virtual pathology images of melanoma cored regions (A-D) showing 
different types of immune cell infiltration 
Histopathological findings (x20 magnification) show digitally extracted cored 
regions containing (A) lots of lymphocytes, (B) some neutrophils (highlighted by 
the black arrow) and some melanophages (dark brown), (C) some eosinophils 
(one of these is highlighted by the black arrow) and some lymphocytes and (D) 
lots of plasma cells (one of these is highlighted by the black arrow). 
  
A B 
C D 
76 
 
Figure 2.22 Virtual pathology images of cored regions showing (A) mitoses and 
(B) blood vessels 
Histopathological findings (x20 magnification) show digitally extracted cored 
regions containing (A) 4 mitoses (annotated with black arrows) and (B) 5 blood 
vessels (annotated with black arrows). To be counted as a blood vessel, the 
lumen had to contain red cells. Although there are several lumina with red cells in 
this case, the definition necessitated that melanoma cells and collagen had to 
intervene between lumina to be counted as separate blood vessels.  
A 
B 
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2.7 Statistical methods 
2.7.1 Categorical variables 
The Pearson’s chi-squared test for independence was used to test the association 
between two categorical variables. Fisher’s exact test was used if the value in a single 
cell was less than 5.  
2.7.2 Continuous variables 
The mean and standard deviation were used to summarise continuous variables with a 
normally distributed frequency distribution. The median and range were used to 
summarise continuous variables with a non-normal frequency distribution. The 
Wilcoxon rank sum test was used to examine the association between a non-normally 
distributed continuous variable and a dichotomous variable. The Kruskal-Wallis test 
was used where there were ≥3 categories.  
2.7.3 Clinical factors 
STATA v12.1 (IC) was used for initial statistical analyses. STATA v14.2 (SE) was 
subsequently used to permit analyses of gene expression data, which involved a larger 
number of variables [188]. Age at diagnosis was analysed as a continuous variable. 
Sex (female versus male) was analysed as a binary variable. Site of primary melanoma 
was analysed as a categorical variable in broad (limbs, trunk, head and other) and site-
specific categories (e.g. subungual). Although the majority of cases assessed were 
primary cutaneous melanomas, the “other” category consisted of melanomas located at 
the following sites: ear, nose and throat (ENT; n=6), acral (n=16), anal (n=5), cervix 
(n=1), clitoris (n=1), foot (n=16), hand (n=4), penis (n=3), perineal (n=1), subungual 
(n=12), vaginal (n=5) and vulval (n=13). The broad categories were generally used due 
to small numbers in the site-specific categories. AJCC stage was generated by 
incorporating the following whole tumour measures: Breslow thickness (using AJCC 
cut-off points), microscopic ulceration and the cored region mitotic count (as 0 versus 
≥1) and information from histology reports and clinical notes regarding microsatellites, 
nodal and visceral metastases, which had been extracted by the Section of 
Epidemiology and Biostatistics staff. 
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2.7.4 Whole tumour measures 
2.7.4.1 Breslow thickness 
Breslow thickness was analysed as an ordinal variable, according to the AJCC cut-off 
groups, i.e. ≤1.0mm, 1.01mm-2.0mm, 2.01mm-4.0mm, >4.0mm [43]. 
2.7.4.2 Dominant nodule 
The presence of a dominant nodule was analysed as a binary variable (yes versus no).  
2.7.4.3 Microscopic ulceration 
Ulceration was analysed as a binary variable, with no ulceration as the baseline (i.e. 
yes versus no). The extent of ulceration was analysed as an ordinal variable, with no 
ulceration as the baseline and then dividing measurements for the extent of ulceration 
into four equal groups as follows: (none), <0.87mm, 0.87-<2.4mm, 2.4-<5.15mm and 
≥5.15mm. The cumulative extent of ulceration (for multiple, discontiguous ulcers on the 
same section) was analysed in a similar way, where available. The maximum extent of 
ulceration was used for analysis in preference to the cumulative extent of ulceration, as 
relatively few cases had multiple ulcers on the same section and therefore lacked 
measurements for the cumulative extent of ulceration. 
2.7.4.4 Tumour-infiltrating lymphocytes 
Eight categories of tumour-infiltrating lymphocytes were available for analysis (as 
previously described). However, some of the categories were merged for statistical 
analysis due to small numbers. Totally absent, absent with a perivascular pattern, 
absent with a perifibrotic or regression pattern and focally absent biphasic VGP TILs 
were merged and analysed as “absent”. Non-brisk sparse and non-brisk diffuse were 
analysed separately and merged as “non-brisk”. Brisk diffuse and brisk peripheral were 
summarised as “brisk”. TILs were analysed as an ordinal variable with absent as the 
baseline, followed by non-brisk and, finally, brisk. 
2.7.4.5 Tumour loss 
Tumour loss was analysed as a binary (yes versus no) and a categorical variable: none 
(reference category), deep, both and superficial. The maximum depth of tumour loss 
was analysed as an ordinal variable, with none as the baseline and then dividing the 
depth of tumour loss into four equal categories as follows: (none), <0.71mm, 0.71-
<1.14mm, 1.14mm-<1.63mm and ≥1.63mm. 
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2.7.4.6 Relative tumour loss 
To evaluate tumour loss in terms of the thickness of the melanoma, I generated a new 
variable called relative tumour loss. This was calculated by dividing the depth of tumour 
loss by the Breslow thickness in millimetres. This was then analysed as an ordinal 
variable because 81.8% (643/786) of cases had no relative tumour loss. Therefore, no 
relative tumour loss was the baseline category and the remaining measurements were 
divided into approximately four equal groups as follows: <0.26mm (4.4%, 35/786 
cases), 0.26-<0.52mm (4.5%, 36/786), 0.52-<0.786mm (4.7%, 37/786) and ≥0.786mm 
(4.4%, 35/786). 
2.7.4.7 Tumour-infiltrating melanophages 
The intensity of tumour-infiltrating melanophages was analysed as an ordinal variable: 
none, very few, moderate and lots. Their pattern was also analysed as an ordinal 
variable, using a similar approach to that described for TILs, i.e. first as eight 
categories and then summarised as absent, non-brisk or brisk. 
2.7.5 Cored region measures 
2.7.5.1 The proportion and percentage of stroma 
The proportion of stroma was converted to a percentage by multiplying each value by 
100. The percentage of stroma was analysed as a continuous variable and as ordinal 
variables: by dividing into 2 categories by the median (i.e. high versus low as follows: 
≥32.69% (50.1%, 352/702 cases) versus <32.69% (49.9%, 350/702 cases)), or 
quintiles (0-<17% (19.4%, 136/702 cases), 17<27% (20.9%, 147/702), 27-<38% 
(20.4%, 143/702), 38-<52% (20.5%, 144/702) and ≥52% (18.8%, 132/702)). Quintiles 
were chosen instead of tertiles or quartiles in order to retain as much information from 
the continuous measure as possible. Various binary cut-off points were also explored 
to assess if a particular cut-off point was more predictive than another (15%, 20%, 
30%, 40% and 49%). The binary and quintile analyses were exploratory and were 
tested to assess whether or not using a categorical variable was more significantly 
predictive than using the continuous variable. 
2.7.5.2 The quality of the stroma 
The quality of the stroma was analysed as a categorical variable as follows: compact 
(baseline), loose and mixed. 
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2.7.5.3 Melanoma cell shape 
Melanoma cell shape was analysed as a categorical variable in several combinations. 
Specific categories included round/ovoid, epithelioid, spindle, super spindle, naevoid, 
plasmacytoid and balloon. Round/ovoid was the most numerous cell shape and 
therefore was chosen as the reference category (baseline) in the statistical models. 
Cell shape was also explored using a composite variable for round/ovoid and 
epithelioid, while retaining the other categories. Round/ovoid was merged with 
epithelioid cell shape for survival analyses because intraobserver analysis showed that 
it was difficult to distinguish epithelioid cell shape from round/ovoid. Where a mixed cell 
shape was recorded, the dominant (first listed) cell shape was assigned and used for 
statistical analyses. 
2.7.5.4 Melanoma cell structure 
Melanoma cell structure was analysed as a categorical variable as follows: nests 
(baseline), sheets, fascicles and dispersed. 
2.7.5.5 Melanoma cell pigmentation 
Melanoma cell pigmentation was analysed as an ordinal variable: absent (baseline), 
faint, moderate, high and very high. 
2.7.5.6 The core immune cell infiltrate 
The core immune cell infiltrate was analysed as a binary variable (no versus yes). Yes 
was used as the baseline in the statistical models because the majority of cases had 
an immune cell infiltrate (and the baseline category was generally assigned to the 
largest category of discrete categorical variables for statistical modelling). 
For survival analyses, the barely perceptible category for the extent of the core immune 
cell infiltrate was merged with “no” as there were very few cases with no immune cell 
infiltrate and the hazard ratios were similar. The extent of the immune cell infiltrate was 
then analysed as an ordinal variable: no/barely perceptible (baseline), some, moderate 
and lots.  
The following factors were analysed as ordinal variables, with no/barely perceptible 
core immune cell infiltrate as the baseline: the lymphocytic, plasma cell, macrophage or 
melanophage, neutrophilic or eosinophilic infiltrate. No/barely perceptible core immune 
cell infiltrate was used as the baseline because the other immune cell constituents 
were not further assessed if the overall core immune cell infiltrate was regarded as 
absent or barely perceptible. Similarly, the location of the core immune cell infiltrate 
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was analysed as a categorical variable as follows: no/barely perceptible core immune 
cell infiltrate; at the tumour/stroma interface; dispersed between tumour cells; and both. 
For the extent of the individual immune cell components (e.g. lymphocytes), the 
no/barely perceptible category (for the core immune cell infiltrate) was used as the 
baseline for the reasons described above and to increase the statistical power and then 
analysed as an ordinal variable in a similar way, i.e. no/barely perceptible, some, 
moderate and lots. 
2.7.5.7 The number of mitoses 
The number of mitoses was analysed as an ordinal variable by dividing the frequency 
distribution of mitoses into tertiles as follows: 0 (baseline), 1-2 and ≥3. The number of 
mitoses was also analysed as a binary variable for incorporation into AJCC stage (7th 
edition) [43] as follows: 0 and ≥1. 
2.7.5.8 The number of blood vessels 
The number of blood vessels was analysed in a similar way to mitoses: as an ordinal 
variable as follows: 0 (baseline), 1-2 and ≥3. 
 
2.8 Interobserver and intraobserver variation studies 
Cross-tabulation of categorical variables was performed. The percentage agreement, 
kappa statistic, 95% confidence intervals and p-values were calculated. The Spearman 
correlation coefficient was calculated for non-normally distributed continuous variables. 
Scatter plots were used to illustrate the variation between two continuous measures. 
 
2.9 Melanoma relapse and survival analyses 
Cox proportional hazards models were used to generate hazard ratios, 95% confidence 
intervals and p-values for the likelihood of melanoma relapse or melanoma-specific 
death. Univariable and multivariable analyses were performed for each variable. 
Kaplan-Meier curves were used to graphically illustrate the time to melanoma relapse 
or melanoma-specific death. Box and whisker plots were used to illustrate how the 
frequency distribution of the continuous variables differed between categories of the 
categorical variables. Receiver Operator Characteristic (ROC) curves, based on logistic 
regression, were used to illustrate the area under the curve accounted for by AJCC 
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stage or the percentage of stroma alone and combined AJCC stage and the POS in 
predicting melanoma relapse and melanoma-specific death. 
 
2.10 Analysis of the melanoma transcriptome 
2.10.1 Analysis of the association between the transcriptome 
and the percentage of stroma 
Linear regression models were performed to establish whether the percentage of 
stroma could predict the expression of each Illumina® probe. The mean expression, 
correlation coefficient, standard error and p-value for each probe was calculated. The 
p-values were corrected for multiple testing using the Bonferroni and false discovery 
rate (FDR) methods. The Bonferroni-corrected p-values were ranked in order of 
significance from high to low. I elected to utilise the Bonferroni-corrected p-value in 
order to restrict the analysis to the most significantly associated genes. Where more 
than one probe was available per gene, the probe with the highest level of detection 
was retained. Unsupervised hierarchical clustering was performed using probes with a 
Bonferroni-corrected p-value<0.05 in Cluster 3.0 [189]. Enrichment analyses were 
performed using MetaCore™ for gene probes within each cluster of the heat map in 
order to assess the pathways that were up- and downregulated in association with 
increasing POS. In MetaCore™, the threshold was set to 0 and the p-value to 1 and 
signals in both directions were selected (to show genes that were up- or down-
regulated). 
2.10.2 Analysis of the interaction between the transcriptome, 
the percentage of stroma and survival 
I assessed the effect of the POS on survival in patients with low gene expression and 
then separately for patients with high gene expression. A likelihood ratio test was 
performed between a model including the interaction between the POS and gene 
expression and a model including only the main effects of the POS and gene 
expression. The p-value for the interaction was calculated from the likelihood ratio test. 
The p-values were corrected for multiple testing using the Bonferroni and FDR 
methods. 
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2.10.3 Analysis of the association between the transcriptome 
and the extent of either the core immune cell or lymphocytic 
infiltrates 
Linear regression was performed to establish whether the extent of the core immune 
cell infiltrate, using a test for trend, could predict the expression of each Illumina® 
probe. The mean expression for each category of the core immune cell infiltrate and 
the correlation coefficient, standard error and p-value was calculated for each probe. 
The p-values were corrected for multiple testing using the Bonferroni and FDR 
methods. The Bonferroni-corrected p-values were ranked in order of significance from 
high to low. Where more than one probe was available per gene, the probe with the 
highest level of detection was retained. Unsupervised hierarchical clustering was 
performed using probes with a Bonferroni-corrected p-value<0.05 in Cluster 3.0 [189]. 
Enrichment analyses were performed using MetaCore™ for gene probes within each 
cluster of the heat map in order to assess the pathways that were up- and 
downregulated in association with the extent of the core immune cell infiltrate (the test 
for trend). In MetaCore™, the threshold was set to 0 and the p-value to 1 and signals in 
both directions were selected (to show genes that were up- or down-regulated). The 
same approach was used for the extent of the core lymphocytic infiltrate. 
2.10.4 Analysis comparing the transcriptome and the 
percentage of stroma and the extent of the core immune cell 
and lymphocytic infiltrates 
The POS was calculated using positive scoring for a range of stromal constituents, 
including collagen and various immune cells. Therefore, a comparative enrichment 
analysis was performed using MetaCore™ to assess the pathways that were similar 
and differentially expressed between the POS, the extent of the core immune cell 
infiltrate overall and the extent of the core lymphocytic infiltrate. In MetaCore™, the 
threshold was set to 0 and the p-value to 1. Upregulated signals were selected to see 
which pathways were most significantly positively associated with each factor. 
2.10.5 Analysis of cancer history, BAP1 variants and BAP-like 
histopathology 
Cross-tabulation of cancer history and BAP1 variants was performed to assess the 
association between each cancer type and the presence of a BAP1 variant. Separate 
analyses were performed for the presence of a benign BAP1 variant versus no variant 
and for the presence of a deleterious BAP1 variant versus no variant. The Fisher’s 
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exact test was used where a cell contained a value <5 and the Pearson’s chi-squared 
test was used where each cell contained a value of ≥5. Similar cross-tabulations and 
calculations were performed to assess the association between each cancer type and 
the presence of BAP-like histopathological changes. Odds ratios and 95% confidence 
intervals were calculated. 
2.10.6  Analysis of BAP-like histopathology or ALK-fusion like 
histopathology and the transcriptome 
The T-test was performed to establish the association between either the presence or 
absence of BAP-like histopathology in the primary melanoma and each Illumina® 
probe. The mean expression for each category (no and yes) and the fold-change, 
standard error and p-value were calculated for each probe. The p-values were 
corrected for multiple testing using the Bonferroni and FDR methods. The Bonferroni-
corrected p-values were ranked in order of significance from high to low. Where more 
than one probe was available per gene, the probe with the highest level of detection 
was retained. A similar approach was used to establish the association between or 
ALK fusion-like histopathology and each Illumina® probe. 
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Chapter 3 Inter- and intraobserver variation in the 
histopathological assessment of primary cutaneous 
melanomas 
Melanoma pathology involves the examination of microscopic features of the tumour, 
using haematoxylin and eosin (H&E)-stained tissue sections. Visual clues, including the 
tumour shape, cellular components and physical dimensions, are used to categorise 
the melanoma. These features are observational and, consequently, open to 
interpretation. 
In approaching this PhD, from a background of clinical dermatology, it was important to 
first learn the basics of melanoma pathology. I trained using textbooks and through 
one-to-one training with Dr Will Merchant, consultant dermatopathologist (Pathologist 
B). An initial learning period was anticipated, during which discrepancies between our 
pathology assessments could be identified and addressed. Indeed, the histopathology 
literature contains much evidence of interobserver variation between 
dermatopathologists, even among pathologists from the same institution, as described 
below. 
This chapter examines both interobserver and intraobserver variation. The results are 
presented in separate stages, reflecting changes in the protocol. Early in the course of 
research, I utilised a light microscope and a protocol that had been developed by Prof. 
Martin Cook, consultant dermatopathologist, (Appendix B). I used these training set 
cases to learn melanoma pathology and to identify discrepancies between my 
pathology assessments and those of another consultant dermatopathologist 
(Pathologist A) who had previously assessed cases using the same protocol, a subset 
of which overlapped with my cases. The first part of the chapter examines the 
interobserver variation between my measures and those of Pathologist A. A database 
of Pathologist A’s reviews was available. I used the data collected opportunistically to 
compare my skills with those of a consultant dermatopathologist using the same 
protocol. In practice, however, it also served as a learning opportunity. When 
differences occurred, I was subsequently able to resolve them by review with the Dr 
Merchant (Pathologist B), with whom I trained. 
My understanding of the complexity of melanoma pathology increased over time. 
Therefore, as my knowledge increased through one-to-one training with Dr Merchant, I 
was conscious of the need to develop a new protocol that would be robust and 
reproducible. During this process, the factors that were retained were those for which 
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interobserver agreement was highest or which were regarded to be important. In 
addition, novel measures were developed, under the guidance of my supervisors. To 
determine the level of reproducibility of this new (virtual pathology) protocol, I examined 
both inter- and intraobserver agreement. This interobserver variation analysis was 
performed using data recorded by Dr Merchant (Pathologist B). Both whole-tumour and 
cored region (sampled using a TMA needle) measures were developed for the virtual 
pathology protocol, the results of which are reported separately. 
Figure 3.1 provides an overview of the number of cases assessed for inter- and 
intraobserver variation, using each protocol. 
 
Figure 3.1: Flowchart for inter- and intraobserver variation analyses.  
Whole tumour measures were available for the light microscope (training set) and 
virtual pathology protocols. Cored region measures were also recorded using the 
virtual pathology protocol.   
This chapter will address the following aims: 
 To examine interobserver variation in the histopathological assessment of 
primary cutaneous melanomas, using the Prof. Cook protocol, between my 
training set cases and the archived review of Pathologist A. 
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 To assess inter- and intraobserver variation in the histopathological review of 
primary cutaneous melanomas for both whole-tumour and cored region 
measures using a newly developed, virtual pathology protocol. 
 
3.1 Reported interobserver agreement in the histopathological 
assessment of melanoma 
The application of histopathological factors to prognostic estimation depends upon 
consistency between histopathologists, but as discussed below, many studies have 
shown considerable variation for some measures, indicating a degree of subjectivity. 
Breslow thickness is considered to be the most reproducible histopathological measure 
of primary cutaneous melanoma [190, 191]. Despite this, variation of up to 0.86mm has 
been noted among 3 pathologists from the same institution [192], while another study 
showed a mean interobserver variation of 0.76mm [193]. In a retrospective study of 
588 cases, Patrawala et al. noted discordance in Breslow thickness 66% of the time, 
however the reviewing pathologist was unblinded to the initial clinical report [194]. 
These cases were reviewed at a tertiary referral centre and, therefore, the 
interobserver variation might reflect the complexity of the cases [194]. 
Good agreement has been found for microscopic ulceration status, with kappa 
statistics in the range of 0.69 [195] to 0.87 [196]. There was lower agreement for 
regression with a median kappa of 0.32 [197] and similar variability in histological 
subtype, with a kappa of 0.48 [198]. In an interobserver study of tumour-infiltrating 
lymphocytes (TILs) (n=74), agreement was slight (kappa=0.12), using a binary variable 
(i.e. present versus absent) [199]. Smaller studies report kappa statistics in the range 
0.47 to 0.77 for TILs [27, 200, 201]. 
Interobserver agreement has been reported to be better, although somewhat variable, 
for mitotic count. In one study of thin (Breslow thickness <1mm) melanomas (n=92), 
the interclass correlation coefficient was 0.81 for 4 observers using H&E sections and 
improved further to 0.90 with the use of phosphohistone H3 (pHH3) immunostaining 
(which stains all phases of mitoses) [202]. A retrospective study (n=4924) showed a 
similar interclass correlation (0.83) for mitotic count; however, the second observer was 
not blinded [203]. The high level of agreement may reflect the fact that thinner 
melanomas were examined in these studies, thus the selection of the “hot spot” would 
be less likely to be open to interpretation than for thicker tumours. Monshizadeh et al. 
reported a kappa of 0.69 for mitotic count (n=35) [199]. In contrast to these findings, 
Garbe et al. reported a kappa statistic of 0.09 for mitotic count among 17 pathologists 
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who reviewed the same slide [204]. They noted that the number of mitoses often 
differed by between 0 and 4 mitoses between observers [204]. The kappa statistic 
improved to 0.35 when the number of mitoses was categorised as follows: 0-1, ≥2 
[204].  
In a study by Broekart et al. (n=20), interobserver weighted kappa scores among 11 
pathologists ranged from 0.35 to 0.69 across a range of histopathological variables 
[155]. Melanoma cell pigmentation was among the most reproducible variables, whilst 
there was moderate agreement for melanoma cell shape and histological subtype and 
fair agreement for nesting [155]. In another study, the kappa for the predominant 
melanoma cell type (n=57) was 0.43 between observers [199]. 
Eriksson et al. reported about 20% overall variation among pathologists in the reporting 
of melanoma [195]. Distinction of in situ from early invasive melanoma and of true from 
artefactual ulceration contributed to discordant results [195]. Even slight changes in the 
reporting of early melanomas impact on decisions about surgical margins and the 
consideration of sentinel node biopsy [195]. Another study found that such discordance 
led to a change in stage in about a quarter of cases and recommendations for surgical 
margins and sentinel node biopsy were modified in 12% and 16% cases, respectively 
[205]. Patrawala et al. reported similar findings, with changes in stage occurring in 19% 
cases and corresponding recommendations for surgical margins and sentinel node 
biopsy in 10% and 8% cases, respectively [194]. Variability in the reporting of 
melanocytic lesions prompted the development of the “Melanocytic Pathology 
Assessment Tool and Hierarchy for Diagnosis” (MPATH-Dx) classification scheme, 
which defines 5 categories, ranging from a benign melanocytic nevus to melanoma, 
and corresponding recommendations, ranging from no intervention to wide excision 
[206]. The interrater kappa for the classification scheme among 3 pathologists was 
0.58 [207] and similar results were reported for 16 pathologists, with a mean 
unweighted kappa of 0.57 [208]. 
Analysis of intraobserver concordance for the histopathological assessment of 
cutaneous melanoma is less frequently reported, however, variation tends to be less 
within than between observers [192, 197]. Colloby et al. reported the results of inter- 
and intraobserver variation for 3 observers, with intraobserver kappa values in the 
range of 0.54-0.78 for Breslow thickness and 0.23-0.55 for Clark’s level [192]. A 
median kappa of 0.51 has been reported for regression [197]. Garbe et al. reported 
slight to fair intraobserver agreement for mitotic count, with kappas in the range of 
0.18-0.35 [204]. 
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3.2 Methods  
3.2.1 Assessment of the level of agreement for inter- and 
intraobserver variation studies 
Cross-tabulation of categorical variables was performed. The percentage agreement, 
kappa statistic and corresponding 95% confidence intervals (95% CI) and p-values 
were calculated. The percentage agreement was calculated by adding the total number 
of cases that agreed in each category, dividing by the total number of cases and 
multiplying by 100. The percentage agreement includes missing values in the total, 
whereas the observed and expected agreement, which is calculated by the kappa 
statistic, does not include missing values. The kappa statistic was used to compare the 
observed agreement to the agreement that would be expected by chance and values 
were interpreted according to Table 3.1. 
Table 3.1: Kappa statistic and the strength of agreement. 
The strength of agreement for inter- and intraobserver variation analyses was 
interpreted using the kappa statistic cut-off points shown. (Adapted from Viera et 
al. [209]). 
Kappa statistic Strength of agreement 
<0 Less than chance 
0 Chance 
0.01-0.20 Slight 
0.21 -0.40 Fair 
0.41-0.60 Moderate 
0.61-0.80 Substantial 
0.81-0.99 Almost perfect 
1.0 Perfect 
The Spearman correlation coefficient was calculated for continuous variables. Scatter 
plots were used to illustrate the variation between two continuous measures. 
 
3.3 Interobserver variation in whole-tumour measures using a 
light microscope 
I recorded a detailed histopathological review of 205 cases in this way using the Prof. 
Cook protocol. For 47 of these slides, I had access to the recorded measurements of a 
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consultant dermatopathologist (Pathologist A). For the purpose of interobserver 
studies, these 47 cases were dropped from the analysis because I had used 
Pathologist A’s records to inform my measurements, leaving 158 cases. Of the 158 
remaining cases, Pathologist A’s review was unavailable for 76 cases. Therefore, 82 
cases remained, which were used for interobserver variation studies. 
3.3.1 Histological subtype 
There was moderate interobserver agreement for histological subtype (Table 3.2). The 
majority of cases were superficial spreading melanomas. There was some overlap in 
the classification of superficial spreading and nodular subtypes. Each observer had 
classified one case as acral lentiginous melanoma, while the other observer had 
recorded superficial spreading melanoma for the same case. 
3.3.2 The maximum macroscopic diameter 
Measurements for the maximum macroscopic diameter were available for 82 cases in 
my data and just 2 cases in Pathologist A’s data. In the first case, the measurements 
were similar, differing by 0.5mm. In the second case, the measurements differed by 
2.3mm. It was not possible to ascertain whether or not the same slides/levels were 
used for the assessment. I used research H&E sections, whereas Pathologist A had 
access to clinical sections. However, the same number of slides were available for 56% 
of (46/82) cases. 
3.3.3 Growth phase 
There was fair agreement for growth phase (Table 3.3). The majority of cases were in 
vertical growth phase (VGP). I classified 9 cases as VGP when Pathologist A 
categorised them as radial growth phase (microinvasive).  
3.3.4 Clark’s level 
Clark’s level was poorly reproduced between observers (21%; 17/82; kappa=0.002 
(95% CI -0.07-0.09), p=0.5, data not shown). 
3.3.5 Breslow thickness 
The median difference in Breslow thickness between my measures and those of 
Pathologist A was 0.2 (range=0-1.2) mm. The Spearman correlation coefficient was 
0.94 (p=3x10-37), indicating excellent agreement (Figure 3.2). 
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Table 3.2: Cross-tabulation of histological subtype for my measures (SOS) and 
those of Pathologist A (A). 
There was 79% (65/82) agreement. Kappa=0.53 (95% CI 0.30-0.72), p=7x10-11. 
 Histological subtype (A) 
Histological subtype 
(SOS) 
Superficial 
spreading 
Nodular 
Acral 
lentiginous 
Other Total 
Superficial spreading 54 4 1 3 62 
Nodular 1 8 0 0 9 
Acral lentiginous 1 0 0 0 1 
Other 4 0 0 3 7 
Missing 1 0 0 2 3 
Total 61 12 1 8 82 
Table 3.3: Tabulation of growth phase for my measures (SOS) and those of 
Pathologist A (A). 
There was 83% (68/82) agreement. Kappa=0.24 (95% CI -0.02-0.58), p=0.001. 
 Growth phase (A) 
Growth phase (SOS) 
Radial 
(in situ) 
Radial 
(microinvasive) 
Vertical Missing Total 
Radial (in situ) 2 0 0 1 3 
Radial (microinvasive) 1 0 2 1 4 
Vertical 0 9 66 0 75 
Total 3 9 68 2 82 
 
Figure 3.2: Scatter plot of Breslow thickness for my measures (on the y-axis) and 
for Pathologist A (on the x-axis).  
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There was substantial interobserver agreement for Breslow thickness (Table 3.4). 
Nonetheless, cases that had the greatest differences in Breslow thickness (and for 
which slides were still available) were reviewed with a second dermatopathologist (with 
whom I was training, Pathologist B) as learning points. Some of the differences in 
Breslow thickness could be accounted for as follows: a highly convoluted epidermis, 
which made the choice of site for the measurement difficult (and for which there is no 
formal guideline available); a difficult case where the base was heavily infiltrated by 
plasma cells.  Immunohistochemically-stained sections had also been available to 
Pathologist A in the latter case. 
Table 3.4: Breslow thickness (mm) for my measures (SOS) and those of 
Pathologist A (A), using the AJCC cut-off points [43]. 
There was 77% (63/82) agreement. Kappa=0.72 (95% CI 0.56-0.84), p<1x10-16. 
 Breslow thickness (A) 
Breslow 
thickness (SOS) 
≤1.00mm 
1.01 - 
2.00mm 
2.01 - 
4.00mm 
>4.00mm Missing Total 
≤1.00mm 22 4 0 0 3 29 
1.01-2.00mm 4 21 3 0 0 28 
2.01-4.00mm 0 3 12 2 0 17 
>4.00mm 0 0 0 8 0 8 
Total 26 28 15 10 3 82 
3.3.6 Dominant nodule 
Interobserver concordance for the presence or absence of a dominant nodule was poor 
(Table 3.5). The kappa statistic was 0, suggesting that the observed agreement 
occurred by chance only. Also, the presence of a dominant nodule had not been 
recorded by Pathologist A and, therefore, the kappa statistic does not reflect the 
observed agreement. 
3.3.7 Microscopic ulceration 
There was almost perfect agreement for microscopic ulceration (Table 3.6). Ulceration 
width was available in 13 cases. The median difference in ulceration width was 0.6 
(range 0-13) mm. The Spearman correlation coefficient for ulceration width was 0.77 
(p=0.002).   
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Table 3.5: Cross-tabulation of the presence or absence of a dominant nodule 
(mm) for my measures (SOS) and those of Pathologist A (A). 
There was 34% (28/82) agreement. Kappa=0 (95% CI not calculable). 
 Dominant nodule (A) 
Dominant nodule (SOS) No Yes Missing Total 
No 27 0 5 32 
Yes 40 0 2 42 
Missing 7 0 1 8 
Total 74 0 8 82 
Table 3.6: Cross-tabulation of microscopic ulceration status for my measures 
(SOS) and those of Pathologist A (A). 
There was 93% (76/82) agreement for ulceration. Kappa=0.84 (95% CI 0.70-
0.99), p=2 x10-14. 
 Ulceration status (A) 
Ulceration status (SOS) No Yes Missing Total 
No 62 2 2 66 
Yes 2 14 0 16 
Total 64 16 2 82 
3.3.8 Tumour-infiltrating lymphocytes (TILs) 
There was slight interobserver agreement for TILs (Table 3.7). 
Table 3.7: Cross-tabulation of tumour-infiltrating lymphocytes for my measures 
(SOS) and those of Pathologist A (A). 
There was 43% (35/82) agreement for TILs. Kappa=0.14 (95% CI 0.02-0.30), 
p=0.02. 
  TILs (A) 
TILs (SOS) Absent Non-brisk Brisk 
Non-
evaluable 
Missing Total 
Absent 1 1 1 0 1 4 
Non-brisk 13 27 13 0 1 54 
Brisk 1 5 7 0 0 13 
Non-evaluable 6 2 1 0 1 10 
Missing 0 0 1 0 0 1 
Total 21 35 23 0 3 82 
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3.3.9 Regression 
Although the percentage agreement for regression was high (89%, 73/82), the kappa 
statistic indicates slight agreement (0.2; Table 3.8). This reflects the rarity of the 
occurrence of regression, where there is good agreement in its absence but agreement 
for its presence is weaker. 
Table 3.8: Cross-tabulation of regression for my measure (SOS) and those of 
Pathologist A (A). 
There was 89% (73/82) agreement for regression. Kappa=0.2 (95% CI -0.03-
0.60), p=0.003. 
 Regression (A) 
Regression (SOS) No Yes Uncertain Missing Total 
No 72 0 1 2 75 
Yes 3 1 0 0 4 
Uncertain 3 0 0 0 3 
Total 78 1 1 2 82 
The stage of regression was recorded for 5 cases in my data and just 1 in Pathologist 
A’s data. In the single case recorded by Pathologist A, it was recorded as stage 1 in my 
data and as stage 2 by Pathologist A. The thickness of regression was recorded by 
both observers for one case and the value differed by 0.5mm. 
3.3.10 Mitotic count 
Agreement was only fair for mitotic count (Table 3.9), possibly reflecting differences in 
selection of a “hot spot” for counting, or indeed, different H&E sections being used for 
assessment. 
Table 3.9: Cross-tabulation of mitotic count for my measures (SOS) and those of 
Pathologist A (A). 
There was 55% (45/82) agreement. Kappa=0.35 (95% CI 0.17-0.51), p=3x10-6. 
 Mitotic count (A) 
Mitotic count (SOS) 0 1-2 ≥3 Missing Total 
0 13 7 0 3 23 
1-2 11 12 8 0 31 
≥3 2 6 20 0 28 
Total 26 25 28 3 82 
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3.3.11 Microsatellites 
There was 91% (75/82) agreement for microsatellite status. The kappa statistic was 0 
because the expected agreement was the same as the observed, indicating that the 
agreement could have occurred by chance. Therefore, although the percentage 
agreement was high, the strength of the agreement was poor. This also reflects the 
rarity of the occurrence of microsatellites, where agreement between observers was 
high in its absence but low in its presence. Of the 82 cases, 4 were deemed to have 
microsatellites by Pathologist A. None of these were recorded as having microsatellites 
in my data. Therefore, these 4 cases were reviewed with Pathologist B (with whom I 
was training). Two of the four cases were considered to have microsatellites by 
Pathologist B. The other 2 cases were not deemed to have microsatellites: 1 showed 
artefactual adherence of cells at the edge of the section and the other fell short of the 
definition of microsatellites (as the tissue between the base of the melanoma and the 
underlying tumour was fibrotic and inflamed). 
3.3.12 Vascular invasion 
The strength of agreement for vascular invasion was fair (Table 3.10). 
3.3.13 Perineural invasion 
The negative kappa statistic indicated that there was less than chance agreement for 
perineural invasion (kappa -0.01, Table 3.11). This also reflects the rarity of the 
measure in this data set. 
3.3.14 Distance to the peripheral and deep margins 
Measurements to the peripheral and deep margins were available for 78/82 (95%) 
cases. The median difference between each observer for the peripheral margin was 
0.5 (range 0-6.7). The median difference between each observer for the deep margin 
was 0.99 (range 0-10). 
3.3.15 Melanoma cell shape 
There was slight agreement for melanoma cell shape (Table 3.12). Pathologist A 
classified 24 cases as having a small cell/naevoid cell shape, which I had recorded as 
epithelioid. This occurred in the opposite direction to a smaller extent. 
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Table 3.10: Cross-tabulation of vascular invasion for my measures (SOS) and 
those of Pathologist A (A). 
There was 87% (71/82) agreement. Kappa=0.23 (95% CI 0-0.56), p=0.0002. 
 Vascular invasion (A) 
Vascular invasion (SOS) No Yes Uncertain Missing Total 
No 70 0 0 2 72 
Yes 6 1 1 0 8 
Uncertain 2 0 0 0 2 
Total 78 1 1 2 82 
Table 3.11: Cross-tabulation of perineural invasion for my measures (SOS) and 
those of Pathologist A (A). 
There was 88% (72/82) agreement. Kappa=-0.01 (95% CI -0.04-0), p=0.6. 
  Perineural invasion (A) 
Perineural invasion (SOS) No Yes Uncertain Missing Total 
No 72 0 1 6 79 
Yes 2 0 0 0 2 
Uncertain 1 0 0 0 1 
Total 75 0 1 6 82 
Table 3.12 Cross-tabulation of melanoma cell shape for my measures (SOS) and 
those of Pathologist A (A). 
There was 46% (38/82) agreement. Kappa=0.19 (95% CI 0.06-0.34), p=0.003. 
 Melanoma cell type (A) 
Melanoma 
cell type (SOS) 
Epithelioid 
Small cell/ 
naevoid 
Spindle Spitzoid Balloon Missing Total 
Epithelioid 26 24 4 0 0 2 56 
Small cell/ 
naevoid 
3 9 0 0 0 0 12 
Spindle 0 5 3 0 0 0 8 
Spitzoid 1 0 0 0 0 0 1 
Balloon 0 1 0 0 0 0 1 
Other 2 0 0 0 0 0 2 
Missing 1 0 1 0 0 0 2 
Total 33 39 8 0 0 2 82 
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3.3.16 Melanoma cell pigmentation 
There was slight agreement for melanoma cell pigmentation (Table 3.13).  
Table 3.13: Cross-tabulation of melanoma cell pigmentation for my measures 
(SOS) and those of Pathologist A (A). 
There was 12% (10/82) agreement. Kappa=0.03 (95% CI -0.08-0.19), p=0.3. 
 Melanoma cell pigmentation (A) 
Melanoma cell 
pigmentation 
(SOS) 
No Mild Moderate Severe Missing Total 
No 3 0 0 0 0 3 
Mild 13 2 0 0 0 15 
Moderate 6 6 3 0 0 15 
Severe 1 1 0 0 0 2 
Missing 25 14 6 0 2 47 
Total 48 23 9 0 2 82 
I had recorded mild or moderate pigmentation for 19 cases where Pathologist A scored 
absent pigmentation. One case which I had graded as having severe pigmentation was 
recorded as absent pigmentation by Pathologist A. Data for melanoma cell 
pigmentation were missing for several cases, which limited the analysis of 
interobserver variation. 
3.3.17 Interpretation of interobserver agreement using a light 
microscope and Prof. Cook’s protocol 
The results show that the best interobserver agreement was for Breslow thickness and 
microscopic ulceration. Variables for which the strength of agreement was weakest 
included microsatellites, TILs, perineural invasion, melanoma cell shape and 
melanoma cell pigmentation. 
On the basis of these results, cases with discrepancies were reviewed with Pathologist 
B (with whom I trained), where possible. In the development of the subsequent virtual 
pathology protocol, a decision was made to drop several factors, including those for 
which interobserver agreement was weakest. These dropped measures included 
histological subtype, growth phase, Clark’s level, microsatellites, vascular and 
perineural invasion. New measures and corresponding definitions were developed, in 
order to optimise reproducibility (Chapter 2), under the guidance of my supervisors, 
particularly, Dr Merchant. It was decided to enumerate mitoses and to classify 
melanoma cell shape within the cored regions, instead of the whole tumour. The 
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grading of melanoma cell pigmentation was changed, using a modified version of the 
approach reported by Viros et al. [108] and would be recorded within the cored region 
rather than for the whole tumour. 
 
3.4 Interobserver variation in whole-tumour measures using 
virtual pathology 
Twenty cases were selected to assess interobserver variation between my recorded 
measures and those of an experienced, consultant dermatopathologist (Pathologist B) 
using the new virtual pathology protocol. The selection of cases was random, except 
that cases were avoided if they had been flagged as being especially difficult or if the 
image quality was noted to be poor. 
3.4.1 Breslow thickness 
Perfect interobserver agreement was observed for the measurement of Breslow 
thickness (Table 3.14). 
Table 3.14: Cross-tabulation of Breslow thickness for my measurements (SOS) 
and those of Pathologist B (B). 
There was 100% (20/20) agreement using the AJCC cut-off points [43]. 
Kappa=1.0, p=3x10-11. 
 Breslow thickness (B) 
Breslow thickness (SOS) ≤1.00 mm 1.01-2.00 mm 2.01-4.00 mm >4.00 mm Total 
≤1.00mm 1 0 0 0 1 
1.01-2.00mm 0 6 0 0 6 
2.01-4.00mm 0 0 10 0 10 
>4.00mm 0 0 0 3 3 
Total 1 6 10 3 20 
The Spearman correlation coefficient was 0.99 (p=7x10-18), indicating excellent 
agreement (Figure 3.3). 
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Figure 3.3: Scatter plot of Breslow thickness (as a continuous measure), as 
recorded by me (SOS, on the y-axis) and by Dr Merchant (B, on the x-axis). 
3.4.2 Dominant nodule 
Interobserver agreement was substantial for the presence or absence of a dominant 
nodule (Table 3.15). 
Table 3.15: Cross-tabulation of the presence or absence of a dominant nodule for 
my measures (SOS) and those of Pathologist B (B). 
There was 90% (18/20) agreement. Kappa=0.69 (95% CI 0.31-1.00), p=0.0006. 
 Dominant nodule (B) 
Dominant nodule (SOS) No Yes Total 
No 15 0 15 
Yes 2 3 5 
Total 17 3 20 
3.4.3 Microscopic ulceration 
There was substantial agreement for microscopic ulceration (Table 3.16). The extent of 
ulceration could be compared between observers in 3 cases and the differences 
ranged from 0.4-1.1mm. 
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Table 3.16: Cross-tabulation of microscopic ulceration for my measures (SOS) 
and those of Pathologist B (B). 
There was 90% (18/20) agreement for microscopic ulceration status. Kappa=0.69 
(95% CI 0.29-1.00), p=0.001. 
 Ulceration status (B) 
Ulceration status (SOS) No Yes Total 
No 15 1 16 
Yes 1 3 4 
Total 16 4 20 
3.4.4 Tumour-infiltrating lymphocytes (TILs) 
Interobserver agreement was moderate for TILs (Table 3.17). 
Table 3.17: Cross-tabulation of the pattern of tumour-infiltrating lymphocytes for 
my measures (SOS) and those of Pathologist B (B). 
There was 60% (12/20) agreement. Kappa=0.41 (95% CI 0.11-0.72), p=0.001. 
 TILs (B) 
TILs (SOS)  
Totally 
absent 
Non-brisk 
sparse 
Non-brisk 
peripheral 
Brisk 
peripheral 
Brisk 
diffuse 
Not 
assessable 
Total 
Totally absent 1 0 0 0 0 0 1 
Non-brisk sparse 2 6 0 0 1 0 9 
Non-brisk 
peripheral 
0 2 3 0 0 0 5 
Brisk peripheral 0 2 0 1 0 0 3 
Brisk diffuse 0 0 0 0 0 0 0 
Not assessable 0 1 0 0 0 1 2 
Total 3 11 3 1 1 1 20 
3.4.5 The presence or absence of tumour loss 
During the development of the virtual pathology protocol, the regression variable was 
dropped and tumour loss was recorded instead (Chapter 2). Interobserver agreement 
was fair for tumour loss (Table 3.18). 
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Table 3.18: Cross-tabulation of the presence or absence of tumour loss for my 
measures (SOS) and those of Pathologist B (B). 
There was 85% (17/20) agreement. Kappa=0.32 (95% CI -0.27-0.90), p=0.07. 
 Tumour loss (B) 
Tumour loss (SOS) No Yes Total 
No 16 1 17 
Yes 2 1 3 
Total 18 2 20 
3.4.6 The type of tumour loss 
Interobserver agreement was fair for the type of tumour loss (Table 3.19). Four cases 
were available for comparison for the depth of tumour loss. Differences ranged from 
0.2mm to 1.4mm. 
3.4.7 The intensity of tumour-infiltrating melanophages (TIMs) 
There was almost perfect agreement for the intensity of tumour-infiltrating 
melanophages (TIMs, Table 3.20). 
3.4.8 The pattern of tumour-infiltrating melanophages (TIMs) 
There was perfect agreement for the pattern of TIMs (Table 3.21). 
Table 3.19: Cross-tabulation of the type of tumour loss for my measures (SOS) 
and those of Pathologist B (B). 
There was 85% (17/20) agreement. Kappa=0.33 (95% CI -0.07-1.0), p=0.04. 
 Type of tumour loss (A) 
Type of tumour loss (SOS) Absent Deep Superficial Total 
Absent 16 0 1 17 
Deep 1 0 0 1 
Superficial 1 0 1 2 
Total 18 0 2 20 
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Table 3.20: Cross-tabulation of the intensity of tumour-infiltrating melanophages 
for my measures (SOS) and those of Pathologist B (B). 
There was 90% (18/20) agreement. Kappa=0.85 (95% CI 0.65-1.0), p=5x10-9. 
 TIMs intensity (B) 
TIMs intensity (SOS)  None Very few Moderate Lots Total 
None 8 0 0 0 8 
Very few 1 6 1 0 8 
Moderate 0 0 3 0 3 
Lots 0 0 0 1 1 
Total 9 6 4 1 20 
Table 3.21: Cross-tabulation of the pattern of tumour-infiltrating melanophages 
for my measures (SOS) and those of Pathologist B (B). 
There was 100% (20/20) agreement. Kappa=1.0, p=1x10-8. 
 TIMs (B) 
TIMs (SOS)  
Totally 
absent 
Non-brisk 
sparse 
Non-brisk 
peripheral 
Not 
assessable 
Total 
Totally absent 5 0 0 0 5 
Non-brisk sparse 0 12 0 0 12 
Non-brisk peripheral 0 0 2 0 2 
Not assessable 0 0 0 1 1 
Total 5 12 2 1 20 
 
3.5 Intraobserver variation in whole-tumour measures using 
virtual pathology 
In order to derive estimates of intraobserver agreement, I revisited 20 cases that I had 
reported in the preceding 12 months (median 6, range 5-6 months) using the virtual 
pathology protocol (Appendix C). I avoided cases that had been flagged as being 
especially difficult, requiring further assessment with Pathologist B. The first set of 
recordings was called set 1 and the second set was referred to as set 2. 
3.5.1 Breslow thickness 
There was almost perfect intraobserver agreement for Breslow thickness (Table 3.22; 
Figure 3.4). 
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Table 3.22 Breslow thickness measurements in the first (Breslow thickness 1) 
and second (Breslow thickness 2) sets, using the AJCC cut-off points [43]. 
There was 95% (19/20) agreement for Breslow thickness category. Kappa=0.92 
(95% CI 0.69-1.0), p=6x10-10. 
 Breslow thickness 2 
Breslow thickness 1 ≤1.00mm 1.01-2.00mm 2.01-4.00mm >4.00 mm Total 
≤1.00mm 3 0 0 0 3 
1.01-2.00mm 0 10 1 0 11 
2.01-4.00mm 0 0 5 0 5 
>4.00mm 0 0 0 1 1 
Total 3 10 6 1 20 
 
 
 
Figure 3.4: Scatter plot of Breslow thickness (as a continuous measure), which I 
recorded in the first (1, on the x-axis) and second (2, on the y-axis) sets. 
Spearman correlation coefficient=0.98, p=4x10-14. 
3.5.2 Dominant nodule 
There was 95% (19/20) agreement for the presence or absence of a dominant nodule 
(kappa=0 because the observed and expected agreement were the same, indicating 
chance agreement only, Table 3.23). The presence of a dominant nodule was rare in 
the cases studied and, therefore, the results may not be reflective of the true level of 
agreement. 
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Table 3.23: Cross-tabulation of the presence or absence of a dominant nodule. 
95% (19/20) cases were categorised the same way in both sets. Kappa=0 (95% 
CI not calculable). 
 Dominant nodule 2 
Dominant nodule 1 No Yes Total 
No 19 0 19 
Yes 1 0 1 
Total 20 0 20 
3.5.3 Microscopic ulceration 
There was perfect intraobserver agreement for microscopic ulceration (Table 3.24). 
The extent of ulceration was measured in the single case with ulceration and was 
similar for each set (1.3mm for set 1 and 1.1mm for set 2). 
Table 3.24: Cross-tabulation of microscopic ulceration status for set 1 and set 2. 
There was 100% (20/20) agreement for microscopic ulceration status. 
Kappa=1.0, p=4x10-6. 
 Ulceration status 2 
Ulceration status 1 No Yes Total 
No 19 0 19 
Yes 0 1 1 
Total 19 1 20 
 
3.5.4 Tumour-infiltrating lymphocytes (TILs) 
There was 75% (15/20) agreement (kappa=0.63, indicating substantial agreement), 
using a protocol adapted from Clemente et al. (Table 3.25) [61]. 
3.5.5 The presence or absence of tumour loss 
There was substantial agreement for the presence or absence of tumour loss (Table 
3.26). 
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Table 3.25: Cross-tabulation of tumour-infiltrating lymphocytes in the first (TILs 
1) and second (TILs 2) sets, using a protocol adapted from Clemente et al. 
[61]. 
There was 75% (15/20) agreement using this classification. Kappa=0.63 (95% CI 
0.29-0.85), p=2x10-6. 
 TILs 2 
TILs 1 
Totally 
absent 
Focally 
absent 
(biphasic  
VGP) 
Non-
brisk 
sparse 
Non-brisk 
peripheral 
Brisk 
peripheral 
Not 
assessable 
Total 
Totally absent 2 0 0 0 0 0 2 
Focally absent 
(biphasic VGP) 
0 0 1 0 0 0 1 
Non-brisk sparse 0 0 4 2 0 0 6 
Non-brisk peripheral 0 0 2 5 0 0 7 
Brisk peripheral 0 0 0 0 3 0 3 
Not assessable 0 0 0 0 0 1 1 
Total 2 0 7 7 3 1 20 
Table 3.26: Cross-tabulation of the presence or absence of tumour loss in set 1 
and set 2. 
There was 90% (18/20) agreement for tumour loss. Kappa=0.62 (95% CI 0.15-
1.0), p=0.001. 
 Tumour loss 2 
Tumour loss 1 No Yes Total 
No 16 2 18 
Yes 0 2 2 
Total 16 4 20 
3.5.6 The type of tumour loss 
There was substantial agreement for the type of tumour loss (Table 3.27). Two cases 
were available for comparison of the depth of tumour loss and the differences were as 
follows: 0.05mm and 0.2mm. 
3.5.7 The intensity of tumour-infiltrating melanophages (TIMs) 
There was moderate agreement for the intensity of TIMs between the first and second 
sets (Table 3.28).  
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Table 3.27: Cross-tabulation of the type of tumour loss in set 1 and set 2. 
There was 90% (18/20) agreement for the type of tumour loss. Kappa=0.62 (95% 
CI 0.15-1.0), p=0.001. 
 Type of tumour loss 2 
Type of tumour loss 1 Absent Deep Total 
Absent 16 2 18 
Deep 0 2 2 
Total 16 4 20 
Table 3.28: Cross-tabulation of the intensity of melanophages in set 1 and set 2. 
There was 70% (14/20) agreement. Kappa=0.58 (95% CI 0.31-0.80), p=0.00001. 
 TIMs intensity 2 
TIMs intensity 1  None Very few Moderate Lots Total 
None 3 2 0 0 5 
Very few 0 5 2 0 7 
Moderate 0 0 5 1 6 
Lots 0 1 0 1 2 
Total 3 8 7 2 20 
3.5.8 The pattern of tumour-infiltrating melanophages (TIMs) 
Intraobserver agreement was also moderate for the pattern of TIMs (Table 3.29). 
3.5.9 Interpretation of inter- and intraobserver agreement for whole-
tumour measures 
Both inter- and intra-observer agreement were highest for Breslow thickness and 
microscopic ulceration, using the virtual pathology protocol. These findings were 
consistent with initial interobserver results using a light microscope. There was better 
agreement for TILs and tumour loss (rather than regression) using the new virtual 
pathology protocol. Yet, interobserver agreement for tumour loss was fair. 
Intraobserver agreement was even better for TILs and tumour loss. Overall, there was 
moderate to substantial intraobserver agreement for whole-tumour measures, using the 
virtual pathology protocol. Table 3.30 summarises the findings for inter- and 
intraobserver variation analyses of whole tumour measures. 
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Table 3.29: Cross-tabulation of the pattern of tumour-infiltrating melanophages 
(TIMs) in set 1 and set 2, using the 8 categories, adapted from a protocol by 
Clemente et al. [61]. 
There was 75% (15/20) agreement for the pattern of TIMs. Kappa= 0.56 (95% CI 
0.27-0.91), p=0.0006. 
 TIMs 2 
TIMs 1  
Totally 
absent 
Focally 
absent 
(biphasic 
VGP) 
Non-brisk 
sparse 
Non-brisk 
peripheral 
Not 
assessable 
Total 
Totally absent 1 0 0 0 0 1 
Focally absent 
(biphasic VGP) 
0 0 0 1 0 1 
Non-brisk sparse 1 0 7 2 0 10 
Non-brisk 
peripheral 
0 0 1 6 0 7 
Not assessable 0 0 0 0 1 1 
Total 2 0 8 9 1 20 
 
 
 
 
Table 3.30 (following page): Summary table of the results for inter- and 
intraobserver analyses of whole-tumour measures. 
The percentage agreement, kappa statistic, 95% confidence intervals (95%CI), p-
value and strength of agreement are shown for factors recorded using a light 
microscope and/or virtual pathology protocol. For the virtual pathology protocol, 
melanoma cell shape and melanoma cell pigmentation were recorded in the 
cored region rather than in the whole tumour. NA=not applicable. NC=not 
calculable.  
Note that the variable used for tumour-infiltrating lymphocytes (TILs) differed 
between the initial assessment using a light microscope and the virtual pathology 
protocol. The TILs variable in the light microscope study had 3 categories 
(absent, non-brisk and brisk), whilst the TILs variable for the virtual pathology 
protocol consisted of 8 categories (please see Chapter 2 for more details). 
 
 Whole-tumour measures 
 
Interobserver agreement 
(light microscope, training set) 
Interobserver agreement 
(virtual pathology) 
Intraobserver agreement 
(virtual pathology) 
Factor 
% 
Agreement 
Kappa 
(95%CI) 
p-value 
Strength of 
agreement 
% 
Agreement 
Kappa 
(95%CI) 
p-value 
Strength of 
agreement 
% 
Agreement 
Kappa 
(95%CI) 
p-value 
Strength of 
agreement 
Histological 
subtype 
79 
0.53 
(0.30-0.72) 
7x10-11 Moderate NA NA NA NA NA NA NA NA 
Growth phase 83 
0.24 
(-0.02-0.58) 
0.001 Fair NA NA NA NA NA NA NA NA 
Clark’s level 21 
0.002 
(-0.07-0.09) 
0.5 Chance NA NA NA NA NA NA NA NA 
Breslow 
thickness 
77 
0.72 
(0.56-0.84) 
<1x10-16 Substantial 100 1.0 3x10-11 Perfect 95 
0.92 
(0.69-1.0) 
6x10-10 
Almost 
perfect 
Dominant 
nodule 
34 0 (NC) NC Chance 90 
0.69 
(0.31-1.0) 
0.0006 Substantial 95 0 (NC) NC Chance 
Microscopic 
ulceration 
93 
0.84 
(0.70-0.99) 
2x10-14 
Almost 
perfect 
90 
0.69 
(0.29-1.0) 
0.001 Substantial 100 
1.0 
(1.0-1.0) 
4x10-6 Perfect 
Tumour-
infiltrating 
lymphocytes 
43 
0.14 
(0.02-0.30) 
0.02 Slight 60 
0.41 
(0.11-0.72) 
0.001 Moderate 75 
0.63 
(0.29-0.85) 
2x10-6 Substantial 
Regression 89 
0.20 
(-0.03-0.6) 
0.003 Slight NA NA NA NA NA NA NA NA 
Presence or 
absence of 
tumour loss 
NA NA NA NA 85 
0.32 
(-0.27-0.9) 
0.07 Fair 90 
0.62 
(0.15-1.0) 
0.001 Substantial 
Type of 
tumour loss 
NA NA NA NA 85 
0.33 
(-0.07-1.0) 
0.04 Fair 90 
0.62 
(0.15-1.0) 
0.001 Substantial 
1
0
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 Whole-tumour measures 
 
Interobserver agreement 
(light microscope, training set) 
Interobserver agreement 
(virtual pathology) 
Intraobserver agreement 
(virtual pathology) 
Factor 
% 
Agreement 
Kappa 
(95%CI) 
p-value 
Strength of 
agreement 
% 
Agreement 
Kappa 
(95%CI) 
p-value 
Strength of 
agreement 
% 
Agreement 
Kappa 
(95%CI) 
p-value 
Strength of 
agreement 
Intensity of 
tumour-
infiltrating 
melanophages 
NA NA NA NA 90 
0.85 
(0.65-1.0) 
5x10-9 
Almost 
perfect 
70 
0.58 
(0.31-0.80) 
0.00001 Moderate 
Pattern of 
tumour-
infiltrating 
melanophages 
NA NA NA NA 100 1.0 1x10-8 Perfect 75 
0.56 
(0.27-0.91) 
0.0006 Moderate 
Mitotic count 55 
0.35 
(0.17-0.51) 
3x10-6 Fair NA NA NA NA NA NA NA NA 
Microsatellites 91 0 (NC) NC Chance NA NA NA NA NA NA NA NA 
Vascular 
invasion 
87 
0.23 
(0-0.56) 
0.0002 Fair NA NA NA NA NA NA NA NA 
Perineural 
invasion 
88 
-0.01 
(-0.04-0) 
0.6 
Less than 
chance 
NA NA NA NA NA NA NA NA 
Melanoma cell 
shape 
46 
0.19 
(0.06-0.34) 
0.003 Slight NA NA NA NA NA NA NA NA 
Melanoma cell 
pigmentation 
12 
0.03 
(-0.08-0.19) 
0.3 Slight NA NA NA NA NA NA NA NA 
 
 
1
0
9
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3.6 Interobserver variation in cored region measures using 
virtual pathology 
The transition to virtual pathology brought about the prospect of developing a new 
approach, including the use of bespoke software and annotating a particular region of 
interest. When I commenced my PhD, staff in the Section of Epidemiology and 
Biostatistics had already begun to generate whole-genome transcriptomic data (from 
tissue microarray (TMA) core biopsies of primary melanomas), which ultimately 
culminated in 703 transcriptomes. This presented the opportunity to describe the 
estimated cored regions in detail, which would facilitate subsequent comparisons of the 
histopathological appearances with gene expression data. Therefore, I annotated and 
digitally extracted a 600-micron region of tumour, which was estimated to correspond 
to the site that had been sampled using a 0.6mm TMA needle. The following inter- and 
intraobserver analyses refer to measures recorded on this cored region. 
The selection of cases for interobserver variation of the cored region was randomly 
selected, except that cases with poor image quality were avoided. Dr Merchant and I 
had each reviewed the same thirty cores (in 16 cases), and the resulting data were 
used for interobserver variation analyses of the cored region (except for the percentage 
of stroma, for which 26 cores were available for analysis). Four cases had one core, 10 
cases had 2 cores and 2 cases had 3 cores available for analysis. 
3.6.1 The percentage of stroma 
Twenty-six cases were available for comparison of the percentage of stroma between 
observers (Figure 3.5). The Spearman correlation coefficient for the percentage of 
stroma for my recorded measures and those of Pathologist B was 0.7 (p=0.0001), 
indicating a strong association. 
3.6.2 Stroma quality 
Interobserver agreement was slight for the quality of the stroma (Table 3.31). 
3.6.3 Melanoma cell shape 
There were thirty cases available for comparison of melanoma cell shape. There was 
moderate interobserver agreement for melanoma cell shape (Table 3.32). 
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Figure 3.5: Scatter plot of the percentage of stroma, recorded by me (SOS, on the 
y-axis) and by Pathologist B (x-axis). 
Table 3.31: Cross-tabulation of stroma quality for my measures (SOS) and those 
of Pathologist B (B). 
There was 60% (18/30) agreement. Kappa=0.21 (95% CI -0.11-0.49), p=0.03. 
 Stroma quality (B) 
Stroma quality (SOS)  Compact Loose Mixed Not assessable Total 
Compact 15 0 1 6 22 
Loose 1 2 0 0 3 
Mixed 2 0 0 1 3 
Not assessable 1 0 0 1 2 
Total 19 2 1 8 30 
Table 3.32: Cross-tabulation of melanoma cell shape for my measures (SOS) and 
those of Pathologist B (B). 
There was 73% (22/30) agreement. Kappa 0.49 (95% CI 0.24-0.77), p=8x10-8. 
 Melanoma cell shape (B) 
Melanoma cell shape 
(SOS) 
Round/ovoid Epithelioid Spindle Naevoid Total 
Round/ovoid 17 0 0 0 17 
Epithelioid 7 0 0 0 7 
Spindle 0 0 2 1 3 
Naevoid 0 0 0 3 3 
Total 24 0 2 4 30 
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3.6.4 Melanoma cell structure 
Interobserver agreement was slight for melanoma cell structure (Table 3.33). 
Table 3.33: Cross-tabulation of melanoma cell structure for my measures (SOS) 
and those of Pathologist B (B). 
There was 40% (12/30) agreement. Kappa=0.08 (95% CI -0.11-0.32), p=0.3. 
 Melanoma cell structure (B) 
Melanoma cell structure (SOS) Nests Sheets Fascicles Dispersed Total 
Nests 4 7 0 0 11 
Sheets 1 8 1 1 11 
Fascicles 6 2 0 0 8 
Dispersed 0 0 0 0 0 
Total 11 17 1 1 30 
3.6.5 Melanoma cell pigmentation 
There was almost perfect agreement for melanoma cell pigmentation (Table 3.34). 
Table 3.34: Cross-tabulation of melanoma cell pigmentation for my measures 
(SOS) and those of Pathologist B (B). 
There was 93% (28/30) agreement. Kappa=0.82 (95% CI 0.52-1.0), p=9x10-10. 
 Melanoma cell pigmentation (B) 
Melanoma cell pigmentation (SOS) Absent Faint Moderate Total 
Absent 23 0 0 23 
Faint 0 3 0 3 
Moderate 1 1 2 4 
Total 24 4 2 30 
3.6.6 The presence or absence of a core immune cell infiltrate 
There was moderate agreement between observers for the presence or absence of an 
immune cell infiltrate within the cored region (Table 3.35). 
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Table 3.35: Cross-tabulation of the presence or absence of the core immune cell 
infiltrate for my measures (SOS) and those of Pathologist B (B). 
There was 83% (25/30) agreement. Kappa=0.57 (95% CI 0.26-0.88), p=0.0003. 
 Core immune cell infiltrate (B) 
Core immune cell infiltrate 
(SOS) 
No Yes Total 
No 5 0 5 
Yes 5 20 25 
Total 10 20 30 
3.6.7 The extent of the core immune cell infiltrate 
Similarly, there was moderate agreement for the extent of the core immune cell 
infiltrate (Table 3.36). 
Table 3.36: Cross-tabulation of the extent of the core immune cell infiltrate for my 
measures (SOS) and those of Pathologist B (B). 
There was 70% (21/30) agreement. Kappa=0.59 (95% CI 0.37-0.78), p=4x10-9. 
 Extent of core immune cell infiltrate (B) 
Extent of core immune 
cell infiltrate (SOS) 
None 
Barely 
perceptible 
Some Moderate Total 
None 5 0 0 0 5 
Barely perceptible 5 6 2 0 13 
Some 0 0 8 1 9 
Moderate 0 0 1 2 3 
Total 10 6 11 3 30 
The none/barely perceptible categories were merged (as “no/barely perceptible”) and 
used as the reference group for analyses of the core immune cell subsets. This is 
because further details about the core immune cell subsets were not recorded unless 
the core immune cell infiltrate was classified as some, moderate or lots (i.e. not 
recorded if the core immune cell infiltrate was deemed to be absent or barely 
perceptible).  
3.6.8 The location of the core immune cell infiltrate 
There was moderate agreement for the location of the core immune cell infiltrate (Table 
3.37). 
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Table 3.37: Cross-tabulation of the location of the core immune cell infiltrate for 
my measures (SOS) and those of Pathologist B (B). 
There was 77% (23/30) agreement. Kappa=0.62 (95% CI 0.42-0.83), p=1x10-8. 
 Location of core immune cell infiltrate (B) 
Location of core immune 
cell infiltrate (SOS) 
No/barely 
perceptible 
At the tumour/ 
stroma interface 
Dispersed Both Total 
No/barely perceptible 16 1 0 1 18 
At the tumour/ 
stroma interface 
0 1 0 0 1 
Dispersed 0 1 2 1 4 
Both 0 3 0 4 7 
Total 16 6 2 6 30 
3.6.9 The presence or absence of a core lymphocytic infiltrate 
There was substantial agreement for the presence or absence of a core lymphocytic 
infiltrate (Table 3.38). 
Table 3.38: Cross-tabulation of the presence or absence of a core lymphocytic 
infiltrate for my measures (SOS) and those of Pathologist B (B). 
There was 90% (27/30) agreement. Kappa=0.80 (95% CI not calculable), 
p=2x10-6. 
 Core lymphocytic infiltrate (B) 
Core lymphocytic infiltrate 
(SOS) 
No/barely perceptible No Yes Total 
No/barely perceptible 16 0 2 18 
No 0 0 0 0 
Yes 0 1 11 12 
Total 16 1 13 30 
3.6.10 The extent of the core lymphocytic infiltrate 
Interobserver agreement was substantial for the extent of the core lymphocytic infiltrate 
(Table 3.39). 
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Table 3.39: Cross-tabulation of the extent of the core lymphocytic infiltrate for 
my measures (SOS) and those of Pathologist B (B). 
There was 87% (26/30) agreement. Kappa=0.76 (95% CI 0.53-0.94), p=3x10-8. 
 Extent of core lymphocytic infiltrate (B) 
Extent of core 
lymphocytic infiltrate 
(SOS) 
No/barely 
perceptible 
None Some Moderate Total 
No/barely perceptible 16 0 2 0 18 
None 0 0 0 0 0 
Some 0 1 8 0 9 
Moderate 0 0 1 2 3 
Total 16 1 11 2 30 
3.6.11 The presence or absence of a core plasma cell infiltrate 
Agreement was almost perfect for the presence or absence of a core plasma cell 
infiltrate, although it was infrequently present (Table 3.40). 
Table 3.40: Cross-tabulation of the presence or absence of a core plasma cell 
infiltrate for my measures (SOS) and those of Pathologist B (B). 
There was 90% (27/30) agreement. Kappa=0.82 (95% CI 0.61-1.0), p=1x10-8. 
 Core plasma cell infiltrate (B) 
Core plasma cell infiltrate 
(SOS) 
No/barely perceptible No Yes Total 
No/barely perceptible 16 2 0 18 
No 0 9 0 9 
Yes 0 1 2 3 
Total 16 12 2 30 
3.6.12 The extent of the core plasma cell infiltrate 
Similarly, agreement was almost perfect for the extent of the core plasma cell infiltrate 
(Table 3.41). 
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Table 3.41: Cross-tabulation of the extent of the core plasma cell infiltrate for my 
measures (SOS) and those of Pathologist B (B). 
There was 90% (27/30) agreement. Kappa=0.82 (95% CI 0.61-1.0), p=1x10-8. 
 Extent of core plasma cell infiltrate (B) 
Extent of core plasma 
cell infiltrate (SOS) 
No/barely 
perceptible 
None Some Total 
No/barely perceptible 16 2 0 18 
None 0 9 0 9 
Some 0 1 2 3 
Total 16 12 2 30 
3.6.13 The presence or absence of a core melanophage 
infiltrate 
Interobserver agreement was substantial for the presence or absence of 
melanophages within the core (Table 3.42). 
Table 3.42: Cross-tabulation of the presence or absence of a core melanophage 
infiltrate for my measures (SOS) and those of Pathologist B (B). 
There was 90% (27/30) agreement. Kappa=0.83 (95% CI 0.61-1.0), p=1x10-10. 
 Core melanophage infiltrate (B) 
Core melanophage infiltrate 
(SOS)  
No/barely perceptible No Yes Total 
No/barely perceptible 16 2 0 18 
No 0 5 0 5 
Yes 0 1 6 7 
Total 16 8 6 30 
3.6.14 The extent of the core melanophage infiltrate 
Agreement was substantial for the extent of melanophages infiltrating the cored region 
(Table 3.43). 
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Table 3.43: Cross-tabulation of the extent of the core melanophage infiltrate for 
my measures (SOS) and those of Pathologist B (B). 
There was 87% (26/30) agreement. Kappa=0.78 (95% CI 0.60-0.95), p=4x10-11. 
 Extent of core melanophage infiltrate (B) 
Extent of core 
melanophage infiltrate 
(SOS) 
No/barely 
perceptible 
None Some Moderate Total 
No/barely perceptible 16 2 0 0 18 
None 0 5 0 0 5 
Some 0 1 4 0 5 
Moderate 0 0 1 1 2 
Total 16 8 5 1 30 
3.6.15 The presence or absence of a core neutrophilic infiltrate 
Agreement was almost perfect for the presence or absence of a neutrophilic infiltrate 
within the core (Table 3.44). 
Table 3.44: Cross-tabulation of the presence or absence of a core neutrophilic 
infiltrate for my measures (SOS) and those of Pathologist B (B). 
There was 93% (28/30) agreement. Kappa=0.87 (95% CI 0.67-1.0), p=6x10-8. 
 Core neutrophilic infiltrate (B) 
Core neutrophilic infiltrate 
(SOS)  
No/barely perceptible No Yes Total 
No/barely perceptible 16 2 0 18 
No 0 11 0 11 
Yes 0 0 1 1 
Total 16 13 1 30 
3.6.16 The extent of the core neutrophilic infiltrate 
A core neutrophilic infiltrate was noted in one case, the extent of which was recorded 
as “some” by both observers (Table 3.45). The extent of the core neutrophilic infiltrate 
was infrequently recorded. Interobserver agreement was almost perfect. 
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Table 3.45: Cross-tabulation of the extent of the core neutrophilic infiltrate for my 
measures (SOS) and those of Pathologist B (B). 
There was 93% (28/30) agreement. Kappa=0.87 (95% CI 0.67-1.0), p=6x10-8. 
 Core neutrophilic infiltrate (B) 
Core neutrophilic infiltrate 
(SOS) 
No/barely perceptible None Some Total 
No/barely perceptible 16 2 0 18 
None 0 11 0 11 
Some 0 0 1 1 
Total 16 13 1 30 
3.6.17 The presence or absence of a core eosinophilic infiltrate 
There was substantial interobserver agreement for the presence or absence of a core 
eosinophilic infiltrate (Table 3.46). 
Table 3.46: Cross-tabulation of the presence or absence of a core eosinophilic 
infiltrate for my measures (SOS) and those of Pathologist B (B). 
There was 87% (26/30) agreement. Kappa=0.74 (95% CI 0.51-0.93), p=3x10-6. 
 Core eosinophilic infiltrate (B) 
Core eosinophilic infiltrate 
(SOS) 
No/barely perceptible No Yes Total 
No/barely perceptible 16 2 0 18 
No 0 10 1 11 
Yes 0 1 0 1 
Total 16 13 1 30 
3.6.18 The extent of the core eosinophilic infiltrate 
There was a similar level of agreement for the extent of the core eosinophilic infiltrate, 
although this was infrequently reported (Table 3.47). 
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Table 3.47 Cross-tabulation of the extent of the core eosinophilic infiltrate for my 
measures (SOS) and those of Pathologist B (B). 
There was 87% (26/30) agreement. Kappa=0.74 (95% CI 0.51-0.93), p=3x10-6. 
 Extent of core eosinophilic infiltrate (B) 
Extent of core 
eosinophilic infiltrate 
(SOS) 
No/barely 
perceptible 
None Some Total 
No/barely perceptible 16 2 0 18 
None 0 10 1 11 
Some 0 1 0 1 
Total 16 13 1 30 
3.6.19 The number of mitoses within the cored region 
The Spearman correlation coefficient for the number of mitoses within the cored region 
was 0.9 (p=4x10-12). Interobserver agreement was almost perfect for the number of 
core mitoses (Table 3.48). 
Table 3.48: Cross-tabulation of the number of core mitoses for my measures 
(SOS) and those of Pathologist B (B). 
There was 87% (26/30) agreement. Kappa=0.80 (95% CI 0.57-0.95), p=2x10-10. 
 Number of core mitoses (B) 
Number of core mitoses 
(SOS) 
0 1-2 ≥3 Total 
0 9 0 0 9 
1-2 2 9 1 12 
≥3 0 1 8 9 
Total 11 10 9 30 
3.6.20 The number of blood vessels within the cored region 
The Spearman correlation coefficient for the number of blood vessels within the cored 
region was 0.8 (p=2x10-7). Interobserver agreement was fair for the enumeration of 
blood vessels within the cored region (Table 3.49). 
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Table 3.49: Cross-tabulation of the number of core blood vessels for my 
measures (SOS) and those of Pathologist B (B). 
There was 60% (18/30) agreement. Kappa=0.40 (95% CI 0.14-0.66), p=0.001. 
 Number of core blood vessels (B) 
Number of core blood vessels 
(SOS) 
0 1-2 ≥3 Total 
0 5 2 0 7 
1-2 5 6 2 13 
≥3 0 3 7 10 
Total 10 11 9 30 
 
3.7 Intraobserver variation in cored region measures using 
virtual pathology 
In order to assess intraobserver variation for the cored region measures, I repeated an 
assessment of the cored regions for twenty cases that had been reviewed in the 
previous 12 months (median 6, range 5-6 months). These were the same cases 
referred to previously, in which intraobserver variation of whole tumour measures using 
virtual pathology was assessed. The first set of recordings was called set 1 and the 
second set was referred to as set 2. 
3.7.1 Percentage of stroma within the cored regions 
The Spearman correlation coefficient for the percentage of stroma between set 1 and 
set 2 was 0.9 (p=6x10-8), indicating a strong association (Figure 3.6). 
3.7.2 Stroma quality 
The kappa statistic suggests slight agreement because neither of the cores with a 
mixed infiltrate agrees. However, compact stroma was frequently recorded and there 
was very good agreement for this stroma quality overall (Table 3.50). 
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Figure 3.6 Scatter plot of the percentage of stroma in set 1 and set 2. 
Table 3.50: Cross-tabulation of the stroma quality in set 1 and set 2. 
There was 70% (14/20) agreement. Kappa=0.05 (95% CI -0.11-0.36), p=0.4. 
 Stroma quality 2 
Stroma quality 1  Compact Loose Mixed Total 
Compact 14 0 1 15 
Loose 1 0 1 2 
Mixed 2 0 0 2 
Not assessable 1 0 0 1 
Total 18 0 2 20 
3.7.3 Melanoma cell shape 
Intraobserver agreement was substantial for melanoma cell shape (Table 3.51). The 
analysis highlights limitations in the distinction of round/ovoid and epithelioid cell 
shapes from one another. 
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Table 3.51 Cross-tabulation of melanoma cell shape for set 1 and set 2. 
There was 80% (16/20) agreement for cell shape. Kappa=0.69 (95% CI 0.42-
0.92), p=6x10-6). 
 Melanoma cell shape 2 
Melanoma cell shape 1  Round/ovoid Epithelioid Spindle Total 
Round/ovoid 6 4 0 10 
Epithelioid 0 7 0 7 
Spindle 0 0 3 3 
Total 6 11 3 20 
3.7.4 Melanoma cell structure 
Intraobserver agreement was moderate for melanoma cell structure (Table 3.52). 
Table 3.52: Cross-tabulation of melanoma cell structure in set 1 and set 2. 
There was 75% (15/20) agreement. Kappa 0.58 (95% CI 0.28-0.90), p=0.0001. 
 Melanoma cell structure 2 
Melanoma cell structure 1  Nests Sheets Fascicles Total 
Nests 9 0 1 10 
Sheets 2 2 1 5 
Fascicles 1 0 4 5 
Total 12 2 6 20 
3.7.5 Melanoma cell pigmentation 
There was almost perfect agreement for melanoma cell pigmentation (Table 3.53). 
Absent pigmentation was the most commonly recorded grade of pigmentation. 
Table 3.53 Cross-tabulation of melanoma cell pigmentation in set 1 and set 2. 
There was 85% (17/20) agreement. Kappa=0.82 (95% CI 0.57-1.0), p=7x10-9. 
 Melanoma cell pigmentation 2 
Melanoma cell pigmentation 1 Absent Faint Moderate High Total 
Absent 12 0 0 0 12 
Faint 1 2 0 0 3 
Moderate 0 0 3 0 3 
High 0 0 1 1 2 
Total 13 2 4 1 20 
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3.7.6 The presence or absence of a core immune cell infiltrate 
There was fair agreement for the presence or absence of an immune cell infiltrate 
within the cored region (Table 3.54). 
Table 3.54 Cross-tabulation of the core immune cell infiltrate in set 1 and set 2. 
There was 85% (17/20) agreement. Kappa=0.35 (95% CI -0.17-0.86), p=0.02. 
 Core immune cell infiltrate 2 
Core immune cell infiltrate 1  No Yes Total 
No 1 3 4 
Yes 0 16 16 
Total 1 19 20 
3.7.7 The extent of the core immune cell infiltrate 
Intraobserver agreement was higher for the extent of the core immune cell infiltrate 
(Table 3.55). 
Table 3.55: Cross-tabulation of the extent of the core immune cell infiltrate in set 
1 and set 2. 
There was 65% (13/20) agreement. Kappa=0.53 (95% CI 0.25-0.78), p=6x10-6. 
 Extent of core immune cell infiltrate 2 
Extent of core immune 
cell infiltrate 1  
None 
Barely 
perceptible 
Some Moderate Lots Total 
None 1 3 0 0 0 4 
Barely perceptible 0 2 1 0 0 3 
Some 0 0 6 2 0 8 
Moderate 0 0 1 3 0 4 
Lots 0 0 0 0 1 1 
Total 1 5 8 5 1 20 
3.7.8 The location of the core immune cell infiltrate 
There was moderate agreement for the location of the core immune cell infiltrate (Table 
3.56). 
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Table 3.56: Cross-tabulation of the location of the core immune cell infiltrate in 
the cored regions for set 1 and set 2. 
There was 70% (14/20) agreement. Kappa=0.59 (95% CI 0.35-0.85), p=1x10-6. 
 Location of core immune cell infiltrate 2 
Location of core immune 
cell infiltrate 1  
No/barely 
perceptible 
At the tumour/ 
stroma interface 
Dispersed Both Total 
No/barely perceptible 6 0 0 1 7 
At the tumour/ stroma 
interface 
0 2 1 3 6 
Dispersed 0 0 1 1 2 
Both 0 0 0 5 5 
Total 6 2 2 10 20 
3.7.9 The presence or absence of a core lymphocytic infiltrate 
There was almost perfect agreement for the presence or absence of a core 
lymphocytic infiltrate (Table 3.57). 
Table 3.57: Cross-tabulation of the presence or absence of a core lymphocytic 
infiltrate in set 1 and set 2. 
There was 95% (19/20) agreement. Kappa=0.92 (95% CI 0.78-1.0), p=3x10-9. 
 Core lymphocytic infiltrate 2 
Core lymphocytic infiltrate 1  No/barely perceptible No Yes Total 
No/barely perceptible 6 1 0 7 
No 0 5 0 5 
Yes 0 0 8 8 
Total 6 6 8 20 
3.7.10 The extent of the core lymphocytic infiltrate 
Intraobserver agreement was substantial for the extent of the lymphocytic infiltrate 
within the cored region (Table 3.58). 
  
125 
Table 3.58: Cross-tabulation of the extent of the core lymphocytic infiltrate for 
set 1 and set 2. 
There was 85% (17/20) agreement. Kappa=0.79 (95% CI 0.61-1.0), p=5x10-10. 
 Extent of core lymphocytic infiltrate 2 
Extent of core 
lymphocytic infiltrate 1 
No/barely 
perceptible 
None Some Moderate Lots Total 
No/barely perceptible 6 1 0 0 0 7 
None 0 5 0 0 0 5 
Some 0 0 5 2 0 7 
Moderate 0 0 0 0 0 0 
Lots 0 0 0 0 1 1 
Total 6 6 5 2 1 20 
3.7.11 The presence or absence of a core plasma cell infiltrate 
Intraobserver agreement was almost perfect, however, none of the cores assessed had 
a plasma cell infiltrate, which limits the interpretation of these results (Table 3.59). 
Table 3.59: Cross-tabulation of the presence or absence of a core plasma cell 
infiltrate for set 1 and set 2. 
There was 95% (19/20) agreement. Kappa=0.89 (95% CI 0.67-1.00), p=0.00003. 
 Core plasma cell infiltrate 2 
Core plasma cell infiltrate 1  No/barely perceptible No Total 
No/barely perceptible 6 1 7 
No 0 13 13 
Total 6 14 20 
3.7.12 The presence or absence of a core melanophage 
infiltrate 
There was almost perfect intraobserver agreement for the presence or absence of 
melanophages within the cored region (Table 3.60). 
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Table 3.60: Cross-tabulation of the presence of an infiltrate of core 
melanophages for set 1 and set 2. 
There was 95% (19/20) agreement. Kappa=0.91 (95% CI 0.67-1.0), p=1x10-7. 
 Core melanophage infiltrate 2 
Core melanophage infiltrate 1  No/barely perceptible No Yes Total 
No/barely perceptible 6 0 1 7 
No 0 2 0 2 
Yes 0 0 11 11 
Total 6 2 12 20 
3.7.13 The extent of the core melanophage infiltrate 
There was moderate agreement for the extent of melanophages within the cored region 
(Table 3.61). 
Table 3.61: Cross-tabulation of the extent of the core melanophage infiltrate for 
set 1 and set 2. 
There was 65% (13/20) agreement. Kappa=0.54 (95% CI 0.32-0.86), p=9x10-7. 
 Extent of core melanophage infiltrate 2 
Extent of core 
melanophage infiltrate 1  
No/barely 
perceptible 
None Some Moderate Lots Total 
No/barely perceptible 6 0 1 0 0 7 
None 0 2 0 0 0 2 
Some 0 0 2 2 0 4 
Moderate 0 0 0 3 4 7 
Lots 0 0 0 0 0 0 
Total 6 2 3 5 4 20 
3.7.14 The presence or absence of a core neutrophilic infiltrate 
Similarly, intraobserver agreement was almost perfect for the core neutrophilic infiltrate, 
however, it appears that only one of the cores analysed contained neutrophils (Table 
3.62). 
3.7.15 The extent of the core neutrophilic infiltrate 
Substantial agreement is indicated by the kappa statistic, however, the extent of the 
core neutrophilic infiltrate was recorded as some in set 1 and moderate in set 2. The 
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rarity of neutrophils within the core limits conclusions about intraobserver agreement 
(Table 3.63.) 
Table 3.62: Cross-tabulation of the presence of a core neutrophilic infiltrate for 
set 1 and set 2. 
There was 95% (19/20) agreement. Kappa=0.9 (95% CI 0.67-1.0), p=2x10-6. 
 Core neutrophilic infiltrate 2 
Core neutrophilic infiltrate 1  No/barely perceptible No Yes Total 
No/barely perceptible 6 1 0 7 
No 0 12 0 12 
Yes 0 0 1 1 
Total 6 13 1 20 
Table 3.63: Cross-tabulation of the extent of the core neutrophilic infiltrate for set 
1 and set 2. 
There was 90% (18/20) agreement. Kappa=0.8 (95% CI 0.57-1.0), p=0.00001. 
 Core neutrophilic infiltrate 2 
Core neutrophilic infiltrate 1  No/barely perceptible None Some Moderate Total 
No/barely perceptible 6 1 0 0 7 
None 0 12 0 0 12 
Some 0 0 0 1 1 
Moderate 0 0 0 0 0 
Total 6 13 0 1 20 
3.7.16 The presence or absence of a core eosinophilic infiltrate 
It appears that none of the cores had an eosinophilic infiltrate, therefore, it is not 
possible to make inferences about its reproducibility as a recorded measure (Table 
3.64). 
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Table 3.64: Cross-tabulation of the presence of a core eosinophilic infiltrate for 
set 1 and set 2. 
There was 95% (19/20) agreement. Kappa=0.89 (95% CI 0.67-1.0), p=0.00003. 
 Core eosinophilic infiltrate 2 
Core eosinophilic infiltrate 1  No/barely perceptible No Total 
No/barely perceptible 6 1 7 
No 0 13 13 
Total 6 14 20 
3.7.17 The number of mitoses within the cored region 
The Spearman correlation coefficient for the number of mitoses, as a continuous 
variable, in set 1 and set 2 was 0.57 (p=0.01). There was substantial agreement for the 
number of mitoses within the core (Table 3.65). 
Table 3.65: Cross-tabulation of the number of core mitoses for set 1 and set 2. 
There was 75% (15/20) agreement. Kappa=0.63 (95% CI 0.35-0.91), p=0.00001. 
 Number of mitoses within the cored region 2 
Number of mitoses within 
the cored region 1  
0 1-2 ≥3 Total 
0 3 0 0 3 
1-2 2 7 0 9 
≥3 2 1 5 8 
Total 7 8 5 20 
3.7.18 The number of blood vessels within the cored region 
The Spearman correlation coefficient for the number of blood vessels within the cored 
regions for set 1 and set 2 was 0.84 (p=3x10-6). There was moderate agreement for the 
number of blood vessels within the core (Table 3.66). 
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Table 3.66: Cross-tabulation of the number of core blood vessels for set 1 and 
set 2. 
There was 75% (15/20) agreement. Kappa=0.56 (95% CI 0.15-0.84), p=0.001. 
 Number of blood vessels within the cored region 2 
Number of blood vessels 
within the cored region 1  
0 1-2 ≥3 Total 
0 1 1 0 2 
1-2 0 7 3 10 
≥3 0 1 7 8 
Total 1 9 10 20 
3.7.19 Interpretation of inter- and intraobserver agreement for 
cored region measures 
Interobserver agreement was weakest for the quality of the stroma and melanoma cell 
structure within the cored region. There was higher interobserver agreement for 
melanoma cell shape in the cored region than within the whole tumour using a light 
microscope. There was substantial interobserver agreement for melanoma cell 
pigmentation and the core immune cell infiltrates. These findings suggest that 
interobserver agreement could be improved by performing a focused assessment of 
such measures within smaller regions of the melanoma. 
There was high intraobserver concordance for cored region measures overall, 
particularly for the presence or absence of lymphocytes or melanophages within the 
core. The grading of the extent of the core immune cell infiltrate was more variable and 
there was only slight agreement for the quality of the stroma, although the kappa 
statistic may be misleading due to the rarity of loose and mixed types of stroma. 
There was a strong association for the percentage of stroma recorded for both 
observers and within the same observer. Table 3.67 provides a summary of the 
findings for inter- and intraobserver variation analyses of cored region measures. 
Table 3.67 (on following page): Summary table of the results for inter- and 
intraobserver analyses of cored region measures. 
The Spearman correlation coefficient (rho), percentage agreement, kappa statistic, 
95% confidence intervals (95%CI), p-value and strength of agreement are shown for 
factors recorded using the virtual pathology protocol. The extent of the plasma cell 
infiltrate and melanophages within the cored region were not available for intraobserver 
variation analysis because the cores that were assessed did not contain either of these 
cells. NA = not applicable. NC = not calculable. 
 Cored region measures 
 Interobserver agreement (virtual pathology) Intraobserver agreement (virtual pathology) 
Factor 
Spearman 
rho 
% 
Agreement 
Kappa 
(95%CI) 
p-value 
Strength of 
agreement 
Spearman 
rho 
% 
Agreement 
Kappa 
(95%CI) 
p-value 
Strength of 
agreement 
Percentage of stroma 0.7   0.0001  0.9   6x10-8  
Quality of the stroma  60 
0.21  
(-0.11-0.49) 
0.03 Fair  70 
0.05 
(-0.11-0.36) 
0.4 Slight 
Melanoma cell shape  73 
0.49  
(0.24-0.77) 
8x10-8 Moderate  80 
0.69 
(0.42-0.92) 
6x10-6 Substantial 
Melanoma cell structure  40 
0.08 
(-0.11-0.32) 
0.3 Slight  75 
0.58 
(0.28-0.9) 
0.0001 Moderate 
Melanoma cell 
pigmentation 
 93 
0.82 
(0.52-1.0) 
9x10-10 Almost perfect  85 
0.82 
(0.57-1.0) 
7x10-9 
Almost 
perfect 
Presence or absence of core 
immune cell infiltrate 
 83 
0.57 
(0.26-0.88) 
0.0003 Moderate  85 
0.35 
(-0.17-0.86) 
0.02 Fair 
Extent of core immune cell 
infiltrate 
 70 
0.59 
(0.37-0.78) 
4x10-9 Moderate  65 
0.53 
(0.25-0.78) 
6x10-6 Moderate 
Location of core immune 
cell infiltrate 
 77 
0.62 
(0.42-0.83) 
1x10-8 Substantial  70 
0.59 
(0.35-0.85) 
1x10-6 Moderate 
Presence or absence of core 
lymphocytic infiltrate 
 90 
0.80 
(NC) 
2x10-6 Substantial  95 
0.92 
(0.78-1.0) 
3x10-9 
Almost 
perfect 
Extent of core lymphocytic 
infiltrate 
 87 
0.76 
(0.53-0.94) 
3x10-8 Substantial  85 
0.79 
(0.61-1.0) 
5x10-10 Substantial 
Presence or absence of core 
plasma cell infiltrate 
 90 
0.82 
(0.61-1.0) 
1x10-8 Almost perfect  95 
0.89 
(0.67-1.0) 
0.00003 
Almost 
perfect 
Extent of core plasma cell 
infiltrate 
 90 
0.82 
(0.61-1.0) 
1x10-8 Almost perfect  NA NA NA NA 
1
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 Cored region measures 
 Interobserver agreement (virtual pathology) Intraobserver agreement (virtual pathology) 
Factor 
Spearman 
rho 
% 
Agreement 
Kappa 
(95%CI) 
p-value 
Strength of 
agreement 
Spearman 
rho 
% 
Agreement 
Kappa 
(95%CI) 
p-value 
Strength of 
agreement 
Presence or absence of core 
macrophage/melanophage 
infiltrate 
 90 
0.83 
(0.61-1.0) 
1x10-10 Almost perfect  95 
0.91 
(0.69-1.0) 
1x10-7 
Almost 
perfect 
Extent of core 
macrophage/melanophage 
infiltrate 
 87 
0.78 
(0.6-0.95) 
4x10-11 Substantial  65 
0.54 
(0.32-0.86) 
9x10-7 Moderate 
Presence or absence of core 
neutrophilic infiltrate 
 93 
0.87 
(0.67-1.0) 
6x10-8 Almost perfect  95 
0.90 
(0.67-1.0) 
2x10-6 
Almost 
perfect 
Extent of core neutrophilic 
infiltrate 
 93 
0.87 
(0.67-1.0) 
6x10-8 Almost perfect  90 
0.80 
(0.57-1.0) 
0.00001 Substantial 
Presence or absence of core 
eosinophilic infiltrate 
 87 
0.74 
(0.51-0.93) 
3x10-6 Substantial  95 
0.89 
(0.67-1.0) 
0.00003 
Almost 
perfect 
Extent of core eosinophilic 
infiltrate 
 87 
0.74 
(0.51-0.93) 
3x10-6 Substantial  NA NA NA NA 
Core mitoses (tertiles)  87 
0.80 
(0.57-0.95) 
2x10-10 Substantial  75 
0.63 
(0.35-0.91) 
0.00001 Substantial 
Core blood vessels  60 
0.40 
(0.14-0.66) 
0.001 Fair  75 
0.56 
(0.15-0.84) 
0.001 Moderate 
 
1
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3.8 Summary 
 Breslow thickness, microscopic ulceration, the POS, melanoma cell 
pigmentation, the presence or absence of a core lymphocytic infiltrate and its 
extent and the number of core mitoses (categorised as tertiles) were factors for 
which reproducibility was highest. 
 Growth phase, Clark’s level, the presence or absence of a dominant nodule, 
regression, microsatellites, vascular and perineural invasion, the quality of the 
stroma, melanoma cell structure and the number of blood vessels were poorly 
reproduced. 
 Interobserver agreement improved for the grading of TILs when a modified 
version of Clemente et al.’s [61] protocol was utilised. 
 Tumour loss was variably reported between observers, however, it was highly 
reproducible within the same observer. 
 The presence of a plasma cell, neutrophilic or eosinophilic infiltrate within the 
core was seldom recorded. 
 
3.9 Discussion 
Consistency in the histopathological assessment of melanoma is crucial for the 
estimation of prognosis. Interobserver agreement was highest for Breslow thickness 
and microscopic ulceration, irrespective of the protocol used. Initial histopathology 
training with a light microscope highlighted several discrepancies, which are likely to 
reflect the training nature of the cases analysed and the complexity of melanoma 
pathology. Reassessment of measures was performed to seek factors that would have 
the best reproducibility. Several factors were dropped prior to commencing the 
histopathological review using virtual pathology. These included measures for which 
the weakest interobserver agreement was observed, i.e. microsatellites and perineural 
invasion. Interobserver agreement was also slight for regression, TILs, melanoma cell 
shape and pigmentation. These measures were modified and retained for assessment 
using the virtual pathology protocol because they were of particular interest. 
The first study of interobserver variation using a light microscope was complicated by a 
number of factors. Firstly, it is likely that the consultant pathologist had reviewed clinical 
sections, whilst I had used research sections in the majority of cases. Consequently, 
additional sections that had been stained for immunohistochemistry were not included 
in my analysis. Some of the differences seen could be accounted for by the use of 
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different sections. Patrick et al. found a mean increase of 0.12mm for Breslow 
thickness in half of cases, comparing serial sections of thin melanomas [210]. In 
addition, it was my first time reviewing melanoma pathology slides independently, in 
tandem with the gradual accumulation of knowledge, having had limited clinical 
exposure to histopathology. For this protocol, training was provided by a different 
consultant pathologist (Dr Merchant, Pathologist B) to the one who acted as the 
observer (Pathologist A). Potential differences in the approach of each pathologist 
might have contributed further to variability. The protocol which I used had been 
developed by Prof. Cook, however, the approach to the parameters within the protocol 
were interpreted by the training consultant pathologist and I. Our approach might have 
differed from what had been intended by Prof. Cook and Pathologist A. 
Studies of interobserver variation in the reporting of melanoma pathology have been 
recorded in different contexts in the literature. Some describe retrospective studies, 
where the second observer was privy to the report of the first and the reporting 
pathologists had different levels of specialisation [199, 203]. This unblinding could have 
resulted in more favourable reproducibility scores. 
The subsequent interobserver variation analysis for whole tumour measures was 
based on a different protocol, using different technology and was recorded for different 
observers (Dr Merchant and I, as opposed to Pathologist A and I). Interobserver 
studies using this virtual pathology protocol showed a high degree of concordance. 
This might reflect the fact that the training dermatopathologist was the second observer 
for this analysis. Additionally, some of the measures were relatively novel and had 
been developed in collaboration with the training pathologist. Furthermore, it was 
possible to record images of annotated measurements using virtual pathology, which 
might have increased reproducibility for these factors. Better interobserver agreement 
was observed for TILs using the virtual pathology protocol, in which a modified version 
of the approach by Clemente et al. was employed (discussed in more detail in Chapter 
2) [61]. However, agreement was still moderate, highlighting the subjective nature of 
the measure. The results of the initial interobserver analysis (using Prof. Cook’s 
protocol) had indicated difficulties in recognising regression. Therefore, the regression 
variable was re-defined as tumour loss and the extent of melanophages within the 
tumour was also recorded separately (discussed in more detail in Chapter 2). There 
was substantial to almost perfect interobserver agreement for the intensity and pattern 
of melanophages, respectively, which suggests that these cells were easily recognised, 
perhaps due to the presence of pigment. However, there was only a modest 
improvement in concordance for the presence of tumour loss using the new approach, 
which might reflect the subjective nature of this measure. Intraobserver agreement for 
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the whole-tumour measures was moderate to substantial for most factors, being 
highest for Breslow thickness and microscopic ulceration. There was moderate to 
substantial agreement for the presence of tumour loss and the intensity and pattern of 
melanophages within the whole tumour. Limitations of the virtual pathology study 
include the relatively small number of cases available for comparison for interobserver 
variation analysis and intraobserver concordance was not examined in the second 
observer (Pathologist B). 
The use of virtual pathology enabled me to develop new measures and to focus on a 
precise region of tumour. By digitally extracting the cored region, it was possible to be 
certain that both observers assessed the exact same part of the tumour. The cored 
region measures, including the percentage of stroma, were highly reproducible. The 
poorest interobserver agreement was recorded for melanoma cell structure, the quality 
of the stroma and for the number of blood vessels within the cored region, indicating 
that these measures could be more subjective. Broekart et al. previously reported 
moderate interobserver agreement for nesting, which was one element recorded in the 
melanoma cell structure variable (kappa ~0.4) [155]. Interobserver agreement was only 
slight in this regard, however, intraobserver agreement was better. This might imply 
that although there were some differences in its interpretation, my data were recorded 
consistently. It was not surprising that there was limited reproducibility for the number 
of blood vessels within the core, as it was difficult to define the boundary, where one 
blood vessel began and ended, relative to its tributaries. Artefactual haemorrhage 
could also have led to discrepancies in the enumeration of blood vessels, as the 
definition I used to record their presence was of red cells within a lumen. 
Overall, there was moderate to almost perfect intraobserver agreement using the 
virtual pathology protocol, suggesting that consistent entries were made during the 
period of data recording. The poorest agreement was for the quality of the stroma, 
however, compact stroma predominated which limited the number of cases available 
for comparison with other types of stroma. Intraobserver agreement was fair for the 
presence of a core immune cell infiltrate but was higher for other core immune cell 
variables. Lymphocytes and melanophages predominated within the cored regions, 
indicating that these immune cells could underlie some of the biological variation in 
melanoma. 
The factors that were most consistently reproduced were Breslow thickness and 
microscopic ulceration. These histopathological features have been incorporated into 
AJCC stage and are therefore used to predict outcome from cutaneous melanoma [43]. 
Their high degree of reproducibility is likely to contribute to their prognostic power in 
large data sets, such as those used to determine stage. Microsatellites also contribute 
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to AJCC stage [43] but interobserver agreement was poor for this factor using the Prof. 
Cook protocol, which might reflect the training nature of the data set. The apparent 
rarity of the occurrence of microsatellites within the data set limits the conclusions that 
could be drawn, however, it appeared that this measure was subjective, despite its 
definition. The results for the percentage of stroma, measured using RandomSpot© 
[185], were concordant within and between observers. This highlights a novel factor 
that could be incorporated into the histopathological assessment of primary 
melanomas, were it to be of diagnostic or prognostic significance. The application of 
the software being limited by the need for digitised pathology images, which could 
restrict its clinical use. 
In the future, if I were designing a study to examine interobserver variation among 
pathologists, I would include 3 or more observers and a larger number of cases. A 
variable for which a high level of concordance was achieved between the three 
observers, would be considered highly reproducible. For measures where results were 
more variable, a process of discussion and review would be needed in order to reach a 
consensus about the approach, similar to that reported by Carney et al. [207]. If 
reproducibility continued to be low, the measure would be regarded as subjective and 
unlikely to be reproducible. During my PhD, interobserver variation was studied 
between different observers, using different protocols, therefore, it was not possible to 
achieve consensus between 3 or more observers but it may be feasible to evaluate in 
the future. 
In summary, measures that would have been predicted to be highly reproducible, such 
as Breslow thickness and ulceration were consistently reported. The recording of other 
factors, used in the histopathological reporting of melanoma pathology, was more 
variable. Highly reproducible results were achieved using a newly developed, virtual 
pathology protocol. A unique data set was made available to me at the beginning of my 
PhD, which I hope to have further enriched through this research. Several novel 
measures were developed, the potential prognostic implications of which will be 
explored in Chapter 4. 
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Chapter 4 Melanoma-specific relapse and survival 
4.1 Introduction 
A detailed overview of the factors known to be associated with melanoma prognosis is 
provided in Chapter 1. Briefly, clinical, histopathological and molecular profiles have 
been reported to play a role. Adverse clinical factors include advancing age [6, 7] and 
male sex [16, 19, 211]. The AJCC staging system (7th edition) incorporates several 
histopathological measures, which have been established to be predictors of outcome 
in melanoma, e.g. Breslow thickness, microscopic ulceration and, for stage IB 
melanomas, mitotic count/mm2 [43]. The AJCC 8th edition will be effective from 1st 
January 2017 but in my thesis, I will refer only to the 7th edition, which I used in my 
research. 
The width of ulceration has also been reported to be an important prognostic factor. 
Day et al. proposed that an ulceration width >3mm was hazardous [55]. Grande Sarpa 
et al. calculated the ulceration width as a percentage of the maximum diameter and 
noted that the presence of >2% and >5% ulceration was associated with an increased 
risk of sentinel lymph node positivity and melanoma-specific death, respectively [54]. 
Another study showed that an ulceration width >5mm or a percentage ulceration >70% 
was associated with a significantly increased risk of melanoma-specific death [53]. 
Although the biological basis of ulceration has not been fully elucidated, it has been 
reported to be an established predictor of a better response to interferon therapy [167], 
suggesting that understanding the biological determinants of ulceration is important. 
Activation of pro-inflammatory cytokines and biological pathways associated with 
wound healing have been identified in ulcerated primary melanomas [49], suggesting 
that these tumours harbour a pro-tumourigenic, inflammatory milieu. Consistent with 
this hypothesis, ulcerated melanomas display increased microvessel density, 
lymphovascular invasion and macrophage infiltration [50]. Therefore, I was interested 
to quantify the extent of microscopic ulceration, to assess whether or not this might 
prove to be an independent predictor of outcome in participants recruited to the Leeds 
Melanoma Cohort Study. 
As discussed in Chapter 1, there are conflicting results regarding the significance of 
other histopathological measures, e.g. tumour-infiltrating lymphocytes (TILs) [24, 27, 
60-62, 64, 65, 67, 212] and regression [72, 74, 80, 81, 213-215]. Several studies have 
reported TILs to be an independent predictor of outcome in melanoma, with brisk TILs 
137 
having the best prognosis [27, 60-63]. However, in others, TILs have no independent 
prognostic value [25, 64-67]. This could reflect the subjective nature of the 
classification of TILs or variation in the cohorts studied (consisting of melanomas with 
different thicknesses). In view of these findings and the revolutionary advances in 
immunotherapy for the treatment of melanoma [216], I was interested to classify TILs 
using a protocol adapted from Clemente et al. [61], which was developed to better 
capture the variation in the distribution of TILs within primary melanomas. 
The prognostic significance of regression is more controversial. It has been reported to 
occur more frequently in patients with adverse clinical characteristics, e.g. older age 
and male sex [74] but more favourable histopathological features, e.g. a lower mitotic 
count and absence of ulceration [75]. Some studies have established a protective role 
for regression in primary melanoma [74, 76, 79]. However, Rubenstein et al. reported 
an association with false-negative sentinel node biopsies and hypothesised that a 
similar mechanism could have led to regression in the lymph node [71]. Other studies 
have demonstrated a worse outcome, with an increased risk of metastasis, particularly 
among thin melanomas [82-84, 86]. This suggests the possibility that the true Breslow 
depth could have been underestimated, due to the erosion of the invasive edge of the 
tumour. Regression of 50% or more of the melanoma has been reported to increase 
the risk of death [78]. 
Regression has been postulated to result from host-mediated, immunologic tumour 
destruction [71], however, Bastian et al. cited telomere “crisis” as a putative mechanism 
[73]. Telomeres are repetitive nucleotide sequences at the ends of chromosomes, 
which are designed to maintain their integrity and to prevent inadvertent fusion with 
other chromosomes [217]. Telomeres shorten with successive cell divisions and on 
exposure to carcinogens and are known to decrease with age [217]. It is this shortening 
that determines the number of divisions that a cell will undergo in its lifetime [73]. 
Mutations can lead to telomere dysfunction, which permits cancer cells to continue to 
divide unchecked, exposing the DNA and increasing the chances of fusion with other 
chromosomes [73]. A critical point is reached, known as “crisis”, which is induced by 
these chromosomal abnormalities and this initiates cell death (“apoptosis”) [73]. This 
process might trigger some of the cancer cells to activate telomerase and to become 
immortal and can be viewed as an evolutionary process [73], suggesting that regions of 
tumour cell death may be associated with the concomitant generation of clonal 
populations which would be linked to a worse prognosis. The alternative hypothesis, 
therefore, is that regression in some tumours might reflect tumour cell death related to 
intrinsic events within the tumour rather than an immune event, and that this process 
might result in the selection of more aggressive cancer cells. 
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Due to the lack of clarity about the prognostic role of regression in melanoma, I elected 
to record a detailed assessment of factors that are considered to represent regression, 
namely, a region of tumour that has vanished (“tumour loss”). I was also interested to 
measure its depth and location with respect to the tumour, in light of the fact that ≥50% 
regression had previously been shown to predict an increased risk of death [78]. 
Furthermore, I calculated the “relative tumour loss” by dividing the depth of tumour loss 
by the Breslow thickness, to assess whether this might more accurately reflect the 
degree of tumour loss and whether or not it might be a better predictor of outcome. 
Moreover, I graded the intensity and pattern of macrophages/melanophages (TIMs), 
which could be seen in association with regression [73] and because of their possible 
association with a particularly aggressive tumour biology, e.g. microscopic ulceration 
[49]. 
The AJCC staging system is a powerful tool in predicting melanoma prognosis, yet, it is 
estimated that unexplained variation in the predicted survival of up to 32% remains 
[151]. Moreover, there are several features of primary cutaneous melanomas, which 
have long been described by pathologists but are of undetermined significance, e.g. 
melanoma cell pigmentation. Viros et al. performed a detailed morphological analysis 
of 302 primary cutaneous melanomas and found that BRAF-mutated melanomas 
tended to have rounder, larger and more heavily pigmented melanoma cells [108], 
thereby implying genomic variation is impacting on pigmentation. Melanoma cell 
pigmentation can also be viewed as a marker of differentiation [111], with amelanotic 
melanomas likely to represent a less differentiated state. An inverse relationship 
between pigmentation and cell elasticity has been demonstrated in melanoma cells and 
this appears to inhibit their capacity to migrate in vitro [114]. However, some studies 
have suggested a potentially hazardous role for pigmentation [111, 115]. 
Furthermore, two distinct patterns of cancer cell migration have been reported, based 
upon in vitro and murine models, a faster, rounded, “amoeboid” type and an elongated, 
“mesenchymal” type [105]. There is some evidence that these patterns of cell 
movement might correspond with morphological characteristics in formalin-fixed, 
paraffin-embedded (FFPE) sections of primary cutaneous melanoma [107] and I 
decided, therefore, to assess the association between melanoma cell shape and 
melanoma-specific survival. The virtual pathology protocol, which I developed under 
the supervision of Prof. Newton-Bishop and Drs Will Merchant and Darren Treanor, 
incorporated some of these descriptors of uncertain significance. 
Apart from histopathological factors, molecular profiles can help to delineate subgroups 
that are distinct in terms of survival [149-151]. To date, many of these profiles have 
been generated predominantly using metastatic melanoma samples, due to the limited 
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availability of cryopreserved primary melanoma tissue [149, 153]. The Leeds group has 
succeeded in amassing H&E-stained, archival sections from primary melanoma 
tumours with matched transcriptomic data for 703 cases, over several years. The 
transcriptomic data were generated from RNA extracted from a 0.6mm diameter core 
taken horizontally through the deepest part of the tumour and were generated using the 
Illumina® DASL assay, designed to produce high quality data from formalin-fixed 
(degraded) RNA. Using primary melanomas, the group has replicated the molecular 
profiles reported by Harbst et al. [150, 151], named by them as pigmentation, 
proliferative, high-immune and normal-like. More recently, the Leeds group has utilised 
a bioinformatics approach, developed by the group of Jerome Galon and known as the 
“immunome” [174] to study the role of immune cell subsets within primary melanoma 
tumours, at a gene expression level. The Galon group derived lists of genes that data 
had suggested are exclusively expressed by specific immune cell subsets and then 
used the expression of those genes to infer the presence of 28 immune cell subsets in 
tumour tissue [174]. Galon’s group worked predominantly on colon cancer. 
The basis of the statistical analysis reported herein refers to 798 cases from the Leeds 
Melanoma Cohort Study for which I recorded a detailed histopathological review of the 
primary, using a virtual pathology protocol. A detailed assessment was recorded for the 
whole tumour and the cored regions. The latter could be identified in 702 cases (the 
remaining cases lacking black markings on the glass slides, which corresponded to 
regions of the block that had been sampled using a tissue microarray (TMA) biopsy 
needle). Transcriptomic data were available for 703 cases but only 676 of these had 
been studied using the virtual pathology protocol (H&E sections were unavailable for 
assessment in the remainder). Therefore, of the 798 cases assessed using the virtual 
pathology protocol, 676 had gene expression data, including 596 cases with data for 
both gene expression and cored region measures. 
The aims that this chapter will address are as follows: 
 To summarise the clinical and histopathological characteristics of the 798 cases 
that were reviewed using the virtual pathology protocol 
 To assess which clinical and histopathological factors (scored within the whole 
tumour and cored regions) were statistically significant predictors of melanoma 
relapse and melanoma-specific survival in univariable and multivariable 
analyses, using Cox proportional hazards models  
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4.2 Methods 
Relapse and survival (based on melanoma-specific death) times were censored at 10 
years. Cox proportional hazards models were used to generate hazard ratios (HR), 
95% confidence intervals (95% CI) and p-values for the likelihood of melanoma relapse 
or melanoma-specific death. Univariable and multivariable analyses were performed for 
clinical factors, including age at diagnosis and sex; and histopathological factors in the 
whole tumour and within the cored regions. Tests for trend were performed for ordered 
categorical variables where there appeared to be increasing hazard ratios when testing 
with individual categories. Kaplan-Meier curves were used to graphically represent the 
time to melanoma relapse or melanoma-specific death. 
The AJCC stage variable was generated using a mixture of clinical and 
histopathological data for the whole tumour and cored region measures as follows: 
Breslow thickness and microscopic ulceration (whole tumour) and the presence or 
absence of mitoses in core 1. Although more than one cored region was examined for 
423 cases, the first core was used for this analysis, to increase the statistical power (as 
all cases for which cored region measures were available had a least one core) and 
because comparisons of measures between the first and second cores showed similar 
results (Appendix D). 
Data on microsatellite status, micro- and macrometastases and metastatic disease had 
previously been recorded for each case by Section staff from the histology reports and 
clinical notes. These data were incorporated into the stage variable. In 8 patients, 
where stage could not be computed due to missing Breslow thickness and/or mitoses, 
the stage recorded from the histology reports and clinical notes was used instead. 
Relapse and survival data were generated by departmental staff by extraction from the 
clinical notes, contact with the patient annually, data requests to the GP and cancer 
registry data. 
For relapse and survival analyses, the round/ovoid melanoma cell shape category was 
merged with the epithelioid cell shape category because the results of intraobserver 
studies showed that the distinction between these subtypes was poorly reproducible 
(Chapter 3). 
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4.3 Results 
4.3.1 Descriptive statistics and univariable analysis 
Descriptive statistics, unadjusted HRs, 95% CI and p-values are reported for clinical 
factors in Table 4.1, for whole tumour measures in Table 4.2 and for cored region 
measures in Table 4.3. 
4.3.1.1 Clinical factors 
Table 4.1 shows unadjusted HRs for melanoma relapse and melanoma-specific death 
and the corresponding 95% CI and p-values for clinical factors. The mean age at 
diagnosis was 56 years; 54% (430/798) cases were female. The most common site of 
primary melanoma was the limbs (44%, 349/798). Approximately 86% (683/798) cases 
had AJCC stage I or II disease. 
The median relapse survival time was 4.8 years (range 0-10 years; censored at 10 
years) and the median melanoma-specific survival time was 5.8 years (range 0.5-10 
years; censored at 10 years) (data not shown). In univariable analysis, an older age at 
diagnosis was a poor prognostic factor, contributing to a 2% increased risk of relapse 
(HR 1.02, 95% CI 1.01-1.03, Cox proportional hazards model, p=0.00001) and a 3% 
increased risk of death from melanoma (HR 1.03, 95% CI 1.02-1.04, Cox proportional 
hazards model, p=3x10-7) for every year older. 
Table 4.1 (on following page): Unadjusted hazard ratios for relapse and 
melanoma-specific death for clinical factors.  
The unadjusted hazard ratios (HR), 95% confidence intervals (95% CI) and p-values 
were estimated from Cox proportional hazards models. The second column refers to 
descriptive statistics for the factor in the first column. N = number of cases. S.D. = 
standard deviation. ‘N’ in 3rd and 7th columns refers to the number of cases in the 
statistical model(s). “Other” refers to sun-protected sites, including acral, subungual, 
genital, anal, and ear, nose and throat (ENT). The test for trend was performed for 
AJCC stage [43] because this was an ordered variable and there was an increasing 
trend in the hazard ratios for individual AJCC stage categories. Events refers to the 
number of cases that had either relapsed or died due to melanoma. Exact p-values are 
provided where possible. STATA (the statistical package) could not provide exact p-
values for some variables because they were so significant (e.g. AJCC stage III/IV) and 
the estimated p-values are provided instead. The reference category (baseline) is the 
first category listed for each of the categorical variables. 
   
Melanoma relapse 
(N=797, 253 events) 
Melanoma-specific death 
(N=798, 207 events) 
Factor 
Mean (S.D.) or 
Median (range) or N (%) 
N HR 95% CI p-value N HR 95% CI p-value 
Age at diagnosis (years) 56.3 (12.8) 797 1.02 1.01-1.03 0.00001 798 1.03 1.02-1.04 3x10-7 
Sex  797    798    
     Male 368 (46.1)  1.0    1.0   
     Female 430 (53.9)  0.7 0.5-0.9 0.003  0.7 0.5-0.9 0.007 
Site of primary melanoma  797    798    
     Limbs 349 (43.7)  1.0    1.0   
     Trunk 269 (33.7)  1.4 1.1-1.9 0.02  1.7 1.2-2.4 0.001 
     Head 88 (11.0)  1.4 0.9-2.1 0.1  1.2 0.7-2.0 0.5 
     Other 92 (11.6)  2.3 1.6-3.3 6x10-6  2.9 2.0-4.3 9x10-8 
AJCC stage  796    797    
     I 339 (42.5)  1.0    1.0   
     II 344 (43.1)  2.8 2.1-3.8 6x10-11  2.6 1.8-3.6 7x10-8 
     III/IV 114 (14.3)  4.8 3.4-6.9 <1x10-16  5.6 3.8-8.3 <1x10-16 
     Missing 1 (0.1)         
     Test for trend   2.2 1.8-2.6 <1x10-16  2.4 1.9-2.9 <1x10-16 
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Female sex was significantly protective for both melanoma relapse and death (HR for 
relapse 0.7, 95% CI 0.5-0.9, Cox proportional hazards model, p=0.003 and HR for 
melanoma-specific death 0.7, 95% CI 0.5-0.9, Cox proportional hazards model, 
p=0.007). Cases whose melanomas were located on the trunk or “other” sites (sun-
protected sites, including acral, subungual, genital, anal, and ear, nose and throat 
(ENT)) had a significantly increased risk of relapse (HR for “other” site 2.3, 95% CI 1.6-
3.3, Cox proportional hazards model, p=6x10-6) and melanoma-specific death (HR for 
“other” site 2.9, 95% CI 2.0-4.3, Cox proportional hazards model, p=9x10-8) compared 
to the limbs. AJCC stage was significantly predictive of a poorer outcome. There was a 
significant trend in the HRs for advancing AJCC stage, both for melanoma relapse and 
death. 
4.3.1.2 Whole-tumour measures 
Data for whole-tumour measures are presented in Table 4.2.  
 
 
 
 
 
Table 4.2 (on following page): Unadjusted hazard ratios for melanoma relapse 
and melanoma-specific death for whole-tumour measures 
Unadjusted hazard ratios (HR), 95% confidence intervals (95% CI) and p-values 
were estimated from Cox proportional hazards models. The second column refers 
to descriptive statistics for the factor. N=number of cases. S.D.=standard 
deviation. ‘N’ in 3rd and 7th columns refers to the number of cases in the statistical 
model. Events refers to the number of cases that either relapsed or died due to 
melanoma. * AJCC cut-off points [43] were used to define Breslow thickness 
categories. ** For one patient, tumour loss was present but the type of tumour 
loss could not be assessed. Exact p-values are provided where possible. STATA 
could not provide exact p-values for some variables because they were so 
significant and the estimated p-values are provided instead (e.g. the test for trend 
for Breslow thickness). The reference category (baseline) is the first category 
listed for each of the categorical variables. 
   
Melanoma relapse 
(N=797, 253 events) 
Melanoma-specific death 
(N= 798, 207 events) 
Factor 
Mean (S.D.) or 
Median (range) or N (%) 
N HR 95%CI p-value N HR 95% CI p-value 
Breslow thickness (mm)* 2 (0.5-19.5) 788    789    
     ≤1.00 83 (10.4)  1.0    1.0   
     1.01-2.00 312 (39.1)  2.3 1.2-4.7 0.02  2.2 1.04-4.6 0.04 
     2.01-4.00 272 (34.1)  4.3 2.2-8.5 0.00003  3.9 1.9-8.2 0.0002 
     >4.00 122 (15.3)  9.6 4.8-19.1 2x10-10  7.6 3.7-16.0 7x10-8 
     Missing 9 (1.1)         
     Test for trend   2.0 1.8-2.4 <1x10-16  1.9 1.6-2.2 3x10-15 
Dominant nodule  797    798    
     No 721 (90.4)  1.0    1.0   
     Yes 77 (9.6)  2.6 1.9-3.7 3x10-9  2.1 1.5-3.0 0.00007 
Microscopic ulceration  797    798    
     No 621 (77.8)  1.0    1.0   
     Yes 177 (22.2)  2.6 2.0-3.3 6X10-13  2.3 1.7-3.1 9x10-9 
Extent of microscopic ulceration (mm) 2.5 (0.1-17.4) 795    796    
     None 621 (77.8)  1.0    1.0   
     <0.87 43 (5.4)  2.4 1.5-3.8 0.0002  2.1 1.2-3.5 0.006 
     0.87-<2.4 44 (5.5)  2.0 1.2-3.2 0.004  1.5 0.9-2.7 0.1 
     2.4-<5.15 44 (5.5)  2.8 1.8-4.3 4x10-6  2.8 1.8-4.5 0.00002 
     ≥5.15 44 (5.5)  3.2 2.1-4.9 3x10-8  3.0 1.9-4.7 4x10-6 
     Missing 2 (0.3)         
     Test for trend   1.4 1.3-1.5 5x10-13  1.3 1.2-1.5 2x10-9 
1
4
4
 
   
Melanoma relapse 
(N=797, 253 events) 
Melanoma-specific death 
(N= 798, 207 events) 
Factor 
Mean (S.D.) or 
Median (range) or N (%) 
N HR 95%CI p-value N HR 95% CI p-value 
Tumour-infiltrating lymphocytes  706    706    
     Absent 52 (6.5)  1.0    1.0   
     Non-brisk 581 (72.8)  0.6 0.4-1.02 0.06  0.7 0.4-1.1 0.09 
     Brisk 73 (9.2)  0.7 0.4-1.3 0.3  0.5 0.2-1.01 0.05 
     Missing 92 (11.5)         
     Test for trend   0.9 0.6-1.2 0.4  0.7 0.5-1.0 0.05 
Tumour loss  793    793    
     No 649 (81.3)  1.0    1.0   
     Yes 144 (18.1)  1.5 1.1-2.0 0.007  1.5 1.1-2.1 0.008 
     Missing 5 (0.6)         
Type of tumour loss **  792    792    
     None 649 (81.3)  1.0    1.0   
     Deep 72 (9.0)  1.1 0.7-1.8 0.6  1.2 0.7-1.9 0.5 
     Both 22 (2.8)  3.0 1.7-5.2 0.0002  2.3 1.2-4.4 0.01 
     Superficial 49 (6.1)  1.5 0.97-2.4 0.07  1.8 1.1-2.9 0.02 
     Missing 6 (0.8)         
Depth of tumour loss (mm) 1.1 (0.2-7.2) 793    793    
     None 649 (81.3)  1.0    1.0   
     <0.71 41 (5.2)  1.1 0.7-1.9 0.7  1.4 0.8-2.5 0.2 
     0.71-<1.14 36 (4.5)  0.9 0.5-1.8 0.8  0.9 0.4-1.8 0.7 
     1.14-<1.63 31 (3.9)  1.8 1.02-3.0 0.04  1.9 1.1-3.4 0.03 
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Melanoma relapse 
(N=797, 253 events) 
Melanoma-specific death 
(N= 798, 207 events) 
Factor 
Mean (S.D.) or 
Median (range) or N (%) 
N HR 95%CI p-value N HR 95% CI p-value 
     ≥1.63 36 (4.5)  2.6 1.7-4.2 0.00004  2.2 1.3-3.7 0.003 
     Missing 5 (0.6)         
     Test for trend   1.2 1.1-1.4 0.00009  1.2 1.1-1.3 0.001 
Relative tumour loss (mm) 0.5 (0.04-1.6) 786    786    
     None 643 (80.6)  1.0    1.0   
     <0.26 35 (4.4)  2.0 1.3-3.3 0.004  2.4 1.5-4.1 0.001 
     0.26-<0.52 36 (4.5)  2.0 1.3-3.3 0.003  2.0 1.2-3.4 0.01 
     0.52-<0.786 37 (4.6)  1.4 0.8-2.4 0.2  1.2 0.6-2.3 0.6 
     ≥0.786 35 (4.4)  0.7 0.3-1.4 0.3  0.8 0.4-1.8 0.6 
     Missing 12 (1.5)         
     Test for trend   1.1 0.96-1.2 0.3  1.1 0.9-1.2 0.3 
Intensity of tumour-infiltrating 
macrophages/melanophages 
 789    790    
     None 256 (32.1)  1.0    1.0   
     Very few 286 (35.8)  0.9 0.7-1.2 0.4  0.9 0.7-1.3 0.7 
     Moderate 175 (21.9)  0.96 0.7-1.4 0.8  0.8 0.6-1.2 0.3 
     Lots 73 (9.2)  1.0 0.6-1.6 1.0  0.8 0.5-1.4 0.4 
     Missing 8 (1.0)         
     Test for trend   1.0 0.9-1.1 0.9  0.9 0.8-1.1 0.2 
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Melanoma relapse 
(N=797, 253 events) 
Melanoma-specific death 
(N= 798, 207 events) 
Factor 
Mean (S.D.) or 
Median (range) or N (%) 
N HR 95%CI p-value N HR 95% CI p-value 
Pattern of tumour-infiltrating 
macrophages/melanophages 
 708    708    
Absent 140 (17.5)  1.0    1.0   
Non-brisk 560 (70.2)  0.8 0.6-1.2 0.3  0.9 0.6-1.3 0.7 
Brisk 8 (1.0)  0.3 0.04-2.3 0.3  0.9 0.2-3.6 0.8 
Missing 90 (11.3)         
Test for trend   0.8 0.6-1.1 0.2  0.9 0.7-1.3 0.6 
 1
4
7
 
148 
Breslow thickness was available for 789 cases (Table 4.2). The median Breslow 
thickness was 2mm (range 0.5-19.5mm). Figure 4.1 shows a histogram of the 
frequency distribution of the Breslow thickness. 
Microscopic ulceration was present in 22% (177/798) cases (Table 4.2). Figure 4.2 
shows the frequency distribution for the extent (width) of ulceration. 
Data on tumour loss (where this means a clear deficit within the silhouette of the 
melanoma at 4x magnification; being composed of a variable presence of lymphocytes, 
melanophages and/or fibrous tissue) were available for 793 cases. Tumour loss was 
present in 18% (144/798) of cases. Figure 4.3 shows the frequency distribution of the 
depth of tumour loss. Due to the skewed frequency distributions, the extent of 
ulceration and the depth of tumour loss were grouped into approximate quartiles for the 
time-to-event analyses. The reference categories were “no ulceration” and “no tumour 
loss”, respectively. 
 
Figure 4.1: Histogram of the frequency distribution of the Breslow thickness  
The histogram shows the frequency distribution in 789 cases reviewed using the 
virtual pathology protocol. 
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Figure 4.2: Histogram of the frequency distribution of the measurements of the 
extent of ulceration. 
The median extent of ulceration was 2.5mm (range 0.1-17.4mm). 
 
Figure 4.3: Histogram of the frequency distribution of the measurements of the 
depth of tumour loss. 
The median depth of tumour loss was 1.1mm (range 0.2-7.2mm). 
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The results of the univariable analysis of all whole-tumour measures are summarised in 
Table 4.2. As expected, increasing Breslow thickness was associated with an 
increased risk of relapse and melanoma-specific death. Hazard ratios increased for 
each Breslow thickness cut-off point (derived from AJCC stage [43]) and tests for trend 
were highly significant (e.g. HR 1.9, 95% CI 1.6-2.2, Cox proportional hazards model, 
p=3x10-15 for melanoma-specific death). The presence of a dominant nodule and the 
presence of microscopic ulceration were each significantly associated with a poor 
prognosis. The HRs for the presence of brisk or non-brisk tumour-infiltrating 
lymphocytes (TILs) were less than 1, suggesting a protective effect compared to 
absent TILs but the tests did not reach statistical significance. The presence of tumour 
loss was associated with a poor prognosis and this result was statistically significant, 
particularly if both deep and superficial types were present (referred to as “both” in 
Table 4.2). Increasing depth of tumour loss (measured in mm) was associated with an 
increased risk of melanoma relapse and death, especially when the thickness reached 
>1.63mm, compared to none. The corresponding tests for trend were highly statistically 
significant. Neither the intensity nor the pattern of tumour-infiltrating melanophages 
significantly influenced relapse or melanoma-specific death. 
4.3.1.3 Cored region measures 
Cored region variables were recorded on 702 cases for which black markings were still 
present on the histology slides (corresponding to the sites that had been cored using a 
TMA biopsy needle) prior to the slides being cleaned with ethanol and scanned, to 
create the virtual pathology repository of primary melanoma images. Table 4.3 
summarises the frequency distribution of each cored region factor and the 
corresponding unadjusted HR, 95% CI and p-value for both melanoma relapse and 
death.  
The median estimated percentage of stromal content was 32.7% (range 0-98.1%) 
(Table 4.3, page 151). Figure 4.4 shows the histogram of the frequency distribution of 
the percentage of stroma (POS). 
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Figure 4.4: Histogram of the frequency distribution of the percentage of stroma 
The median POS was 32.69%. 
Table 4.3 (on following page): Unadjusted hazard ratios for melanoma relapse 
and melanoma-specific death for cored region measures 
Unadjusted hazard ratios (HR), 95% confidence intervals (95% CI) and p-values 
were estimated from Cox proportional hazards models. The second column refers 
to descriptive statistics for the factor in the first column. N=number of cases. 
S.D.=standard deviation. ‘N’ in 3rd and 7th columns refers to the number of cases 
in the statistical model. Events refers to the number of cases that had either 
relapsed or died due to melanoma. No/barely perceptible* refers to the absence 
of a core immune cell infiltrate or its presence to a barely perceptible extent. 
These were grouped together as the reference category (baseline) for analyses 
of other core immune cell variables, e.g. lymphocytes. Yes* for the presence of a 
core immune cell infiltrate in this table means that the extent of the core immune 
cell infiltrate was either some, moderate or lots. Exact p-values are provided 
where possible. STATA could not provide exact p-values for some variables 
because they were so significant and the estimated p-values are provided instead 
(e.g. the test for trend for core mitoses). The reference category (baseline) is the 
first category listed for each of the categorical variables. Some of the hazard 
ratios, 95% CIs and/or p-values could not be calculated because there were no 
events for that category (e.g. plasmacytoid cell shape), i.e. none of these cases 
had relapsed or died due to melanoma. NC = not calculable. 
   
Melanoma relapse 
(N=701, 223 events) 
Melanoma-specific death 
(N= 702, 181 events) 
Factor 
Mean (S.D.) or 
Median (range) or N (%) 
N HR 95% CI p-value N HR 95% CI p-value 
Percentage of stroma (continuous) 32.69 (0-98.08) 701 0.98 0.97-0.99 8X10-9 702 0.97 0.97-0.98 6x10-9 
Percentage of stroma (quintiles)  701    702    
   0-<17 136 (17.0)  1.0    1.0   
   17-<27 147 (18.4)  0.7 0.5-0.97 0.03  0.8 0.6-1.2 0.4 
   27-<38 143 (17.9)  0.6 0.4-0.8 0.004  0.5 0.3-0.8 0.004 
   38-<52 144 (18.1)  0.4 0.2-0.6 3x10-6  0.3 0.2-0.5 4x10-6 
   ≥52 132 (16.6)  0.3 0.2-0.4 1x10-7  0.3 0.2-0.5 7x10-6 
   Missing 96 (12.0)         
   Test for trend   0.7 0.7-0.8 4x10-10  0.7 0.6-0.8 1x10-9 
Percentage of stroma (15% cut-off)  701    702    
   0-15 107 (13.4)  1.0    1.0   
   >15 595 (74.6)  0.5 0.3-0.6 9X10-7  0.5 0.4-0.7 0.00005 
   Missing 96 (12.0)         
Percentage of stroma (20% cut-off)  701    702    
   0-20 172 (21.6)  1.0    1.0   
   >20 530 (66.4)  0.5 0.4-0.6 2x10-7  0.5 0.3-0.6 1x10-6 
   Missing 96 (12.0)         
Percentage of stroma (30% cut-off)  701    702    
   0-30 321 (40.2)  1.0    1.0   
   >30 381 (47.7)  0.5 0.4-0.7 1x10-6  0.5 0.3-0.6 5x10-7 
   Missing 96 (12.0)         
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Melanoma relapse 
(N=701, 223 events) 
Melanoma-specific death 
(N= 702, 181 events) 
Factor 
Mean (S.D.) or 
Median (range) or N (%) 
N HR 95% CI p-value N HR 95% CI p-value 
Percentage of stroma (40% cut-off)  701    702    
   0-40 438 (54.9)  1.0    1.0   
   >40 264 (33.1)  0.4 0.3-0.6 2x10-7  0.4 0.3-0.6 2x10-7 
   Missing 96 (12.0)         
Percentage of stroma (49% cut-off)  701    702    
   0-49 536 (67.2)  1.0    1.0   
   >49 166 (20.8)  0.5 0.3-0.7 0.00004  0.4 0.3-0.6 0.00009 
   Missing 96 (12.0)         
Percentage of stroma (median cut-off)  701    702    
   0-<32.69 350 (43.9)  1.0    1.0   
   ≥32.69 352 (44.1)  0.5 0.3-0.6 2x10-8  0.4 0.3-0.6 2x10-8 
   Missing 96 (12.0)         
Quality of the stroma  651    651    
   Compact 595 (74.6)  1.0    1.0   
   Loose 22 (2.8)  0.8 0.4-1.6 0.5  0.8 0.3-1.8 0.6 
   Mixed 34 (4.2)  0.5 0.2-1.05 0.07  0.5 0.2-1.2 0.1 
   Missing 147 (18.4)         
Melanoma cell shape  699    700    
   Round/ovoid/epithelioid 602 (75.4)  1.0    1.0   
   Spindle 60 (7.5)  0.8 0.5-1.3 0.3  0.8 0.4-1.4 0.4 
   Super spindle 14 (1.8)  0.4 0.1-1.7 0.2  0.6 0.2-2.5 0.5 
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Melanoma relapse 
(N=701, 223 events) 
Melanoma-specific death 
(N= 702, 181 events) 
Factor 
Mean (S.D.) or 
Median (range) or N (%) 
N HR 95% CI p-value N HR 95% CI p-value 
   Naevoid 16 (2.0)  0.9 0.4-2.1 0.8  1.3 0.6-2.9 0.6 
   Plasmacytoid 6 (0.8)  NC NC NC  NC NC NC 
   Balloon 2 (0.2)  5.7 1.4-23.2 0.01  2.0 0.3-14.3 0.5 
   Missing 98 (12.3)         
Melanoma cell structure  694    695    
   Nests 413 (51.8)  1.0    1.0   
   Sheets 134 (16.8)  1.7 1.2-2.3 0.001  1.8 1.3-2.6 0.001 
   Fascicles 127 (15.9)  1.2 0.8-1.7 0.3  1.2 0.8-1.8 0.3 
   Dispersed 21 (2.6)  1.9 0.98-3.6 0.06  2.0 0.9-4.0 0.07 
   Missing 103 (12.9)         
Melanoma cell pigmentation  699    700    
   Absent 522 (65.4)  1.0    1.0   
   Faint 45 (5.6)  0.99 0.6-1.7 1.0  0.9 0.5-1.7 0.8 
   Moderate 82 (10.3)  0.8 0.5-1.2 0.2  0.6 0.3-1.05 0.07 
   High 46 (5.8)  1.2 0.7-1.9 0.5  0.9 0.5-1.7 0.7 
   Very high 5 (0.6)  0.9 0.1-6.3 0.9  2.7 0.7-11.0 0.2 
   Missing 98 (12.3)         
   Test for trend   0.98 0.9-1.1 0.8  0.9 0.8-1.1 0.3 
Core immune cell infiltrate (categorised)  698    699    
   Yes (immune cells, excluding barely 
    perceptible) 
400 (50.1)  1.0    1.0   
1
5
4
 
   
Melanoma relapse 
(N=701, 223 events) 
Melanoma-specific death 
(N= 702, 181 events) 
Factor 
Mean (S.D.) or 
Median (range) or N (%) 
N HR 95% CI p-value N HR 95% CI p-value 
   No (immune cells) 33 (4.2)  2.0 1.2-3.4 0.01  2.4 1.3-4.3 0.004 
   Barely perceptible (immune cells) 266 (33.3)  1.8 1.4-2.4 0.00003  2.3 1.7-3.1 2x10-7 
   Missing 99 (12.4)         
Extent of the core immune cell infiltrate  698    699    
   No/barely perceptible* 299 (37.5)  1.0    1.0   
   Some (immune cells) 252 (31.6)  0.7 0.5-0.9 0.005  0.5 0.3-0.7 0.00002 
   Moderate (immune cells) 100 (12.5)  0.4 0.2-0.7 0.0002  0.4 0.2-0.6 0.0002 
   Lots (immune cells) 48 (6.0)  0.3 0.2-0.7 0.003  0.4 0.2-0.8 0.01 
   Missing 99 (12.4)         
   Test for trend   0.7 0.6-0.8 2x10-6  0.6 0.5-0.8 2x10-6 
Location of the core immune cell infiltrate  696    697    
   No/barely perceptible* 299 (37.5)  1.0    1.0   
   At the tumour/stroma interface 126 (15.8)  0.6 0.4-0.9 0.005  0.5 0.3-0.7 0.001 
   Dispersed between tumour cells 150 (18.8)  0.6 0.4-0.8 0.003  0.4 0.3-0.7 0.0001 
   Both 122 (15.3)  0.5 0.3-0.7 0.001  0.4 0.3-0.7 0.0002 
   Missing 101 (12.6)         
Core lymphocytic infiltrate  697    698    
   No/barely perceptible* 299 (37.5)  1.0    1.0   
   No (lymphocytes) 132 (16.5)  0.8 0.6-1.1 0.2  0.7 0.5-0.97 0.04 
   Yes (lymphocytes) 267 (33.5)  0.4 0.3-0.6 5x10-7  0.3 0.2-0.5 5x10-9 
   Missing 100 (12.5)         
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Melanoma relapse 
(N=701, 223 events) 
Melanoma-specific death 
(N= 702, 181 events) 
Factor 
Mean (S.D.) or 
Median (range) or N (%) 
N HR 95% CI p-value N HR 95% CI p-value 
   Test for trend   0.7 0.6-0.8 5x10-7  0.6 0.5-0.7 3x10-9 
Extent of the core lymphocytic infiltrate  697    698    
   No/barely perceptible* 299 (37.5)  1.0    1.0   
   No (lymphocytes) 132 (16.6)  0.8 0.6-1.1 0.2  0.7 0.5-0.97 0.04 
   Some (lymphocytes) 179 (22.4)  0.5 0.4-0.8 0.0004  0.4 0.3-0.6 6x10-6 
   Moderate (lymphocytes) 47 (5.9)  0.3 0.1-0.7 0.002  0.2 0.05-0.5 0.001 
   Lots (lymphocytes) 41 (5.1)  0.2 0.1-0.6 0.002  0.3 0.1-0.7 0.006 
   Missing 100 (12.5)         
   Test for trend   0.7 0.6-0.8 1x10-7  0.6 0.5-0.7 8x10-9 
Core plasma cell infiltrate  696    697    
   No/barely perceptible* 299 (37.5)  1.0    1.0   
   No (plasma cells) 384 (48.1)  0.6 0.4-0.7 0.00001  0.4 0.3-0.6 5x10-8 
   Yes (plasma cells) 14 (1.8)  0.4 0.1-1.4 0.2  0.6 0.2-1.8 0.3 
   Missing 101 (12.6)         
   Test for trend   0.6 0.4-0.7 0.00001  0.5 0.3-0.6 2x10-7 
Extent of the core plasma cell infiltrate  696    697    
   No/barely perceptible* 299 (37.5)  1.0    1.0   
   No (plasma cells) 384 (48.1)  0.6 0.4-0.7 0.00001  0.4 0.3-0.6 5x10-8 
   Some (plasma cells) 12 (1.5)  0.5 0.2-1.7 0.3  0.7 0.2-2.1 0.5 
   Moderate (plasma cells) 0 (0)  NC NC NC  NC NC NC 
   Lots (plasma cells) 2 (0.3)  NC NC NC  NC NC NC 
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Melanoma relapse 
(N=701, 223 events) 
Melanoma-specific death 
(N= 702, 181 events) 
Factor 
Mean (S.D.) or 
Median (range) or N (%) 
N HR 95% CI p-value N HR 95% CI p-value 
   Missing 101 (12.6)         
   Test for trend   0.6 0.4-0.7 0.00001  0.5 0.3-0.6 2x10-7 
Core macrophage/melanophage infiltrate  697    698    
   No/barely perceptible* 299 (37.5)  1.0    1.0   
   No (macrophages/melanophages) 121 (15.2)  0.6 0.4-0.8 0.003  0.4 0.3-0.7 0.0002 
   Yes (macrophages/melanophages) 278 (34.8)  0.6 0.4-0.7 0.00009  0.4 0.3-0.6 3x10-6 
   Missing 100 (12.5)         
   Test for trend   0.7 0.6-0.9 0.00005  0.7 0.5-0.8 1x10-6 
Extent of the core 
macrophage/melanophage infiltrate 
 697    698    
   No/barely perceptible* 299 (37.5)  1.0    1.0   
   No (macrophages/melanophages) 121 (15.2)  0.6 0.4-0.8 0.003  0.4 0.3-0.7 0.0002 
   Some (macrophages/melanophages) 118 (14.8)  0.5 0.4-0.8 0.002  0.4 0.2-0.7 0.0002 
   Moderate (macrophages/melanophages) 112 (14.0)  0.7 0.4-0.96 0.03  0.5 0.3-0.8 0.004 
   Lots (macrophages/melanophages) 48 (6.0)  0.4 0.2-0.8 0.008  0.4 0.2-0.8 0.02 
   Missing 100 (12.5)         
   Test for trend   0.8 0.7-0.9 0.0002  0.8 0.7-0.9 0.00003 
Core neutrophilic infiltrate  696    697    
   No/barely perceptible* 299 (37.5)  1.0    1.0   
   No (neutrophils) 386 (48.4)  0.5 0.4-0.7 5x10-6  0.4 0.3-0.6 6x10-8 
   Yes (neutrophils) 12 (1.5)  1.2 0.5-2.8 0.7  0.5 0.1-1.9 0.3 
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Melanoma relapse 
(N=701, 223 events) 
Melanoma-specific death 
(N= 702, 181 events) 
Factor 
Mean (S.D.) or 
Median (range) or N (%) 
N HR 95% CI p-value N HR 95% CI p-value 
   Missing 101 (12.6)         
   Test for trend   0.6 0.5-0.8 0.00006  0.5 0.3-0.6 1x10-7 
Extent of the core neutrophilic infiltrate  696    697    
   No/barely perceptible* 299 (37.5)  1.0    1.0   
   No (neutrophils) 386 (48.4)  0.5 0.4-0.7 5x10-6  0.4 0.3-0.6 6x10-8 
   Some (neutrophils) 12 (1.5)  1.2 0.5-2.8 0.7  0.5 0.1-1.9 0.3 
   Moderate (neutrophils) 0 (0)  NC NC NC  NC NC NC 
   Lots (neutrophils) 0 (0)  NC NC NC  NC NC NC 
   Missing 101 (12.6)         
   Test for trend   0.6 0.5-0.8 0.00006  0.5 0.3-0.6 1x10-7 
Core eosinophilic infiltrate  696    697    
   No/barely perceptible* 299 (37.5)  1.0    1.0   
   No (eosinophils) 396 (49.6)  0.6 0.4-0.7 0.00001  0.4 0.3-0.6 7x10-8 
   Yes (eosinophils) 2 (0.3)  NC NC NC  NC NC NC 
   Missing 101 (12.6)         
   Test for trend   0.5 0.4-0.7 7x10-6  0.4 0.3-0.6 4x10-8 
Extent of the core eosinophilic infiltrate  696    697    
   No/barely perceptible* 299 (37.5)  1.0    1.0   
   No (eosinophils) 396 (49.6)  0.6 0.4-0.7 0.00001  0.4 0.3-0.6 7x10-8 
   Some (eosinophils) 2 (0.3)  NC NC NC  NC NC NC 
   Moderate (eosinophils) 0 (0)  NC NC NC  NC NC NC 
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Melanoma relapse 
(N=701, 223 events) 
Melanoma-specific death 
(N= 702, 181 events) 
Factor 
Mean (S.D.) or 
Median (range) or N (%) 
N HR 95% CI p-value N HR 95% CI p-value 
   Lots (eosinophils) 0 (0)  NC NC NC NC NC NC NC 
   Missing 101 (12.6)         
   Test for trend   0.5 0.4-0.7 7x10-6  0.4 0.3-0.6 4x10-8 
Core mitoses (tertiles) 1 (0-31) 694    695    
   0 206 (25.8)  1.0    1.0   
   1-2 257 (32.2)  1.9 1.2-2.8 0.004  1.9 1.2-3.0 0.008 
   ≥3 232 (29.1)  4.5 3.1-6.7 3x10-14  4.2 2.7-6.5 2x10-10 
   Missing 103 (12.9)         
   Test for trend   2.2 1.8-2.7 <1x10-16  2.1 1.7-2.6 3x10-12 
Core blood vessels 2 (0-64) 699    700    
   0 122 (15.3)  1.0    1.0   
   1-2 264 (33.1)  1.04 0.7-1.5 0.8  0.9 0.6-1.3 0.6 
   ≥3 314 (39.4)  0.9 0.6-1.2 0.4  0.9 0.6-1.3 0.5 
   Missing 98 (12.3)         
   Test for trend   0.9 0.8-1.1 0.3  0.9 0.8-1.1 0.6 
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The majority (75%, 595/798) of cases had a compact stroma (Table 4.3). Melanoma 
cells with a round/ovoid/epithelioid appearance were the most common type to be 
identified within the cored region. In more than half of cases, melanoma cells were 
arranged in nests. Interestingly, absent pigmentation was recorded in 65% (522/798) of 
cored regions. Most (83%, 666/798) cored regions contained an immune cell infiltrate, 
although this was barely perceptible in one third of cases overall. The most commonly 
reported immune cell infiltrates within the cored region were lymphocytes and 
melanophages, whilst plasma cells, neutrophils and eosinophils were infrequently 
recorded. The presence of ≥3 mitoses or ≥3 blood vessels was recorded in 29% 
(232/798) and 39% (314/798) of cored regions, respectively. Figure 4.5 shows the 
frequency distribution of mitoses within the core. Due to the skewed frequency 
distribution, this measure was grouped into approximate tertiles for the time-to-event 
analyses (categories 0, 1-2 and ≥3). Similarly, the number of blood vessels within the 
core was grouped as 0, 1-2 and ≥3 (histogram not shown). 
 
Figure 4.5 Histogram of the frequency distribution of the number of mitoses 
within the core 
The median number of core mitoses was 1 (range 0-31). The number of mitoses 
was grouped into approximately three equal groups (tertiles). 
In the univariable analysis, the POS was significantly associated with a decreased risk 
of relapse (HR 0.98, 95% CI 0.97-0.99, Cox proportional hazards model, p=8x10-9) and 
melanoma-specific death (HR 0.97, 95% CI 0.97-0.98, Cox proportional hazards 
model, p=6x10-9) (Table 4.3). For every percentage increase in the POS, there was a 
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2% decreased risk of melanoma relapse and a 3% decreased risk of death and this 
was highly statistically significant. The POS was also divided into quintiles to see 
whether there was a decreasing risk per quintile. There was a clear trend to decreasing 
risk of relapse and death with increasing quintiles of the POS. A definitive cut-off point 
for the POS, to help to stratify cases according to prognosis, could not be identified. 
Balloon cells appeared to increase the risk of relapse, compared to 
round/ovoid/epithelioid cells (HR 5.7, 95% CI 1.4-23.2, Cox proportional hazards 
model, p=0.01), however they were recorded in just 2 (0.2%) cases. The presence of 
melanoma cells arranged in sheets within the cored region was significantly hazardous 
for both melanoma relapse and death when compared with nests (HR for relapse 1.7, 
95% CI 1.2-2.3, Cox proportional hazards model, p=0.001 and HR for melanoma-
specific death 1.8, 95% CI 1.3-2.6, Cox proportional hazards model, p=0.001). The 
degree of melanoma cell pigmentation did not influence outcome. The increasing 
abundance of immune cells within the cored region (referred to as the “extent of core 
immune cell infiltrate”), particularly of lymphocytes (referred to as the “extent of core 
lymphocytic infiltrate”), was associated with a decreased risk of melanoma relapse and 
death. In total, 4% (33/798) cases lacked a core immune cell infiltrate. One third of 
cases (266/798) had a barely perceptible core immune cell infiltrate, whilst half of 
cases (400/798) had a core immune cell infiltrate graded as some, moderate or lots. As 
there were only 33 cases that lacked a core immune cell infiltrate and the HRs for “no” 
and “barely perceptible” were similar, these were grouped together for statistical 
analyses. This was utilised as the reference category (baseline) for analyses of the 
location of the core immune cell infiltrate and of the core immune cell subtypes (e.g. the 
extent of the core lymphocytic infiltrate) to increase the statistical power. The 
corresponding tests for trend were highly statistically significant. The presence of 
mitoses within the cored region was significantly hazardous for melanoma relapse (HR 
1.9, 95% CI 1.2-2.8, Cox proportional hazards model, p=0.004 for 1-2 versus 0 mitoses 
and HR 4.5, 95% CI 3.1-6.7, Cox proportional hazards model, p=3x10-14 for ≥3 versus 
0 mitoses) and death (HR 1.9, 95% CI 1.2-3.0, Cox proportional hazards model, 
p=0.008 for 1-2 versus 0 mitoses and HR 4.2, 95% CI 2.7-6.5, Cox proportional 
hazards model, p=2x10-10 for ≥3 versus 0 mitoses) and there was a significant trend 
with increasing numbers of mitoses. Neither the presence nor the number of blood 
vessels within the cored region were significantly associated with melanoma relapse or 
death. 
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4.3.2 Multivariable relapse analysis 
4.3.2.1 Selection of variables from the univariable analysis for the 
multivariable relapse analyses 
In multivariable analyses of melanoma relapse, I elected to adjust for AJCC stage 
rather than the Breslow thickness, microscopic ulceration and the number of core 
mitoses because AJCC stage is utilised clinically to predict outcome. The test for trend 
was used for AJCC stage in multivariable analyses because there was a trend for HRs 
and it was highly statistically significant in unadjusted analysis (Table 4.1). 
In univariable analyses of the whole tumour measures, the presence of a dominant 
nodule and the depth of tumour loss were significant predictors of melanoma relapse 
(Table 4.2). The depth of tumour loss was selected for multivariable analyses, in 
preference to the type of tumour loss (or to the relative tumour loss), because it was a 
stronger predictor of relapse (Table 4.2). The test for trend was used in multivariable 
analyses in preference to analysing individual categories for the depth of tumour loss 
because the test for trend was highly significant (Table 4.2) and using this reduced the 
degrees of freedom, thereby increasing the statistical power and hence, the ability to 
detect significant effects. Therefore, a multivariable model was constructed including 
the presence of a dominant nodule and the depth of tumour loss plus age, sex, AJCC 
stage and the site of primary melanoma (data not shown). In this model, age, sex, 
“other” body site, AJCC stage, the presence of a dominant nodule and the depth of 
tumour loss remained independent predictors of melanoma relapse (data not shown). 
Of the cored region variables, the POS, melanoma cell shape, melanoma cell structure 
and all of the core immune cell infiltrate variables were significant predictors of 
melanoma relapse (Table 4.3). In pairwise analyses, the core immune cell infiltrate 
variables were shown to be highly associated with each other (data not shown). For 
example, the Spearman correlation coefficient between the extent of the core immune 
cell infiltrate and the extent of the core lymphocytic infiltrate was 0.9 (p=2x10-245) (Table 
4.4). Also, the reference category (baseline) for each of the core immune cell subtypes 
was the same, i.e. “no/barely perceptible” immune cell infiltrate, which was recorded in 
299 cases. The extent of the core immune cell infiltrate and the extent of the core 
lymphocytic infiltrate were chosen to be used in separate multivariable models (Table 
4.5 and Table 4.6) as these were the most significant predictors of melanoma relapse 
in univariable analyses out of the core immune cell subtypes (Table 4.3). 
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Table 4.4: Cross-tabulation of the extent of the core immune cell and 
lymphocytic infiltrates.  
The reference category (no/barely perceptible for the core immune cell infiltrate) is the 
same for each of these factors. As previously discussed, this was because the 
presence of a barely perceptible core immune cell infiltrate conferred a similar hazard 
ratio to an absent core immune cell infiltrate. This merged no/barely perceptible 
category was then used as the reference category (baseline) for specific types of 
immune cells (lymphocytes in this case) to increase the statistical power. 
 Extent of the core lymphocytic infiltrate 
Extent of the 
core immune 
cell infiltrate 
N (%) 
No/barely 
perceptible 
(immune 
cells) 
None  Some Moderate Lots Total 
No/barely 
perceptible 
(immune cells) 
299 (100) 0 (0) 0 (0) 0 (0) 0 (0) 
299 
(100) 
Some 
(immune cells) 
0 (0) 87 (65.9) 156 (87.2) 8 (17) 0 (0) 
251 
(36) 
Moderate 
(immune cells) 
0 (0) 35 (26.5) 19 (10.6) 37 (78.7) 9 (22) 
100 
(14.3) 
Lots 
(of immune 
cells) 
0 (0) 10 (7.6) 4 (2.2) 2 (4.3) 32 (78) 
48 
(6.9) 
Total 299 (100) 132 (100) 179 (100) 47 (100) 41 (100) 
698 
(100) 
4.3.2.2 The multivariable model for melanoma relapse 
A multivariable model, combining clinical, whole tumour and cored region measures 
included the following factors: age, sex, site of primary melanoma, AJCC stage, the 
presence of a dominant nodule, the depth of tumour loss, the POS, melanoma cell 
shape, melanoma cell structure and the extent of the core immune cell infiltrate (Table 
4.5). The results show that age, “other” site, AJCC stage, the presence of a dominant 
nodule, the depth of tumour loss, the POS, balloon cells, dispersed structure and the 
extent of the core immune cell infiltrate remained independent predictors of relapse. 
The HR for “other” body site versus limbs was 1.6 (95% CI 1.1-2.4, Cox proportional 
hazards model, p=0.02). Balloon cell shape conferred a HR of 6.1 (95% CI 1.5-26.0, 
Cox proportional hazards model, p=0.01) when compared with the reference category 
(baseline) of round/ovoid/epithelioid, however, there were only 2 patients with balloon 
cell shape and the confidence interval was very wide. Both cases with balloon cell 
shape relapsed by 4 years. 
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Dispersed cell structure conferred a HR of 2.7 (95% CI 1.3-5.8, Cox proportional 
hazards model, p=0.01) when compared with nests (Table 4.1). Again, there were 
small numbers of patients with dispersed cell structure and, therefore, the estimates 
may be unstable. Therefore, the multivariable analysis was repeated for the same 
factors, excluding melanoma cell shape. 
The second statistical model in Table 4.5 (on the right) shows the results of the 
multivariable analysis for the same factors, excluding melanoma cell shape. In this 
model, age, AJCC stage, the presence of a dominant nodule, the depth of tumour loss, 
the POS and the extent of the core immune cell infiltrate remained independent 
predictors of relapse. 
A similar analysis was then performed using the extent of the core lymphocytic 
infiltrate, instead of the extent of the core immune cell infiltrate. Table 4.6 shows the 
results of the multivariable model, including age, sex, site of primary melanoma, AJCC 
stage, the presence of a dominant nodule, the depth of tumour loss, the POS, 
melanoma cell shape, melanoma cell structure and the extent of the core lymphocytic 
infiltrate. Age, “other” site, AJCC stage, the presence of a dominant nodule, the depth 
of tumour loss, the POS, balloon cells, dispersed structure and the extent of the core 
lymphocytic infiltrate remained independent predictors of relapse. 
The second statistical model in Table 4.6 (on the right) shows the results of the 
multivariable model, including age, sex, site of primary melanoma, AJCC stage, the 
presence of a dominant nodule, the depth of tumour loss, the POS, melanoma cell 
structure and the extent of the core lymphocytic infiltrate. Melanoma cell shape was 
excluded from this model, for the reasons previously discussed. Age, AJCC stage, the 
presence of a dominant nodule, the depth of tumour loss and the POS remained 
independent predictors of relapse. The extent of the core lymphocytic infiltrate was 
marginally significant. 
Multivariable models were performed for the other immune cell types (e.g. 
macrophages, plasma cells, etc.), however, none of these immune cell subtypes were 
independently predictive of melanoma relapse (data not shown). 
 
 Table 4.5: Hazard ratios for melanoma relapse for clinical, whole-tumour and cored region measures (including the extent of the core 
immune cell infiltrate, with and without melanoma cell shape) 
Adjusted hazard ratios (HR), 95% confidence intervals (95% CI) and p-values were estimated from multivariable Cox proportional hazards 
models.  N refers to the number of cases. There were 687 cases in the statistical model. The number of cases analysed per category is 
provided. Events refers to the number of cases that had relapsed. The reference category (baseline) is the first category listed for each of the 
categorical variables. The first column provides the name and, where relevant, the categories for the variable. The first multivariable analysis 
includes melanoma cell shape (2nd-5th columns). The HR and 95% CI for plasmacytoid cell shape could not be calculated because there were 
no events in this category, i.e. none of these cases had relapsed. The multivariable analysis was repeated excluding melanoma cell shape (last 
4 columns). NC = not calculable. NA = not applicable.  
 Multivariable analysis including melanoma cell shape Multivariable analysis excluding melanoma cell shape 
 Melanoma relapse (N=687, 216 events) Melanoma relapse (N=687, 216 events) 
Factor N Adjusted HR 95% CI p-value N Adjusted HR 95% CI p-value 
Age at diagnosis (years) 687 1.02 1.01-1.03 0.003 687 1.02 1.01-1.03 0.006 
Sex         
   Male 318 1.0   318 1.0   
   Female 369 0.8 0.6-1.03 0.08 369 0.8 0.6-1.05 0.1 
Site of primary melanoma         
   Limbs 296 1.0   296 1.0   
   Trunk 231 1.1 0.8-1.6 0.5 231 1.1 0.8-1.5 0.7 
   Head 81 1.1 0.7-1.7 0.7 81 1.1 0.7-1.7 0.8 
   Other 79 1.6 1.1-2.4 0.02 79 1.5 0.98-2.2 0.06 
AJCC stage - Test for trend 687 1.9 1.6-2.4 8x10-10 687 1.9 1.6-2.4 4x10-10 
1
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  Multivariable analysis including melanoma cell shape Multivariable analysis excluding melanoma cell shape 
 Melanoma relapse (N=687, 216 events) Melanoma relapse (N=687, 216 events) 
Factor N Adjusted HR 95% CI p-value N Adjusted HR 95% CI p-value 
Dominant nodule         
   No 614 1.0   614 1.0   
   Yes 73 1.6 1.1-2.3 0.02 73 1.7 1.2-2.5 0.007 
Depth of tumour loss (mm)         
   Test for trend 687 1.1 1.01-1.3 0.03 687 1.1 1.02-1.3 0.03 
Percentage of stroma (continuous) 687 0.99 0.98-0.99 0.04 687 0.99 0.98-0.99 0.01 
Melanoma cell shape         
   Round/ovoid/epithelioid 590 1.0   NA NA   
   Spindle 60 0.8 0.4-1.3 0.3 NA NA NA NA 
   Super spindle 14 0.2 0.1-1.1 0.06 NA NA NA NA 
   Naevoid 15 0.8 0.3-2.2 0.7 NA NA NA NA 
   Plasmacytoid 6 NC NC NC NA NA NA NA 
   Balloon 2 6.1 1.5-26.0 0.01 NA NA NA NA 
Melanoma cell structure         
   Nests 410 1.0   410 1.0   
   Sheets 130 0.9 0.6-1.3 0.7 130 0.9 0.6-1.2 0.4 
   Fascicles 127 1.1 0.7-1.6 0.8 127 0.9 0.6-1.4 0.7 
   Dispersed 20 2.7 1.3-5.8 0.01 20 1.9 0.9-4.1 0.09 
Extent of the core immune cell 
infiltrate 
        
   Test for trend 687 0.8 0.7-0.97 0.03 687 0.8 0.7-0.99 0.04 
1
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 Table 4.6: Hazard ratios for melanoma relapse for clinical, whole-tumour and cored region measures (including the extent of the core 
lymphocytic infiltrate, with and without melanoma cell shape) 
Adjusted hazard ratios (HR), 95% confidence intervals (95% CI) and p-values were estimated from multivariable Cox proportional hazards 
models. N = number of cases in the statistical model. Events = number of relapsed cases. The reference category (baseline) is the first category 
listed for each categorical variable. The first column provides the name and, where relevant, the categories for the variable. The first 
multivariable analysis includes melanoma cell shape, the second excludes melanoma cell shape. The HR and 95% CI for plasmacytoid cell 
shape could not be calculated because there were no relapse events in this category. NC = not calculable. NA = not applicable. 
 
Multivariable analysis including 
melanoma cell shape 
Multivariable analysis excluding 
melanoma cell shape 
 Melanoma relapse (N= 687, 216 events) Melanoma relapse (N= 687, 216 events) 
Factor N Adjusted HR 95% CI p-value N Adjusted HR 95% CI p-value 
Age at diagnosis (years)  1.02 1.01-1.03 0.003  1.02 1.005-1.03 0.006 
Sex     318    
   Male 318 1.0   369 1.0   
   Female 369 0.8 0.6-1.04 0.09  0.8 0.6-1.05 0.1 
Site of primary melanoma         
   Limbs 296 1.0   296 1.0   
   Trunk 231 1.1 0.8-1.6 0.6 231 1.1 0.8-1.5 0.7 
   Head 81 1.1 0.7-1.7 0.7 81 1.04 0.7-1.6 0.9 
   Other 79 1.6 1.1-2.4 0.02 79 1.5 0.97-2.2 0.07 
AJCC stage         
   Test for trend 687 1.9 1.5-2.3 3x10-9 687 1.9 1.5-2.4 1x10-9 
1
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Multivariable analysis including 
melanoma cell shape 
Multivariable analysis excluding 
melanoma cell shape 
 Melanoma relapse (N= 687, 216 events) Melanoma relapse (N= 687, 216 events) 
Factor N Adjusted HR 95% CI p-value N Adjusted HR 95% CI p-value 
Dominant nodule         
   No 614 1.0   614 1.0   
   Yes 73 1.6 1.1-2.3 0.02 73 1.7 1.2-2.5 0.007 
Depth of tumour loss (mm)         
   Test for trend 687 1.1 1.01-1.3 0.04 687 1.1 1.01-1.3 0.03 
Percentage of stroma (continuous) 687 0.99 0.98-0.99 0.03 687 0.99 0.98-0.99 0.009 
Melanoma cell shape         
   Round/ovoid/epithelioid 590 1.0   NA NA   
   Spindle 60 0.8 0.4-1.3 0.3 NA NA NA NA 
   Super spindle 14 0.2 0.1-1.04 0.06 NA NA NA NA 
   Naevoid 15 0.8 0.3-2.2 0.7 NA NA NA NA 
   Plasmacytoid 6 NC NC NC NA NA NA NA 
   Balloon 2 6.3 1.5-26.5 0.01 NA NA NA NA 
Melanoma cell structure         
   Nests 410 1.0   410 1.0   
   Sheets 130 0.9 0.6-1.3 0.7 130 0.9 0.6-1.2 0.4 
   Fascicles 127 1.05 0.7-1.5 0.8 127 0.9 0.6-1.3 0.7 
   Dispersed 20 2.8 1.3-6.0 0.008 20 2.0 0.9-4.1 0.08 
Extent of the core lymphocytic infiltrate         
   Test for trend 687 0.8 0.7-0.98 0.03 687 0.9 0.7-1.0 0.05 
1
6
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4.3.3 Multivariable melanoma-specific survival analysis 
In multivariable melanoma-specific survival analyses, AJCC stage was used in 
preference to Breslow thickness, microscopic ulceration and the core mitotic count, for 
the same reasons as previously discussed (Section 4.3.2.1). In terms of other whole-
tumour measures, the presence of a dominant nodule and the type and depth of 
tumour loss were predictors of melanoma-specific death in univariable analyses (Table 
4.2). The test for trend for the depth of tumour loss was used in multivariable analyses, 
as this was a more powerful predictor than the categorised variable or the type of 
tumour loss (or the relative tumour loss) (Table 4.2). A multivariable model was 
constructed consisting of age, sex, site of primary melanoma, AJCC stage, the 
presence of a dominant nodule and the depth of tumour loss (data not shown). In this 
model, age, “other” body site and AJCC stage remained independent predictors of 
melanoma-specific death (data not shown). The presence of a dominant nodule and 
the test for trend for the depth of tumour loss were not independent predictors of death 
and, therefore, were not carried forward to subsequent multivariable analyses 
containing the cored region measures (data not shown). 
Of the cored region factors, the POS, melanoma cell structure and all of the core 
immune cell infiltrate variables were predictive for melanoma-specific death in 
univariable analyses (Table 4.3). Figure 4.6 shows the Kaplan-Meier survival estimates 
for melanoma-specific death for high and low POS (based on the median cut-off point). 
The extent of the core immune cell infiltrate and the extent of the core lymphocytic 
infiltrate were the most significant predictors of melanoma-specific death in univariable 
analyses of cored immune infiltrate measures (Table 4.3). Therefore, a multivariable 
model was constructed, containing age, sex, site of primary melanoma, AJCC stage, 
the POS, melanoma cell structure and each of the following factors separately: the 
extent of the core immune cell infiltrate and the extent of the core lymphocytic infiltrate 
(Table 4.7). The results show that age, “other” site, AJCC stage, the POS and 
dispersed structure remained independent predictors of melanoma-specific death. The 
extent of the core immune cell infiltrate was marginally significant. The HR for “other” 
body site versus limbs was 1.8 (95% CI 1.2-2.8, Cox proportional hazards model, 
p=0.007). Dispersed structure conferred a HR of 2.4 (95% CI 1.1-5.5, Cox proportional 
hazards model, p=0.03) when compared with nests. There were small numbers of 
patients with dispersed structure and, therefore, the estimates may be unstable. 
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Figure 4.6: Kaplan-Meier curves and risk table for melanoma-specific survival for 
cases with high and low percentage of stroma 
The median (32.69%) was used as the cut-off point to define cases with a high 
(≥32.69%) or low (<32.69) POS. Cases with a high POS tended to survive longer 
(HR 0.4, 95% CI 0.3-0.6, Cox proportional hazards model, p=2x10-8). 
The second statistical model in Table 4.7 shows the results of the multivariable 
analysis containing age, sex, site of primary melanoma, AJCC stage, the POS, 
melanoma cell structure and the extent of the core lymphocytic infiltrate. Age, “other” 
body site, AJCC stage, the POS, dispersed structure and the extent of the core 
lymphocytic infiltrate remained independent predictors of survival. 
 
Table 4.7 (on following page): Hazard ratios for melanoma-specific death for 
clinical, whole-tumour and cored region measures (including either the 
extent of the core immune cell or lymphocytic infiltrate) 
Adjusted hazard ratios (HR), 95% confidence intervals (95% CI) and p-values 
were estimated from multivariable Cox proportional hazards models. N refers to 
the number of cases in the statistical model. Events refers to the number of cases 
that had died due to melanoma. The reference category (baseline) is the first 
category listed for each of the categorical variables. 
  
Multivariable analysis with the extent 
of the core immune cell infiltrate 
Multivariable analysis with the extent 
of the core lymphocytic infiltrate 
 Melanoma-specific death (N=692, 177 events) Melanoma-specific death (N= 692, 177 events) 
Factor N Adjusted HR 95% CI p-value N Adjusted HR 95% CI p-value 
Age at diagnosis (years)  1.03 1.02-1.04 0.00004  1.03 1.02-1.04 0.00005 
Sex         
   Male 320 1.0   320 1.0   
   Female 372 0.8 0.6-1.1 0.3 372 0.8 0.6-1.2 0.3 
Site of primary melanoma         
   Limbs 297 1.0   297 1.0   
   Trunk 232 1.4 0.97-2.1 0.07 232 1.4 0.9-2.0 0.1 
   Head 81 0.9 0.5-1.6 0.8 81 0.9 0.5-1.6 0.7 
   Other 82 1.8 1.2-2.8 0.007 82 1.7 1.1-2.6 0.02 
AJCC stage         
   Test for trend 692 2.3 1.8-2.9 9x10-12 692 2.2 1.7-2.8 6x10-11 
Percentage of stroma (continuous) 692 0.99 0.98-0.99 0.005 692 0.99 0.98-0.99 0.009 
Melanoma cell structure         
   Nests 411 1.0   411 1.0   
   Sheets 133 1.1 0.7-1.6 0.7 133 1.1 0.7-1.6 0.7 
   Fascicles 127 1.02 0.7-1.5 0.9 127 1.0 0.7-1.5 1.0 
   Dispersed 21 2.4 1.1-5.5 0.03 21 2.4 1.1-5.5 0.03 
Extent of the core immune cell infiltrate or 
extent of the core lymphocytic infiltrate 
        
   Test for trend 692 0.8 0.7-0.99 0.05 692 0.8 0.7-0.9 0.01 
 
1
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Figure 4.7 shows the Kaplan-Meier curves for the time-to-event analysis for melanoma-
specific death by the type of melanoma cell structure. 
 
Figure 4.7: Kaplan-Meier curves and risk table for melanoma-specific survival for 
each melanoma cell structure.  
The curve for dispersed cell structure appeared to be more unstable than the 
curves for other cell structures, which might reflect the small numbers in this 
group. “Nests” was the reference category. Table 4.3 shows the HRs, 95% CI 
and p-values for melanoma-specific death according to melanoma cell structure. 
Dispersed cell structure was not statistically significant in univariable survival 
analysis but was an independent predictor in multivariable analyses (Table 4.7). 
Figure 4.8 shows the Kaplan-Meier curves for melanoma-specific survival by the extent 
of the core immune cell infiltrate. 
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Figure 4.8: Kaplan-Meier curves and risk table for melanoma-specific survival by 
the extent of the core immune cell infiltrate  
Cases with a core immune cell infiltrate categorised as no/barely perceptible 
tended to have a worse outcome, compared to some, moderate or lots (test for 
trend, Cox proportional hazards model, p=2x10-6). 
 
Figure 4.9 shows the Kaplan-Meier curves for melanoma-specific survival by the extent 
of the core lymphocytic infiltrate. 
Multivariable models were performed for the other core immune cell subset variables 
and the results were similar for the presence of plasma cells, neutrophils and 
eosinophils, however, the presence of macrophages was not significant in multivariable 
analysis (data not shown). 
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Figure 4.9: Kaplan-Meier curves and risk table for melanoma-specific survival by 
the extent of the core lymphocytic infiltrate 
No/barely perceptible refers to the extent of the core immune cell infiltrate, which 
was the reference category (baseline) for the analyses of the core immune cell 
subtypes. Cases with a core immune cell infiltrate categorised as no/barely 
perceptible tended to have the shortest interval to melanoma-specific death, 
followed by cases without a core lymphocytic infiltrate. If the core immune cell 
infiltrate was classified as no or barely perceptible, no further assessment was 
done for the type of immune cells present, e.g. lymphocytes or macrophages. 
Although cases in the “no lymphocytes” category lacked lymphocytes, other types 
of immune cells within the core could have contributed to the benefit seen 
compared to cases within the no/barely perceptible category. Of the 132 cases in 
the “no lymphocytes” category, the following immune cells were present within 
the core: macrophages/melanophages (n=132), plasma cells (n=1), neutrophils 
(n=6). Cases with a core lymphocytic infiltrate tended to survive longer (test for 
trend, Cox proportional hazards model, p=8x10-9). 
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4.4 Summary 
In terms of clinical factors, older age at diagnosis, male sex, trunk, “other” site of 
primary melanoma and advancing AJCC stage were significantly predictive of an 
increased risk of both melanoma relapse and death in univariable analyses (Table 4.1). 
Age, “other” site and stage remained independent prognostic factors in multivariable 
analyses, both for relapse and melanoma-specific death (Table 4.5, Table 4.6 and 
Table 4.7). 
Regarding whole-tumour measures, increasing Breslow thickness, the presence of a 
dominant nodule, microscopic ulceration, and its increasing extent, the presence of 
tumour loss, “both” or superficial types of tumour loss, an increasing depth of tumour 
loss and a relative tumour loss of <0.26mm or 0.26-<0.52mm were significantly 
associated with an increased risk of both melanoma relapse and death in univariable 
analyses (Table 4.2). The pattern of TILs was not significantly associated with relapse 
and it was of borderline statistical significance in predicting melanoma-specific death 
(Table 4.2). Neither the intensity nor the pattern of TIMs was significantly predictive of 
either melanoma relapse or death in univariable analyses (Table 4.2). AJCC stage was 
used in multivariable analyses instead of Breslow thickness, microscopic ulceration 
and the number of mitoses because stage incorporates all of these factors and is what 
is used clinically to predict outcome. The presence of a dominant nodule and the test 
for trend for the increasing depth of tumour loss were independently hazardous for 
melanoma relapse (Table 4.2 and Table 4.2) but not melanoma-specific death (data 
not shown). This could reflect a lack of statistical power in the survival analysis, i.e. 
fewer cases had died than had relapsed. 
Several of the new histopathological variables, which were recorded within the cored 
region, were significant prognostic factors (Table 4.3). The POS was significantly 
protective for both melanoma relapse and death in univariable analyses and remained 
an independent predictor in multivariable analyses (Table 4.5, Table 4.6 and Table 4.7) 
but the quality of the stroma had no significant effect (Table 4.3). In univariable and 
multivariable analyses, balloon cell shape was significantly hazardous for melanoma 
relapse (Table 4.3, Table 4.5 and Table 4.6) but not death. The multivariable analyses 
for relapse were repeated without melanoma cell shape (Table 4.5 and Table 4.6) 
because only balloon cell shape showed significance in the model, however, only 2 
cases had a balloon cell shape. A melanoma cell structure composed of sheets was 
significantly hazardous for both melanoma relapse and death in univariable analyses 
(Table 4.3) but the dispersed cell structure was an independent prognostic factor in 
multivariable analyses for relapse (Table 4.5 and Table 4.6) and death (Table 4.7). The 
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degree of melanoma cell pigmentation was not predictive of either relapse or death 
(Table 4.3). 
A detailed analysis of the immune cell infiltrates within the cored region was performed. 
An increasing extent of immune cells within the core, particularly lymphocytes, was 
significantly protective for both relapse and melanoma-specific death in univariable 
analyses (Table 4.3). The test for trend for the extent of the core immune cell infiltrate 
was an independent prognostic factor for relapse (Table 4.5) but was of borderline 
statistical significance for melanoma-specific death (Table 4.7). The test for trend for 
the core lymphocytic infiltrate was of borderline statistical significance for relapse in 
multivariable analyses (Table 4.6) and was independently protective for melanoma-
specific death (Table 4.7). All categories for the locations of immune cells within the 
core (at the tumour-stroma interface, etc.) were protective for both relapse and death, 
in univariable analyses (Table 4.3). Both the presence and absence of core 
macrophages/melanophages were protective for melanoma relapse and death, in 
univariable analyses (Table 4.3). This may be because out of the 121 patients with 
absent macrophages/melanophages within the core, 118 had a core lymphocytic 
infiltrate (data not shown). Plasma cells, neutrophils and eosinophils were infrequently 
recorded within the core (Table 4.3). 
Mitoses were enumerated within the core and their increasing number was significantly 
hazardous for both melanoma relapse and death, in univariable analyses (Table 4.3). 
The presence or absence of core mitoses was incorporated into the generated AJCC 
stage IB variable, instead of the reported mitotic count (data not shown). 
Overall, age and AJCC stage were consistently predictive of a poor prognosis in 
multivariable analyses for both melanoma relapse (Table 4.5 and Table 4.6) and death 
(Table 4.7). The dispersed melanoma cell structure was significantly hazardous in 
multivariable analyses (Table 4.5, Table 4.6 and Table 4.7). The POS and the extent of 
either the core immune cell or lymphocytic infiltrate were predictive of a better outcome 
for both relapse (Table 4.5 and Table 4.6) and melanoma-specific death (Table 4.7) in 
multivariable analyses (although the immune cell infiltrates were of borderline statistical 
significance in some of the multivariable models; Table 4.6 and Table 4.7). The 
consistency of the results for independent prognostic factors between multivariable 
Cox proportional hazards models for relapse and melanoma-specific death, suggests 
that these measures are robust. 
Although similar results were obtained for multivariable relapse and survival analyses, 
there were some exceptions. The presence of a dominant nodule and the depth of 
tumour loss were predictive of melanoma relapse (Table 4.5 and Table 4.6) but not 
death (data not shown). Many of the core immune cell variables remained significant in 
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multivariable survival analyses but were not significantly associated with relapse, 
including the presence of immune cells dispersed between tumour cells and the test for 
trend for the following core immune cell subtypes: plasma cells, neutrophils and 
eosinophils (data not shown). 
 
4.5 Discussion 
This was a unique study of a large primary melanoma cohort in the UK, which 
assessed the effect of both recognised and novel histopathological factors on survival. 
The cohort was representative of the sex distribution for melanoma [218], although 
participants were slightly younger than the UK average [2]. Older age at diagnosis has 
previously been shown to be an independent prognostic factor in cutaneous melanoma 
[6-8] and this was replicated in my project, with a 3% increased risk of death for every 
year older (Table 4.7). This not inconsiderable effect is the focus of intense research 
currently in other centres. Decreased self-detection [11], more aggressive tumour 
characteristics [7, 8] and immunosenescence [12] have previously been cited in the 
literature as possible causes for this effect and I plan to explore this in future research. 
Sex has also been reported to be an independent predictor of melanoma-specific 
death, with females tending to survive longer [17, 219]. Similarly, in this study, female 
sex was protective in univariable analysis (Table 4.1) but lost statistical significance in 
multivariable analyses (Table 4.7). This could reflect the relatively small numbers 
studied. “Other” site of primary (including acral, subungual and genital melanomas) 
was significantly hazardous in multivariable analyses for both melanoma relapse and 
death (Table 4.1). Melanomas at these sites are difficult to detect, however, the effect 
persisted after adjusting for stage, suggesting that such melanomas possess a distinct 
biology. A poor outcome has previously been demonstrated for melanomas at vulval, 
vaginal and acral sites [38-40] and c-KIT mutations occur more frequently in acral and 
mucosal melanomas, supporting the hypothesis that the biology of these melanomas 
might be different.  
As expected, AJCC stage was a highly significant predictor of both melanoma relapse 
and death (Table 4.1), consistent with findings in larger data sets [43, 44]. Moreover, 
established prognostic factors, including Breslow thickness [22, 43, 45] and 
microscopic ulceration [43] were significantly hazardous (Table 4.2) and were 
incorporated into the AJCC stage variable for multivariable analyses. There was a 
convincing trend in the hazard ratios for an increasing extent (width) of ulceration and 
the test for trend was highly significant (Table 4.2), indicating that no particular cut-off 
point was more prognostic than another and suggesting that the extent of ulceration 
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should be measured on a continuous scale. Previous studies have reported different 
prognostic cut-off points for the extent of ulceration [53-56]. The extent of ulceration 
could be an indicator of the duration of ulceration or it might be a marker of a more 
profound, pro-tumourigenic inflammatory response within the melanoma. Jewell et al. 
showed that genes involved in wound healing were upregulated in ulcerated compared 
to non-ulcerated melanomas [49]. 
The presence of a dominant nodule was an independent predictor of melanoma 
relapse (Table 4.5 and Table 4.6) but not death (data not shown), consistent with 
another study, although the authors’ definition of a dominant nodule differed to mine 
[70]. The explanation for the independent effect of a dominant nodule for relapse but 
not for survival could be a reflection of the lack of statistical power, in that there were 
fewer events in the multivariable survival analysis, i.e. fewer patients had died than had 
relapsed. Therefore, this might prove to be an independent predictor of survival in a 
larger data set. Furthermore, melanomas that had a dominant nodule were significantly 
thicker, more likely to be ulcerated and to have a higher core mitotic count and a lesser 
extent of immune cell infiltration within the core (data not shown). The literature on the 
topic of a dominant nodule is sparse but the hypothesis is that it represents a clonal 
expansion of a population of tumour cells [70]. The nodular melanoma subtype is 
regarded as an indicator of a more aggressive tumour, being associated with a higher 
mitotic count [220] and an increased risk of death [221]. Superficial spreading 
melanomas tend to have a nested pattern [187], however, some contain a nodular 
component. Lateral epidermal involvement, of up to 3 rete ridges beyond the vertical 
growth phase melanoma [187], may be present in nodular melanomas. These 
somewhat arbitrary limits make subtype distinctions less precise. I recorded the 
presence of a dominant nodule, hypothesising that this feature could reflect a more 
aggressive tumour. My study provided some support for this hypothesis. 
Surprisingly, TILs within the whole tumour were not a significant predictor of relapse 
and were of borderline statistical significance in predicting melanoma-specific death 
(Table 4.2). Brisk TILs are reported to have the best prognosis and tend to occur more 
frequently in thin melanomas [61]. Therefore, the lack of statistical significance in my 
study could be a reflection of the thicker melanomas reviewed. Although TILs are part 
of the minimum data set recorded by pathologists [51] in the reporting of primary 
cutaneous melanoma, they have not been incorporated into AJCC stage [43]. This 
might reflect the subjective nature of the measure [199]. I utilised a modified version of 
the approach adopted by Clemente et al., however, the number of cases allocated to 
some of the subgroups was small and, ultimately, had to be merged into 3 categories 
(absent, non-brisk and brisk) for statistical analyses. Apparently, this method did not 
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improve the predictive power of TILs, although replication in a larger data set might 
show a significant effect. As previously discussed, some studies have demonstrated 
TILs to be an independent prognostic factor [24, 27, 69], while others have not 
corroborated these findings [25, 65, 67]. It was remarkable that the extent of the core 
lymphocytic infiltrate was independently protective for melanoma-specific death (Table 
4.7). There was a weak, positive correlation between TILs within the whole tumour and 
the extent of the core lymphocytic infiltrate (Spearman rho=0.2, p=3x10-7, data not 
shown), which is not entirely surprising, given that the TMA core biopsy was obtained 
from the region of tumour that had the least immune cell infiltration. The extent of the 
core lymphocytic infiltrate was moderately correlated with the ESTIMATE immune 
score (Spearman rho=0.5, p=3x10-31, data not shown). Similarly, the Cancer Genome 
Atlas Network reported that cases with enrichment for the expression of immune cell 
genes had a higher lymphocyte score (a score of the extent and distribution of 
lymphocytes) and a better survival, although they analysed a mixture of primary and 
metastatic melanoma cases [153]. The significant predictive power of the extent of the 
core lymphocytic infiltrate suggests the possibility that pathologists could focus on a 
specific region within the advancing edge of the melanoma for the assessment of TILs, 
which might increase the reproducibility of this measure and might be more informative 
of outcome. Although heterogeneity is a feature of cutaneous melanoma [117, 222], 
the findings suggest the possibility that a cored sample of the advancing tumour edge 
might represent an informative snapshot of the melanoma, however, future research 
could clarify whether or not this is the case. 
There are conflicting reports in the literature regarding the prognostic significance of 
regression. Some studies have proposed a protective role [72, 74, 77, 79], while others 
have reported a worse prognosis in association with regression [82, 84, 86]. In this 
study, the presence, type and depth of tumour loss were significantly hazardous for 
melanoma relapse and death in univariable analyses (Table 4.2). This was particularly 
significant when the tumour loss reached a depth >1.63mm (Table 4.2). In contrast, the 
“deep” subtype of tumour loss did not reach statistical significance in univariable 
analysis. “Deep” tumour loss was defined as tumour loss within the dermis, in the 
absence of direct contact with the dermo-epidermal junction. Therefore, its depth in 
millimetres is likely to have varied between tumours. I also calculated the “relative 
tumour loss” by dividing the depth of tumour loss by the Breslow thickness, considering 
that this might more accurately reflect the effect of regression in the context of the size 
of the melanoma, however, the depth of tumour loss was a more significant predictor 
(Table 4.2). Moreover, the depth of tumour loss was an independent predictor of 
melanoma relapse (Table 4.5 and Table 4.6) but not death (data not shown). The latter 
could reflect a lack of statistical power. It is dermatological dogma that regression 
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represents a host immune response to the tumour, however, the findings of this study 
do not support this premise. An alternative hypothesis is that regression represents 
“crisis”, a stage in the evolution of a potentially more aggressive melanoma, and that 
the accompanying tumour cell apoptosis is the antigenic stimulus that drives immune 
cells into the region of tumour destruction [73]. In addition, an association between 
tumour loss and necrosis, an adverse prognostic factor [223], cannot be ruled out. 
Macrophages are often used to define areas of regression [74] and tumour-associated 
macrophages have been reported to be associated with angiogenesis [50], invasion 
and metastasis in cancer [224]. 
Furthermore, I graded the intensity and pattern of TIMs across the whole tumour but 
there was no significant association with either relapse or melanoma-specific death 
(Table 4.2). An increasing extent of melanophages within the core was significantly 
protective, however their absence was also protective in univariable analysis, 
suggesting that the beneficial effects noted might have been accounted for by other 
immune cells within the core (Table 4.3). Moreover, the extent of melanophages within 
the core was not an independent prognostic factor (data not shown). It was not 
possible to determine the polarisation of the macrophages identified, i.e. whether they 
were “M1” type macrophages, associated with anti-tumour immunity or alternatively 
activated “M2” type macrophages, which have a role in tumour remodelling and are 
associated with pro-tumourigenic inflammation [170, 224]. 
In terms of other core immune cell variables, the presence of a core immune cell 
infiltrate (of any type) was protective, irrespective of its proximity to the tumour cells (at 
the tumour/stroma interface, dispersed between tumour cells or both) (Table 4.3). 
Plasma cells, neutrophils and eosinophils were infrequently recorded within the core 
(Table 4.3), indicating that these types of immune cells appear to be rarely 
encountered within the thickest part of the melanoma. The lack of specific immune cell 
populations within the deep tumour suggests an incomplete immune response. An 
increasing extent of lymphocytes within the core was protective, suggesting no 
evidence of T cell exhaustion [225]. 
It is increasingly recognised that tumour stroma is effectively part of the cancer “organ” 
and that the environment may be either pro-tumourigenic or protective [226]. I was 
therefore interested in exploring the relationship between the POS and outcome. The 
cores were consistently taken from the deepest part of the tumour, which had the least 
amount of inflammation/stroma so that the data could be compared between tumours. I 
found that the POS within the cored region was a powerful prognostic factor in 
multivariable analyses, independent of age, AJCC stage, the site of primary melanoma 
and other combinations of factors (Table 4.5, Table 4.6 and Table 4.7). The POS was 
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calculated by the positive scoring of immune cells and non-immune stromal 
components, including collagen. Therefore, the protective effect conferred by the POS 
could be a reflection of the degree of lymphocytic infiltration within the core or, 
alternatively, might be due to non-immune stromal constituents. This finding will be 
explored further in Chapter 5. 
There was a striking abundance of round/ovoid/epithelioid melanoma cells within the 
core, thus, limiting comparisons with rarer cell types (Table 4.3). The hazard ratios for 
balloon cells suggest a hazardous effect on melanoma relapse but not death, however, 
the number of cases in this category was very small. Balloon cells are known to be a 
rare finding [227] and their biological significance has not been fully elucidated [228]. 
Hypotheses proffered include defective melanosome formation and adipocytic 
degeneration [228]. Balloon cells can also occur within melanocytic naevi [229]. 
Although balloon cell melanomas have been reported to metastasise, their metastatic 
behaviour is thought to be similar to other melanoma subtypes [228, 230]. The 
suggestion that balloon cells are hazardous in this study, therefore, may simply reflect 
the small numbers. 
Nests were the most common type of melanoma cell structure to be recorded and a 
dispersed cell structure was independently hazardous in some multivariable analyses 
for relapse (Table 4.5 and Table 4.6) and death (Table 4.7). The biological significance 
of this finding is uncertain and, again, might reflect the small numbers in this category. 
Neither the degree of melanoma cell pigmentation nor the number of core blood 
vessels had an impact on melanoma relapse or death (Table 4.3). Pigmentation is 
considered to be a marker of melanocyte differentiation [111] and amelanotic 
melanomas tend to be more advanced at the time of presentation [231], therefore, it is 
surprising that pigmentation had no effect on outcome. However, melanoma cells are 
capable of “switching” between states of high and low pigmentation [116], so it is 
possible that the H&E section, taken at one point within the lifetime of the melanoma 
was not representative of its plasticity, evolution and, hence, its metastatic potential. 
Moreover, it is possible that the pigmentation recorded within the core was not 
representative of pigmentation within the whole tumour. The TMA core biopsy was 
taken from the advancing edge of the tumour and it is possible that these melanocytes 
were less well differentiated, which is suggested by the overwhelming majority of cases 
having an amelanotic appearance within the core. Unfortunately, I did not record 
pigmentation in other regions of the tumour, which means it is not possible to verify this 
hypothesis. Furthermore, analysing pigmentation as a binary variable, i.e. present 
versus absent, might be more informative and this could be explored in future 
research. I enumerated blood vessels within the core because I was interested to 
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establish whether or not they might be predictive of outcome. Ulcerated tumours have 
previously been shown to be associated with an increased microvessel density and 
hence a more aggressive tumour [50]. However, the number of core blood vessels was 
not predictive of outcome. This could reflect the relatively poor reproducibility of the 
variable (Chapter 3). The definition I used to assert the presence of a blood vessel was 
that red cells were present within a lumen. This was used in an effort to overcome 
difficulties in deciphering individual blood vessels from its tributaries. Nonetheless, it 
was problematic and enumeration of the core blood vessels proved difficult. This might 
explain the lack of prognostic effect and one could argue that the use of 
immunohistochemistry to stain vessels might have been more productive. 
Previous studies have reported a strong prognostic role for mitotic count [26, 43, 59]. 
The presence of ≥1 mitosis is used to define AJCC stage IB (7th edition) [43] but has 
not been retained in the 8th edition (in press). In this study, there was a significantly 
increased risk of both melanoma relapse and death in association with an increasing 
number of core mitoses (Table 4.3). This suggests that, in the future, pathologists 
could enumerate mitoses within one 600 micron region within the thickest part of the 
primary melanoma, containing the least amount of immune and non-immune stroma. 
This could be beneficial in clinical practice, particularly in view of the time required to 
apply the “hotspot” method for calculating mitotic count [232]. However, interobserver 
studies regarding the selection of the appropriate 600 micron region between 
pathologists would be needed, in order to establish reproducibility in this regard. 
One of the limitations of the study was the sample size: much larger numbers of cases 
were analysed to determine the factors that were selected for the AJCC stage [43]. I 
did not record the histological subtype and microsatellites using the virtual pathology 
protocol. These measures were dropped following the results of interobserver studies 
in my earlier histological review using a light microscope (Chapter 3). I relied upon 
information about microsatellite status, nodal and visceral metastatic disease, which I 
incorporated into the AJCC stage variable [43], based upon data that had previously 
been extracted from clinical notes and histology reports by Section staff. The 
histopathological review was based on a biased set of primary melanomas, being 
inherently thicker and more likely to be ulcerated and possibly mitotically active: these 
tumours had to have a minimum thickness of 0.75mm. In this study, there was a bias 
towards sampling thicker tumours and some of the histopathological characteristics 
might reflect this bias. Nonetheless, the data are uniquely based on a population-
ascertained cohort. A further limitation of the study was that mitoses were enumerated 
within the cored region and not within the whole-tumour. Despite this, the core mitotic 
count appeared to be a significant prognostic factor. Some of the recorded factors were 
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based on “eyeball” measures, e.g. the extent of the core immune cell infiltrate and 
immune cell subtypes, which could be subject to interobserver variation and might limit 
reproducibility. Yet, their high statistical significance in this study suggests that these 
measures were recorded in a consistent manner. 
In summary, this study reports an analysis of clinical factors and of a detailed 
histopathological assessment of >700 primary melanomas. The study was original in 
many ways, being based on a large cohort of population-ascertained melanoma cases 
with detailed clinical and survival data. The median follow-up for these cases was 5.8 
years, providing a reasonably strong basis upon which to draw conclusions about 
melanoma-specific survival. Furthermore, the histopathological review was carried out 
by a single observer, with good intra- and interobserver agreement (Chapter 3). 
Several novel histopathological factors were developed and analysed, some of which 
showed significant prognostic power, e.g. the extent of the core immune cell and 
lymphocytic infiltrates and the POS. As expected, established predictors of survival, 
e.g. age and AJCC stage remained independent prognostic factors, replicating the 
findings of previous studies [8, 43]. Moreover, an increasing number of core mitoses 
was significantly hazardous for both relapse and death. Surprisingly, sex and TILs, 
which have been shown to be independent predictors of outcome in some previous 
studies [22, 27], were not independently or significantly predictive of relapse or death, 
respectively. This might be due to the relatively small numbers studied or the bias 
towards sampling thicker primary melanomas. 
In the future, I would like to verify my findings in an independent data set. Furthermore, 
the curious finding of the POS being independently protective for melanoma-specific 
death was exciting, as it could represent a potential biomarker in melanoma. Therefore, 
I decided to explore whether or not this effect was additive to AJCC stage. This work 
will be presented in Chapter 5. 
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Chapter 5 Stroma 
5.1 Introduction 
In this chapter, I will explore the role of the stromal content within primary melanomas. 
The stroma, or “non-tumour” component, comprises a diverse array of structures and 
cell types, including connective and adipose tissue, endothelial cells, fibroblasts and an 
assortment of immune cells, including lymphocytes, neutrophils, macrophages, 
eosinophils and plasma cells [138, 233]. In my study, I have defined and measured all 
non-tumour cell structures as stroma, so that I have included fibroblasts, immune cells 
and structural components, e.g. collagen, as “stroma”. 
I chose to evaluate the stroma as a potential prognostic biomarker because of the 
evidence to suggest that the stroma plays an active role in tumour development. The 
nature of the melanoma microenvironment has been explored in previous studies [132, 
234-241]. The stroma, although clearly a multicomponent factor, is largely made up of 
connective tissue and thus, the role of stromal fibroblasts in cancer progression has 
received much attention [238, 240, 242-244]. Fibroblasts have been reported to play a 
role in the chemoresistance of melanoma cells to doxorubicin [238] and vemurafenib 
[245]. In addition, the nature of “normal”, resident fibroblasts is postulated to differ from 
cancer-associated fibroblasts (CAFs) [246], with the latter adopting features of 
myofibroblasts and demonstrating increased expression of alpha-smooth muscle actin 
[247]. Stromal mesenchymal cells and fibrocytes, expressing fibroblast-activation 
protein alpha (FAP), can evoke an immunosuppressive microenvironment [248] and 
senescent fibroblasts are thought to play a role in melanoma progression [249]. 
Fibroblasts, situated in disparate regions of the melanoma are thought to have different 
characteristics, i.e. resident fibroblasts in pre-existent adjacent tissue versus 
myofibroblasts at the advancing peritumoural zone [132]. Zhou et al. reported that 
melanomas grew more rapidly in a mouse model in the presence of fibroblasts in which 
beta-catenin had been deactivated [250]. In contrast, there was increased apoptosis, 
cell cycle arrest and a decrease in markers of epithelial-mesenchymal transition in 
melanomas occurring in the presence of normal dermal fibroblasts [250]. This suggests 
that CAFs and native fibroblasts may have divergent roles in cutaneous melanoma and 
that the distinction of CAFs from untransformed fibroblasts may be important. 
An interplay exists between melanoma cells and their neighbouring stroma, 
communicating via the release of growth factors, cytokines and through cell-to-cell 
contact [132]. In the process of invasion, melanoma cells interact with the stroma. 
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Remodelling of the extracellular matrix (ECM) occurs in the presence of proteolytic 
enzymes called matrix metalloproteinases (MMPs) [251]. This transition is carefully 
balanced by the secretion of MMPs and their inhibitors, so-called “tissue inhibitors of 
metalloproteinases” [251] and appears to be important in terms of melanoma 
progression. For example, MMP-1, 2 and 9 have been reported to be associated with 
melanoma cell invasion [252] and a worse prognosis [251, 253]. 
Attachment to the extracellular matrix (ECM) is an attribute of normal cells and 
dysregulation of adhesion molecules permits the detachment and migration of cancer 
cells in the process of invasion and metastasis [254]. Loss of E-cadherin expression is 
characteristic of this phenomenon, referred to as “epithelial-to-mesenchymal transition” 
[254] and the stroma has been implicated in promoting its evolution. Izar et al. derived 
melanoma cell cultures from 50 patients with stage III/IV melanoma and identified 
BRAF and NRAS mutations in 19 and 11 cases, respectively [255]. By performing a 
series of in vitro experiments on the 30 cases with BRAF/NRAS mutations, they 
identified a subpopulation of cells that lacked these driver mutations [255]. They 
surmised that these cells were CAFs, based on their lack of BRAF/NRAS mutations 
and their expression of FAP, among other markers [255]. In order to gather more 
evidence in support of this supposition, they performed a transcriptomic analysis, which 
revealed 200 genes that were significantly enriched among the “CAFs” and the 
expression of these genes had also previously been reported to be highly variable 
among leukocytes, endothelial cells and FAP+ fibroblasts in colorectal cancer [255]. A 
significant overlap in the gene expression signature was identified between these 
“CAFs” and that reported for FAP+ fibroblasts [255]. The top biological pathway 
associated with these “CAFs” revealed enrichment of genes involved in the epithelial-
mesenchymal transition [255]. Furthermore, the “CAFs” were reported to grow more 
rapidly in a melanoma cell-conditioned medium, compared with media conditioned with 
either “CAFs” or normal dermal fibroblasts [255]. Moreover, for 2 of the 3 cases 
presented, the melanoma cells were reported to grow more efficiently in the presence 
of CAF-conditioned medium, compared with a medium conditioned with normal dermal 
fibroblasts [255]. The results support the hypothesis that a two-way communication 
could exist between melanoma cells and their stromal neighbours, and that CAFs might 
promote melanoma cell proliferation. 
In order to assess whether or not melanoma cell invasion might be influenced by CAFs, 
Izar et al. performed cell invasion assays using melanoma cell lines [255]. All 6 cell 
lines that had been co-cultured with their matched CAFs, allowing for direct cell-to-cell 
contact, were reported to show enhanced invasion [255]. Conversely, only half (3/6) of 
the cases that had been grown in matched CAF-conditioned media were reported to 
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show similar invasion [255]. These findings suggest that CAFs might promote 
melanoma cell invasion and that direct cell-to-cell contact between melanoma cells and 
CAFs could enhance this process. 
Contrary to reports of a hazardous role for the microenvironment, the “non-immune” 
component of the stroma might promote the delivery of immune cells to the tumour, 
thereby assisting in the mounting of an appropriate host immune response in reprisal 
against the tumour [235, 256]. Whether this non-immune compartment is a passive 
bystander or an instigator of immune cell infiltration remains to be seen. Melanoma is 
regarded to be a highly immunogenic tumour [257]. I recorded a measure of the non-
tumour compartment (the percentage of stroma (POS)), which comprised a melange of 
immune and non-immune, stromal cells. Therefore, the quantification of the immune 
cell fraction may well have played an important role in the protective effects of the POS 
in my study. Melanoma is capable of eliciting a variable immune response, the nature 
and extent of which may contribute to survival [129, 212]. Tumour-infiltrating 
lymphocytes have been shown to be of prognostic significance in some studies [60-63, 
212], while others have failed to show an independent survival advantage [64, 65, 67]. 
The durability of response to immunotherapy in metastatic melanoma supports the 
view that the immune system is critical in combatting melanoma and improving survival 
[126, 129, 258, 259]. In a study of 333 melanomas from the Cancer Genome Atlas, 
composed of a mixture of primary and metastatic samples, the lymphocyte score was 
shown to be a protective factor [153]. This score was generated based on the 
“distribution” (the fraction of tumour infiltrated by lymphocytes; 0, <25%, 25-50%, 
>50%) and the “density” (absent, mild, moderate or severe) of lymphocytes within the 
tumour sample [153]. Lymphocyte-specific protein tyrosine kinase (LCK), which is 
involved in T-lymphocyte signalling, was enriched in samples with a high immune gene 
expression signature and its protein expression was significantly associated with the 
lymphocyte score and a more favourable outcome [153]. Spleen-associated tyrosine 
kinase (SYK), which is linked to B-lymphocyte signalling, was also upregulated in the 
immune gene signature but its protein expression was not significantly associated with 
outcome [153]. 
The melanoma microenvironment may also be affected by ageing [260]. A recent study 
reported that melanomas grew at a slower rate but were associated with increased 
angiogenesis and lung metastases in older versus younger mice [260]. Decreased 
proliferation and increased melanoma cell invasion were recorded for melanoma cells 
grown in a medium conditioned with aged rather than young fibroblasts (obtained from 
donors >55 and <35 years of age, respectively) [260]. 
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The POS was identified as an independent prognostic factor in survival analyses 
(Chapter 4) in my study. For every percentage increase in stroma, there was a 
corresponding 1% decreased risk of melanoma-specific death, adjusting for age, sex, 
the site of primary melanoma, AJCC stage, melanoma cell structure and the extent of 
the core immune cell infiltrate (adjusted HR for the POS 0.99, 95% CI 0.98-0.99, Cox 
proportional hazards model, p=0.005). As a novel histopathological biomarker for 
primary cutaneous melanoma, this observation appeared to be worth exploring further. 
The prognostic effect of stromal content has previously been reported for several 
cancers. In the majority of studies, a high proportion of stroma is associated with a poor 
prognosis, while in a minority, it is protective. Cancers in which a higher quantity of 
stroma has been reported to be associated with a worse prognosis include colorectal 
cancer [137, 139, 141, 261], oesophageal squamous cell carcinoma [140], gastric 
[142], ovarian [138, 262], non-small cell lung cancer [134], hepatocellular carcinoma 
[135] and triple-negative breast cancer [131]. Stromal cells have also been reported to 
have a pro-tumoural effect in follicular lymphoma [263]. Conversely, a higher stromal 
content is associated with a better outcome in oestrogen receptor-positive breast 
cancer [136] and lung adenocarcinoma [264], while it is of no proven prognostic value 
in inflammatory breast cancer [265] and laryngeal squamous cell carcinoma [266]. A 
worse outcome has been observed in early stage cervical adenocarcinoma for cases 
with a higher proportion of stroma but the latter was not an independent predictor, 
although the sample size was small [267].  
These findings suggest that the contribution of the stromal compartment might be 
tissue/tumour-specific. There is some evidence, albeit limited, that the composition and 
nature of the stroma may vary by location, for example, renal, colon and prostate cell 
lines have been reported to be more responsive to immunotherapy and less 
vascularised when inoculated into a subcutaneous rather than a visceral site [268].  
The diverse observed effects of stromal content may be attributable to experimental 
variation. The reported studies utilised different methods to quantify the stromal content 
(e.g. systematic random sampling using a microscope with an eyepiece graticule 
containing a grid or digital methods, e.g. RandomSpot©) [185]. The lack of a consistent 
approach in the estimation of the relative proportions of stroma and tumour has led to 
controversy regarding the best method to use [265, 269]. Furthermore, Webster et al. 
used automated image analysis to quantify the amount of stroma within biobank 
specimens, which included 70 melanomas [145]. However, the automated technique 
failed to analyse 10/70 (14%) cases [145]. They found that the median percentage of 
stroma was about 26% (range 0.2%-93.2%) in melanoma [145]. Recently, Rashed et 
al. reported that the density of melanoma cells, estimated at the site of the Breslow 
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thickness measurement, was an independent predictor of melanoma-specific death in a 
series of 100 cases of primary cutaneous melanoma [270]. Cases with a higher 
melanoma cell density had an increased risk of melanoma-specific death [270]. Using a 
light microscope, they recorded an “eyeball” measure of melanoma cell density to the 
nearest 5% [270]. 
Moreover, there are reported differences in how stroma is described qualitatively, i.e. 
there are variable definitions for stroma. Some studies have considered the cellular and 
structural components, while others have largely addressed the latter. Where the 
structural component was considered important, there was variation in how different 
“types” of collagen were reported. Smolle et al. studied the density and calibre of 
collagen fibres in 12 melanomas and 12 melanocytic naevi, using automated image 
analysis of azan trichrome-stained sections (which stains collagen fibres blue) [143]. 
They found that collagen was more abundant towards the periphery of both 
melanomas and benign melanocytic naevi and that the calibre of collagen fibres was 
greater at the periphery than at the centre of melanomas, although there was no 
significant difference in the collagen fibre diameter within naevi between the centre and 
the periphery [143]. Collagen of the surrounding reticular dermis was thicker still [143]. 
Moreover, benign melanocytic naevi contained more collagen than the melanomas and 
the collagen had a more delicate appearance in the former [143]. The study size was 
small and failed to account for the thickness of the melanomas (which were >1mm 
thick) and of the naevi [143]. It is possible that the observed differences were due to 
naevi occupying the papillary dermis, compared to melanomas, which most likely 
invaded the reticular dermis [143]. Nonetheless, the observations are interesting and 
suggest the possibility that intrinsic differences in the quantity of stroma may exist 
between naevi and melanomas. Melanomas with a greater quantity (as opposed to 
diameter) of collagen might more closely resemble benign naevi biologically and thus, 
have a better prognosis. However, the way in which the POS was estimated using 
RandomSpot© did not account for the collagen fibre diameter and, therefore, it is also 
possible that a higher POS reflects thicker rather than more abundant collagen fibres 
within melanoma. 
Although I reported that the POS was protective for melanoma death in my study, 
Smolle et al. reported that the presence of an increased area of “pre-existing” collagen 
(>0.13mm2) within primary melanomas (n=267), as measured by automated image 
analysis of H&E sections, was significantly hazardous for survival, however, it lost 
statistical significance after adjusting for Breslow thickness in a multivariable survival 
analysis [144]. They identified the tumour stroma as being “wavy” in consistency, 
having abundant fibroblasts and inflammatory cells, and forming septa between tumour 
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nests, whereas they considered pre-existing collagen to be thicker, more compact and 
acellular [144]. The authors noted a weak, positive correlation between the area of the 
collagen and Breslow thickness [144]. The algorithm used by Smolle et al. did not 
measure the “fine collagenous structures of the stroma itself” [144] but instead, was 
based on the automated recognition of a previously digitally annotated collagen fibre, to 
retain only “pre-existing collagen fibres from the reticular dermis” in the measurement 
[144]. This might account for the incongruity between their results and mine. In 
addition, I would suspect that the distinction of pre-existing collagen from the tumour 
stroma is likely to be subjective, although they report >95% concordance between 
observers [144]. My measurement of the POS included both immune cells, and 
collagen that was located between tumour cells. It is therefore likely that the measures 
Smolle et al. refer to are not directly comparable to mine because of the 
aforementioned differences and because it appears that they did not include immune 
cells in their score. Indeed, the same authors studied 344 cutaneous/subcutaneous 
melanoma metastases and found that the presence of a peripheral fibrous capsule, or 
fibrous septa and fibroblasts within the tumour were associated with a better outcome 
[271]. Conversely, the incorporation of pre-existing collagen from the reticular dermis or 
adipocytes within the metastases were indicative of an increased risk of death [271]. 
Bioinformatics techniques can also be employed to gauge the relative proportions of 
tumour and stroma within samples. A recent pan-cancer analysis of tumour purity, 
applied a series of bioinformatics algorithms to analyse the transcriptomes of 21 
cancers within the Cancer Genome Atlas (TCGA) data set [272]. A tumour purity of 
>90% was found in only 12% cutaneous melanomas, while a tumour purity <60% was 
present in 20% of cases [272]. Sampling from disparate regions of the same tumour 
generated similar results for tumour purity [272]. These findings must be interpreted in 
the context of the data set, however, which was largely composed of metastatic 
melanoma samples. One of the programmes utilised in the TCGA study was 
ESTIMATE, i.e. Estimation of STromal and Immune cells in MAlignant Tumour tissues 
using Expression data [169]. This is an algorithm that generates immune and stromal 
scores based on gene expression signatures, derived through a process of gene 
filtering [169]. These scores are then combined as the ESTIMATE score, from which 
the tumour purity score is derived [169]. The TCGA and public databases were used to 
identify >10,000 commonly expressed genes [169]. The immune score was determined 
as follows: genes that were enriched (2-fold higher expression) in haematopoietic cells 
compared to other normal cells were retained [169]; leukocyte methylation scores (in 
ovarian carcinoma) were used to identify genes that were differentially expressed 
between samples containing high versus low immune cell infiltration [169]; overlapping 
genes between the two gene lists were ranked to isolate 141 genes, upon which the 
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immune score is based [169]. The stromal score was generated as follows: genes that 
were present in normal, non-haematopoietic cells were compared to genes that were 
expressed in tumour or stromal samples that had been extracted by laser capture 
microdissection of breast, colorectal and ovarian cancers [169]; genes that displayed 
low variation in cancer cell lines or had reduced expression in glioma-like stem cells 
were then removed from the list, leaving 141 genes to form the basis of the stromal 
score [169]. The evaluation of the immune and stromal scores across a range of 
cancers suggested that these signatures were each measuring different components 
[169]. Furthermore, leukocyte methylation scores were highly correlated with the 
immune score but not the stromal score [169]. The predicted tumour purity calculated 
using ESTIMATE was comparable to that obtained using an alternative, DNA copy 
number based-algorithmic approach, called ABSOLUTE [169, 273]. Disappointingly, 
there was a weak correlation between the immune, stromal and ESTIMATE scores and 
the histopathologically-estimated percentage of tumour, stroma and lymphocytes 
(using H&E sections) [169]. Comparatively poorer correlations were noted between 
ABSOLUTE and the histopathological estimation of tumour purity [169]. 
Immune cell subsets within the tumour microenvironment can also be explored using 
gene expression data. Bindea et al. developed a compilation of transcriptomic profiles, 
based on the existing literature, which were considered to be specific for 28 distinct 
immune cell subsets and by means of a bioinformatics approach, examined the 
immune microenvironment of colorectal cancer [174]. They reported that the nature 
and location of the infiltrating immune cell subsets or the “immunome” was dynamic 
with respect to cancer progression, indicating a complex relationship between the 
tumour and its host immune response [174]. This approach has been modified by the 
Leeds Melanoma Group to better understand the role of the immune response in 
primary cutaneous melanoma. Dr Jeremie Nsengimana tailored this approach for use 
in melanoma by filtering out genes that had been reported to be highly expressed by 
normal melanocytes (as per a publically available database [274]), or genes that had 
been shown to be highly expressed by melanoma cell lines by previous PhD students 
within the group. By performing unsupervised clustering of this modified gene list for 
cases in the Leeds Melanoma Cohort Study, he was able to identify 6 clusters that 
showed distinctive differences in the expression of genes associated with these 
immune cell subsets (paper submitted). 
In this chapter, I have elected to employ some of these techniques to elucidate the 
transcriptomic correlates of the stromal compartment. The following aims will be 
addressed: 
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 To assess the association between the POS and clinical and histopathological 
factors for cases in the Leeds Melanoma Cohort Study. 
 To establish whether or not combining the POS with AJCC stage (7th edition) 
[43] could improve the accuracy of the prediction of melanoma-specific death in 
these primary melanoma cases, by performing ROC curve analyses. 
 To investigate the association between the POS and the “immunome”, to better 
understand the contribution of the immune cell component of the POS. 
 To examine the association between the histopathological estimate of the POS 
and ESTIMATE [169], which utilises gene expression signatures to calculate 
immune, stromal and tumour purity scores. 
 To explore the association between the POS and the corresponding primary 
melanoma transcriptome, derived from TMA core biopsies of formalin-fixed, 
paraffin-embedded (FFPE) tumour, using an agnostic approach. 
 To assess whether or not there is a statistical interaction between the POS, the 
transcriptome and melanoma-specific death. 
 To employ an agnostic approach to assess the association between the extent 
of both the core immune cell and lymphocytic infiltrates, independently, and the 
transcriptome. 
 To delineate the top biological pathways that are up- and/or downregulated in 
association with each of the following: the POS, the extent of the core immune 
cell and lymphocytic infiltrates, separately, and as a comparative experiment, by 
performing enrichment analyses using MetaCore™ (version 6.28, © 2016 
Thomson Reuters). 
 
5.2 Methods 
As previously discussed in Chapter 2, I annotated a 600 micron square onto the virtual 
pathology image, corresponding to the cored region. Fifty arrowheads were overlaid 
onto the square, using RandomSpot©. Each arrow was scored as ‘t’ if the arrowhead 
landed on tumour and ‘s’ if it landed on stroma. Therefore, all tissue that was not 
tumour was scored as stroma, except for non-informative regions, which were scored 
as ‘▪’. Similarly, when an arrowhead landed on squamous epithelium or a hair follicle, it 
was scored as “▪”. As a result, the stromal score consisted of a mixture of different 
stromal components, including collagen, blood vessels and a variety of immune cells, 
i.e. lymphocytes, macrophages/melanophages, plasma cells, neutrophils, and 
eosinophils. 
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The median and range for the POS was calculated for each of the clinical and 
histopathological categorical factors. Box and whisker plots were used to graphically 
illustrate the frequency distribution for the POS by the categorical variable of interest. 
The Spearman correlation coefficient was calculated to assess the association 
between the POS and continuous variables, e.g. age at diagnosis. The Wilcoxon rank-
sum test was performed to assess the association between the POS and binary 
variables. The Kruskal-Wallis test was performed to assess the association between 
the POS and unordered categorical variables with >2 categories. Non-parametric tests 
for trend were performed to assess the association between the POS and ordered 
categorical variables. 
Receiver operator characteristic (ROC) curves were plotted to estimate the area under 
the curve for melanoma-specific relapse or death accounted for by the AJCC stage and 
the POS, alone and combined. This statistical calculation does not take the time to 
event into account. 
Cox proportional hazards models were used to estimate hazard ratios (HR), 95% 
confidence intervals (95% CI) and p-values for the likelihood of melanoma-specific 
death. Multivariable survival analyses were performed for the POS, the ESTIMATE 
score, tumour purity, immune and stromal scores (five multivariable models). 
Univariable linear regression models were performed to test whether POS could predict 
the expression of each Illumina® probe. The mean expression, correlation coefficient, 
standard error and p-value were calculated. Bonferroni and false discovery rate (FDR) 
correction methods were applied to correct the p-values for multiple testing. A 
sensitivity analysis was also performed, excluding outliers for the POS (>87% POS; 
calculated as being more than 1.5 x interquartile range (IQR) higher than the 75th 
percentile of the POS). 
Similarly, univariable linear regression models were performed firstly to test whether  
the extent of the core immune cell infiltrate could predict the expression of each 
Illumina® probe and then to assess whether or not the extent of the core lymphocytic 
infiltrate could predict the expression of each Illumina® probe, to generate 
corresponding correlation coefficients, standard errors and p-values. Bonferroni and 
FDR correction methods were applied to correct the p-values for multiple testing. 
The Bonferroni-corrected p-values were used to rank genes that were most 
significantly associated with each of the following variables: the POS, the test for trend 
for both the extent of the core immune cell infiltrate and the extent of the core 
lymphocytic infiltrate. This was selected in preference to the FDR-corrected p-value 
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because it is a more stringent test and would rationalise the number of genes, thereby 
identifying the genes that were most significantly associated with the factor of interest. 
To establish whether or not there was a statistical interaction between the POS and the 
transcriptome on melanoma-specific survival, I performed an interaction analysis as 
follows: I assessed the effect of the POS on melanoma-specific survival in cases with 
low gene expression and then separately in cases with high gene expression for each 
of the Illumina® probes. A likelihood ratio test was performed between a statistical 
model including the interaction between the POS and the gene expression and a model 
including only the main effects of the POS and the gene expression. The p-value for 
the interaction was calculated using a likelihood ratio test. Bonferroni and FDR 
correction methods were applied to correct the p-values for multiple testing. 
Unsupervised hierarchical clustering was performed using Cluster 3.0 for the genes 
that were most significantly associated with the POS or the test for trend for the extent 
of each of the core immune cell and lymphocytic infiltrates. A Bonferroni-corrected p-
value of <0.05 was used as a cut-off point to identify the most highly ranked probes 
and, where more than one probe was available for a gene, the probe with the highest 
level of detection was retained. Heat maps were viewed using Java TreeView 
(v1.1.6r4). Separate enrichment analyses were performed using MetaCore™ (version 
6.28, © 2016 Thomson Reuters) for the genes within each cluster for each heat map, in 
order to identify the pathways that were up- or downregulated in the corresponding 
cluster. 
A comparative enrichment analysis was performed using MetaCore™ (version 6.28, © 
2016 Thomson Reuters), to evaluate the pathways associated with the top ranked 
1000 genes (with a Bonferroni-corrected p-value of <0.05) for the POS and the test for 
trend for the extent of the core immune cell and lymphocytic infiltrates.  
The ESTIMATE score, tumour purity, immune and stromal scores [169] were 
generated by Dr Jeremie Nsengimana, using R (version 2.15.3), which I subsequently 
used for analyses of their association with the POS (by calculating Spearman 
correlation coefficients) and the effect of the ESTIMATE scores on melanoma-specific 
survival (using Cox proportional hazards models). Dr Jeremie Nsengimana also 
performed unsupervised clustering for a gene list modified from Bindea et al. [174] to 
generate the “immunome” clusters, which I then used to analyse for the association 
with the POS (by performing the Kruskal-Wallis test). 
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5.3 Results 
5.3.1 The percentage of stroma in 702 cases from the Leeds 
Melanoma Cohort Study 
Figure 5.1 shows the frequency distribution for the POS within the cored region. It was 
notable that the median POS was 32.69%, although values ranged from 0% to 98.1%.  
 
 
Figure 5.1: Histogram of the percentage of stroma 
The frequency distribution of the POS is shown for 702 cases in which the POS 
was recorded. 
Figure 5.2 shows examples of different amounts of stroma within the cored regions. 
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Figure 5.2: Virtual pathology images of digitally-extracted cored regions showing 
variation in the stromal content of primary melanomas 
A) A cored region with a low stromal content (x20 magnification). The POS was 
12%. B) A cored region with a moderate stromal content (x20 magnification). The 
POS was 32%. C) A cored region with abundant stroma (x20 magnification). The 
POS was 50%. D) A cored region with 68% stroma (x20 magnification). 
 
  
A B 
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5.3.2 The percentage of stroma and clinical factors 
The POS was associated with several clinical factors (Table 5.1). There was an inverse 
correlation between the POS and age at diagnosis. Females tended to have a higher 
POS within their primary melanoma (median POS in females 35.3% and median POS 
in males 29.7%, Wilcoxon rank-sum, p=0.04). The POS tended to be lower within 
primary melanomas located on the trunk compared to other sites, although this was not 
statistically significant. Cases presenting with AJCC stage I melanoma, tended to have 
a higher POS (stage I, II, III/IV medians 40.4%, 25.5% and 28.8% respectively, non-
parametric test for trend, p<1x10-16, Figure 5.3). Cases whose primary melanomas 
harboured a NRAS mutation tended to have a lower POS than the BRAF-mutated 
melanomas (median 25.5% and 33.3%, respectively) and this difference was 
statistically significant (Kruskal-Wallis, p=0.004). Figure 5.4 shows the frequency 
distribution for the POS for cases with a BRAF or NRAS mutation or cases that were 
wild type for both BRAF and NRAS. 
 
Figure 5.3: Box and whisker plots for the percentage of stroma by AJCC stage 
The POS was highest in AJCC stage I melanomas (Table 5.1). 
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Table 5.1: The median (range) for the percentage of stroma and statistical tests 
(and corresponding p-values) for the pairwise associations between the 
percentage of stroma and clinical factors, including BRAF and NRAS 
mutation status. 
The median percentage of stroma (POS) is not shown for age at diagnosis, which 
was tested as a continuous variable, for each year at diagnosis. AJCC stage was 
missing for 1 case and BRAF/NRAS mutation status was available for 565 cases. 
The statistic indicates the statistical test performed. Spearman’s rho=the 
Spearman correlation coefficient. 
Factor Number Median (range) Statistic P-value 
Age at diagnosis (years)   Spearman’s rho = -0.16 0.00002 
Sex 
     Male 326 29.7 (1.9-95.9) Wilcoxon rank-sum 0.04 
     Female 376 35.3 (0-98.1)   
     Total 702    
Site of primary melanoma 
     Limbs 300 35.3 (0-94.2) Kruskal-Wallis 0.27 
     Trunk 237 28.8 (2.0-98.1)   
     Head 82 30.8 (3.9-83.0)   
     Other 83 32.0 (0-92.3)   
     Total 702    
AJCC stage 
     I 281 40.4 (3.8-98.1) Non-parametric test for 
trend 
<1x10-16 
     II 319 25.5 (0-92.3)  
     III/IV 101 28.8 (0-94.2)   
     Total 701    
Mutation status 
     BRAF positive 260 33.3 (1.9-93.3) Kruskal-Wallis 0.004 
     NRAS positive 146 25.5 (0-84.6)   
     Wild type 159 34.6 (0-98.1)   
     Total 565    
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Figure 5.4 Box and whisker plots for the percentage of stroma by BRAF/NRAS 
mutation status 
NRAS-mutated melanomas had a lower POS (Table 5.1). 
5.3.3 The percentage of stroma and whole-tumour histopathological 
measures 
Table 5.2 shows the median (range) POS in relation to whole-tumour measures and 
the results of statistical tests for the pairwise associations. There was an inverse 
relationship between the POS and Breslow thickness, with melanomas ≤1mm thick 
having the highest amount of stroma and this was highly statistically significant (non-
parametric test for trend, p<1x10-16). The median POS was 53.1% in cases with a 
Breslow thickness ≤1mm, compared with 36% for cases 1.01-2mm thick, 25.5% for 
cases 2.01-4mm thick and 22.9% for melanomas >4mm in thickness (non-parametric 
test for trend, p<1x10-16). Figure 5.5 shows the frequency distribution for the POS by 
Breslow thickness (using the AJCC 7th edition cut-off points) [43].  
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Figure 5.5: Box and whisker plots for the percentage of stroma by Breslow 
thickness category (using AJCC cut-off points) [43] 
There was a significant inverse association between the POS and Breslow 
thickness (Table 5.2). 
Similarly, ulcerated melanomas or melanomas containing a dominant nodule tended to 
have significantly less stroma (median for ulcerated 24.5% and non-ulcerated 34.7%; 
median with a dominant nodule 17.3% and without a dominant nodule 34.6%, Table 
5.2). It follows that cases with a lesser extent (width) of ulceration (<0.87mm) tended to 
have more stroma than cases with more extensive ulceration. Interestingly, there was 
no significant difference in the POS according to the pattern of tumour-infiltrating 
lymphocytes (TILs; Kruskal-Wallis, p=0.87) or by the presence or absence of tumour 
loss (Wilcoxon rank-sum, p=0.18). There was a borderline significant association 
between the POS and the intensity of tumour-infiltrating macrophages/melanophages 
(TIMs), with melanomas that had lots of TIMs tending to have more stroma compared 
to cases with none, very few or moderate TIMs (non-parametric test for trend, p=0.05). 
Melanomas with a brisk pattern of TIMs tended to have more abundant stroma, 
however, this was not statistically significant (non-parametric test for trend, p=0.16). 
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Table 5.2: The median (range) for the percentage of stroma and statistical tests 
(and corresponding p-values) for the association between the percentage of 
stroma and whole-tumour factors 
The Breslow thickness categories were defined using the AJCC cut-off points (7th 
edition) [43]. The extent of microscopic ulceration was categorised as none and 
the remaining values were divided into 4 approximately equal categories. The 
depth of tumour loss and relative tumour loss were categorised in a similar way. 
The statistic indicates the statistical test performed. The footnote provides the 
number of cases in which tumour-infiltrating lymphocytes (TILs) and 
macrophages/melanophages (TIMs) were non-evaluable. This occurred when the 
entire base of the tumour could not be visualised, e.g. due to shave excision. 
Factor Number Median (range) Statistic p-value 
Breslow thickness (mm) 
     ≤1.00 67 53.1 (16.7-98.1) Non-parametric test 
for trend 
<1x10-16 
     1.01-2.00 267 36.0 (2.2-95.9)  
     2.01-4.00 249 25.5 (0-93.3)   
     >4.00 113 22.9 (1.9-92.3)   
     Total 696    
Dominant nodule 
     No 627 34.6 (0-98.1) Wilcoxon rank-sum 5x10-11 
     Yes 75 17.3 (1.9-69.6)   
     Total 702    
Microscopic ulceration 
     No 538 34.7 (1.9-98.1) Wilcoxon rank-sum 4x10-8 
     Yes 164 24.5 (0-82.0)   
      Total 702    
Extent of microscopic ulceration (mm) 
     None 538 34.7 (1.9-98.1) Non-parametric test 
for trend 
3x10-8 
     <0.87 39 28.0 (2.1-82.0)  
     0.87-<2.4 40 19.4 (2.2-70.0)   
     2.4-<5.15 42 24.3 (0-81.3)   
     ≥5.15 41 24.0 (0-51.1)   
     Total 700    
Tumour-infiltrating lymphocytes 
     Absent 49 34.0 (0-80.0) Kruskal-Wallis 0.87 
     Non-brisk 501 33.3 (0-94.2)   
     Brisk 72 32.4 (3.8-98.1)   
     Total 622*    
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Factor Number Median (range) Statistic p-value 
Tumour loss 
     No 573 33.3 (0-92.3) Wilcoxon rank-sum 0.18 
     Yes 124 29.0 (3.8-98.1)   
     Total 697    
Type of tumour loss  
     None 573 33.3 (0-92.3) Kruskal-Wallis 0.15 
     Deep 56 34.0 (3.8-98.1)   
     Both 21 22.9 (9.8-94.2)   
     Superficial 46 27.6 (4.4-95.9)   
     Total 696    
Depth of tumour loss (mm) 
     None 573 33.3 (0-92.3) Non-parametric test 
for trend 
0.07 
     <0.71 38 32.1 (4.4-89.2)  
     0.71-<1.14 30 38.4 (6.3-98.1)   
     1.14-<1.63 24 30.7 (8.5-60.0)   
     ≥1.63 32 28.8 (3.8-84.6)   
     Total 697    
Relative tumour loss (mm) 
     None 570 33.3 (0-92.3) Non-parametric test 
for trend 
0.5 
     <0.26 35 19.2 (4.4-65.0)  
     0.26-<0.52 29 25.0 (7.7-93.3)   
     0.52-<0.786 33 36.0 (3.8-95.9)   
     ≥0.786 26 37.1 (5.8-98.1)   
     Total 693    
Tumour-infiltrating macrophages/melanophages 
     None 236 32.2 (0-92.3) Non-parametric test 
for trend 
0.05 
     Very few 245 31.7 (1.9-95.9)  
     Moderate 148 32.0 (0-98.1)   
     Lots 67 37.3 (2.6-94.2)   
     Total 696    
Pattern of tumour-infiltrating macrophages/melanophages 
     Absent 133 32.0 (3.8-83.3) Non-parametric test 
for trend 
0.16 
     Non-brisk 485 33.3 (0-98.1)  
     Brisk 5 54.5 (19.6-76.7)   
     Total 623**    
*    Tumour-infiltrating lymphocytes could not be assessed in 76 patients 
** Pattern of tumour-infiltrating macrophages/melanophages could not be assessed 
      in 75 patients 
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5.3.4 The percentage of stroma and cored region histopathological 
measures 
Table 5.3 shows the median (range) POS and its pairwise associations with the cored 
region measures. Cases with a “mixed” quality of stroma tended to have a higher POS 
(Kruskal-Wallis, p=0.01). Cores with balloon cells tended to have a sparse amount of 
stroma but there were only 2 cases in this category (Kruskal-Wallis, p=0.01). As 
expected, cores with a structure classified as “sheets” tended to have the least amount 
of stroma (Kruskal-Wallis, p=0.0001). An increasing degree of melanoma cell 
pigmentation within the core was associated with a higher POS (non-parametric test for 
trend, p=0.00005). The presence of a core immune cell infiltrate and its increasing 
extent were each significantly associated with a higher POS (The median POS was 
62.6% for cases with lots of immune cells within the cored region, compared to 24% for 
none, 34.7% for some and 41.6% for moderate, non-parametric test for trend, 
p<1x10-16). Figure 5.6 shows the frequency distribution for the POS by the extent of the 
core immune cell infiltrate. 
 
Figure 5.6: Box and whisker plots for the percentage of stroma by the extent of 
the core immune cell infiltrate 
There was a significant association between the POS and the increasing extent 
of the core immune cell infiltrate (Table 5.3). 
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Table 5.3: The median (range) for the percentage of stroma and statistical tests 
(and corresponding p-values) for the association between the percentage of 
stroma and cored region factors 
The core immune cell infiltrate was recorded as absent (no) or present (yes). If 
the core immune cell infiltrate was considered to be barely perceptible, further 
assessment of the presence and extent of the core immune cell subsets (e.g. 
lymphocytes) was not performed. Therefore, the “yes” category for the core 
immune cell infiltrate contained cases for which the extent was barely perceptible, 
some, moderate or lots. The core immune cell infiltrate is divided into no, barely 
perceptible and yes in order to provide more detail. The POS was similar for 
cores with an absent or barely perceptible immune cell infiltrate and therefore, the 
no/barely perceptible categories were merged. Similar hazard ratios had also 
been shown for these two categories in univariable survival analyses (Chapter 4). 
This no/barely perceptible core immune cell infiltrate was then used as the 
baseline for subsequent immune cell categories, e.g. the location of the immune 
cell infiltrate, the core lymphocytic infiltrate. Categories for core mitoses and core 
blood vessels were assigned on the basis of 3 approximately equal groups 
(tertiles). The statistic indicates the statistical test performed. 
Factor Number Median (range) Statistic p-value 
Quality of the stroma 
     Compact (Figure 2.15) 595 33.3 (0-98.1) Kruskal-Wallis 0.01 
     Loose 22 37.2 (12.5-87.9)   
     Mixed 34 49.4 (4.4-89.2)   
     Total 651    
Melanoma cell shape 
     Round/ovoid/epithelioid 602 32.6 (0-98.1) Kruskal-Wallis 0.01 
     Spindle 60 27.5 (0-94.2)   
     Super spindle 14 38.6 (22.0-92.3)   
     Naevoid 16 39.6 (14.6-81.0)   
     Plasmacytoid 6 53.8 (29.2-65.3)   
     Balloon 2 17.2 (11.5-22.9)   
     Total 700    
Melanoma cell structure 
     Nests 413 36.5 (3.8-98.1) Kruskal-Wallis 0.0001 
     Sheets 134 19.4 (0-84.6)   
     Fascicles 127 28.8 (3.8-94.2)   
     Dispersed 21 69.6 (28.1-95.9)   
     Total 695    
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Factor Number Median (range) Statistic p-value 
Melanoma cell pigmentation 
     Absent 522 30.6 (0-95.9) Non-parametric 
test for trend 
0.00005 
     Faint 45 29.8 (5.8-80.0)  
     Moderate 82 37.2 (10.6-93.3)   
     High 46 42.0 (1.9-98.1)   
     Very high 5 36.0 (28.3-94.2)   
     Total 700    
Immune cell infiltrate (categorised) 
     No 33 21.6 (5.8-68.1) Non-parametric 
test for trend 
<1x10-16 
     Barely perceptible 266 24.5 (0-92.3)  
     Yes 400 38.5 (1.9-98.1)   
     Total 699    
Extent of immune cell infiltrate 
     No/barely perceptible 
     immune cell infiltrate 
299 24.0 (0-92.3) Non-parametric 
test for trend 
<1x10-16 
     Some 252 34.7 (1.9-83.0)  
     Moderate 100 41.6 (9.8-81.6)   
     Lots 48 62.6 (21.7-98.1)   
     Total 699    
Location of immune cell infiltrate 
     No/barely perceptible 
     immune cell infiltrate 
299 24.0 (0-92.3) Kruskal-Wallis 0.0001 
     At the tumour/stroma 
     interface 
126 35.3 (1.9-83.0)   
     Dispersed between 
     tumour cells 
150 40.6 (2.2-98.1)   
     Both 122 42.7 (4.4-81.0)   
     Total 697    
Lymphocytic infiltrate 
     No/barely perceptible 
     immune cell infiltrate 
299 24.0 (0-92.3) Non-parametric 
test for trend 
<1x10-16 
     No 132 30.7 (1.9-84.6)  
     Yes 267 44.0 (4.4-98.1)   
     Total 698    
Extent of lymphocytic infiltrate 
     No/barely perceptible 
     immune cell infiltrate 
299 24.0 (0-92.3) Non-parametric 
test for trend 
<1x10-16 
     No 132 30.7 (1.9-84.6)  
     Some 179 38.5 (4.4-94.2)   
     Moderate 47 44.2 (12.5-81.6)   
     Lots 41 60.8 (26.9-98.1)   
     Total 698    
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Factor Number Median (range) Statistic p-value 
Plasma cell infiltrate 
     No/barely perceptible 
     immune cell infiltrate 
299 24 (0-92.3) Non-parametric 
test for trend 
<1x10-16 
     No 384 38.5 (1.9-98.1)  
     Yes 14 44.3 (7.7-78.7)   
     Total 697    
Extent of plasma cell infiltrate 
     No/barely perceptible 
     immune cell infiltrate 
299 24.0 (0-92.3) Non-parametric 
test for trend 
<1x10-16 
     None 384 38.5 (1.9-98.1)  
     Some 12 44.3 (7.7-78.7)   
     Moderate 0 -   
     Lots 2 39.5 (28.0-51.0)   
     Total 697    
Macrophage/melanophage infiltrate 
     No/barely perceptible 
     immune cell infiltrate 
299 24.0 (0-92.3) Non-parametric 
test for trend 
4x10-16 
     No 121 40.0 (4.4-95.9)  
     Yes 278 38.0 (1.9-98.1)   
     Total 698    
Extent of macrophage/melanophage infiltrate 
     No/barely perceptible 
     immune cell infiltrate 
299 24.0 (0-92.3) Non-parametric 
test for trend 
2x10-16 
     None 121 40.0 (4.4-95.9)  
     Some 118 36.8 (2.2-98.1)   
     Moderate 112 37.3 (1.9-81.6)   
     Lots 48 51.0 (14.3-94.2)   
     Total 698    
Neutrophilic infiltrate 
     No/barely perceptible 
     immune cell infiltrate 
299 24.0 (0-92.3) Non-parametric 
test for trend 
<1x10-16 
     No 386 38.8 (1.9-98.1)  
     Yes 12 37.5 (15.7-81.3)   
     Total 697    
Extent of neutrophilic infiltrate 
     No/barely perceptible 
     immune cell infiltrate 
299 24.0 (0-92.3) Non-parametric 
test for trend 
<1x10-16 
     None 386 38.8 (1.9-98.1)  
     Some 12 37.5 (15.7-81.3)   
     Moderate 0 -   
     Lots 0 -   
     Total 697    
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Factor Number Median (range) Statistic p-value 
Eosinophilic infiltrate 
     No/barely perceptible 
     immune cell infiltrate 
299 24.0 (0-92.3) Non-parametric 
test for trend 
<1x10-16 
     No 396 38.5 (1.9-98.1)  
     Yes 2 41.4 (23.9-59.0)   
     Total 697    
Extent of eosinophilic infiltrate 
     No/barely perceptible 
     immune  cell infiltrate 
299 24.0 (0-92.3) Non-parametric 
test for trend 
<1x10-16 
     None 396 38.5 (1.9-98.1)  
     Some 2 41.4 (23.9-59.0)   
     Moderate 0    
     Lots 0    
     Total 697    
Core mitoses (tertiles) 
     0 206 45.0 (10.4-98.1) Non-parametric 
test for trend 
<1x10-16 
     1-2 257 33.3 (0-84.6)  
     ≥3 232 20.9 (0-76.9)   
     Total 695    
Core blood vessels 
     0 122 33.0 (0-93.3) Non-parametric 
test for trend 
0.91 
     1-2 264 34.0 (1.9-98.0)  
     ≥3 314 31.3 (0-95.9)   
     Total 700    
Cores that had immune cells which were both dispersed between tumour cells and at 
the tumour/stroma interface tended to have more stroma (Kruskal-Wallis, p=0.0001). 
Cases with a lymphocytic infiltrate within the cored region had a higher POS compared 
to cases without a lymphocytic infiltrate or to cases with an absent or minimal 
(no/barely perceptible) immune cell infiltrate within the core (non-parametric test for 
trend, p<1x10-16). Similarly, an increasing abundance (extent) of lymphocytes within the 
core was associated with a higher POS (non-parametric test for trend, p<1x10-16). 
Figure 5.7 shows the frequency distribution for POS by the extent of the lymphocytic 
infiltrate within the cored region. 
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Figure 5.7: Box and whisker plots for the percentage of stroma by the extent of 
the core lymphocytic infiltrate 
There was a significant trend for an increasing POS in association with an 
increasing extent of lymphocytes within the core (non-parametric test for trend, 
p<1x10-16, Table 5.3). 
Few cases had plasma cells, neutrophils or eosinophils within the cored region, 
indicating that these immune cells were infrequently encountered in the advancing part 
of the melanoma, which had been selected for TMA sampling and, therefore, by 
definition had the least amount of immune cells/stroma. There was a trend for an 
increasing extent of core macrophages/melanophages to have a higher POS (non-
parametric test for trend, p=2x10-16). There was a highly significant inverse relationship 
between the POS and the number of core mitoses. The POS was lowest in cores with 
≥3 mitoses (20.9%), compared to 33.3% for cores with 1-2 mitoses and 45% where no 
mitoses were recorded within the core (non-parametric test for trend, p<1x10-16) but no 
significant difference was seen for the number of blood vessels within the core (non-
parametric test for trend, p=0.91). Figure 5.8 shows the frequency distribution of the 
POS by the number of core mitoses (tertiles). 
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Figure 5.8: Box and whisker plots for the percentage of stroma by the number of 
core mitoses (tertiles) 
A significant inverse association with the number of mitoses within the cored 
region was noted (Table 5.3). 
5.3.5 The percentage of stroma and melanoma relapse 
ROC curves for melanoma relapse showed that AJCC stage alone accounted for 67% 
of the area under the curve, whilst the POS alone contributed to 63%. When combined, 
the prognostic effect was increased, such that AJCC stage and the POS predicted 
melanoma relapse accurately 70% of the time (Figure 5.9). 
5.3.6 The percentage of stroma and melanoma-specific survival 
Similarly, ROC curves showed that AJCC stage accounted for 67% of the area under 
the curve for melanoma-specific death, whilst POS alone accounted for 64%. The 
effect of AJCC stage and the POS was additive, predicting melanoma-specific death 
accurately 70% of the time (Figure 5.10). 
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Figure 5.9: Receiver operator characteristic curves for the effect of AJCC stage 
alone, the percentage of stroma alone and AJCC stage and the percentage 
of stroma combined on melanoma relapse  
The predictive power was improved by the addition of the POS to AJCC stage 
(increasing by 3%) compared to AJCC stage alone. 
 
Figure 5.10: Receiver operator characteristic curves for the effect of AJCC stage 
alone, the percentage of stroma alone and AJCC stage and the percentage 
of stroma combined on melanoma-specific death 
The predictive power was improved by the addition of the POS to AJCC stage 
(increasing by 3%) compared to AJCC stage alone.  
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5.3.7 The percentage of stroma and the “immunome” 
In order to better understand the relationship between the POS and the immune cell 
components, I assessed the association between the POS and the six “immunome” 
clusters. These clusters were derived by Dr Jeremie Nsengimana (Section 5.2). Cluster 
4 had the worst outcome and the lowest gene expression for immune cells relative to 
the other clusters (data not shown). Figure 5.11 shows the heat map for the 
unsupervised clustering analysis of the modified immunome gene list in 703 cases from 
the Leeds Melanoma Cohort Study. 
 
 
Figure 5.11: Heat map for unsupervised clustering of the modified immunome 
gene list 
Two gene clusters (from top to bottom) and 6 distinct tumour clusters are shown 
(from left to right). The tumour clusters are represented by the labels at the top, 
numbered 1-6. The uppermost of the two gene clusters is dominated by genes 
expressed by macrophages, immature dendritic cells (iDCs) and mast cells. The 
lowermost gene cluster is dominated by genes expressed by cytotoxic cells, T 
cells, natural killer cells (NK) and activated dendritic cells (aDCs). Red=gene 
upregulation. Green=gene downregulation. 
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Figure 5.12 shows the frequency distribution of the POS by the six immunome clusters. 
Interestingly, cluster 4 also had the lowest median value for the POS and there was a 
significant association between the POS and the immunome clusters (Figure 5.12). 
 
Figure 5.12: Box and whisker plots for the percentage of stroma by the 
“immunome” clusters 
The median POS for the immunome clusters were as follows: 35.1%, 42%, 
29.6%, 21.6%, 43.9% and 36.3% for clusters 1, 2, 3, 4, 5 and 6, respectively. 
There was a significant association between the POS and the immunome 
clusters (Kruskal-Wallis, p=0.0001). 
5.3.8 The percentage of stroma and ESTIMATE 
As previously discussed, ESTIMATE produces an ESTIMATE score, which represents 
the combined immune and stromal scores, and a separate tumour purity score [169]. 
The frequency distribution for each of these scores is shown in Figure 5.13 - Figure 
5.16. The ESTIMATE scores were generated by Dr Jeremie Nsengimana, using R 
(version 2.15.3). 
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Figure 5.13: Histogram of the immune score 
The histogram shows the frequency distribution of the immune score (n=676) 
produced by ESTIMATE, which has a bimodal appearance. The score was 
generated based on the expression of 141 immune genes. 
 
Figure 5.14: Histogram of the stromal score 
The histogram shows the frequency distribution of the stromal score (n=676), 
which follows a normal distribution. This score was produced by ESTIMATE and 
was based on the expression of 141 stromal genes. 
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Figure 5.15 Histogram of the ESTIMATE score 
The histogram shows the frequency distribution for the ESTIMATE score (n=676), 
which represents the addition of the immune and stromal scores. 
 
Figure 5.16 Histogram of the tumour purity 
The histogram shows the frequency distribution for the tumour purity score 
(n=653), which is derived from the ESTIMATE score. 1 represents pure tumour 
(equivalent to 100%) and 0.1 represents only 10% tumour. The median tumour 
purity was 0.72 (72%).  
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There was a positive correlation between the POS and several of the ESTIMATE-
derived scores, including the immune score (Spearman rho=0.29, p=5x10-13), the 
stromal score (Spearman rho=0.36, p=8x10-20) and the ESTIMATE score (Spearman 
rho=0.34, p=3x10-17). Conversely there was a negative correlation between the POS 
and the tumour purity score (Spearman rho=-0.32, p=5x10-15). 
5.3.9 The percentage of stroma (POS), ESTIMATE score, tumour 
purity, immune and stromal scores as predictors of 
melanoma-specific death 
I have shown, using simple pairwise analyses, that the POS was associated with each 
of the ESTIMATE scores. Next, I will explore whether or not each of the ESTIMATE 
scores was independently prognostic of melanoma-specific death, in multivariable 
survival analyses. Table 5.4 shows the results of five multivariable survival models, 
each adjusted for age, sex, site of primary, AJCC stage, melanoma cell structure and 
the extent of the core immune cell infiltrate, for each of the following variables: the 
POS, ESTIMATE score, tumour purity, immune and stromal scores. The POS, 
ESTIMATE score, tumour purity, immune and stromal scores were each independent 
prognostic factors in these models, all being protective except for the tumour purity 
score, which appeared to be hazardous (HR for the tumour purity score 1.01, 95% CI 
1.0-1.02, Cox proportional hazards model, p=0.002). The p-values in Table 5.4 suggest 
that ESTIMATE’s stromal score is the strongest predictor of melanoma-specific death 
(Cox proportional hazards model, p=0.0002). 
 
 Table 5.4: Adjusted hazard ratios (HRs) and 95% confidence intervals (95% CI) for the effects of the POS, ESTIMATE score, tumour purity 
score, immune score and stromal score on melanoma-specific death, adjusted for age, sex, site of primary, AJCC stage, melanoma 
cell structure and the extent of the core immune cell infiltrate 
The percentage of stroma (POS), ESTIMATE score, immune and stromal scores were independently protective for melanoma-specific death (as 
indicated by hazard ratios <1.0 and p-values <0.05). The tumour purity score was hazardous. N=the number of cases. The number of events 
refers to the number of melanoma-specific deaths. 95% CI=95% confidence interval. 
 Melanoma Death 
 
POS 
N=692 (177 events) 
ESTIMATE score 
N=589 (153 events) 
Tumour purity score 
N=568 (149 events) 
Immune score 
N=589 (153 events) 
Stromal score 
N=589 (153 events) 
Factor 
Adjusted HR 
(95% CI) 
p-value 
Adjusted HR 
(95% CI) 
p-value 
Adjusted HR 
(95% CI) 
p-value 
Adjusted HR 
(95% CI) 
p-value 
Adjusted HR 
(95% CI) 
p-value 
Age at diagnosis (years) 
1.03 
(1.02-1.04) 
0.00004 
1.03 
(1.02-1.05) 
0.00004 
1.03 
(1.02-1.05) 
0.00008 
1.03 
(1.02-1.05) 
0.00004 
1.03 
(1.02-1.05) 
0.00003 
Sex           
     Male 1  1  1  1  1  
     Female 
0.84 
(0.61-1.15) 
0.27 
0.85 
(0.61-1.20) 
0.36 
0.86 
(0.61-1.21) 
0.38 
0.85 
(0.61-1.19) 
0.35 
0.84 
(0.60-1.17) 
0.31 
Site of primary melanoma           
     Limbs 1  1  1  1  1  
     Trunk 
1.41 
(0.97-2.05) 
0.07 
1.70 
(1.13-2.56) 
0.01 
1.61 
(1.06-2.43) 
0.02 
1.70 
(1.13-2.57) 
0.01 
1.66 
(1.10-2.51) 
0.02 
     Head 
0.93 
(0.55-1.59) 
0.80 
0.92 
(0.51-1.65) 
0.77 
0.85 
(0.47-1.54) 
0.59 
0.93 
(0.52-1.66) 
0.80 
0.89 
(0.50-1.60) 
0.71 
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  Melanoma Death 
 
POS 
N=692 (177 events) 
ESTIMATE score 
N=589 (153 events) 
Tumour purity score 
N=568 (149 events) 
Immune score 
N=589 (153 events) 
Stromal score 
N=589 (153 events) 
Factor 
Adjusted HR 
(95% CI) 
p-value 
Adjusted HR 
(95% CI) 
p-value 
Adjusted HR 
(95% CI) 
p-value 
Adjusted HR 
(95% CI) 
p-value 
Adjusted HR 
(95% CI) 
p-value 
     Other 
1.81 
(1.18-2.79) 
0.007 
1.70 
(1.07-2.70) 
0.02 
1.63 
(1.02-2.60) 
0.04 
1.71 
(1.07-2.71) 
0.02 
1.73 
(1.09-2.74) 
0.02 
AJCC stage           
     Test for trend 
2.26 
(1.79-2.85) 
9x10-12 
2.33 
(1.81-3.00) 
7x10-11 
2.34 
(1.81-3.03) 
1x10-10 
2.31 
(1.79-2.99) 
1x10-10 
2.39 
(1.85-3.08) 
2x10-11 
POS or ESTIMATE score or 
Tumour purity score or Immune 
score or Stromal score 
0.99 
(0.98-0.99) 
0.005 
0.99 
(0.98-0.99) 
0.0003 
1.01 
(1.00-1.02) 
0.002 
0.99 
(0.98-0.99) 
0.001 
0.97 
(0.96-0.99) 
0.0002 
Melanoma cell structure           
     Nests 1  1  1  1  1  
     Sheets 
1.08 
(0.74-1.58) 
0.67 
1.45 
(0.98-2.14) 
0.06 
1.48 
(1.00-2.19) 
0.05 
1.49 
(1.01-2.21) 
0.05 
1.35 
(0.92-1.99) 
0.13 
     Fascicles 
1.02 
(0.68-1.54) 
0.92 
1.15 
(0.74-1.80) 
0.54 
1.13 
(0.72-1.78) 
0.59 
1.16 
(0.74-1.82) 
0.51 
1.12 
(0.72-1.75) 
0.63 
     Dispersed 
2.44 
(1.09-5.48) 
0.03 
2.09 
(0.98-4.47) 
0.06 
1.75 
(0.75-4.11) 
0.20 
1.90 
(0.89-4.05) 
0.10 
2.28 
(1.06-4.90) 
0.03 
Extent of immune cell infiltrate           
     Test for trend 
0.81 
(0.66-0.99) 
0.05 
0.82 
(0.67-1.01) 
0.06 
0.80 
(0.65-0.99) 
0.05 
0.82 
(0.67-1.01) 
0.06 
0.80 
(0.65-0.98) 
0.03 
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Table 5.5 shows the results of multivariable survival analyses, adjusted for age, sex, 
site of primary, AJCC stage, melanoma cell structure and the extent of the core 
lymphocytic infiltrate, for each of the following variables: the POS, ESTIMATE score, 
tumour purity, immune and stromal scores. The POS and each of the ESTIMATE 
scores were independent predictors of melanoma-specific death. As before, the POS, 
ESTIMATE score, immune and stromal scores were protective, whilst ESTIMATE’s 
tumour purity score was hazardous (Table 5.5). 
5.3.10 The percentage of stroma and the transcriptome 
I performed 29354 univariable linear regression models, regressing the POS on all 
29354 probes in the Illumina® DASL assay in order to establish the transcriptomic 
correlates of the POS (please see Chapter 2). Similar results were obtained using a 
sensitivity analysis (to exclude outliers with a POS >87%; data not shown). 
Unsupervised hierarchical clustering was performed using the top ranked gene probes 
found to be most significantly associated with the POS, by selecting genes that had a 
Bonferroni-corrected p-value <0.05 (and the best detected probe where >1 probe was 
available for a gene). Figure 5.17 shows the resultant heat map, ranked from low to 
high POS. Two distinct clusters can be discerned. Of the top 2180 genes identified to 
be significantly associated with increasing POS, 1064 genes were downregulated. The 
top 10 pathways identified by MetaCore™ enrichment analyses for the probes in each 
cluster are shown. Cell cycle pathways were enriched in cases with low stroma, whilst 
T-cell signalling and chemotaxis were among the top ranked pathways in cases with 
high stroma. 
Table 5.5 (on following page): Adjusted hazard ratios (HRs) and 95% confidence 
intervals (95% CI) for the effects of the POS, ESTIMATE score, tumour 
purity, immune and stromal scores on melanoma-specific death, adjusted 
for age, sex, site of primary, AJCC stage, melanoma cell structure and the 
extent of the core lymphocytic infiltrate 
The percentage of stroma (POS), ESTIMATE score, immune and stromal scores 
were independently protective of melanoma-specific death (as indicated by 
hazard ratios <1.0 and p-values <0.05). The tumour purity score was hazardous. 
One of the lines in the table reads as follows: “POS or ESTIMATE score or 
Tumour purity score or Immune score or Stromal score”. This line refers to which 
of the 5 statistical models the HRs, 95% CI and p-values correspond.  N=the 
number of cases. The number of events refers to the number of melanoma-
specific deaths. 95% CI=95% confidence interval. 
   
 Melanoma Death 
 
POS 
N=692 (177 events) 
ESTIMATE score 
N=589 (153 events) 
Tumour purity score 
N=568 (149 events) 
Immune score 
N=589 (153 events) 
Stromal score 
N=589 (153 events) 
Factor 
Adjusted HR 
(95% CI) 
p-value 
Adjusted HR 
(95% CI) 
p-value 
Adjusted HR 
(95% CI) 
p-value 
Adjusted HR 
(95% CI) 
p-value 
Adjusted HR 
(95% CI) 
p-value 
Age at diagnosis (years) 
1.03 
(1.02-1.04) 
0.00005 
1.03 
(1.02-1.05) 
0.00005 
1.03 
(1.02-1.05) 
0.0001 
1.03 
(1.02-1.05) 
0.00005 
1.03 
(1.02-1.05) 
0.00004 
Sex           
     Male 1  1  1  1  1  
     Female 
0.84 
(0.62-1.15) 
0.28 
0.85 
(0.60-1.19) 
0.34 
0.85 (0.61-
1.20) 
0.36 
0.85 
(0.60-1.19) 
0.33 
0.83 
(0.59-1.17) 
0.29 
Site of primary melanoma           
     Limbs 1  1  1  1  1  
     Trunk 
1.38 
(0.95-2.00) 
0.10 
1.65 
(1.09-2.49) 
0.02 
1.55 
(1.03-2.35) 
0.04 
1.66 
(1.10-2.50) 
0.02 
1.61 
(1.07-2.43) 
0.02 
     Head 
0.92 
(0.54-1.56) 
0.75 
0.90 
(0.50-1.62) 
0.72 
0.83 
(0.46-1.51) 
0.54 
0.91 
(0.51-1.63) 
0.75 
0.87 
(0.49-1.56) 
0.65 
     Other 
1.71 
(1.11-2.65) 
0.02 
1.63 
(1.02-2.60) 
0.04 
1.56 
(0.97-2.50) 
0.07 
1.64 
(1.03-2.61) 
0.04 
1.64 
(1.03-2.62) 
0.04 
AJCC stage           
     Test for trend 
2.20 
(1.74-2.78) 
6x10-11 
2.26 
(1.75-2.93) 
5x10-10 
2.27 
(1.74-2.95) 
1x10-9 
2.25 
(1.74-2.92) 
6x10-10 
2.31 
(1.78-2.99) 
2x10-10 
POS or ESTIMATE score or 
Tumour purity score or Immune 
score or Stromal score 
0.99 
(0.98-0.99) 
0.009 
0.99 
(0.98-0.99) 
0.001 
1.01 
(1.00-1.02) 
0.004 
0.99 
(0.98-0.99) 
0.004 
0.98 (0.96-
0.99) 
0.0003 
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  Melanoma Death 
 
POS 
N=692 (177 events) 
ESTIMATE score 
N=589 (153 events) 
Tumour purity score 
N=568 (149 events) 
Immune score 
N=589 (153 events) 
Stromal score 
N=589 (153 events) 
Factor 
Adjusted HR 
(95% CI) 
p-value 
Adjusted HR 
(95% CI) 
p-value 
Adjusted HR 
(95% CI) 
p-value 
Adjusted HR 
(95% CI) 
p-value 
Adjusted HR 
(95% CI) 
p-value 
Melanoma cell structure           
     Nests 1  1  1  1  1  
     Sheets 
1.09 
(0.75-1.59) 
0.65 
1.45 
(0.98-2.14) 
0.06 
1.48 (1.00-
2.19) 
0.05 
1.49 
(1.01-2.20) 
0.05 
1.36 
(0.92-2.00) 
0.13 
     Fascicles 
1.00 
(0.66-1.51) 
1.0 
1.13 
(0.72-1.76) 
0.60 
1.11 
(0.71-1.75) 
0.65 
1.14 
(0.73-1.78) 
0.57 
1.09 
(0.70-1.71) 
0.69 
     Dispersed 
2.45 
(1.09-5.50) 
0.03 
2.14 
(1.00-4.60) 
0.05 
1.81 
(0.77-4.25) 
0.17 
1.96 
(0.92-4.18) 
0.08 
2.35 
(1.09-5.04) 
0.03 
Extent of lymphocytic infiltrate           
     Test for trend 
0.80 
(0.68-0.95) 
0.01 
0.83 
(0.69-0.99) 
0.04 
0.81 
(0.67-0.97) 
0.03 
0.82 
(0.69-0.99) 
0.03 
0.81 
(0.68-0.96) 
0.02 
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Figure 5.17: Heat map and functional annotation for stroma-associated genes  
A) The gene dendrogram and heat map for stroma-associated genes are shown. 
Going from left to right across the heat map, the tumours are ordered from low to 
high POS (using the continuous values for POS). The genes in Cluster 1 were 
upregulated in melanomas with low POS, while genes in Cluster 2 were 
upregulated in melanomas with high POS. Red=gene upregulation. Green=gene 
downregulation.  
Separate enrichment analyses were performed for genes within each of the two 
gene clusters, using MetaCore™. The top ten pathways for each gene cluster are 
shown (B and C). The first gene cluster (low POS) was enriched in cell cycle and 
the second (high POS) was enriched in immune pathways.  
  
A B 
C 
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5.3.11 Interaction analysis between the percentage of stroma 
(POS), the transcriptome and melanoma-specific death 
There was no significant statistical interaction between the POS and the transcriptome 
on melanoma-specific death (data not shown). 
5.3.12 The extent of the core immune cell infiltrate and the 
transcriptome 
The POS was composed of a mixture of immune and non-immune stromal cells. The 
extent of the core immune cell infiltrate was also predictive of melanoma-specific 
survival (Chapter 4). Therefore, I next explored the association between the core 
immune cell infiltrate and the transcriptome. This was done by performing 29354 linear 
regression models, regressing the extent of the core immune cell infiltrate (test for 
trend) on each of the 29354 probes in the Illumina® DASL assay (please see Section 
5.2). Unsupervised hierarchical clustering using the top ranked gene probes that were 
most significantly associated with the extent of the core immune cell infiltrate 
(Bonferroni-corrected p-value <0.05) was performed using Cluster 3.0. Figure 5.18 
shows the resultant heat map, ranked from none to lots of immune cells within the 
core. Of the top 1288 genes, only 356 were inversely associated with an increasing 
extent of the core immune cell infiltrate. Unsurprisingly, the top 10 pathways that were 
upregulated in association with increasing amounts of immune cell infiltration (within 
the core) included immune pathways, particularly T- and B-cell signalling. 
5.3.13 The extent of the core lymphocytic infiltrate and the 
transcriptome 
The core immune cell infiltrate was composed of various immune cell subtypes, 
however, apart from lymphocytes and macrophages/melanophages, other immune cell 
subtypes were infrequently recorded within the core (Chapter 4). I decided to assess 
the association between the extent of the core lymphocytic infiltrate and the 
transcriptome because this was an independent predictor of survival in multivariable 
survival analyses and the macrophage/melanophage infiltrate was not (Chapter 4). 
Furthermore, arrowheads that had landed on lymphocytes within the core (using 
RandomSpot©) would have been incorporated into the POS calculation and, ultimately, 
I wanted to see if it was possible to distinguish which genes were associated with the 
core lymphocytes and which genes might be more likely to be related to other non-
immune components. Of the top 1542 genes identified as being significantly associated 
with the extent of the core lymphocytic infiltrate, only 400 were downregulated. 
222 
Unsupervised clustering of the top ranked genes associated with the extent of the core 
lymphocytic infiltrate was performed in a similar way to that described above. Figure 
5.19 shows the heat map, which is ranked according to increasing amounts (extent) of 
lymphocytic infiltrate within the cored region. Similar immune pathways were 
upregulated in association with an increasing extent of lymphocytic infiltrate, as had 
previously been identified in association with an increasing extent of immune cell 
infiltration within the core. 
 
 
 
 
 
 
 
 
 
 
Figure 5.18 (on following page): Heat map and functional annotation for genes 
associated with the increasing extent of the core immune cell infiltrate 
A) The gene dendrogram and heat map for genes associated with the increasing 
extent of the core immune cell infiltrate (test for trend) are shown. Going from left 
to right across the heat map, the tumours are ordered by an increasing extent of 
the core immune cell infiltrate. The genes in Cluster 1 were upregulated in 
melanomas with a low extent of core immune cells. The genes in Cluster 2 were 
upregulated in melanomas with a high extent of core immune cells. Red=gene 
upregulation. Green=gene downregulation.  
Separate enrichment analyses were performed for genes within each of the two 
gene clusters, using MetaCore™. The top ten pathways for each gene cluster are 
shown (B and C). There were 356 genes within the first (uppermost) gene cluster, 
therefore, the pathways may not be reliable due to the relatively small number of 
genes for a MetaCore™ analysis. Melanomas in the second (lowermost) gene 
cluster (higher extent of core immune cell infiltrate) were enriched in immune 
pathways.  
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Figure 5.19: Heat map and functional annotation for genes associated with the 
increasing extent of the core lymphocytic infiltrate 
A) The gene dendrogram and heat map for genes associated with the increasing 
extent of the core lymphocytic infiltrate (test for trend) are shown. Going from left 
to right across the heat map, there is an increasing extent of the core lymphocytic 
infiltrate. Red=gene upregulation. Green=gene downregulation.  
A 
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(Figure 5.19 legend cont.) Separate enrichment analyses were performed for 
genes within each of the two gene clusters, using MetaCore™. The top ten 
pathways for each gene cluster are shown (B and C). There were 400 genes 
within Cluster 1 and, therefore, the pathways may not be reliable (due to the 
relatively small number of genes for a MetaCore™ analysis). Melanomas in 
Cluster 2 (higher extent of the core lymphocytic infiltrate) were enriched in 
immune pathways. 
5.3.14 Comparative enrichment analysis for the percentage of 
stroma and the extent of the core immune cell and 
lymphocytic infiltrates using MetaCore™ 
MetaCore™ enrichment analyses of the top ranked genes for the POS and the extent 
of the core immune cell and lymphocytic infiltrates identified immune pathways as 
being significantly upregulated in association with each of these variables. In order to 
better understand the overlap in the pathways, I next performed a comparative 
enrichment experiment. Of the top 1000 genes for each of the POS and the extent of 
the core immune cell and lymphocytic infiltrates, one of the genes that was identified as 
being unique to the POS gene list was stromal-derived factor 1 (SDF1; Figure 5.20). 
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Figure 5.20: Image of the MetaCore™ immune response “immunological synapse 
formation” pathway  
The pathway indicates which proteins are proposed to be mediating the signalling 
between the antigen presenting cell and the T lymphocyte. Red thermometers 
indicate upregulation of the corresponding gene in the transcriptome data set. 
There is upregulation of MHC class II, CD80 (a B-cell marker), CD86 (present on 
antigen presenting cells) and corresponding upregulation of T-cell markers, 
including CD3, CD4, CD2, and CD28. 
Interestingly, SDF1 (highlighted by orange hatched box) is uniquely upregulated 
in association with the POS (thermometer 1) but not with the extent of the core 
immune cell infiltrate (thermometer 2) or the core lymphocytic infiltrate 
(thermometer 3).  
227 
(Figure 5.20 legend cont.) There is also upregulation of its receptor, C-X-C 
chemokine receptor 4 (CXCR4, also highlighed in orange hatched box) however 
this is not confined to the POS. Also upregulated in all three data sets are the 
integrins, ITGB2 and alpha-L/beta 2 integrin. T-cell activation occurs downstream 
of SDF1.  
MetaCore™ Key: ADAP = adhesion and degranulation-promoter adapter protein. 
ARF6 = Adenosine diphosphate-ribosylation factor 6. ARP = actin-related protein 
2 homolog. C3G (also known as RAPGEF1) = Rap Guanine nucleotide exchange 
factor 1. CALDAG-GEF = Calcium and diacylglycerol-related guanine nucleotide 
exchange factor. CBL = Cbl proto-oncogene. CD refers to cluster of 
differentiation. CrkL = Crk-like proto-oncogene. CDC42 = cell division control 
protein 42. DAG = diacylglycerol. DOCK2 = Dedicator of cytokinesis 2. Fyn = 
proto-oncogene tyrosine kinase. Grb2 = growth factor receptor-bound protein 2. 
ICAM = Intracellular adhesion molecule. IP3 = inositol triphosphate. ITGB2 = 
integrin beta 2. LFA3 = lymphocyte function-associated antigen 3 (also known as 
CD58). PI3K = phosphoinositide 3-kinase. PIP5K1A = phosphatidylinositol-4-
phosphate 5-kinase type 1 alpha. PLC = phospholipase C. PtdIns = 
phosphatidylinositol. RAC (1 or 2) = Ras-related C3 botulinum toxin substrate (1 
or 2). RAP1A = Ras-related protein Rap-1A. SKAP1: Src kinase-associated 
phosphoprotein 1. SLP76 = lymphocyte cytosolic protein 2. SMAC=Second 
mitochondrial-derived activator of caspase. TCR = T-cell receptor. VAV1 = Vav 
guanine nucleotide exchange factor. WASP = Wiskott-Aldrich Syndrome Protein. 
Interaction arrows: B, binding; +P, phosphorylation; T, transformation; Z, 
catalysis, ?, unspecified. 
5.3.15 Stromal-derived factor 1 and melanoma-specific death 
In light of the strong association between SDF1 and the POS, I was interested to 
assess whether or not SDF1 expression might also influence survival, particularly due 
to conflicting reports in the literature (discussed later). Figure 5.21 shows the frequency 
distribution for the logged SDF1 gene expression within 676 cases for which 
histopathological review and transcriptomic data were available. 
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Figure 5.21 Histogram of SDF1 gene expression (ILMN_1689111 probe) 
The histogram shows the frequency distribution for the logged SDF1 gene 
expression in 676 cases from the Leeds Melanoma Cohort Study. The mean 
expression was 7.9 (standard deviation 1.0). 
In a univariable survival analysis, SDF1 gene expression was significantly protective 
for melanoma-specific death (HR 0.79, 95% CI 0.69-0.90, Cox proportional hazards 
model, p=0.0005). Furthermore, in a multivariable model, adjusting for age, sex, site of 
primary, AJCC stage, the POS, melanoma cell structure and the extent of the core 
immune cell infiltrate, SDF1 was an independent predictor of melanoma-specific death 
(HR 0.8, 95% CI 0.68-0.94, Cox proportional hazards model, p=0.005). To assess 
whether or not its receptors, C-X-C chemokine receptor type 4 (CXCR4) and C-X-C 
chemokine receptor type 7 (CXCR7), might also be prognostic, I performed survival 
analyses using their respective gene expression values. The findings revealed that 
CXCR4 was protective in a univariable analysis for melanoma-specific death (HR 0.85, 
95% CI 0.76-0.95, Cox proportional hazards model, p=0.005). CXCR4 was also an 
independent predictor of survival in a multivariable analysis, adjusting for age, sex, site 
of primary, AJCC stage, melanoma cell structure and the extent of the core immune 
cell infiltrate (HR 0.86, 95% CI 0.76-0.99, Cox proportional hazards model, p=0.04) but 
it lost statistical significance after adjusting for the POS (Cox proportional hazards 
model, p=0.06). CXCR7 was not significantly associated with melanoma-specific death 
in a univariable model (HR 0.92, 95% CI 0.82-1.03, Cox proportional hazards model, 
p=0.2).  
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5.4 Summary 
My findings can be summarised as follows: 
 The median POS within primary cutaneous melanomas in this study was 
32.7%, consistent with findings of a smaller study, in which the average amount 
of stroma was reported to be 26% [145]. There was an inverse association 
between the POS and the following factors: age, AJCC stage, Breslow 
thickness, dominant nodule, microscopic ulceration and the number of core 
mitoses. The striking inverse association between the POS and several 
histopathological factors, which are considered to be predictive of poor survival, 
could reflect inadvertent sampling of some normal tissue in thinner tumours. 
The POS was lowest in NRAS-mutant tumours compared to BRAF-mutant and 
wild type melanomas. Increasing values for the POS were associated with 
female sex, increasing TIMs (borderline statistical significance), mixed stroma 
quality, dispersed melanoma cell structure, increasing melanoma cell 
pigmentation and an increasing extent of the core immune cell and lymphocytic 
infiltrates. 
 The effect of combining the POS and AJCC stage was additive in terms of 
predicting either melanoma relapse or melanoma-specific death. The addition of 
the POS increased the power of prediction by 3% for both relapse and death. 
 The POS was significantly associated with the immunome. Notably, immunome 
cluster 4, which contained the lowest expression of immune cell genes, also 
had the lowest value for the POS. The POS was significantly associated with 
each of ESTIMATE’s scores, being positively associated with the ESTIMATE 
score, the immune and stromal scores and inversely associated with the tumour 
purity score. The POS and each of the ESTIMATE scores were independently 
prognostic in multivariable survival analyses and each of the ESTIMATE scores 
were more powerful predictors of melanoma-specific survival than the POS, 
with the ESTIMATE stromal score being the most significant. Therefore, 
although the POS is associated with ESTIMATE, it does not appear to simply 
be a reflection of the amount of immune cells present. 
 Immune cell signalling pathways were upregulated and cell cycle pathways 
were downregulated in association with the POS. Similarly, immune cell 
pathways were enriched in association with the extent of the core immune cell 
and lymphocytic infiltrates. A comparative enrichment analysis revealed that 
SDF1 was unique to the POS gene list. Moreover, SDF1 was an independent 
prognostic factor, conferring a protective effect for melanoma-specific death. Its 
receptor CXCR4 but not CXCR7, was protective for melanoma-specific death 
230 
but lost statistical significance in a multivariable model including the POS. There 
was no significant statistical interaction between the POS, the transcriptome 
and melanoma-specific survival. 
 
5.5 Discussion 
The POS was an independent prognostic factor (Chapter 4) and was associated with a 
number of interesting observations. The POS was significantly inversely associated 
with age and male sex, suggesting that it might reflect host factors associated with 
biological variation. Although melanomas with more aggressive histopathological 
characteristics have been reported to be associated with older age at diagnosis [7] and 
male sex [14], the explanation for this apparent disparity has not been fully elucidated. 
It is known that host factors, such as advancing age [260, 275] and smoking [276] 
contribute to changes in the tumour microenvironment that can promote cancer. 
Advancing age has been linked to decreased self-detection among melanoma patients 
[11]. That being the case, one might expect that melanomas at less visible sites might 
have had a lower POS. However, there was no significant association between the 
POS and the site of primary melanoma, although the median POS was lowest in 
truncal primaries. Ageing has also been linked to immunosenescence [12], which might 
account for the inverse association observed in association with the POS because core 
immune cells were incorporated into the calculation of the POS. A more detailed 
analysis of the histopathological factors associated with age would help to clarify this. It 
is well-recognised that females diagnosed with melanoma tend to have a better 
prognosis [22, 23]. As previously discussed, female sex was protective for melanoma-
specific death in a univariable survival analysis but lost statistical significance in 
multivariable survival analyses (Chapter 4). Several hypotheses have been offered for 
the sex disparity, including effects mediated by hormones and host immunity [31]. 
Conversely, there does not appear to be a significant difference in the pattern of TILs in 
primary melanomas between the sexes [33, 64]. Nonetheless, it is possible that more 
subtle differences in the nature of the immune landscape could exist and may not be 
captured by this measure. Furthermore, the production of collagen might vary by sex, 
which could also be reflected in the POS. Oestrogen has been reported to increase 
collagen synthesis [277, 278], and a reduction in MMP activity has been linked to 
progesterone [277]. Moreover, androgens have been reported to impair wound healing 
due by alterations in MMP production [279]. The possibility that differences exist in the 
stromal composition of primary melanomas between men and women is an exciting 
prospect, worthy of further exploration. 
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The POS was inversely associated with Breslow thickness, ulceration and mitotic 
count, and, therefore, the observed differences by age and sex could reflect a more 
destructive primary tumour in these subgroups. In addition, cell cycle pathways were 
upregulated in cases with a low POS, suggesting that these tumours were more 
proliferative. Indeed, a criticism of my findings may be that the protective effect of the 
POS might reflect the reverse: that a lower POS might be a marker of a less 
proliferative, less aggressive tumour. However, the fact that the POS was an 
independent predictor of survival, after adjusting for age, sex and AJCC stage 
suggests that the POS might not simply be a read-out of the aggressiveness of the 
melanoma. The POS conferred an additional 3% predictive power, over and above 
AJCC stage (Figure 5.9 and Figure 5.10), indicating that the histopathological 
estimation of the POS as a prognostic marker would be worth evaluating in an 
independent cohort. 
Furthermore, the POS was significantly associated with BRAF/NRAS mutation status, 
with a lower POS being recorded in melanomas harbouring an NRAS mutation. The 
results further support the notion that a biological explanation could underlie variations 
in the POS. NRAS-mutated melanomas are reported to be associated with adverse 
tumour characteristics [37], including nodular melanoma [280], however, no significant 
differences were observed in the proportions of nodular melanomas among cases with 
an NRAS mutation compared with a BRAF mutation (data not shown, analysis 
performed by Faye Elliott). A recent study has reported that brisk TILs are less likely to 
occur in NRAS-mutated primary melanomas [37], suggesting that a more 
immunosuppressive tumour microenvironment might exist in these tumours. The 
acquisition of resistance to BRAF inhibitor therapy has been reported to result in the 
increased production of MMPs [251]. Intriguingly, increased production of type I 
collagen has been described in association with BRAF inhibition, both in melanoma cell 
lines and in mice [281]. Conversely, variably increased expression of SDF1 and 
CXCR4 has been reported in dermal fibroblasts, grown in a medium conditioned with a 
BRAF-mutant melanoma cell line [282]. Therefore, although the reported findings are 
somewhat conflicting, the driver mutation status could shape not only the immune cell 
infiltrate but also the extent of collagen within primary melanomas, which might have 
therapeutic implications. 
The observation that the POS was inversely associated with melanoma cell 
pigmentation is fascinating. As previously discussed, pigmentation is regarded to be a 
marker of melanocyte differentiation [111], therefore, it is possible that the nature of the 
tumour-stroma cross-talk might differ based on the level of melanocyte differentiation. 
Furthermore, melanoma cells with a high degree of pigmentation have been reported 
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to have reduced cell elasticity and, hence, an impaired capacity for invasion [114]. I 
would be keen to validate these findings in an independent data set. 
A significant association was observed between the POS and the core immune cell 
variables, which is not surprising because these were included in the calculation of the 
POS. Furthermore, the downregulation of cell cycle pathways is indicative of the 
relative absence of melanoma cells within samples that had a high POS. Nonetheless, 
the consistent upregulation of immune cell and downregulation of cell cycle pathways 
is proof-of-concept that histopathological observations have transcriptomic correlates. 
Moreover, the POS remained an independent predictor of outcome, after adjusting for 
either the core immune cell or lymphocytic infiltrates in multivariable survival analyses 
(Chapter 4), indicating that although the POS reflects the presence of immune cells, 
the non-immune stromal constituents might also have a protective effect. 
For the majority of cancers, studies indicate a hazardous role for increasing amounts of 
stroma. The reason for the contrasting findings of this project is not entirely clear. 
Melanoma is recognised as being one of the most highly immunogenic tumours [257], 
therefore, the immune cell infiltrate could have been responsible for the beneficial 
effects of the POS. One hypothesis is that stroma may promote or inhibit tumour 
growth, depending on the nature of that stroma and the cancer with which it is 
associated. Furthermore, many of the reported studies refer to cancers located at 
mucosal sites. Intrinsic differences might exist between the immune microenvironment 
of the skin and other tissues [268, 283] but further research could clarify this 
supposition. 
The expression of MMPs has also been reported to vary according to site [284] and 
this might have contributed to differences in the effect of the POS on survival in various 
cancers. Moreover, Henriet et al. reported that fibrillar collagen inhibited the 
proliferation of melanoma cells in vitro [285], which suggests that the non-immune 
stroma could be contributing to the protective effect of the POS. 
The region of tumour selected for analysis could also have influenced the results. In 
this study, I focused on a pre-defined region of the primary melanoma that was towards 
the invasive margin but was considered to be relatively deficient in immune and non-
immune stromal cells. Inevitably some stromal “contamination” occurred. However, the 
conclusions drawn are appropriately based on comparisons within the sample set. 
In contrast to the findings of Smolle et al., who reported that an increased area of pre-
existing collagen was hazardous in primary melanomas, this study showed that the 
POS was independently protective for melanoma-specific death [144]. However, there 
were notable differences in the approach used by Smolle et al., for example, immune 
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cells were not recorded as part of their calculation [144]. In a recent study, Rashed et 
al. showed that the density of melanoma cells within the region of the Breslow 
thickness measurement was hazardous [270]. I found that ESTIMATE’s tumour purity 
score was hazardous for melanoma-specific survival, lending further support to this 
discovery. 
Desmoplastic melanoma is characterised by an abundance of collagenous stroma 
[286] and as such, is a biological example of the protective effects of the stroma within 
primary cutaneous melanoma, tending to present with more localised disease [100]. 
The nature of the stromal fibroblasts may be shaped by interactions with cancer cells, 
including the release of soluble factors, as well as cell-to-cell contact between cancer 
and stromal cells [247, 287]. Furthermore, there is evidence to suggest that physical 
force can activate normal fibroblasts, leading to alterations in the structure of 
fibronectin and in biochemical signalling [288], which could account for the inverse 
association between adverse features of the primary melanoma and the POS, as a 
more rapidly proliferating tumour might induce such changes in fibroblasts. 
One of the strengths of the study is that all of the H&E sections were reviewed by Prof. 
Newton-Bishop and were marked for the purpose of TMA core sampling in a consistent 
way so that the data were comparable within the data set. Furthermore, a detailed 
histopathological assessment of a large number of melanomas collected from 
participants in a population-ascertained cohort, was performed by a single observer, 
with a high intra-observer reproducibility (Chapter 3). Moreover, transcriptomic data 
were available for the majority of these cases. By performing a comprehensive 
histopathological review of the cored region, it was possible to explore the 
corresponding transcriptomic correlates. This is the first study to utilise RandomSpot© 
to estimate the POS within a large cohort of primary melanomas and to explore its 
association with transcriptomic data derived from that region of the tumour.  
The discovery that the POS was highly significantly protective for melanoma-specific 
death was surprising, in view of the abundance of literature in many cancers 
suggesting that the POS might be hazardous. A strong role for immune cells is implied 
by the consistent enrichment of immune cell pathways in association with a high 
stromal content. It was noteworthy that TILs within the whole tumour were not an 
independent prognostic factor in this study, although the core lymphocytic infiltrate was 
protective (Chapter 4). The revolutionary impact of immunotherapy in the treatment of 
advanced melanoma [216, 289] highlights the importance of anti-tumour immunity in 
melanoma. In spite of durable responses to immunotherapy [216, 289], the proportion 
of patients who respond is low and the potential toxicity high [290]. Identifying which 
factors reliably predict those who will benefit from immunotherapy is the focus of 
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intensive research in many centres. The POS included immune cells and, therefore, its 
protective effect is consistent with the observed clinical responses to immunotherapy. 
Moreover, ESTIMATE’s immune score was significantly predictive of melanoma-
specific survival (Table 5.4 and Table 5.5). In the future, the POS could be evaluated 
as a potential predictive biomarker of response to immunotherapy. Perhaps even more 
intriguing is the evidence to suggest that the non-immune stromal component of the 
POS might be protective. The POS remained an independent prognostic factor, after 
adjusting for the core immune cell infiltrate and the POS was significantly associated 
with not only the ESTIMATE immune score but also the stromal score, which indicates 
that the non-immune stromal component could be important. Moreover, the ESTIMATE 
stromal score was a more powerful predictor of survival. This work helps to inform the 
way histopathologists view melanoma and suggests that describing and quantifying the 
stromal constituents might be just as important as evaluating factors that relate to 
melanoma cell-specific features. 
Comparative enrichment analyses between the POS and the extent of the core 
immune cell and lymphocytic infiltrates revealed a high degree of overlap. SDF1 was 
upregulated in association with the POS but not with either the extent of the core 
immune cell infiltrate overall or the core lymphocytic infiltrate, suggesting that this might 
be a marker of the non-immune stromal compartment. Furthermore, survival analyses 
revealed that SDF1 and its receptor, CXCR4, were protective for melanoma-specific 
death, with SDF1 being an independent prognostic factor. Therefore, a synergy may 
exist between the non-immune and immune stromal constituents, which is worth 
exploring further. The possibility that SDF1 was expressed by immune cells, or even by 
melanoma cells, cannot be ruled out, however, the strong association between the 
POS and SDF1, and not the extent of the core lymphocytic infiltrate or tumour 
percentage, suggests that this was not the case. 
SDF1, also known as CXCL12, is a chemokine that is reported to induce chemotaxis of 
lymphocytes, monocytes and dendritic cells [291]. SDF1 protein expression has 
previously been demonstrated to be high in normal skin, particularly within fibroblasts, 
although it may also be expressed by other cell types, including immune, endothelial 
and cancer cells [292]. In an organotypic melanoma culture, SDF1 expression by 
melanoma cells induced the migration of cytotoxic T lymphocytes towards them [241]. 
In mouse models of melanoma, colon and lung cancer, adenoviral gene transfer of 
SDF1 resulted in the accumulation of dendritic cells and CD8+ T cells within the 
tumours, a corresponding reduction in tumour growth and increased survival [291]. 
Furthermore, in a melanoma mouse model, the injection of tumour cells expressing 
SDF1 led to tumour rejection in half of the mice and the tumours were heavily infiltrated 
235 
by lymphocytes [293]. In a study of 64 primary melanomas, McConnell et al. reported 
divergent effects for SDF1 and its receptor, CXCR4 [294]. The epidermal expression of 
SDF1 protein was protective for melanoma metastasis-free survival, whilst CXCR4 
expression by melanoma cells was associated with increased metastases among 
AJCC stage II cases only [294]. They reported that the protein expression of CXCR7, 
an alternative receptor and scavenger for SDF1, was localised to vascular endothelial 
cells [294]. Their findings contrast with the results of my project, which revealed that 
both SDF1 and CXCR4 gene expression were protective for melanoma-specific death. 
In a study of 51 primaries and 52 melanoma metastases, Monteagudo et al. compared 
the mRNA expression ratio of SDF1 and CXCR4 [295]. The SDF1/CXCR4 ratio was 
significantly higher in primary melanomas ≤1mm compared to melanomas >1mm in 
thickness, and in primary compared to metastatic melanomas, and the ratio was 
predictive of distant metastasis-free survival [295]. They noted SDF1 protein 
expression in melanoma, endothelial and dendritic cells, lymphocytes and fibroblasts 
and of CXCR4 in all of these cells apart from dendritic cells and fibroblasts [295]. 
Napolitano et al. studied peripheral blood lymphocytes in 195 stage I-III melanoma 
patients and found that cases with CD4+CD45RA+CXCR4+ lymphocyte levels 
comprising >25% of the peripheral blood lymphocytes, had a significantly longer 
disease-free survival [296]. 
Despite the evidence in favour of a protective role for SDF1, several studies also 
suggest a hazardous effect. An in vitro study found that high, but not low, levels of 
SDF1 expression by melanoma cells repelled T cells, resulting in a decrease in the T-
cell infiltration of tumours [297]. Furthermore, hypoxia has been shown to instigate the 
activation of dermal fibroblasts to myofibroblasts, capable of promoting melanoma cell 
invasion and displaying increased secretion of SDF1, vascular endothelial growth 
factor A and interleukin 6 [298]. D’Alterio et al. showed that mice, wild type or 
heterozygote for CXCR4, both developed lung metastases, following inoculation with 
melanoma cells but smaller metastases developed in heterozygote mice [299]. 
Treatment with a CXCR4 inhibitor led to a reduction in lung metastases in both wild 
type and heterozygote mice [299]. SDF1 has also been shown to promote melanoma 
cell invasion across an artificial membrane [300]. The expression of CXCR4 protein in 
primary melanomas has previously been shown to be associated with an increased risk 
of metastasis and death, however, the number of cases was small (n=40 and 71, 
respectively) and the median follow-up was short (32 and 38 months, respectively) 
[301, 302]. 
Further insight into the metastatic process could be gained by assessing the POS and 
SDF1 protein expression in primary cutaneous melanomas and matched metastases in 
236 
a large data set. The cellular source of SDF1 may be crucial. In the future, it may be 
possible to establish whether a higher POS in the primary tumour corresponds to a 
higher POS in the metastasis or if the POS tends to differ between cutaneous, nodal 
and visceral sites. Future work, recording the POS longitudinally in patients with 
metastases could inform therapeutic stratification and, perhaps, help in the 
identification of patients who would most likely benefit from early intervention with 
immunotherapy. The findings of this study suggest that TMA biopsies taken 
horizontally through the advancing edge of primary cutaneous melanomas, on 
average, consist of ~30% stroma. This information could be incorporated into an 
algorithm to inform the interpretation of transcriptomic data, in terms of the relative 
tumour and stromal fractions. Stromal “contamination” may also have implications for 
clinical mutation testing. New gene signatures could be developed that could be of 
even more prognostic significance, by refining the ESTIMATE gene lists and 
incorporating them into a single signature, tailored for use in melanoma. This study 
demonstrated that increasing POS conferred a decreased risk of melanoma-specific 
death, highlighting the need for further characterisation of fibroblasts and other stromal 
constituents within the melanoma microenvironment. The ratio of native dermal 
fibroblasts relative to cancer-associated fibroblasts may be important in determining 
the switch from an inhibitory microenvironment to one that is conducive to cancer 
growth, however, this was not possible to explore during my PhD. Further 
characterisation of the nature of the stroma and the basis of its profound protective 
effects in primary cutaneous melanomas may help to elucidate the key players in the 
non-immune stroma. 
A limitation of the study was that the POS was measured within a segment of the 
primary melanoma rather than across the entire tumour. The amount of stroma could 
have varied from one region of the melanoma to another, particularly in view of the 
intrinsic heterogeneity of primary cutaneous melanoma [117, 222]. Although the 
phenotypic heterogeneity within primaries is well described [117], I argue that the 
manner in which the slides were marked for coring would have reduced this bias. 
Moreover, the POS consisted of several components, including collagen and immune 
cells, which makes it difficult to determine their respective contributions. The 
histopathological assessment focused on a virtual pathology image of the melanoma 
H&E section that had been taken prior to sampling with a TMA needle. Therefore, it is 
possible that the appearance (and the corresponding POS) of the estimated cored 
regions differed slightly from the TMA biopsy samples, due to inherent variation 
between serial H&E sections. Differences could also have occurred in the estimation of 
the cored region on the digital image relative to the TMA biopsy site or between the 
marking on the H&E section and the point of insertion of the TMA needle through the 
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tumour block. In addition, the histopathological assessment was based on a two-
dimensional image of the cored region, whereas the TMA biopsy incorporated a three-
dimensional piece of tissue, obtained through sampling the tumour horizontally. From a 
technical point of view, RandomSpot© software produces a set of arrows, the number 
of which can be selected by the user. Fifty arrows were allocated to each cored region 
on the basis of the results of pilot work (Appendix C). Due to the nature of the 
technique, it is possible that arrows could have landed more frequently on larger 
structures or nuclei, which might have led to overestimation of larger structures/cells. 
This is why a composite score was used for the POS, in preference to recording 
separate counts for each immune cell constituent. Nonetheless, it is possible that the 
technique could have produced inaccurate results for the POS, especially in view of the 
variation in melanoma cell size [117]. It is reassuring, however, that the average 
tumour purity determined by ESTIMATE [169] was ~70% (Figure 5.15). Finally, there 
was a bias towards sampling thicker primary melanomas and, therefore, it is not 
possible to ascertain whether or not similar results would have been obtained for 
melanomas <0.75mm thick. It is probable that thinner primary melanomas would have 
more stroma relative to thick tumours, however, this suspicion is as yet unconfirmed. 
Further work, looking at the POS across the entire primary melanoma, could help to 
clarify whether or not the findings pertaining to the cored region could be applied to the 
whole tumour. However, circumscription of the invasive margin of melanoma, followed 
by spot counting (using RandomSpot©) across the entire tumour, is less likely to be 
practicable in clinical work. This is because the advancing edge of melanoma tends to 
be convoluted as a result of nesting. It would be interesting to devise separate 
histopathological scores for the immune and non-immune cell components, to help to 
decipher their respective significance. Alternative techniques (to RandomSpot©), such 
as the use of disector frames, could be used to explore this [303]. This approach 
utilises counting frames, which adjust for the irregularity of the shapes of objects, thus 
reducing the possibility of over-estimating their frequency within a region of tissue 
[303]. Immunohistochemical studies were not performed in this study, as a limited 
number of tissue sections could be made from the tumour blocks, according to the 
ethical approval that is in place. In any case, conservation of the tumour blocks is 
crucial, to permit clinical mutation testing at a later date, in view of the fact that many of 
the study participants are still living. MetaCore™ enrichment analyses highlighted 
SDF1 as being unique to the stroma gene list, among thousands of genes that were 
significantly associated with the POS. MetaCore™ produces results based on the 
literature and, therefore, there was an inherent bias towards identifying curated 
pathways as being significant. 
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In summary, I have provided strong evidence at both a histopathological and a 
transcriptomic level for the protective effects of a high percentage of stroma in primary 
melanomas. In the future, I would like to evaluate the POS in an independent data set 
to validate this compelling finding. In this study, the POS, ESTIMATE’s scores and 
SDF1 were each independent prognostic factors. Further research, to tease out the 
complex interactions between the tumour and host, and to explore the drivers of SDF1 
upregulation would be advantageous. As previously mentioned, although 
immunotherapy can produce durable effects [126, 289, 304], only a subset of patients 
will respond. Therefore, exploring whether or not the POS could assist in the 
identification of such individuals would be beneficial and alternative therapeutic 
strategies aimed at the non-immune stroma might also be worth evaluating. SDF1 
levels have previously been shown to be quantifiable in the blood [305]. Therefore, in 
the future, studying the effects of circulating SDF1 levels and matched tumour samples 
in melanoma patients, could be worthwhile. I have shown that the POS is a highly 
reproducible parameter, both within and between observers (Chapter 3) and can be 
learned quickly. Although the ESTIMATE stromal score was a more powerful predictor, 
transcriptomic data are not readily available in clinical practice. The POS represents a 
histopathological measure that is inexpensive, reliable and can be measured using 
digital techniques, as in this study, or could be measured using a light microscope with 
a graticule (containing a grid). The results of this study suggest that the incorporation of 
the POS into the histopathological assessment of melanoma would be worthwhile. 
Furthermore, this work provides novel insights into the importance of the stromal 
compartment within primary melanomas and, in the future, how we might consider 
melanoma in terms of its microarchitecture and neighbouring cells. 
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Chapter 6 Histopathological changes associated with BAP1 
mutations or ALK fusions and the melanoma transcriptome 
6.1 Introduction 
The histopathology of melanoma is central to staging and underpins predictions of 
melanoma-specific survival [43].  
There is growing evidence that histopathological characteristics might also help to 
identify patients whose tumours have particular somatic mutations and patients who 
have inherited genetic variation associated with risk, including familial cancer 
predisposition syndromes [159, 306]. Such genotype/phenotype correlations are 
important to elucidate because they could help to identify high-risk patients and to 
clarify the risk of other, associated cancers. This was of particular interest to me 
because the fundamental hypothesis of the thesis was that histopathological features 
might unveil characteristic transcriptomic signatures or associate with individual patient 
factors.  
In this chapter, I will explore what is known about mutation of the BRCA1 associated 
protein 1 (BAP1) gene in terms of cutaneous melanoma histopathology. This gene was 
identified as somatically mutated in lung cancer cell lines and breast cancer [307, 308]. 
Subsequently, somatic mutations and a germline mutation were reported in ocular 
melanoma [309]. Germline BAP1 mutations were shown to be associated with 
increased risk of several cancer types, including ocular and cutaneous melanoma 
[159]. Cutaneous melanocytic lesions in individuals with germline BAP1 mutations had 
an unusual appearance [159], however, similar findings could be identified in patients 
without such germline mutations [306, 310]. Moreover, unusual histopathological 
features were reported in lesions that behaved in a benign fashion, in families with 
germline BAP1 mutations [159], and similar lesions were seen sporadically in the 
population [306]. Whether these lesions occurred in families with germline BAP1 
mutations or in the general population, it has not as yet proved possible to identify 
good prognostic markers, and such lesions are often known as “spitzoid tumours of 
uncertain malignant potential” (STUMP). In this chapter, I will describe work carried out 
in tumours excised from melanoma patients ascertained from the general population in 
the north of England, in whom variants in the BAP1 gene were sought in the germline.  
It has been reported that, at a somatic level, kinase fusions are relatively common in 
spitzoid lesions [311] and that melanocytic lesions with Anaplastic lymphoma kinase 
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(ALK) fusions have a characteristic histopathological appearance (typically reported as 
being exophytic with a plexiform growth pattern, consisting of fascicles of spindle cells) 
[158]. 
This chapter contains work that has recently been published [161] [312]. 
The aims of the project were to:- 
 Determine the proportion of melanomas within the Leeds Melanoma Cohort Study 
(reviewed by me) that had histopathological features, which have previously been 
described in association with germline BAP1 mutations. 
 Determine the proportion of participants that carry germline BAP1 mutations which 
have been predicted to be deleterious, in order to establish the predictive value of 
the histopathological features. 
 Explore the relationship between the presence of a personal or family history of  
cancers  and/or the presence of a germline BAP1 mutation.  
 Examine the association between the presence of characteristic BAP1 
histopathological features and the transcriptome, particularly with respect to BAP1 
and genes proposed to be involved in its signalling pathway. 
 Determine the proportion of melanomas within the Leeds Melanoma Cohort Study 
(reviewed by me) that had histopathological features, which have previously been 
described in association with ALK fusions. 
 Examine the association between the presence of characteristic ALK fusion-like 
histopathological features and the transcriptome, particularly with respect to ALK 
and genes proposed to be fusion partners for ALK. 
 Explore the transcriptomic correlates of the histopathological appearances in 
cutaneous melanomas, which were suggestive of either a BAP1 mutation or an 
ALK fusion, using an agnostic approach. 
6.1.1 Germline BAP1 mutations 
The benefit of linking clinical, histopathological and genetic information is illustrated by 
the discovery of germline mutations in the BAP1 gene.  
There is some evidence from gene expression studies to suggest that two distinct 
molecular profiles might help to distinguish between primary uveal melanomas of 
different metastatic potential, with “class 1” and “class 2” signatures proposed to have 
a lower and a higher risk of metastasis, respectively [313]. In a study of uveal 
melanomas, Harbour et al. identified somatic BAP1 mutations in 26/31 (84%) cases 
with a “class 2” gene expression signature, compared to 1/26 with a “class 1” signature 
[309]. All of the BAP1 mutations were somatic, except for one case in which a germline 
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BAP1 mutation was also confirmed [309]. Wiesner et al. described a novel familial 
cancer predisposition syndrome in two families, which was associated with germline 
mutations in BAP1 [159]. Loss of chromosome 3 or part of its short arm was found by 
array-based comparative genomic hybridization (aCGH) in 50% of the melanocytic 
lesions from three members in the first family described [159]. Massive parallel 
sequencing revealed a frameshift mutation in BAP1 [159]. The wild type allele was 
noted to be somatically mutated, supporting the concept of BAP1 as a tumour 
suppressor gene [159]. In the second family, the germline BAP1 mutation abolished 
the acceptor splice site at the last exon, resulting in retention of the last intron [159]. 
Germline mutation carriers were predisposed to the development of multiple, pink, 
dome-shaped naevi from the second decade onwards, atypical Spitz tumours and both 
cutaneous and uveal melanomas [159]. Inheritance was reported to follow an 
autosomal dominant pattern.  
It is estimated that germline BAP1 mutations account for approximately 1-1.5% of 
cutaneous melanomas [163, 314]. In addition to cutaneous and uveal melanoma, 
subsequent reports have indicated that affected families appear to be at increased risk 
of several other cancers, including mesothelioma [315], meningioma [165], renal cell 
carcinoma [164] and basal cell carcinoma (BCC) [316, 317], among others. Tentative 
associations with cholangiocarcinoma [318], leukaemia [318], gastric [319] and thyroid 
cancer [320] have also been reported. Abdel-Rahman et al. additionally reported a 
positive family history of neuroendocrine carcinoma, breast cancer, colon cancer, lung 
and ovarian adenocarcinomas in such families [165], the significance of which is 
uncertain, considering that some of these cancers are not uncommon in the general 
population and could have been an incidental finding. An association with high-grade 
colorectal and renal cell carcinoma was reported in a recent meta-analysis, however, 
the studies (somewhat confusingly) included patients with somatic BAP1 mutations 
[321]. 
6.1.2 The role of BAP1 
BAP1 is located on chromosome 3p21 and it encodes a nuclear protein, BAP1 [322]. 
BAP1 acts as a deubiquitinating enzyme [308]. The part of the BAP1 protein, which 
confers its deubiquitinase activity, is referred to as the ubiquitin carboxy-terminal 
hydrolase (UCH) domain [308]. It is a member of the polycomb family of proteins, 
which are involved in silencing other genes. The BAP1 protein is thought to act as a 
tumour suppressor, to be involved in DNA repair and its nuclear localisation is crucial 
for its function in mice [323-325]. Kumar et al. reported that BAP1 may paradoxically 
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behave as a survival factor in some cutaneous melanomas, facilitating their 
proliferation [326]. A metabolic regulatory role has also been reported for BAP1 [327]. 
Loss of nuclear BAP1 expression is associated with a worse survival and increased 
risk of relapse in uveal melanoma [328], however, its impact on outcome in cutaneous 
melanoma is yet to be elucidated. Yeh et al. reported no evidence of relapse in 29 
cases of cutaneous melanocytic lesions with isolated loss of chromosome 3 
incorporating the BAP1 locus, however, the mean follow-up time was just 16 months 
and the findings were limited to those with presumed somatic mutations [329]. A recent 
meta-analysis reported a worse outcome in association with inactivation of BAP1 for 
several cancers, except mesothelioma where it appears to confer a better prognosis 
[321]. It is noteworthy that the meta-analysis included studies which contained a 
mixture of cases with somatic and/or germline BAP1 mutations [321]. 
6.1.3 Histopathological assessment of melanocytic lesions in 
association with germline BAP1 mutations 
Naevi, occurring in the context of an inherited BAP1 mutation, although clinically bland, 
have been reported to display an unusual appearance on histopathological 
assessment [159]. At low power magnification, the lesions were symmetrical and 
strikingly dermal. At high power, the melanocytes were variably pleomorphic and were 
composed of a mixture of epithelioid melanocytes with abundant cytoplasm and 
prominent, eosinophilic nucleoli and in a subset, a population of round melanocytes 
with hyperchromatic nuclei [159]. Cutaneous melanocytic lesions, which had features 
that overlapped with melanoma, were regarded to be atypical Spitz tumours, the 
metastatic potential of which was uncertain [159]. Marusic et al. described a case 
series of six melanocytic lesions, including two primary cutaneous melanomas, in the 
setting of an inherited BAP1 mutation [160]. Both melanomas were predominantly 
dermal and were flanked by adjacent naevus cells [160]. Five of the six cases had 
prominent nuclear pseudoinclusions and multinucleated melanocytes [160]. All cases 
showed adipocytic metaplasia [160]. Some of their findings, corroborated in this study, 
have been published [161]. 
6.1.4 Somatic BAP1 mutations 
The biological significance of somatic BAP1 mutations in cutaneous melanoma has not 
been fully elucidated. Wiesner et al. reported that 5% (3/60) of sporadic cutaneous 
melanomas and 11% (2/18) of atypical Spitz tumours harboured somatic BAP1 
mutations [159]. They proposed that somatic BAP1 mutations resulted in a distinctive 
histopathological appearance [159]. Both of the BAP1-mutated atypical Spitz tumours 
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in their study were reported to resemble those described in patients with inherited 
BAP1 mutations [159]. The photomicrograph that was provided for a case of sporadic 
BAP1-mutated melanoma showed similar features [159]. Busam et al. reported similar 
histopathological features in 8 combined melanocytic lesions in 6 people without a 
germline BAP1 mutation [310]. Yeh et al. reported one case of blue naevus-like 
melanoma, which occurred on the scalp of a 64-year-old woman and demonstrated 
loss of nuclear BAP1 staining on immunohistochemistry [329]. The authors reported 
the presence of a prominent lymphocytic infiltrate in half of the cases with biallelic loss 
of BAP1, some lesions containing larger melanocytes with a plasmacytoid appearance, 
in apposition to lymphocytes (which they referred to as “the kiss of death”) [329]. Loss 
of immunohistochemical nuclear staining for BAP1 appeared to correlate with biallelic 
loss of BAP1 [159]. In a subsequent study of 32 atypical Spitz tumours, 28% (n=9) 
showed loss of nuclear BAP1 staining on immunohistochemistry (IHC), the majority 
(89%, 8/9) of which had concomitant BRAF mutations [306], which are unusual in Spitz 
naevi [330-332]. These lesions shared some features with those described in patients 
with germline BAP1 mutations, including distinctive epithelioid melanocytes and the 
presence of multinucleated cells, although these features could also be appreciated to 
a variable degree in lesions where BAP1 was conserved [306]. Piris et al. reported 
that, in patients with germline BAP1 mutations, 67% (20/30) of cutaneous melanocytic 
lesions showed combined BRAFV600E staining and loss of nuclear BAP1 staining, 
whereas nuclear BAP1 staining was conserved in most sporadic naevi and melanomas 
[332]. They reported loss of nuclear BAP1 staining in ~2.5% (2/80) sporadic primary 
melanomas, suggesting the possibility of somatic BAP1 mutations, although the 
histopathological appearance of the sporadic melanomas was unremarkable (n=4) 
[332]. Murali et al. reported that the absence of nuclear BAP1 staining was higher 
(22%; 9/158) in desmoplastic melanomas, with loss of nuclear BAP1 staining in 6% 
(9/158) of melanomas overall [333].  
6.1.5 Other molecular changes in spitzoid lesions 
Apart from BAP1 mutations, which are rare in cutaneous melanocytic lesions, several 
other molecular changes can occur in spitzoid lesions. A distinct subset of Spitz naevi 
with copy number gains in chromosome 11p, incorporating HRAS, has been noted 
[334]. These lesions tended to be intradermal and to consist of pleomorphic 
melanocytes, which were dispersed between collagen bundles at the base [334]. 
Intranuclear inclusions were also noted [334]. The histopathological appearance was 
similar in the 12 cases with gains in chromosome 11p, however, HRAS mutations were 
confirmed in 67% (n=8) of these cases [334]. 
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In an effort to identify further putative molecular changes underlying spitzoid lesions, 
Wiesner et al. performed targeted DNA and RNA sequencing of 182 cancer genes and 
162 kinase-related transcripts, respectively, on 30 Spitz naevi and 8 atypical Spitz 
tumours [311]. Kinase fusions were established in 60% of Spitz naevi and 75% of the 
atypical Spitz tumours [311]. In decreasing order of frequency, ROS1, NTRK1, ALK, 
RET and BRAF were identified in gene fusions [311]. These findings were replicated in 
102 further spitzoid lesions and immunohistochemistry for the respective kinase was 
positive in cases with the corresponding gene fusions [311]. Such fusions could be 
potentially exploited therapeutically, where appropriate, by means of targeted inhibition 
[311]. Subsequently, NTRK3 [335] and MET fusions [336] were identified.  
STUMPs, sometimes referred to as atypical Spitz tumours, represent an entity which 
has uncertain biological behaviour and which displays some features of both a benign 
Spitz naevus and a cutaneous melanoma. Mutations involving the TERT promoter 
have been reported to predict a more aggressive biological behaviour in such lesions, 
associated with an increased likelihood of metastasis, although precise 
histopathological characteristics have not been ascribed to such lesions [337]. 
I was interested to establish whether or not there was a differential transcriptomic 
expression in BAP1 between melanomas, which resembled the melanocytic lesions 
reported to occur in association with BAP1 mutations and those melanomas, which did 
not display such features. In the absence of detectable differences in BAP1 gene 
expression, I sought evidence for alternative molecular changes that have been 
reported in spitzoid lesions. 
6.1.6 ALK fusions and ALK protein expression in melanoma 
The ALK gene, located on chromosome 2p23, encodes a receptor tyrosine kinase 
called anaplastic lymphoma kinase, the activation of which leads to phosphorylation of 
intracellular kinases [338]. ALK fusions can lead to constitutive activation of the 
tyrosine kinase, resulting in uncontrolled proliferation [338]. ALK fusions have 
previously been identified in a spectrum of cancers, including lung cancer [339], 
inflammatory myofibroblastic tumours [340], lymphoma [341] and acral melanoma 
[342]. Kinase inhibitors, such as crizotinib, have been shown to be effective 
therapeutically [343, 344], although acquired resistance may develop [338]. Wiesner et 
al. reported ALK fusions in 10% (14/140) of spitzoid lesions overall, including 11% of 
Spitz naevi, 17% of atypical Spitz tumours and 3% of spitzoid melanomas in that series 
[311]. Busam et al. reported the histopathological characteristics of ALK fusions in a 
series of spitzoid melanocytic lesions, including 5 Spitz naevi and 12 atypical Spitz 
tumours [158]. Histopathological findings included a polypoid appearance and a 
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plexiform growth of fascicles, composed of spindle cells [158]. Of the 17 cases, 15 
were amelanotic [158]. Melanocytes stained positive for ALK on immunohistochemistry 
(IHC) and fluorescence in situ hybridization (FISH) identified tropomyosin 3 (TPM3) 
and dynactin 1 (DCTN1) as the fusion partners in 11 and 6 cases, respectively [158]. 
Yeh et al. subsequently reported a series of 32 cases with ALK fusions, consisting of 6 
Spitz naevi, 22 atypical Spitz tumours and 4 spitzoid melanomas [157]. Whilst the 
majority of the lesions were amelanotic, others were deeply pigmented [157]. The 
fusion partners included NPM1, TPR, GTF3C2 and CLIP1 [157]. The median thickness 
was 2.7mm and 16% of cases were ulcerated, whilst dermal mitoses were present in 
almost half of cases [157]. Lesions tended to be exophytic and were composed of 
fascicles of spindle cells [157]. More recently, Busam et al. reported immunoreactivity 
for ALK in 7/303 primary and 9/300 metastatic melanomas studied [345]. None of these 
lesions had ALK fusions but instead expressed the ALK isoform, ALK alternative 
transcriptional initiation (ALKATI) [345]. In contrast to ALK fusions, the lesions 
expressing ALKATI were composed predominantly of epithelioid melanocytes and 5/7 
primary melanomas were of nodular subtype [345]. Others have suggested that ALK 
expression in melanoma is exceedingly rare [346]. The more recent discovery of ALKATI 
and its histopathological correlates were subsequent to the recording of my 
histopathological assessment. Therefore, henceforth, I report my findings with respect 
to possible ALK fusions rather than appearances associated with ALKATI. 
 
6.2 Methods 
6.2.1 Germline BAP1 status testing 
Germline BAP1 testing was performed by the research group of Dr David Adams from 
the Sanger Institute on previously stored DNA extracted from blood samples from 
participants of the Leeds Melanoma Cohort Study. Samples were available for the 
majority of the cohort. Sorting Intolerant from Tolerant (SIFT) [347] and PolyPhen-2 
[348] were packages used by the Sanger Institute to predict the pathogenicity of 
variants. 
6.2.2 Deubiquitinase assays 
The deubiquitinase function of BAP1 is considered to be central to its role as a tumour 
suppressor [323, 324]. The Sanger Institute, in collaboration with MISSION 
Therapeutics©, performed testing of the deubiquitinase function of BAP1 where a non-
wild type variant was identified. 
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6.2.3 BAP1-like and ALK fusion-like histopathological 
characteristics  
The FileMaker Pro® histopathology database in which I reported detailed 
histopathological assessment of primary melanomas contained a free-text box which 
allowed me to record additional details about each case reviewed, including features 
reported to be typical of BAP1 mutations or kinase fusions. During the course of my 
assessment, I flagged cases with histopathological features associated with BAP1 
mutations using this comments box, in recognition of their potential significance. 
Examples of such features included a variable combination of: an intradermal 
melanocytic proliferation, epithelioid melanocytes, plasmacytoid melanocytes, round 
melanocytes with hyperchromatic nuclei, nuclear pleomorphism, and nuclear 
pseudoinclusions. I also highlighted cases, which had features suggestive of ALK 
fusions, e.g. mainly composed of plump, spindled melanocytes. 
6.2.4 Cancer history 
Participants recruited to the Leeds Melanoma Cohort Study were asked to list their 
personal and family history of cancer at recruitment, as part of a questionnaire. The 
extent of family cancer history and the level of detail provided varied across the cohort: 
participants were very variably aware of family history. The melanoma patients were 
asked to consider inviting their first-degree relatives to take part in the study and it was 
possible to confirm the cancer history in participating family members but not in other 
relatives. Data on personal and family cancer history were then extracted for analysis 
by Section staff. 
Only first- or second- degree relatives were included in the analysis of family history of 
cancer. Cancer diagnoses in the probands and their first- and second-degree relatives 
were verified against Office of National Statistics data and wherever possible, 
pathology reports were obtained. In some cases, the proband provided additional 
information in the questionnaire free-text box, e.g. mesothelioma, which was more 
specific and more likely to reflect an accurate diagnosis than those recorded as “lung 
cancer”. For the most part, family history was recorded by category, e.g. 
kidney/bladder/ureter or lung or brain cancer. For instance, it was not possible to 
ascertain if “brain”, “lung” or “liver” cancers were primary or secondary unless it was 
explicitly stated. 
For the purpose of analysis, I included cases with specific information about the type of 
cancer, i.e. “mesothelioma”, etc. I recorded the presence or absence of the following 
cancers previously reported to occur in families with germline BAP1 mutations in the 
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proband and in the proband’s first- or second-degree relatives: renal cancer, BCC, 
meningioma, mesothelioma, ocular melanoma or a family history of cutaneous 
melanoma. I elected to focus my analysis on these cancers because of the 
aforementioned evidence in the literature, and due to the nature of the cancer history 
database, in which information for several cancer types was recorded using broad 
categories. Therefore, it was not possible to distinguish between primary and 
secondary cancers, e.g. liver. 
Where there was more than one case of cutaneous melanoma in the family, the 
proband was deemed to be the first case recruited (identified by having a lower study 
number) and the second melanoma case was recorded as a positive family history of 
cutaneous melanoma for the proband. The only exception was if each melanoma case 
within the same family had been recruited independently, in which circumstance, each 
melanoma case was regarded as a proband. 
6.2.5 BAP-like phenotype 
A proband was considered to have a BAP-like phenotype if he/she had a history of one 
or more of the following cancers: renal, BCC, meningioma, mesothelioma or ocular 
melanoma. This was called “BAP-like phenotype (proband)”. 
The “BAP-like phenotype (family)” was assigned if a first- or second-degree relative 
had a history of any of the above cancers. The “BAP-like phenotype (proband/family)” 
was assigned if either the proband or the proband’s first- or second-degree relative(s) 
had a history of one of the aforementioned cancers.  
The “BAP-like phenotype MM (family)” was assigned if a first- or second-degree 
relative had one or more of the above cancers or a history of cutaneous melanoma. 
The “BAP-like phenotype MM (proband/family)” was formed by either the proband 
having the “BAP-like phenotype (proband)” or the proband’s first- or second-degree 
relative having the “BAP-like phenotype MM (family)”. 
6.2.6 Statistical analysis of cancer history data and BAP1 variant 
type 
Cancer history was analysed for the following cancers: renal, BCC, meningioma, 
mesothelioma, ocular melanoma (and a family history of cutaneous melanoma). Each 
cancer type was analysed as a dichotomous variable, i.e. as 0 or 1 (where 0=no and 
1=yes), irrespective of the number of each cancer. By extension, the “BAP-like 
phenotype (family)” was equal to 1, even if more than one first- or second-degree 
relative had a cancer of interest, e.g. BCC.  
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Cross-tabulation of each cancer and variant type was performed for the proband and 
family. The Fisher’s exact test p-value was reported if any cell value was <5. The 
Pearson’s chi-squared test p-value was reported if there was no individual cell value 
<5. Cross-tabulation of each of these cancers was performed to compare 2 variant 
categories, i.e. “none” versus “benign” and “none” versus “deleterious”. 
Odds ratios were calculated for having a benign variant versus none and for having a 
deleterious variant versus none, to assess the effect of each variant compared to being 
wild type for BAP1. Exact 95% confidence intervals were calculated, unless there was 
a zero count in a cell, in which case the Cornfield approximation was used. 
The Kruskal-Wallis test was performed to assess whether or not the age at diagnosis 
of melanoma differed by variant type. 
6.2.7 Statistical analysis of BAP-like histopathology 
Any comments in the histopathology database containing “BAP” were reviewed. If the 
comment suggested a BAP-like histopathological appearance in the primary 
melanoma, it was scored as “yes”. All other reviewed cases lacking a comment about 
BAP1 were scored as “no”. This permitted analysis as a dichotomous variable, in a 
similar way to the classification of the cancer history data. 
6.2.8 BAP1 gene expression and transcriptomic analysis 
The student’s t-test was used to assess the association between BAP-like 
histopathology and gene expression for each of the 29,354 probes in the Illumina® WG-
DASL HT12v14 assay. The False Discovery Rate (FDR) correction was performed to 
correct for multiple testing, to reduce the possibility of finding a significant association 
by chance. The ILMN_1768363 probe was used to measure BAP1 gene expression 
from the melanoma tumour. This was the only probe for BAP1 in the Illumina® WG-
DASL HT12v14 assay. Where more than one probe was available for a single gene, 
the probe with the highest level of detection within the cohort was selected.  
6.2.9 ALK gene expression and transcriptomic analysis 
The student’s t-test was used to assess the association between ALK fusion-like 
histopathology and gene expression for each of the 29,354 probes in the Illumina® WG-
DASL HT12v14 assay. The FDR correction was performed to correct for multiple 
testing, as before. The ILMN_1753135 probe was used to measure ALK gene 
expression from the primary melanoma. 
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6.3 Results 
6.3.1 Variants identified by germline BAP1 testing 
In total, there were 1977 cases from the Leeds Melanoma Cohort Study that had a 
stored, DNA sample for genetic testing by the Sanger Institute. Of these, 1868 had no 
variant and were named “none” in the analysis. One hundred cases had a variant that 
was predicted to be “tolerated” by SIFT or “benign” by PolyPhen-2. These were 
grouped together as “benign” for the purpose of analysis. Nine cases had a variant that 
was predicted to be “deleterious” by SIFT or “possibly damaging” or “probably 
damaging” by PolyPhen-2. These were grouped together as “deleterious” for analysis. 
Where SIFT and PolyPhen-2 results were divergent (e.g. “tolerated” by SIFT and 
“possibly damaging” by PolyPhen-2), the group with the more serious variant was 
assigned. This applied to 2/9 cases in the deleterious group. One splice acceptor 
variant, one frameshift variant and one case with both a missense and splice region 
variant were among the variants identified in the “deleterious” group, with the remaining 
cases in the group having missense variants. 
6.3.2 Deubiquitinase assays 
Eight of the nine variants that were predicted to be deleterious by SIFT or PolyPhen-2 
were tested for deubiquitinase activity. The splice acceptor variant was presumed to 
result in BAP1 loss-of-function but the deubiquitinase assay had not been performed, 
because the case was identified through a subsequent round of sequencing. A 
germline BAP1 mutation was, however, confirmed in the proband through clinical 
testing. The frameshift variant and one of the missense variants showed loss of 
deubiquitinase activity. These three cases were regarded as having clear loss-of-
function but the remaining 6 cases with variants predicted to be deleterious did not 
show any significant change in deubiquitinase activity. 
6.3.3 Histopathological assessment of primary melanomas within 
the cohort with features associated with BAP1 mutations 
I completed a detailed histopathological assessment of 798 cases from the Leeds 
Melanoma Cohort Study. The majority of the 798 cases were those intended to be 
sampled for transcriptomic analysis. Of the 798 cases assessed, 64 (8%) had some 
histopathological features described as indicative of a BAP1 mutation. Figure 6.1 
shows some examples of melanomas with BAP-like histopathology. 
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Of the 798 cases, 713 had information on BAP1 variants and cancer history data. 
661/713 cases were not flagged as having histopathological features of a BAP1 
mutation, leaving 52 cases, which had suggestive histopathology and additional 
information about BAP1 variant type and cancer data. 
One of the families under follow-up in the melanoma clinic was recognised by Prof. 
Newton-Bishop as fitting the profile of a germline BAP1 mutation (Figure 6.2). Clinical 
testing confirmed this suspicion. The proband and the proband’s first- and second-
degree relatives were invited to attend for genetic counselling. The proband was a 
participant of the Leeds Melanoma Cohort Study. Although sampling using a TMA core 
biopsy needle had not been performed on this primary melanoma because of its small 
size, a histopathological assessment was recorded. Family members attending the 
local melanoma/pigmented lesion clinics agreed to the review and description of their 
case histories and histopathological findings, which have since been reported [161]. 
Melanocytic lesions from first- and second-degree relatives were reviewed as part of 
the process, although only the assessment of the proband’s melanoma was formally 
recorded in the histopathology database. 
 
 
 
 
 
Figure 6.1 (on following 2 pages): Virtual pathology images of melanomas with 
BAP-like histopathology. 
Histopathological findings show A) a melanocytic proliferation (x10 magnification) 
composed of epithelioid melanocytes, with relative sparing of the dermo-
epidermal junction. Some multinucleated cells are highlighted by the black arrow; 
B) (x10 magnification) a predominantly dermal melanocytic proliferation with 
evidence of adipocytic metaplasia; C) High power view (x40 magnification) of the 
melanoma reveals intranuclear pseudoinclusions (a few of which have been 
highlighted with black arrows). D) Low power view (x4 magnification) of a 
melanocytic proliferation with relative sparing of the dermo-epidermal junction. E) 
High power view (x40 magnification) shows atypical melanocytes. The red arrows 
are pointing to multinucleated melanocytes and the black arrow is pointing to an 
intranuclear pseudoinclusion. 
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Figure 6.2: Pedigree for a family with a germline BAP1 mutation. 
This family was identified by clinical testing. The proband is indicated by a black 
arrow. A splice acceptor site BAP1 variant was identified in the proband. 
MM=melanoma. STUMP=Spitzoid tumour of uncertain malignant potential. 
MELTUMP=Melanocytic tumour of uncertain malignant potential. Malig Blue 
Naevus=Malignant blue naevus. Black diamonds represent cases of primary 
cutaneous melanoma. Red diamonds indicate cases of either STUMP or 
MELTUMP. The blue diamond indicates a case with a malignant blue naevus 
and a meningioma. 
The proband had a melanocytic lesion, which was amelanotic, and clinically banal but 
was excised in view of a history of change. Initial histopathological assessment 
suggested a STUMP. This was diagnosed as a stage II melanoma at the melanoma 
multidisciplinary team meeting and was subsequently widely excised. A second-
degree relative had a history of stage III melanoma (metastatic to a local lymph node 
basin, Figure 6.3A). Another second-degree relative had an unusual lesion on the 
scalp that had been curetted by the patient’s general practitioner who suspected a 
cyst. The specimen had not been sent for histopathological assessment. The lesion 
subsequently recurred and was excised in the department of general surgery. This 
was diagnosed as a malignant blue naevus histopathologically and sadly the patient 
subsequently developed liver metastases. An incidental meningioma was diagnosed 
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on MRI brain. A third-degree relative had a history of asbestos exposure and was 
reported to have died of a pleural mesothelioma. Following clinical testing, the 
proband’s remaining first- and second-degree relatives were invited for a skin 
examination. One of the proband’s third-degree relatives reported a recent history of 
change in a long-standing pink lesion. The lesion was excised in view of this change. 
A STUMP was diagnosed. Subsequent wide local excision and sentinel lymph node 
biopsy were negative for melanoma. A further third-degree relative reported itch in a 
long-standing lesion, which had a reassuring clinical appearance but was diagnosed 
as a melanocytic tumour of uncertain malignant potential (MELTUMP) following 
histopathological examination. 
Histopathological review of melanocytic lesions from this family revealed some 
features, which had previously been described in association with germline BAP1 
mutations [159, 160]. Namely, the primary melanomas from the proband and a 
second-degree relative were both amelanotic. The proband’s melanoma was 
predominantly intradermal and was composed of pleomorphic, epithelioid 
melanocytes, some of which were multi-nucleated and had nuclear pseudoinclusions. 
A few benign melanocytic naevi had previously been excised from the proband, which 
were mainly intradermal, had a symmetrical appearance at low-power magnification 
and some pleomorphism at higher magnification. The second-degree relative’s 
malignant blue naevus lacked an intraepidermal component but this may have been 
due to previous curettage (Figure 6.3B). The third-degree relative’s STUMP was 
predominantly intradermal, consisting of a nodule composed of epithelioid 
melanocytes and an adjacent naevus-like component. Nuclear pseudoinclusions were 
numerous within the epithelioid nodule [161]. 
 
 
Figure 6.3 (following page): Photomicrographs of A) the melanoma lymph node 
metastasis in the proband’s second-degree relative and B) the malignant 
blue naevus in the proband’s second-degree relative. 
A) Nuclear pleomorphism can be appreciated within melanoma cells (x40 
magnification). The black arrow points to an epithelioid melanocyte, with a 
prominent eosinophilic nucleolus and abundant cytoplasm. An intranuclear 
pseudoinclusion is highlighted by the red arrow. B) Histopathological findings (x5 
magnification) reveal a thick melanocytic tumour composed of fascicles of 
spindle cells. There is sparing of the dermo-epidermal junction. This lesion had 
previously been curetted.  
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Eight other probands from the Leeds Melanoma Cohort Study were identified as 
having germline BAP1 mutations which were predicted to be deleterious by the Sanger 
Institute. Their primary melanomas and pedigrees were reviewed. Of the remaining 
two probands with clear loss-of-function variants, one had an amelanotic, intradermal 
melanoma, whilst the other proband had an amelanotic melanoma that was otherwise 
difficult to distinguish from a melanoma in a person who was wild type for BAP1. In the 
other 6 cases with missense, germline BAP1 variants which were predicted to be 
deleterious, the melanomas were unremarkable compared to other melanomas within 
the data set. Table 6.1 summarises the results for the 9 probands with BAP1 variants 
that were predicted to be deleterious. 
 
 
 
 
 
 
 
 
 
 
Table 6.1 (following page): Summary table of BAP1 variants, deubiquitinase 
assay results, cancer history and BAP-like histopathology. 
Cancer history is reported for melanoma probands (other than cutaneous 
melanoma) and for their family members (first- or second-degree relatives were 
considered only). The deubiquitinase assay was not done for the case with a 
splice acceptor site variant because it was detected in a second round of 
sequencing, however, it was predicted to be detrimental to BAP1 function and 
clinical testing confirmed the presence of a germline BAP1 mutation in the 
proband. Three of the nine variants that were predicted to be deleterious by SIFT 
or PolyPhen-2 were categorised as clear loss-of-function based on their 
deubiquitinase assay results (except for the splice acceptor variant, as 
aforementioned). LOF=loss-of-function. NA=not applicable. 
 
 Case BAP1 variant 
Deubiquitinase 
assay 
Category 
Proband cancer history (other 
than cutaneous melanoma) 
Family cancer history (1st & 
2nd-degree relatives only) 
BAP-like histopathology 
(Yes/No) 
1 Splice acceptor site Not done 
Predicted deleterious, 
clear LOF 
NA 
Melanoma, 
malignant blue naevus, 
mesothelioma, meningioma 
Yes 
2 Frameshift Abnormal 
Predicted deleterious, 
clear LOF 
NA 
Melanoma, 
mesothelioma, 
bladder cancer 
Yes 
3 Missense Abnormal 
Predicted deleterious, 
clear LOF 
BCC 
Melanoma, 
renal, gastric cancer, 
cancer unknown site 
No 
4 Missense Normal Predicted deleterious 
BCC, 
lymphoma 
BCC, 
leukaemia, 
uterine cancer 
No 
5 Missense Normal Predicted deleterious NA 
Gastric, 
uterine cancer 
No 
6 Missense Normal Predicted deleterious NA 
BCC, 
colorectal cancer 
No 
7 Missense Normal Predicted deleterious NA Lung cancer No 
8 Missense Normal Predicted deleterious NA NA No 
9 Missense Normal Predicted deleterious NA NA No 
2
5
7
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6.3.4 The association between histopathology, cancer frequency 
and germline BAP1 mutations 
Table 6.2 summarises the analysis of the family history for each of the cancers of 
interest within the proband, the proband’s first- or second-degree relatives or the 
family overall (irrespective of whether the cancer occurred in the proband or in a first- 
or second-degree relative) by variant type and histopathological appearance in the 
proband’s melanoma. Table 6.2 also shows the association between the presence of 
BAP-like histopathological features (in the proband’s melanoma) and having a BAP1 
variant.  
A reported history of mesothelioma or meningioma within either the proband or the 
family was significantly associated with the presence of a deleterious BAP1 variant, 
compared to no variant (Table 6.2). The presence of a family history of one or more of 
the following cancers was associated with a deleterious BAP1 variant: renal cancer, 
BCC, meningioma, mesothelioma or ocular melanoma (“BAP-like phenotype (in the 
family)”). It was notable that there were no cases of ocular melanoma within pedigrees 
in which a deleterious variant had been identified in the proband.  
BAP-like histopathology was significantly associated with a history of mesothelioma in 
either the proband or the family (when taken together) but was not significantly 
associated with any of the other reported cancers. There was no significant 
association between the presence of BAP-like histopathological changes and the 
presence of a deleterious BAP1 variant. 
The mean age at diagnosis was lowest in cutaneous melanoma probands carrying a 
BAP1 variant predicted to be deleterious (49.2 years compared to 57.3 years without a 
variant and 56.9 years in those cases with a benign variant) but this was not 
statistically significant (Kruskal-Wallis test p-value=0.7). 
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Table 6.2 (following page): Cancer history by BAP1 variant type and 
histopathological appearance.  
The cancer history among probands and their first- or second-degree relatives 
(“family”) is reported for each of the following cancers, which are considered to 
be part of the spectrum of cancers seen in families with inherited BAP1 
mutations: renal cancer, basal cell carcinoma (BCC), meningioma, mesothelioma 
and ocular melanoma. The family history of cutaneous melanoma is also 
recorded. The reported cancer history is compared to the BAP1 variant type 
(which was identified among probands by the Sanger Institute) and to the 
recorded histopathological appearance of the proband’s melanoma (cases for 
which I had performed a histopathological review). The histopathological 
appearance (“BAP-like histology”) was categorised as “Yes” or “No”, for the 
presence of histopathological features suggestive of a BAP1 mutation (including 
relative sparing of the dermo-epidermal junction by atypical melanocytes, 
epithelioid melanocytes, pleomorphic melanocytes, nuclear pseudoinclusions, 
multinucleated melanocytes and/or a naevoid component of melanocytes with 
hyperchromatic nuclei). The cancer history is reported separately for probands 
and their family members (first- or second-degree relatives). In addition, the 
cancer history for probands and their first- or second-degree family members 
(“family”) was combined to increase statistical power, by assessing whether or 
not there was a cancer history in either the proband or their family (i.e. either a 
personal or a family history) for each cancer type. The “BAP-like phenotype” and 
the “BAP-like phenotype MM” (described in the Methods) are also compared to 
the BAP1 variant type and the histopathological appearance of the proband’s 
melanoma (BAP-like histopathology). Finally, a comparison between the “BAP-
like histopathology” and the type of BAP1 variant is reported. Fisher’s exact test 
p-values (or Pearson’s chi-squared test p-values, indicated by ‘p’) are reported. 
Fisher’s exact test was used where a cell value was <5. Odds ratios (OR) and 
95% confidence intervals (95% CI) for the likelihood of having a benign versus 
no variant; or of having a deleterious versus no variant, are reported. BCC=Basal 
cell carcinoma. NC=not calculable. NA=not applicable. N=number of cases. 
MM=melanoma. 
  
   Analysis by the type of BAP1 variant 
Analysis by the histopathological 
appearance 
 
Presence of any BAP1 variant in the proband 
(melanoma case) 
Any 
variant 
Benign versus no 
variant 
Predicted deleterious 
versus no variant 
BAP-like histopathology (in the 
proband’s melanoma for which 
central pathology review was 
available, total N=713) 
Cancer history in the 
proband and family 
None 
(N=1868)* 
(Row %) 
Benign 
(N=100)* 
(Row %) 
Predicted 
deleterious 
(N=9) 
(Row %) 
Total 
N (%) 
Fisher’s 
exact 
P-value 
Fisher’s 
exact 
P-value 
OR 
(95% CI) 
Fisher’s 
exact 
P-value 
OR 
(95% CI) 
No 
(N=661) 
(Column %) 
Yes 
(N=52) 
(Column %) 
Fisher’s 
exact 
P-value 
Renal cancer 
(in the proband) 
5 (71.4) 2 (28.6) 0 (0) 7 (100.0) 0.08 0.045 
7.6 
(0.7-47.0) 
1 
0 
(0-174.3) 
3 (0.5) 0 (0) 1 
Renal cancer 
(in the family) 
48 (90.6) 4 (7.5) 1 (1.9) 53 (100.0) 0.1 0.3 
1.6 
(0.4-4.4) 
0.2 
4.7 
(0.1-36.5) 
12 (1.8) 1 (1.9) 1 
Renal cancer 
(in the proband or family) 
53 (88.3) 6 (10.0) 1 (1.7) 60 (100.0) 0.06 0.07 p 
2.2 
(0.7-5.3) 
0.2 
4.3 
(0.1-32.9) 
15 (2.3) 1 (1.9) 1 
BCC 
(in the proband) 
261 (93.9) 14 (5.0) 3 (1.1) 278 (100.0) 0.3 0.99 p 
1.0 
(0.5-1.8) 
0.1 
3.1 
(0.5-14.5) 
99 (15.0) 8 (15.4) 0.9 p 
BCC 
(in the family) 
114 (93.4) 5 (4.1) 3 (2.5) 122 (100.0) 0.02 0.7 p 
0.8 
(0.3-2.0) 
0.02 
7.7 
(1.2-36.5) 
33 (5.0) 1 (1.9) 0.5 
BCC 
(in the proband or family) 
346 (94.5) 17 (4.7) 3 (0.8) 366 (100.0) 0.4 0.7 p 
0.9 
(0.5-1.6) 
0.4 
2.2 
(0.4-10.4) 
119 (18.0) 8 (15.4) 0.6 p 
Meningioma 
(in the proband) 
4 (100.0) 0 (0) 0 (0) 4 (100.0) 1 1 
0 
(0-18.1) 
1 
0 
(0-219.4) 
2 (0.3) 0 (0) 1 
Meningioma 
(in the family) 
0 (0) 0 (0) 1 (100.0) 1 (100.0) 0.005 NC NC 0.005 NC 0 (0) 1 (1.9) 0.07 
Meningioma 
(in the proband or family) 
4 (80.0) 0 (0) 1 (20.0) 5 (100.0) 0.02 1 
0 
(0-18.1) 
0.02 
58.3 
(1.1-670.5) 
2 (0.3) 1 (1.9) 0.2 
2
6
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    Analysis by the type of BAP1 variant 
Analysis by the histopathological 
appearance 
 
Presence of any BAP1 variant in the proband 
(melanoma case) 
Any 
variant 
Benign versus no 
variant 
Predicted deleterious 
versus no variant 
BAP-like histopathology (in the 
proband’s melanoma for which 
central pathology review was 
available, total N=713) 
Cancer history in the 
proband and family 
None 
(N=1868)* 
(Row %) 
Benign 
(N=100)* 
(Row %) 
Predicted 
deleterious 
(N=9) 
(Row %) 
Total 
N (%) 
Fisher’s 
exact 
P-value 
Fisher’s 
exact 
P-value 
OR 
(95% CI) 
Fisher’s 
exact 
P-value 
OR 
(95% CI) 
No 
(N=661) 
(Column %) 
Yes 
(N=52) 
(Column %) 
Fisher’s 
exact 
P-value 
Mesothelioma 
(in the proband) 
0 (0) 0 (0) 1 (100.0) 1 (100.0) 0.005 NC NC 0.005 NC 1 (0.2) 0 (0) 1 
Mesothelioma 
(in the family) 
4 (66.7) 0 (0) 2 (33.3) 6 (100.0) 0.0004 1 
0 
(0-18.1) 
0.0003 
133.1 
(10.1-1084.2) 
1 (0.2) 2 (3.9) 0.02 
Mesothelioma 
(in the proband or family) 
4 (57.1) 0 (0) 3 (42.9) 7 (100.0) 0.000003 1 
0 
(0-18.1) 
0.000003 
233 
(26.7-1660.1) 
2 (0.3) 2 (3.9) 0.03 
Cutaneous melanoma 
(in the family) 
146 (93.0) 8 (5.1) 3 (1.9) 157 (100.0) 0.049 0.95 p 
1.03 
(0.4-2.2) 
0.03 
5.9 
(0.9-27.9) 
47 (7.1) 4 (7.7) 0.8 
Ocular melanoma 
(in the proband) 
0 (0) 0 (0) 0 (0) 0 (0) NC NC NC NC NC 0 (0) 0 (0) NC 
Ocular melanoma 
(in the family) 
2 (100.0) 0 (0) 0 (0) 2 (100.0) 1 1 
0 
(0-36.1) 
1 
0 
(0-439.1) 
1 (0.2) 0 (0) 1 
Ocular melanoma 
(in the proband or family) 
2 (100.0) 0 (0) 0 (0) 2 (100.0) 1 1 
0 
(0-36.1) 
1 
0 
(0-439.1) 
1 (0.2) 0 (0) 1 
BAP-like phenotype 
(in the proband) 
267 (93.4) 16 (5.6) 3 (1.0) 286 (100.0) 0.2 0.6 p 
1.1 
(0.6-2.0) 
0.1 
3.0 
(0.5-14.1) 
102 (15.4) 8 (15.4) 1 p 
BAP-like phenotype 
(in the family) 
166 (93.3) 8 (4.5) 4 (2.2) 178 (100.0) 0.01 0.8 p 
0.9 
(0.4-1.9) 
0.006 
8.2 
(1.6-38.4) 
46 (7.0) 3 (5.8) 1 
BAP-like phenotype MM 
(in the family) 
289 (93.5) 16 (5.2) 4 (1.3) 309 (100.0) 0.08 0.9 p 
1.04 
(0.6-1.8) 
0.04 
4.4 
(0.9-20.4) 
85 (12.9) 5 (9.6) 0.5 p 
2
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    Analysis by the type of BAP1 variant 
Analysis by the histopathological 
appearance 
 
Presence of any BAP1 variant in the proband 
(melanoma case) 
Any 
variant 
Benign versus no 
variant 
Predicted deleterious 
versus no variant 
BAP-like histopathology (in the 
proband’s melanoma for which 
central pathology review was 
available, total N=713) 
Cancer history in the 
proband and family 
None 
(N=1868)* 
(Row %) 
Benign 
(N=100)* 
(Row %) 
Predicted 
deleterious 
(N=9) 
(Row %) 
Total 
N (%) 
Fisher’s 
exact 
P-value 
Fisher’s 
exact 
P-value 
OR 
(95% CI) 
Fisher’s 
exact 
P-value 
OR 
(95% CI) 
No 
(N=661) 
(Column %) 
Yes 
(N=52) 
(Column %) 
Fisher’s 
exact 
P-value 
BAP-like phenotype (in the 
proband or family) 
397 (94.1) 21 (5.0) 4 (0.9) 422 (100.0) 0.2 0.95 p 
0.98 
(0.6-1.6) 
0.1 
3.0 
(0.6-13.8) 
132 (20.0) 10 (19.2) 0.9 p 
BAP-like phenotype MM 
(in the proband or family) 
496 (94.1) 27 (5.1) 4 (0.8) 527 (100.0) 0.5 0.9 p 
1.02 
(0.6-1.6) 
0.3 
2.2 
(0.4-10.3) 
163 (24.7) 12 (23.1) 0.8 p 
BAP-like histopathology 
present (in the proband’s 
melanoma for which a 
histopathology review was 
completed, N=713) 
49 (94.2) 1 (1.9) 2 (3.9) 52 (100.0) 0.1 0.7 
0.4 
(0.01-2.6) 
0.1 
3.6 
(0.4-19.8) 
NA NA NA 
 
2
6
2
 
263 
6.3.5 The relationship between BAP-like histopathology and BAP1 
gene expression 
Figure 6.4 shows the distribution for BAP1 gene expression within the data set. The 
mean (logged) gene expression for BAP1 (as measured by the ILMN_1768363 probe) 
was 7.8 (standard deviation (S.D.) 0.6). 
 
 
Figure 6.4: Histogram of BAP1 gene expression. 
The histogram shows the frequency distribution for BAP1 gene expression of 
(ILMN_1768363 probe) in 676 cases from the Leeds Melanoma Cohort Study 
BAP1 gene expression (as measured by the ILMN_1768363 probe) was available for 
676 of the 798 cases reviewed, with 53 (7.8%) of these cases having BAP-like 
histopathology. BAP1 gene expression was similar in cases with (mean (unlogged) 
expression=214.6) and without features of BAP-like histopathology (mean (unlogged) 
expression=226.5; FDR-corrected p-value=1.0) (Figure 6.5 and Table 6.3). It is 
important to note that gene expression data were only available for 3 of the 9 cases 
with variants which had been predicted to be deleterious and this may have affected 
the results. Each of the three variants was a missense variant and BAP1 (logged) 
gene expression values were as follows: 7.97, 8.40 and 9.03 (Figure 6.6). Neither 
BAP-like histopathology nor BAP1 gene expression was significantly associated with 
melanoma-specific death (data not shown). 
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Figure 6.5 Box and whisker plots of BAP1 expression in cases with and without 
BAP-like histopathology. 
The mean (logged) BAP1 (ILMN_1768363 probe) gene expression (and 
standard deviation) was 7.7 (0.6) and 7.8 (0.5) for cases without and with a BAP-
like histopathology, respectively. The mean gene expression for genes proposed 
to be implicated in the BAP1 pathway and the corresponding t-test p-values are 
summarised in Table 6.3. 
 
Figure 6.6: Histogram of BAP1 (logged) gene expression. 
The histogram shows the frequency distribution for BAP1 gene expression in 676 
cases from the Leeds Melanoma Cohort. Three variants, which were predicted to 
be deleterious by SIFT or PolyPhen-2 and for which gene expression and 
histopathological data were available, are highlighted on the histogram by three 
red lines. 
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6.3.6 The relationship between BAP-like histopathology and gene 
expression of other genes implicated in the BAP1 pathway 
and spitzoid lesions 
The expression of several genes in the putative BAP1 pathway (Figure 6.7) was also 
analysed, comparing cases with and without histopathology suggestive of a BAP1 
mutation (Table 6.3). There was no significant difference in the gene expression of any 
of the following genes, which are implicated in the putative BAP1 pathway: BARD1, 
HCFC1, E2F1, ASXL1, RAD51, YY1 or PRC1 (Table 6.3) [349]. Host cell factor C1 
(HCFC1), which is involved in the regulation of the E2F transcription factors [350], is 
deubiquitinated by BAP1 leading to modulation of cell proliferation [351]. ASXL1 forms 
a complex with BAP1 and has been implicated in its activation [352], however, they 
appear to have divergent effects on downstream gene regulation [353]. 
 
Figure 6.7 (on following page): (Adapted from Ladanyi et al. [349]) The putative 
role of BAP1 in: A) transcription factor regulation, B) chromatin 
modification and C) double-strand DNA break repair.  
A) HCFC1 is a binding partner of BAP1, which interacts with transcription factors 
and is involved in chromatin modification. It is involved in the demethylation of a 
lysine residue in H4 and the methylation of a lysine residue in H3. YY1 is a 
transcription factor that binds HCFC1 and BAP1. B) PRC2 is involved in the 
methylation of a lysine residue in H3, which leads to the recruitment of PRC1. 
This results in the addition of a ubiquitin moiety to lysine 119 of H2A, provoking 
the repression of chromatin and gene silencing. The ubiquitylated H2A may 
complex with and be regulated by BAP1 and ASXL1, leading to the removal of 
the ubiquitin moiety. This state of flux is proposed to influence the expression of 
PRC target genes. C) BAP1 is thought to be involved in DNA repair, the 
mechanism for which has not been fully elucidated. It may associate with BRCA1 
and BARD1 or it might regulate proteins downstream of RAD51. ASXL1, 
Additional sex combs like 1; ATM, Ataxia telangiectasia mutated; BAP1, BRCA1-
associated protein-1; BARD1, BRCA1-associated RING domain protein 1; 
BRCA1, Breast cancer 1; BRCA2, Breast cancer 2, DNA, deoxyribonucleic acid; 
E2F1, E2F Transcription Factor 1; HCFC1, Host-cell factor C1; H2A, Histone 2A; 
H4, Histone 4; H3, Histone 3; me, methyl group; P, phosphate; P53, Tumour 
protein p53; PRC1, Polycomb repressive complex 1; PRC2, Polycomb 
repressive complex 2; RAD51, RAD51 recombinase; Ub, Ubiquitin; YY1, Ying 
yang 1.  
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As previously discussed, BRAF is reported to be mutated in the majority of BAP1-
mutated melanocytic lesions [332]. Therefore, I also tested for differential expression 
in BRAF between cases with and without BAP-like histopathology. There was no 
significant difference in BRAF expression in the presence or absence of BAP-like 
histopathology (Table 6.3). 
Both BAP1 and USP16 deubiquitinate H2A-Ub: BAP1 modulates homologous repair, 
while USP16 is involved in DNA double strand break-induced transcriptional silencing 
[354]. It is not entirely clear whether or not BAP1 and USP16 act independently of one 
another [354]. To explore whether or not the BAP-like histopathological changes might 
reflect an alternative but similar mechanism, I assessed USP16 expression in cases 
with and without BAP-like histopathology. USP16 expression was not significantly 
different between cases with and without consistent histopathology (Table 6.3).  
As previously discussed, spitzoid lesions composed of epithelioid melanocytes, a 
desmoplastic response and some intranuclear inclusions have been reported in 
association with amplification of chromosome 11p and/or HRAS mutations [334]. 
Therefore, I also checked the gene expression of HRAS (ILMN_1773751 probe), 
however, HRAS expression was similar in cases with and without BAP-like 
histopathology (Table 6.3). 
The histopathological appearance of spitzoid lesions with TERT promoter mutations 
have not been elucidated, however, the presence of such mutations has been reported 
to be associated with a more aggressive clinical course [337]. Therefore, recognition of 
the corresponding histopathological appearance could be beneficial. Therefore, I 
decided to explore the possibility that TERT might be implicated in melanomas with 
BAP1-like histopathological features, by comparing TERT gene expression in cases 
with and without such changes. However, there was no statistically significant 
difference in TERT gene expression in cases with and without BAP1-like 
histopathological features (Table 6.3).  
6.3.7 Melanomas with histopathological features suggestive of ALK 
fusions and the relationship with gene expression of ALK and 
its potential fusion partners 
Forty-six (5.8%) cases had histopathological features consistent with an ALK fusion, 
including a plexiform growth pattern and plump, spindle-shaped melanocytes. An 
example is shown in Figure 6.8. 
 
 Table 6.3: Mean gene expression (unlogged and logged) for some genes implicated in the putative BAP1 pathway or in spitzoid lesions 
for cases with and without BAP-like histopathology. 
The student’s t-test p-values are reported for the differential expression (False discovery rate (FDR)-corrected for multiple testing). BAP1, 
BRCA1-associated protein 1. Please see abbreviations for details of other gene names.  
Gene Probe 
Mean gene expression in 
cases without BAP-like 
histopathology 
(unlogged) 
Mean gene expression in 
cases with BAP-like 
histopathology 
(unlogged) 
Mean gene expression in 
cases without BAP-like 
histopathology 
(logged) 
Mean gene expression in 
cases with BAP-like 
histopathology 
(logged) 
T-test FDR 
corrected 
p-value 
ASXL1 ILMN_1726025 231.1 222.6 7.9 7.8 1.0 
BAP1 ILMN_1768363 214.6 226.5 7.7 7.8 1.0 
BARD1 ILMN_2074258 192.5 172.8 7.6 7.4 1.0 
BRAF ILMN_1652472 219.4 251.3 7.8 8.0 1.0 
BRCA1 ILMN_1738027 209.8 186.9 7.8 7.7 1.0 
E2F1 ILMN_2051469 228.2 228.8 7.8 7.8 1.0 
HCFC1 ILMN_1732705 218.0 207.1 7.8 7.7 1.0 
HRAS ILMN_1773751 235.9 222.4 7.8 7.8 1.0 
PRC1 ILMN_1728934 227.6 202.0 7.8 7.7 1.0 
RAD51 ILMN_2363027 231.0 205.2 7.8 7.8 1.0 
TP53 ILMN_1779356 217.3 201.5 7.8 7.7 1.0 
TERT ILMN_2373119 261.7 213.3 8.1 7.8 1.0 
USP16 ILMN_2397230 219.0 202.7 7.8 7.7 1.0 
YY1 ILMN_2181540 223.8 214.8 7.8 7.7 1.0 
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Figure 6.8: Virtual pathology image of a melanoma with ALK fusion-like 
histopathology 
Histopathological findings (x10 magnification) reveal a melanoma with a 
plexiform growth pattern, composed of fascicles of plump, pigmented spindle 
cells. Melanophages can also be seen within the tumour.  
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Of the 798 cases reviewed, 676 had gene expression data and 41 (6.1%) of these 
cases had histopathological changes suggestive of an ALK fusion. The distribution for 
ALK gene expression is shown in Figure 6.9. The mean (logged) gene expression for 
ALK, in the 676 cases for which gene expression was available, was 7.8 (S.D. 1.1). 
 
Figure 6.9: Histogram of the expression of the ILMN_1753135 probe (ALK) in 676 
cases from the Leeds Melanoma Cohort Study. 
Unexpectedly, the mean gene expression for ALK was lower in cases with 
histopathological features of an ALK fusion compared to cases without but this was not 
statistically significant (Table 6.4).  
The relationship between ALK fusion-like histopathology and the expression of the 
following genes, reported to be ALK fusion partners, was assessed: TPM3, DCTN1 
[158, 311], NPM1, TPR, GTF3C2, CLIP1 [157] (Table 6.4). I also explored The Cancer 
Genome Atlas (TCGA) fusion gene database [355] for other potential ALK fusion 
partners. I assessed for the differential expression of some of its potential fusion 
partners: KCNQ5 (melanoma), TPM1 (bladder cancer), EML4 (lung adenocarcinoma, 
thyroid carcinoma), C2ORF61 (ovarian serous cystadenocarcinoma), STRN (thyroid 
carcinoma) (Table 6.4).  
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6.3.8 The relationship between ALK fusion-like histopathology and 
gene expression of other kinases implicated in fusions 
There was no strong evidence, at a gene expression level, to support the presence of 
an ALK fusion in cases with suggestive histopathology. It appeared that there could be 
a degree of overlap in the histopathological features of spitzoid lesions between ALK 
and other kinase fusions [311]. Therefore, I assessed whether or not there were 
differences in the gene expression of other kinases (namely BRAF, MET, NTRK1, 
NTRK3, RET, ROS1) among cases with and without ALK fusion-like histopathology 
(Table 6.4). TERT expression was also assessed, as before. 
Transcriptomic analysis revealed a single gene, Crystallin Mu (CRYM), that was 
significantly upregulated in lesions that had ALK fusion-like histopathology (Table 6.4). 
Figure 6.10 shows the distribution for CRYM gene expression in 676 cases for which 
gene expression data were available. 
 
Figure 6.10: Histogram of the distribution of the CRYM probe (ILMN_2241187). 
Table 6.4 (following page): Mean gene expression (unlogged and logged) for 
some genes implicated in spitzoid lesions, including kinase fusions and 
their binding partners, for cases with and without ALK fusion-like 
histopathology. 
The student’s t-test p-values are reported for the differential expression (FDR-
corrected for multiple testing). ALK=Anaplastic lymphoma kinase. FDR=False 
discovery rate. Please see abbreviations for other gene names. 
 Gene Probe 
Mean gene expression in 
cases without ALK fusion-like 
histopathology (unlogged) 
Mean gene expression in 
cases with ALK fusion-like 
histopathology (unlogged) 
Mean gene expression in 
cases without ALK fusion-like 
histopathology (logged) 
Mean gene expression in 
cases with ALK fusion-like 
histopathology (logged) 
T-test FDR 
corrected 
p-value 
ALK ILMN_1753135 229.1 184.4 7.8 7.5 0.9 
BRAF ILMN_1652472 222.1 216.8 7.8 7.8 1.0 
C2ORF61 ILMN_1790070 226.4 237.6 7.8 7.9 1.0 
CLIP1 ILMN_2404085 214.1 231.1 7.7 8.0 1.0 
CRYM ILMN_2241187 204.1 405.1 7.7 8.7 0.01 
DCTN1 ILMN_2412807 229.8 235.2 7.8 7.8 1.0 
EML4 ILMN_1718297 229.6 226.7 7.8 7.8 1.0 
GTF3C2 ILMN_2356574 222.8 220.9 7.8 7.8 1.0 
KCNQ5 ILMN_2060268 266.2 312.5 8.1 8.3 0.9 
MET ILMN_1715175 231.7 222.7 7.9 7.8 1.0 
NPM1 ILMN_2379762 220.8 186.2 7.8 7.5 0.8 
NTRK1 ILMN_1731777 243.1 209.6 7.9 7.7 0.9 
NTRK3 ILMN_1687967 263.4 303.2 8.0 8.2 0.9 
RET ILMN_1706301 237.6 267.5 7.8 7.9 0.9 
ROS1 ILMN_1811234 255.6 258.3 8.0 8.0 1.0 
STRN ILMN_1749882 228.1 215.2 7.8 7.7 0.9 
TERT ILMN_2373119 270.2 280.4 8.1 8.1 1.0 
TPM1 ILMN_2360710 220.1 223.2 7.8 7.6 1.0 
TPM3 ILMN_1697567 225.3 204.3 7.8 7.8 0.8 
TPR ILMN_1730999 223.6 216.1 7.8 7.8 1.0 
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The mean (unlogged) gene expression of CRYM in cases with ALK fusion-like 
histopathology was almost twice that of cases without such features (Table 6.4, FDR-
corrected p-value=0.01). Figure 6.11 shows the box and whisker plot for ALK fusion-
like histopathology by CRYM gene expression. Neither ALK fusion-like histopathology 
nor CRYM gene expression was significantly associated with melanoma-specific death 
(data not shown). 
 
Figure 6.11: Box and whisker plots showing the gene expression for CRYM 
(ILMN_2241187 probe) by the presence or absence of ALK fusion-like 
histopathology. 
 
6.4 Discussion 
Only 9/1977 cases within the Leeds Melanoma Cohort had BAP1 variants predicted to 
be deleterious by SIFT or PolyPhen-2, indicating that BAP1 mutations are rare in 
cutaneous melanoma probands. Deubiquitinase assays were performed by the Sanger 
Institute. Loss of deubiquitinase activity was confirmed in two of the three cases with 
clear loss-of-function mutations. The deubiquitinase assay was not performed for the 
case with a splice acceptor site variant, however, there was strong a priori evidence to 
suppose that BAP1 function would be affected and a germline BAP1 mutation was 
confirmed on clinical testing. The remaining 6 cases with BAP1 variants that were 
predicted to be deleterious did not display a detectable loss of deubiquitinase function. 
The role of BAP1 beyond its deubiquitinase activity continues to be explored [356]. 
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This might explain why some variants were predicted to be deleterious but did not alter 
deubiquitinase activity. It is also possible that some BAP1 variants fell below the 
threshold of detection of the assay. The other possible explanation is that these 
variants might not be deleterious, even though the software had predicted them to be 
as such. 
A limitation of the cancer history analysis is that cancer subtypes might have been 
under-represented, e.g. mesothelioma could have been recorded as “lung” cancer and 
would not have been included in the analysis. A further limitation is that although the 
cancer data were entered as a positive history of cancer it was not possible to calculate 
the number of affected versus unaffected family members or to account for the size of 
the pedigree. This could have led to an over-representation of cancers in larger 
families and an under-representation in smaller pedigrees. Recall bias could have 
occurred, so that more detailed medical information could have been available in some 
families. Family dynamics around disclosure of cancers among relatives could not be 
accounted for. Educational levels achieved by the probands could also have influenced 
the level of detail provided in the survey. Inevitably adoption or estrangement within the 
family occurred and could not be accounted for. 
Information from pedigrees was, however, informative in predicting carriers of germline 
BAP1 mutations. The presence of a history of meningioma or mesothelioma in 
cutaneous melanoma probands or their first- and second-degree relatives in particular, 
was associated with an increased likelihood of a deleterious BAP1 variant. It was 
interesting to note that none of the families with a deleterious BAP1 variant in this study 
had a history of ocular melanoma. Of the nine cases with deleterious BAP1 variants, 
the family cancer history was more persuasive for the presence of a germline BAP1 
mutation in the three cases with clear loss-of-function variants, compared with the 
other six cases. 
BAP-like histopathology was not significantly associated with the presence of a 
deleterious BAP1 variant, compared to no BAP1 variant. In addition, BAP-like 
histopathology was not significantly associated with any of the following cancers 
(reported in association with the BAP1 tumour predisposition syndrome) or with the 
“BAP-like phenotype”: renal cancer, basal cell carcinoma, meningioma, ocular 
melanoma or a family history of cutaneous melanoma. There was, however, a 
significant association between BAP-like histopathology and the presence of a history 
of mesothelioma in either the proband or the family, when taken together. The findings 
might reflect the small numbers of cases with such cancer histories. Alternatively, 
cases with BAP-like histopathological features could have somatic rather than germline 
BAP1 mutations. This was not possible to verify during my PhD but could be explored 
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in future work, pending ethical approval. It is also possible that the BAP-like 
histopathological features are non-specific and, therefore, may not reliably identify 
cases with either somatic or germline BAP1 mutations. Sequencing of the melanoma 
tumour for somatic mutations might help to clarify this. 
There was no significant association between the presence or absence of BAP-like 
histopathology and BAP1 gene expression. Furthermore, gene expression data were 
available for only 3 of the 9 cases with variants predicted to be deleterious and 
surprisingly, BAP1 gene expression was above average in these cases. In early 
reports of cutaneous lesions in BAP1 mutation carriers, loss of heterozygosity (LOH) 
was demonstrated [159]. Therefore, loss of the wild type allele in germline BAP1 
mutation carriers and a corresponding reduction in BAP1 gene expression would have 
been anticipated. There were three cases with clear loss-of-function BAP1 variants; 
however, their melanomas had not been sampled with a TMA biopsy needle. It would 
have been interesting to assess for LOH in all 9 cases with variants predicted to be 
deleterious, however, this was not possible due to a lack of tumour tissue for all cases. 
Previous reports describe a high frequency of BRAF mutations in BAP1-mutant 
cutaneous melanocytic lesions [306, 332]. The mean expression of BRAF was slightly 
higher in cases with BAP-like histopathology but did not reach statistical significance. 
This observation of course does not preclude the presence of mutations. Furthermore, 
somatic BRAF mutations commonly occur in primary melanomas within the general 
population, irrespective of germline BAP1 mutation status [357]. Transcriptomic 
analysis did not reveal any variation in alternative genes that could be implicated in 
association with the BAP-like histopathological appearance. Conclusions relating to the 
gene expression results in the context of BAP1, are limited by the fact that a minority 
(3/9) of cases with variants predicted to be deleterious had gene expression data 
available for analysis and these were cases with the least compelling pedigrees and 
type of variant (missense). 
The frequency of BAP-like histopathology was relatively high within the cases analysed 
(~8%, 53/676), compared to the low frequency of BAP1 variants predicted to be 
deleterious. This could indicate that such histopathological findings are less specific 
than currently presumed [159]. The database used to record the histopathological 
features with respect to BAP-like and ALK fusion-like changes was not designed with 
the intent of recording such features systematically. It is therefore possible that the 
features were not recorded consistently throughout the study. The high number of 
cases identified with BAP-like histopathology, however, would suggest that the features 
were assessed frequently. 
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There was no significant association between the presence of ALK fusion-like 
histopathology and ALK gene expression. The expression of its proposed fusion 
partners, CLIP1 and NPM1, were not significantly altered in cases with ALK fusion-like 
histopathology. Although not statistically significant, ALK expression was decreased 
rather increased in cases with ALK fusion-like histopathological features. The gene 
expression data did not support the presence of an alternative kinase fusion in such 
cases. Previous studies which reported kinase fusions in spitzoid lesions, utilized 
targeted DNA sequencing, RT-PCR and fluorescence in situ hybridisation (FISH) to 
establish their presence [311]. These methods were not explored in the thesis. CRYM 
gene expression was notably increased in cases with ALK fusion-like histopathology.  
The role of CRYM in melanocytic lesions has not yet been determined. CRYM has 
been identified as a candidate substrate for Protein Kinase A (PKA),  Mitogen-activated 
protein kinase 1 (MAPK1), Protein Kinase N (PKN), LCK/YES novel tyrosine kinase 
(LYN) and FYN [358]. CRYM encodes a type of protein called crystallin, which has 
been implicated in maintenance of the transparency of the ocular lens [359] and in 
binding thyroid hormone, which may be important in thyroid hormone signalling in other 
tissues [360]. Mutations in CRYM have been reported in association with inherited 
deafness [361]. The cBioPortal database (based on the Cancer Genome Atlas Network 
data set, which includes metastatic melanoma cases) reports that somatic CRYM 
mutations occur in approximately 1% of melanomas [362]. Although, its biological role 
in melanoma has not been fully elucidated, CRYM mutations have been reported to 
occur in other cancers including prostate cancer [363], metastatic uterine 
leiomyosarcoma [364] and has been shown to be predictive of treatment failure in head 
and neck squamous cell carcinoma [365]. 
In summary, in this study of population-ascertained cutaneous melanoma cases, there 
was an association between a family history of mesothelioma, meningioma and BCC 
and the presence of a deleterious, germline BAP1 variant. The cancer history was 
particularly strong for three cases with germline BAP1 variants for which there was 
compelling evidence for loss-of-function. We did not identify uveal melanomas in these 
pedigrees. In the original reports of families with germline BAP1 mutations, 
ascertainment was for families with mixed cancers, in addition to uveal cancers. The 
fact that uveal melanomas were not found probably reflects a bias of ascertainment, 
both for the original uveal melanoma families and for our study. Clarity about the risk of 
various cancers is crucial to provide information to families with inherited BAP1 
mutations. This study reflects a lack of data in this regard. In the future, the 
identification of probands using cancer gene panels or exome sequencing may 
produce less biased estimates of cancer risk. 
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Six germline variants were identified by the Sanger Institute that were predicted to be 
deleterious but had apparently normal deubiquitinase activity. In these families, there 
was a personal or family history of either BCC, haematological malignancies, uterine or 
gastrointestinal tract cancers. One case of lung cancer occurred in an elderly relative of 
one of these probands. The significance of the cancer history in these cases is 
uncertain. Unfortunately, it was not possible to perform BAP1 immunohistochemistry or 
to test for loss of the wild type allele in the primary tumours because of lack of FFPE 
tumour tissue.  
BAP-like histopathology was not associated with the presence of a deleterious BAP1 
variant overall, although 2 of the 3 tumours from families with clear loss-of-function 
mutations did have “typical” changes, such as lack of an origin from the epidermis and 
lack of pigmentation. The presence of BAP-like histopathology in the proband’s 
melanoma was significantly associated with a history of mesothelioma in the proband 
or family. The observations in these 2 families suggest then that the unusual 
histopathological appearances of the cutaneous tumours described by Wiesner et al. 
are associated with deleterious germline mutations. The lack of association between 
the histopathological appearances and germline status overall, however, suggests that 
the association is weak: i.e. that these appearances are poorly predictive of germline 
status, not being specific to germline genetic variation.  
The factors underlying the BAP1-like histopathological features at a somatic level are 
unknown. There was no significant difference in BAP1 gene expression in cases with 
and without BAP-like histopathology, and three cases with missense variants 
(predicted to be deleterious) had BAP1 gene expression that was equivalent to or 
higher than the average in the cases studied. Moreover, there was no significant 
association between a BAP-like histopathology and the expression of other genes that 
have been proposed to be involved in its signalling pathway. 
There was no evidence to support the presence of kinase fusions in melanomas that 
appeared to resemble spitzoid lesions with ALK fusion-like histopathology. The number 
of cases with such features was small and the methods used curtailed the further 
exploration of such findings. However, a novel candidate gene, CRYM, was identified 
through transcriptomic analysis, which associated with the ALK fusion-like 
histopathological changes. The mechanism underlying the putative role of CRYM in 
such cases requires further elucidation. Sequencing would help to clarify whether or 
not overexpression was due to either amplification or mutation of CRYM. 
Immunohistochemistry for CRYM, performed on control samples and melanomas with 
and without increased CRYM gene expression would be worthwhile to evaluate CRYM 
protein expression in the context of its corresponding gene expression. Furthermore, 
278 
examining pedigrees of such cases and sequencing of matched blood and tumour 
samples for CRYM mutations, would be worthwhile in assessing for germline CRYM 
mutations. The work presented in this chapter shows proof-of-principle that 
histopathological appearances could have biological correlates (albeit somewhat 
variable), which is the foundation of my thesis. 
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Chapter 7 Final discussion 
The American Joint Committee on Cancer (AJCC) staging system is a powerful tool in 
predicting survival from cutaneous melanoma [43]. Breslow thickness, microscopic 
ulceration, mitoses (7th edition), microsatellites and the burden of nodal or distant 
metastases are central to this classification [43]. The most informative cut-off points for 
Breslow thickness continue to be debated, such that these have now been amended in 
the pending 8th edition of the AJCC staging system (in press), with the proposed new 
cut-off point for stage IA of 0.8mm now approximating the original thickness that had 
been reported by Breslow (0.76mm) to differentiate between cases that are capable of 
metastasis [45]. Although mitotic count had been incorporated into the 7th edition of the 
AJCC staging, to distinguish stage IA from stage IB cutaneous melanoma [43], it has 
not been retained in the forthcoming 8th edition (in press). The results reported in this 
thesis are based on the 7th edition of the AJCC staging system [43]. Consistent with the 
AJCC 7th edition, Breslow thickness, microscopic ulceration and the number of core 
mitoses were among the most highly reproducible and prognostic parameters recorded 
in my study. Furthermore, an increasing extent (width) of ulceration was hazardous for 
melanoma-specific death in univariable survival analyses. The literature reports various 
prognostic cut-off points for the width of ulceration [53-56]. In my project, there was a 
trend in the hazard ratios for an increasing extent of ulceration and a non-parametric 
test for trend was significantly associated with melanoma-specific death, suggesting 
that there might be a benefit to measuring the extent of ulceration on a continuous 
scale. Tumour-infiltrating lymphocytes (TILs) have been shown to be an independent 
prognostic factor in some studies [27, 60-63, 212], while others have failed to 
demonstrate an independent prognostic effect [64, 65, 67] or found TILs to be of 
borderline statistical significance [69]. Nonetheless, the recording of TILs could be 
important, particularly in this era of immunotherapy [216, 289]. I found that TILs (with 
respect to the whole tumour) were of borderline statistical significance in univariable 
survival analysis and were not an independent predictor of melanoma-specific death. It 
was notable that, in this study, there was an inherent bias towards thicker melanomas, 
from which a TMA core biopsy could be obtained without destroying the clinical block. 
Previous studies have shown that brisk TILs tend to decrease with increasing Breslow 
thickness [27, 61, 64]. Interobserver agreement for TILs using the virtual pathology 
protocol was moderate, whereas previously published studies have shown varying 
strengths of agreement between observers [27, 199-201], reflecting the subjective 
nature of the measure. Remarkably, the extent of the lymphocytic infiltrate within the 
cored region was significantly and independently protective for melanoma-specific 
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death. This measure was based on an “eyeballed” estimation, however, precise 
counting of lymphocytes could be performed in the future. The role of regression in 
melanoma is controversial, with some studies reporting a protective effect [74, 79], 
while others indicate a more sinister role [82-84]. Similarly, in this thesis, the presence 
of tumour loss and its increasing depth were significantly hazardous in univariable 
survival analysis. In addition, cases that had both deep and superficial tumour loss 
were at increased risk of melanoma-specific death. Nonetheless, the test for trend for 
the increasing depth of tumour loss was not an independent predictor of outcome. It is 
dogma that regression results from host-mediated anti-tumour immunity [71]. However, 
an alternative hypothesis is that regression represents an intrinsic event within the 
tumour, leading to tumour cell death and the selection of more aggressive tumour cells 
in the evolution of the melanoma [73]. Further research is required to elucidate this 
association. Although there was moderate to perfect inter- and intraobserver 
agreement for the intensity and pattern of tumour-infiltrating melanophages, neither of 
these measures significantly influenced melanoma-specific death. Unfortunately, it was 
not possible to further characterise the polarization of the macrophages/melanophages 
during my PhD. 
At the beginning of my PhD, I noted that primary melanomas were as visually 
captivating when viewed with a microscope, as they are to the naked eye, displaying 
remarkable diversity of cell shape, variation in pigmentation and contrasting 
architectural arrangements, e.g. nests. These striking characteristics have long been 
described by pathologists but were of uncertain prognostic significance. I was keen to 
explore this further. Early studies suggested that cutaneous melanoma relapses 
tended to occur more frequently in association with epithelioid melanocytes within the 
primary melanoma [101], and that spindle cell melanomas had a better prognosis 
[103]. Furthermore, desmoplastic melanomas, which display a markedly spindled 
melanoma cell shape, have a tendency to recur locally but metastasise less frequently 
[99, 100]. Additionally, in vitro cell migration assays have shown that melanoma cells 
with a rounded or “amoeboid” appearance degraded type I collagen more efficiently 
than cells with a “mesenchymal” phenotype [105]. This prompted me to investigate the 
role of melanoma cell-specific features more closely. The grading of melanoma cell 
pigmentation was highly reproducible within and between observers, yet, it was of no 
prognostic significance. There was moderate to substantial agreement for melanoma 
cell shape, yet, the vast majority of cases had a round/ovoid/epithelioid appearance   
and the number of cases in the other categories was small. There was no significant 
effect for melanoma cell shape in survival analyses. Weaker inter- and intraobserver 
reproducibility was noted for melanoma cell structure. Nonetheless, melanoma cell 
“sheets” corresponded to an increased risk of melanoma-specific death in univariable 
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analysis but lost significance in multivariable survival analyses, adjusting for age, sex, 
site of primary, AJCC stage and the extent of either the core immune cell or 
lymphocytic infiltrates. The dispersed cell structure was independently hazardous for 
melanoma-specific death in the same multivariable analyses, although the number of 
cases in this category was small. Therefore, although these features are visually 
intriguing, they did not appear to be of any consequence from a prognostication point 
of view, in this study of over 700 primary tumours. 
In spite of the lack of predictive power, it would appear that these morphological 
distinctions might indicate somatic or germline mutations. Viros et al. showed that 
BRAF-mutated melanomas tended to have large, round, pigmented cells [108]. I was 
interested to assess whether or not the histopathological changes that had been 
reported to occur in association with either a BAP1 mutation or an ALK fusion were 
predictive of differential gene expression in BAP1 or ALK, respectively. BAP-like 
histopathology was recorded in 8% of cases in this data set, a rate that is higher than 
would be expected, in comparison to the rarity of germline BAP1 mutations [314]. This 
begs the question whether or not these melanomas had acquired somatic BAP1 
mutations, however, there was no demonstrable difference in BAP1 gene expression 
between cases with and without a BAP-like histopathological appearance. It is 
noteworthy that no transcriptomic data were available for the three cases with the most 
compelling evidence for BAP1 loss-of-function variants. Unfortunately, it was not 
possible to explore this further with BAP1 immunohistochemistry or to assess for loss 
of heterozygosity due to the limited amount of tissue that could be sampled (as 
previously discussed). Initial reports of cutaneous melanocytic lesions in cases 
harbouring a germline BAP1 mutation were presented as having a characteristic 
histopathological appearance [159] but, subsequently, melanomas with somatic BAP1 
mutations were noted to adopt a similar appearance [306]. Although the features were 
recorded in spitzoid lesions, some of the cases could not be distinguished from 
melanoma and, therefore, I recorded the presence or absence of such features for 
cases in the Leeds Melanoma Cohort Study. There was no significant association 
between a BAP-like histopathology and the presence of a predicted deleterious BAP1 
variant. Therefore, these histopathological features appeared to be poorly predictive of 
germline BAP1 mutations in this study. Data for the personal and/or family history of 
cancers, which had been reported to be associated with germline BAP1 mutations, 
were extracted. Due to the nature of the recorded cancer history, I focused my analysis 
on specific categories, e.g. mesothelioma, as opposed to lung cancer. There was a 
significant association between the presence of a predicted deleterious BAP1 variant 
and the presence of a family history of either mesothelioma or meningioma. BAP-like 
histopathology was significantly associated with the presence of mesotheliomas in the 
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pedigrees. A deubiquitinase assay was used to confirm the biological effects in cases 
harbouring predicted deleterious variants. Unfortunately, this failed to detect expected 
changes in function in 6 cases, possibly as a consequence of a lack of sensitivity. This 
was a large study, in which the prevalence of germline BAP1 mutations, corresponding 
pedigrees and histopathology of melanomas in the probands were assessed. 
Nonetheless, a larger scale study is necessary to inform decisions about clinical testing 
for germline BAP1 mutations and screening for cancers among affected probands and 
their family members. Similarly, ALK fusion-like histopathology was not associated with 
a significant difference in ALK gene expression, or in its proposed binding partners. 
However, the Illumina® probes did not bind across the proposed fusion sites, which 
could account for the lack of association between the ALK fusion-like histopathological 
appearance and the ALK (and binding partners) gene expression results. Alternatively, 
the histopathological appearance might be non-specific. It was not possible to perform 
ALK immunohistochemistry, due to the need to conserve the tumour blocks for clinical 
testing. Regardless, the identification of an association between ALK fusion-like 
histopathology and CRYM gene expression serves as a proof-of-concept that 
histopathological appearances have transcriptomic correlates. The biological 
significance of this finding will be explored in future research. 
This project was unique in several ways. The study was based on a large data set for 
which detailed clinical, histopathological and transcriptomic data were available. The 
median follow-up of participants was 7 years, enabling me to be confident in assessing 
the impact of my recorded histopathology measures on relapse and survival. 
Furthermore, the histopathological assessment was detailed and was performed by a 
single observer with high intraobserver reproducibility. I developed a robust protocol, in 
tandem with the accumulation of knowledge and skills. The virtual pathology platform 
contributed significantly to the originality of the project. This facilitated the development 
of a novel approach, combining a comprehensive histopathological assessment of the 
tumour as a whole but also, importantly, to evaluate the cored regions in detail. This 
enabled me to assess whether or not the microscopic appearance of melanoma could 
have transcriptomic correlates, which could potentially be useful clinically. 
The results of inter- and intraobserver studies provide evidence that the protocol was 
reproducible, although some parameters were more variably reported within or 
between observers, e.g. the presence of tumour loss, the quality of the stroma and the 
number of core blood vessels. It is reassuring that the Breslow thickness and 
microscopic ulceration, which are regarded to be the cornerstones of staging and for 
which the highest interobserver agreement is reported [190, 191, 195, 196], were also 
highly reproducible in my thesis. Moreover, the majority of the newly developed 
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measures pertaining to the cored regions were highly reproducible. The solid 
groundwork had now been laid for analyses of the impact of such factors on 
melanoma-specific relapse and death, aspects that were particularly important to me 
as a dermatologist.  
Nonetheless, it was surprising that TILs were of borderline statistical significance, 
particularly as they had been an independent prognostic factor in interim analyses 
(data not shown), and because immunotherapy has revolutionised the treatment of 
metastatic melanoma [289, 290, 304, 366]. The results could be a reflection of the 
biased data set that I studied, in that these tumours were inherently thicker because 
they had been sampled using a TMA needle. I enumerated mitoses within the cored 
region. Substantial inter- and intraobserver agreement was demonstrable and the 
number of core mitoses was a significant prognostic factor in univariable analysis. This 
suggests the possibility that, in the future, pathologists could focus on a pre-defined 
region of the melanoma, instead of searching for the most mitotically-active region (or 
“hot spot”) [43] within the tumour. I would speculate that this would be likely to save 
time and to be more highly reproducible between observers.  
Survival analyses revealed that Breslow thickness and ulceration status were 
hazardous for melanoma-specific survival. Several other histopathological factors were 
of prognostic significance. There was a convincing trend in the hazard ratios for an 
increasing extent of ulceration, suggesting that not only its presence is important in 
determining outcome but also its extent. Similarly, an increasing depth of tumour loss 
was associated with a worse prognosis, highlighting the importance of recording its 
measurement in millimetres. ROC curve analyses showed that the combination of 
AJCC stage and the percentage of stroma (POS) increased the area under the curve, 
compared to AJCC stage alone. The extent of the core immune cell and lymphocytic 
infiltrates were associated with a better prognosis, indicating that grading the immune 
cell infiltrate, particularly lymphocytes, within the advancing melanoma margin which 
has the least immune cell infiltrate would be worthwhile. Such factors could be 
considered for inclusion in melanoma prediction models in the future. 
Stemming from my research of the cored regions, I discovered that the POS within the 
core was a highly significant, independent prognostic factor. Furthermore, it was 
powerfully protective for melanoma-specific death, such that for every percentage 
increase in stroma, there was a corresponding 1% decrease in melanoma-specific 
death. In addition, ROC curve analyses revealed that the POS added a further 3% 
predictive power to AJCC stage, both for melanoma relapse and death. This contrasted 
starkly with many studies in other cancers inferring a hazardous role for the POS [131, 
134, 135, 137-142, 261, 262]. The POS tended to parallel those factors that are known 
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to be associated with a good outcome, such as younger age at diagnosis [6, 7, 367-
369], female sex [14, 15, 19] and early AJCC stage [43]. The corollary was also true, 
that the POS was inversely associated with factors predictive of a poor outcome, 
namely Breslow thickness [43, 45], microscopic ulceration [43, 48, 53, 54, 56, 370], 
increasing mitoses (albeit measured within the core) and/or more aggressive tumours, 
e.g. NRAS-mutations [37]. Moreover, there was a significant association between the 
POS and the increasing extent of both the core immune cell and lymphocytic infiltrates. 
The beneficial effects of the POS could be due to several factors. It could simply be a 
reflection of a less aggressive primary melanoma: that is that very proliferative tumours 
may destroy or push aside the stroma. Alternatively, the core immune cells could be 
responsible for the survival advantage. Another possibility is that the non-immune 
stroma is mediating the protective effect associated with the POS. Lastly, a 
combination of these factors could be at play, e.g. the non-immune stromal cells might 
be working in harmony with immune cells by facilitating their infiltration and by warding 
off the tumour via physical rigidity. It is difficult to untangle the evidence because the 
POS was a combined measure of the immune and non-immune stromal components 
(due to technical reasons discussed in Chapter 5). At a transcriptomic level, the POS 
was associated with the expression of both immune and non-immune stromal genes. 
Survival analyses of the ESTIMATE scores revealed a highly significant prognostic role 
for both the immune and non-immune compartments. This suggests the possibility that 
a synergy exists between the non-immune and immune stromal cells. The ESTIMATE 
tumour purity score was hazardous for melanoma-specific death and, therefore, it is 
still possible that a high POS could be the result of a less aggressive tumour. 
MetaCore™ enrichment analyses revealed immune cell pathways to be upregulated in 
association with the POS and similarly for the extent of the core immune cell and 
lymphocytic infiltrates. Cell cycle pathways were downregulated in cases with a high 
POS, which might reflect tumour cell “dilution”. Thousands of genes were significantly 
associated with the POS (data not shown). A MetaCore™ comparative enrichment 
analysis of the top 1000 genes associated with each of the POS and the extent of the 
core immune cell and lymphocytic infiltrates, identified SDF1 as being uniquely 
upregulated in association with the POS. SDF1 is a chemokine that is known to 
promote the chemotaxis of lymphocytes, monocytes and dendritic cells [291]. 
Fibroblasts are the main source of SDF1 in the skin, although it can be expressed by a 
variety of cell types, including lymphocytes, endothelial cells and even cancer cells 
[292]. I found that SDF1 expression was independently protective for melanoma-
specific death. Furthermore, expression of its receptor CXCR4 but not CXCR7 (a 
decoy receptor for SDF1) [294], was significantly protective, although it lost statistical 
significance after the addition of the POS to the multivariable model. This is a 
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controversial finding, bearing in mind that the literature contains numerous conflicting 
studies about the prognostic role of both SDF1 and CXCR4, not only in melanoma 
[241, 293-302] but also for other cancers [291, 371-375]. The fact that the POS, the 
ESTIMATE stromal score and SDF1 were each independently protective for 
melanoma-specific death, suggests that primary melanomas with more abundant 
stroma have a better prognosis than do melanomas with sparse amounts of stroma. 
Moreover, that this protective effect may result from the chemotaxis of immune cells 
consequent upon release of chemokines by fibroblasts. This finding warrants further 
research, particularly in view of the fact that I focused on a pre-defined region within 
the melanoma and the amount of stroma could have varied across the tumour.  
A limitation of the study is that virtual pathology is not yet in widespread clinical use in 
the UK, which could affect the translation of some of these measures into clinical 
practice. Furthermore, the cored region variables were based on a pre-determined 
region of the melanoma. It is not known how this could relate to the rest of the tumour, 
especially in view of the fact that melanoma is a highly heterogeneous tumour [117, 
222]. Moreover, the reproducibility of the selection of the region of tumour at the 
invasive margin, relatively deficient in immune cells and collagen, has not been 
assessed. In addition, the extent to which the histopathological description is a true 
reflection of the three-dimensional core is not known. From a practical point of view, 
there were some special considerations in the use FFPE archival specimens for 
transcriptomic studies: RNA degradation [177] had been anticipated due to the time 
that had elapsed between obtaining the original tumour block and the RNA extraction. 
The WG-DASL® assay was designed to overcome these issues [178]. High quality 
results have previously been shown using the WG-DASL® assay (now retired) for RNA 
extracted from melanoma samples [175]. Unfortunately, two plates of RNA failed owing 
to reagent degradation (more than 900 samples were sent to the service provider). A 
further limitation is that inter- and intraobserver agreement could be studied for only a 
small number of cases. Ideally, I would have liked to have assessed the reproducibility 
of the new protocol between 3 independent observers. Furthermore, the POS was a 
composite score of both the immune and non-immune stromal constituents. This led to 
subsequent difficulties in unravelling their relative contributions. Finally, although I had 
access to a large data set, the study was underpowered to provide definitive answers 
in relation to BAP1 germline mutations, due to their rarity in primary cutaneous 
melanoma [314]. 
 The strengths of the study were that the virtual pathology protocol was highly 
reproducible between and within observers. Survival analyses revealed several highly 
significant prognostic measures, both established and new. Among these, the POS 
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was identified as a novel biomarker, which was independently protective for 
melanoma-specific death. Moreover, the results of transcriptomic analysis 
independently support the view that the stroma is protective. This is the largest study to 
date of the prevalence of germline BAP1 mutations within a population-ascertained, 
cutaneous melanoma cohort, which combined pedigree and histopathological 
assessment of primary cutaneous melanomas in the probands. The project has 
produced new hypotheses that will be explored in the future, in this rich data set. 
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 : Definitions 
Definitions used throughout the report are listed below in alphabetical order. 
Term Definition 
Acceptor splice site The splice site at the end of an intron. 
Acral Affecting the hand or foot. 
Acral lentiginous 
melanoma 
A subtype of cutaneous melanoma occurring in the volar or 
subungual skin. The intraepidermal component is usually 
lentiginous in pattern with a “moth eaten” appearance [5]. 
Adenoviral gene 
transfer 
The use of a vector (adenovirus) to deliver genetic material to 
a cell. 
Adhesion molecule 
A cell surface protein that is involved in the attachment of cells 
to the extracellular matrix. 
Adipocytic (fatty) 
degeneration 
The abnormal accumulation of fat within the cytoplasm of a 
cell. 
Adipocytic (fatty) 
metaplasia 
The replacement of normal tissue by fat cells (adipocytes) 
where they are not normally found. 
Agnostic Unbiased. 
Algorithm A computer-based set of rules for calculations. 
ALK fusion-like 
histopathology 
The histopathological appearance of a melanocytic 
proliferation, consisting of plump spindle-shaped melanocytes 
arranged in a plexiform growth pattern and tending to have a 
polypoid silhouette. 
Allele One of a number of forms of the same gene. 
Amelanotic Lacking pigment. 
Amoeboid (cell 
movement) 
A description given to a type of cell movement that has a 
rounded appearance in vitro [105]. 
Angiogenesis The development of new blood vessels. 
Apoptosis Programmed cell death. 
Array-based 
comparative 
genomic 
hybridization 
A molecular technique for analysing the copy number 
variations relative to the number of copies of chromosomes 
within the cell in a test sample compared to a reference 
sample. Fluorescent probes are used for labelling.  
Atypical Spitz 
(spitzoid) tumour 
A melanocytic lesion which displays some features of both a 
Spitz naevus and of melanoma, such that its behaviour cannot 
be reliably predicted [376]. The term is controversial but is 
considered to be interchangeable with Spitzoid Tumour of 
Uncertain Malignant Potential for the purpose of this thesis. 
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Term Definition 
Azan trichrome 
stain 
A histology stain that is formed from a mixture of 3 coloured 
dyes, which stains collagen, basement membrane and mucin 
blue; nuclei are stained red and muscle and red blood cells are 
stained orange to red. 
BAP-like 
histopathology 
The histopathological appearance of a melanocytic (often 
spitzoid) proliferation, consisting of epithelioid melanocytes 
and/or naevoid melanocytes, with a tendency towards 
epidermal sparing, intranuclear pseudoinclusions and 
multinucleated melanocytes. 
Benign melanocytic 
naevus 
A mole (of the skin). 
Biallelic Referring to both alleles. 
Binary variable A variable that has 2 categories. 
Biobank 
A large collection of tissue samples and/or data retained for 
research. 
Bioinformatics The science of analysing complex biological data. 
Biomarker 
A molecule, gene or characteristic that is capable of identifying 
the presence of a disease or a particular characteristic of a 
disease. 
Bonferroni 
correction 
A statistical method of p-value adjustment made for 
simultaneous multiple testing. 
Breslow thickness 
(in mm) 
The measurement between the top of the granular layer of the 
epidermis and the deepest point of invasion of melanoma, or 
where epidermal ulceration is present (and involves the 
thickest region of tumour), the measurement between the base 
of the ulcer and the deepest point of melanoma invasion. The 
measurement excludes melanoma cells apposed to adnexal 
structures or lying within vessels and microsatellites, where 
present [51]. 
Cancer-associated 
fibroblasts 
A subpopulation of fibroblasts that promote tumour growth, 
angiogenesis and metastasis. 
Carcinogen An agent that has the capacity to cause cancer. 
Categorical variable A variable that has ≥2 categories. 
Censoring 
A statistical method of curtailing a time-to-event analysis to a 
fixed point in time, where study participants may be lost to 
follow-up or where the event of interest (relapse or death) has 
not yet occurred within the selected follow-up time period. 
Chemokine A small, chemotactic cytokine. 
Chemoresistance 
The resistance of cancer cells to inhibition by a chemical 
substance. 
Chemotaxis The movement of a cell towards a secreted substance. 
Chip 
A type of micro-array carrying large numbers of genetic 
probes. 
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Term Definition 
Clark level I Melanoma confined to the epidermis. 
Clark level II 
Melanoma begins to encroach on but does not fill the papillary 
dermis. 
Clark level III Melanoma fills and expands the papillary dermis. 
Clark level IV Melanoma invades the reticular dermis. 
Clark level V Melanoma invades the subcutaneous fat. 
Collagen The principal structural protein in connective tissue. 
Confidence interval 
A range of values within which the true effect size or statistic is 
likely to lie based on probability. 
Connective tissue Tissue that supports other tissues or organs. 
Continuous variable A variable with an infinite number of possible values. 
Copy number 
variation 
The number of copies in sections of the genome, which vary 
between individuals. 
Cox proportional 
hazards model 
A statistical method for examining the effect of one or more 
predictor variables on the risk of event per time unit and how it 
changes over time. 
Crisis 
A state of extreme telomere dysfunction, precipitated by 
chromosomal abnormalities and leading to cell death. 
Curated pathway 
A biological pathway that has been constructed or edited by a 
person with expertise in the area. 
Curette 
A surgical instrument that can be used to remove the 
superficial part of a skin lesion and often results in a 
fragmented specimen. 
Cytokine 
A substance that is secreted by a cell (typically an immune 
cell) and has an effect on other cells. 
Cytoplasm The material within a cell, excluding the nucleus. 
Degrees of freedom 
The number of independent values of a statistic that are free to 
vary. 
Dendritic cell A professional antigen-presenting cell. 
Dermo-epidermal 
junction 
The junction between the lower epidermis and the upper 
dermis of the skin. 
Desmoplasia Growth of fibrous or connective tissue. 
Desmoplastic 
melanoma 
A subtype of cutaneous melanoma that is ill-defined and 
variably cellular. It is composed of spindle cells associated with 
dense collagen, and usually occurs on sun-damaged skin [5]. 
Lentigo maligna may be seen in association. 
Deubiquitinating 
enzyme 
An enzyme that removes ubiquitin from other molecules. 
Dichotomous Two different categories. 
Discontiguous 
ulcers 
Ulcers that are separated by normal intervening epidermis. 
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DNA double-strand 
break  
Both strands of the DNA double helix structure have been cut. 
DNA methylation 
The addition of methyl groups to DNA, which may alter its 
activity. 
DNA ploidy 
The DNA content within cells, with normal somatic cells having 
2 copies of each chromosome. 
Driver mutation 
A somatic mutation that confers a growth advantage to the 
cancer cell which carries it and has been positively selected 
during cancer evolution [377]. 
Dyscohesive 
response 
The tendency for cells in the upper dermis to segregate in 
response to early ulceration. 
Eosinophil A white blood cell whose nucleus stains with eosin. 
Eosinophilic Stains readily with eosin. 
Epidermal atrophy 
Thinning of the epidermis due to a reduction in keratinocytes, 
which may be accompanied by flattening of the rete ridges. 
Epithelial-
mesenchymal 
transition 
A process whereby an epithelial cell gains the ability to invade 
and adopt the properties of a mesenchymal stem cell. 
Epithelioid 
melanocyte 
A melanocyte with a round nucleus, a prominent, pink 
nucleolus and variably eosinophilic and often abundant 
cytoplasm [97]. 
Event 
In the context of Cox proportional hazards models, an event 
refers to the occurrence of either melanoma relapse or 
melanoma-specific death (pertaining to the statistical analysis). 
Exogenous Originating outside of the body. 
Exome sequencing A technique of sequencing all of the expressed genes. 
Exon 
The coding part of the RNA transcript or its corresponding 
DNA sequence. 
Exophytic Related to the outward growth of a tumour. 
Expansile Related to expansion. 
Extracapsular 
extension 
The extension of melanoma beyond the capsule of the lymph 
node. 
Extracellular matrix 
A structure that provides support to surrounding cells and is 
composed of extracellular molecules, including collagen, 
proteoglycans and elastin. 
Eyepiece graticule 
A glass disc that contains a fine scale and is inserted into the 
eyepiece of a microscope to allow measurements to be made. 
False discovery rate 
correction 
A statistical method of p-value adjustment that reduces the 
number of false positives when performing multiple testing. 
Fibroblast A cell that synthesises collagen. 
Fibrocyte An inactive mesenchymal cell. 
Fibrosis The thickening and scarring of connective tissue. 
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FISH 
A technique that uses fluorescent probes to label specific 
regions of chromosomes. 
Fold-change 
Describes how much a measure changes from an initial value 
to a final value, calculated using the ratio of the final value 
divided by the initial value. 
Frameshift mutation 
A genetic mutation caused by the insertion or deletion of 
nucleotides in a DNA sequence that is not divisible by three. 
Fusion A combination of two previously separate genes. 
Gene ontology 
A bioinformatics approach to deduce the molecular function 
and biological processes of genes. 
Genome The complete set of genes within a cell. 
Genomics 
The study of the structure or function of the genome (the 
complete set of genes within an organism). 
Germ cell 
A cell that is capable of reproduction by uniting with a similar 
cell from the opposite sex to form an individual. 
Germline 
A mutation that occurs in germ cells, which can be transmitted 
to offspring. 
Granular cell layer 
A layer of the epidermis, also known as the stratum 
granulosum.  
Haematopoiesis The production of blood cells and platelets. 
Hazard ratio 
A statistical ratio that describes the risk of a particular event, 
taking into account the time-to-event. 
Heat map 
A graphical representation of data using colours, especially for 
transcriptomic data. 
Heterozygote An organism that has two different alleles of the same gene. 
Histological subtype 
The category that defines the type of melanoma; largely 
grouped as follows: nodular, superficial spreading, acral 
lentiginous and lentigo maligna melanoma (please see 
Chapter 2 for more details). 
Homologous 
recombination 
repair 
A mechanism of DNA double-strand break repair where the 
genetic information is duplicated from the opposite sister 
chromatid, i.e. the other copy of the duplicated chromosome.  
Immunosenescence 
Gradual decline in immune cell function in association with 
age. 
In situ (melanoma) Melanoma cells are confined to the epidermis. 
In vitro 
An experiment performed in a controlled environment outside 
of a living organism. 
Interphase 
A phase in cell cycle in which the cell copies its DNA in 
preparation for mitosis. 
Interquartile range 
Calculated as the 75th minus the 25th percentile of the 
frequency distribution of a continuous variable. 
Intron 
The non-coding section of an RNA transcript or its 
corresponding DNA. 
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Isoform 
Messenger RNAs produced at the same locus but differing in 
the protein coding DNA sequences, which may affect gene 
function. 
Kamino body 
An eosinophilic, spherical structure (“globoid”) that is often 
found at the dermo-epidermal junction of Spitz naevi. 
Kaplan-Meier 
curve(s) 
A graphical representation of the time to failure, e.g. death. 
Kinase An enzyme that transfers phosphate to another molecule. 
Kruskal-Wallis test 
A non-parametric statistical test to assess whether three or 
more variables have the same distribution (non-parametric 
version of “analysis of variance”). 
Laser capture 
microdissection 
A method of isolating cells or small pieces of tissue by using a 
laser to dissect a microscopic region of interest. 
Lateral The part (of the melanoma) that is furthest from the centre. 
Lentigo maligna 
The in situ phase of lentigo maligna melanoma (i.e. radial 
growth phase; peri-adnexal involvement is frequent). 
Lentigo maligna 
melanoma 
A subtype of cutaneous melanoma characterised by epidermal 
atrophy, a prominent intraepidermal lentiginous component, 
accompanied by evidence of actinic damage or solar elastosis 
and frequently involving adnexal structures [5]. 
Leukocyte 
methylation score 
A score that indicates the extent of DNA methylation in 
leukocytes (white blood cells).  
Likelihood ratio test A test of two hypotheses in frequentist statistical methods. 
Linear regression 
A statistical method used to examine whether an independent 
continuous variable is a linear predictor of a continuous 
outcome measure. 
Loss of 
heterozygosity 
Loss of a gene and its surrounding chromosomal region. 
Lymphocyte 
A white blood cell with a single nucleus, occurring mainly in the 
lymphatic system. 
Lymphovascular 
invasion 
The presence of melanoma cells within lymphatic or blood 
vessels. 
Macrometastasis 
A clinically-detectable lymph node metastasis, confirmed on 
lymphadenectomy or when there is gross extracapsular 
extension [51], i.e. a palpable lymph node due to the 
secondary spread of melanoma. 
Macrophage 
A white blood cell with the capacity to engulf foreign 
substances and debris. 
Massive parallel 
sequencing 
Also known as next generation sequencing. This is a process 
of DNA sequencing in which thousands or millions of DNA 
sequences are produced simultaneously. 
Matrix 
metalloproteinase 
An enzyme that breaks down extracellular proteins, such as 
collagen or elastin. 
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Maturation 
The tendency of melanocytes to become smaller towards the 
base of a benign melanocytic lesion. 
Maximum 
microscopic 
diameter (in mm) 
The distance between the most lateral epidermal nest at either 
side of the melanoma, or where nests are absent, the distance 
between the furthest edges of the invasive component of the 
tumour. (This definition was developed following discussion 
with Dr W. Merchant). 
Median A value that lies at the midpoint of a distribution. 
Melanocyte A cell that produces melanin pigment. 
Melanoma-specific 
death 
Death due to melanoma. 
Melanoma-specific 
survival 
The interval between melanoma diagnosis and the time of 
melanoma-specific death (event) or death due to other causes 
(censored), or the interval between melanoma diagnosis and 
censoring and there is no record of death. 
Melanophage A pigment-laden macrophage. 
Melanosome 
A specialised structure within a melanocyte that is responsible 
for making, storing and transporting melanin pigment. 
MELTUMP 
A melanocytic lesion which displays some features of both a 
benign melanocytic naevus and of melanoma but falls short of 
a diagnosis of melanoma. Its behaviour cannot be reliably 
predicted. 
Mesenchymal 
(phenotype/cell 
movement) 
A description given to a type of cell movement that has an 
elongated appearance in vitro [105]. 
Mesenchymal cell 
A cell that has the capacity to develop into tissues of the 
lymphatic, circulatory or connective tissues. 
Mesothelioma A cancer of the mesothelium. 
Mesothelium The lining of the pleural and peritoneal cavities. 
MetaCore™ 
A bioinformatics package that can be used to input several 
genes and to compute an enrichment analysis, thus providing 
information on biological pathways that are altered in the data 
set. 
Metastasis(-es) 
The development of secondary cancer(s) at a site(s) distant to 
the primary cancer. 
Metastasis-free 
survival 
The interval between melanoma diagnosis and the time of 
melanoma metastasis (event) or death (censored), or the 
interval between melanoma diagnosis and censoring and there 
is no record of metastasis. 
Microarray 
DNA sequences for all of the genes in an organism, arranged 
in a grid for genetic testing. 
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Micrometastasis 
A metastasis detected microscopically, on sentinel lymph node 
biopsy or completion lymphadenectomy, in the absence of any 
clinical abnormality [51]. 
Microsatellite 
The presence of a discontinuous nest of metastatic cells 
>0.05mm in diameter, deep to the invasive melanoma and 
separated by normal dermis of at least 0.3mm [43]. 
Microscopic 
ulceration 
A full thickness epidermal defect, accompanied by reactive 
changes (including neutrophils and fibrin) and surrounding 
epidermal thinning or hyperplasia, in the absence of trauma or 
surgery [51]. 
Mini-wall 
A large digital screen display, consisting of 3 computer 
screens orientated adjacent to each other and linked to a 
single computer. It can be used to view a single item across 
three screens in unison or to display separate items on each 
parallel screen at the same time. 
Missense mutation 
A mutation where a single nucleotide change results in coding 
for a different amino acid. 
Mitosis (-es) 
The process of cell division (occurring within the nucleus), 
where a parent cell divides to form two daughter cells. 
Mitotic rate 
(per mm2) 
The number of dermal mitoses within 1mm2 region of the “hot 
spot” (or area of apparently most numerous dermal mitoses), 
or in the absence of a hot spot, the number of dermal mitoses 
within 1mm2 of a representative dermal mitosis [43]. 
Molecular profile 
A pattern based on gene expression signatures or mutation 
status or genomic characteristics of the tumour. 
Molecule 
A group of atoms bonded together, being the smallest part in a 
chemical element. 
Monocyte 
The largest type of white blood cell. It is capable of 
differentiating into a macrophage. 
Multinucleated Having multiple nuclei. 
Multivariable 
In statistical modelling, multivariable implies that multiple 
predictor variables are included in the model. 
Mutation A structural change in a gene, resulting in a variant form. 
Myofibroblast 
An atypical fibroblast that has features of a fibroblast and a 
smooth muscle cell. 
Naevus/naevi A benign melanocytic lesion (mole). 
Neutrophil 
A white blood cell with a role in innate immunity (rudimentary 
response to foreign substances) and a multi-lobed nucleus. 
Nodular melanoma 
A subtype of cutaneous melanoma characterised by a 
predominant vertical growth phase, with the lateral 
intraepidermal component extending no more than 3 rete 
ridges beyond the vertical growth phase component. (Please 
see Table 2.1). 
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Non-parametric test 
A statistical test that can be performed on a continuous 
variable without making any assumptions about its distribution. 
Nuclear 
hyperchromasia 
A darkly staining nucleus. 
Nuclear 
pleomorphism 
Nuclei that vary in size and shape. 
Nuclear 
pseudoinclusion 
A bleb of cytoplasm, prolapsed into the nucleus. 
Nucleolus (-i) A structural component of the nucleus. 
Nucleotide A molecule, which is a subunit of DNA or RNA. 
Nucleus (-i) A structure within a cell that contains the genetic material. 
Ocular micrometre 
A glass disc containing a ruled scale, which can be inserted 
into the eyepiece of a microscope to make measurements. 
Ordinal variable 
A type of categorical variable, where individual categories are 
ordered. 
Organotypic culture 
The culture of 2 or more cell types from a complex tissue or 
organ. 
Overall survival 
The length of time that patients live after the date of diagnosis 
(of cancer). 
Pagetoid spread The upward spread of atypical melanocytes into the epidermis. 
Pairwise analysis A statistical comparison between 2 variables. 
Papillary dermis The uppermost layer of the dermis. 
Paucicellular Having few cells. 
Perineural invasion The presence of melanoma cells surrounding a nerve. 
Peritoneum The serous membrane that forms the abdominal cavity. 
Phenotype 
The physical characteristics of an individual resulting from the 
interaction between the individual’s genetic make-up 
(genotype) and the environment. 
Plasma 
The liquid component of blood in which the blood cells are 
suspended. 
Plasma cell 
A white blood cell (fully differentiated B cell) that secretes 
antibodies. 
Plasmacytoid Resembling a plasma cell. 
Pleomorphism The variability in size and shape of cells or their nuclei. 
Pleura One of the membranes around the lungs. 
Plexiform Resembling a plexus (or complex network). 
Prognosis The likely course of a medical condition. 
Promoter A segment of DNA that initiates the transcription of a gene. 
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Pyrosequencing 
A DNA sequencing method that depends upon the release of 
pyrophosphate during DNA synthesis. A series of enzymatic 
reactions then result in the release of light that is proportional 
to the number of incorporated nucleotides. 
Quantile 
normalisation 
A statistical method of making two distributions identical. 
Quartile Any of 4 equal groups. 
Quintile Any of 5 equal groups. 
Radial growth 
phase (in situ) 
The presence of intraepidermal melanoma cells, singly or in 
nests [182]. 
Radial growth 
phase 
(microinvasive) 
The presence of intraepidermal melanoma with involvement of 
the papillary dermis but which does not meet the criteria for 
vertical growth phase [182]. 
Radial growth 
phase (RGP) 
melanoma 
Predominantly intraepidermal melanoma, or if present, dermal 
nests consist of <15 cells, are no larger than intraepidermal 
nests and dermal mitoses are absent [5]. (Please see Table 
2.1). 
Reference category 
(baseline) 
The category that is used as the baseline in a statistical model, 
against which other categories are compared. 
Regression 
Replacement of melanoma cells by a variable lymphocytic 
infiltrate, melanophages, telangiectasia and fibrosis and often 
accompanied by epidermal atrophy [77]. 
 Stage 1 regression: some loss of dermal melanoma but 
preservation of the epidermal component [77]. 
 Stage 2 regression: loss of all dermal melanoma but a 
residual junctional component remains [77]. 
 Stage 3 regression: loss of junctional and dermal 
components of melanoma, with resultant dermal scarring 
[77]. 
 Partial regression: loss of part of the tumour mass without 
complete replacement of tumour by inflammatory cells and 
fibrosis [75]. 
 Segmentary regression: complete regression of a segment 
of melanoma [75]. 
Relapse Evidence of recurrence of melanoma. 
Relapse survival 
time 
The interval between melanoma diagnosis and the time of 
melanoma relapse (event) or death (censored), or the interval 
between melanoma diagnosis and censoring and there is no 
record of relapse. 
Relative tumour 
loss 
The Breslow thickness divided by the depth of tumour loss in 
millimetres. 
Rete ridges 
Thickened extensions of the epidermis that protrude into the 
dermis. 
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Reticular dermis 
The layer of dermis that lies beneath the papillary dermis and 
is composed of dense connective tissue. 
ROC curve analysis 
A method of evaluating the true positive and the true negative 
rate. 
RT-PCR 
A technique used to detect RNA, through a process involving 
the amplification of complementary DNA. 
Senescence The loss of a cell’s ability to divide and grow. 
Sentinel lymph 
node biopsy 
A surgical procedure used to evaluate whether or not cancer 
(melanoma) has spread to the first draining lymph node(s). 
Septum (-a) A partition between two chambers or structures. 
Silencing Repressing the expression of a gene. 
Singular value 
decomposition 
A statistical method (similar to a principal components 
analysis), which describes the structure of the data. 
Solar elastosis 
The presence of elastotic fibres in the dermis, which may 
occur singly or may form clumps or amorphous masses [183]. 
Somatic cell A cell of a living organism that is not a reproductive cell. 
Somatic mutation 
A mutation that occurs in somatic cells and is capable of being 
transmitted to daughter cells in the process of cell division. 
Spearman 
correlation 
A statistical method of assessing the dependence between the 
ranking of two variables. 
Spindle-shaped 
melanocyte 
A melanocyte with an elongated, fusiform or cigar-like shape. 
Spitz naevus 
A type of benign melanocytic naevus that was described by 
Sophie Spitz. It is typically pink in colour, although may be 
pigmented. On histopathological assessment, vertical nests of 
epithelioid and spindle cells may be seen. Kamino bodies may 
also be noted. 
Spitz tumours 
Melanocytic lesions with an appearance reminiscent of a Spitz 
naevus. This may refer to Spitz naevi, atypical Spitz tumours 
(lesions which have features that are not typical of a naevus 
but do not fulfil the criteria for melanoma) or spitzoid 
melanomas. The lesions consist of epithelioid/spindle cells 
with abundant cytoplasm and often lack pigment.  
Spitzoid Displaying features of a Spitz naevus. 
Spitzoid Tumour of 
Uncertain Malignant 
Potential 
Please see “Atypical Spitz tumour”. 
Splice site The site at which splicing takes place. 
Splicing 
The process in which introns are removed and exons are 
joined together. 
Sporadic Not inherited. 
Squamous 
epithelium 
The surface covering of the skin, which consists of flattened 
highly differentiated keratinocytes. 
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Term Definition 
Statistical 
interaction 
In a statistical model, the effect of one predictor variable on 
outcome depends on the value of another predictor variable, 
i.e. the effects of two predictor variables on the outcome 
variable are not additive or multiplicative. 
Stem cell 
An undifferentiated cell that is capable of limitless cell division 
and which can give rise to other types of cells. 
Stroma 
The supportive tissue of an organ or tumour, consisting of 
connective tissue, blood vessels and immune cells. 
Subcutaneous Under the skin. 
Subcutis 
The tissue underlying the dermis of the skin, which consists 
mainly of fat. 
Superficial 
spreading 
melanoma 
A subtype of melanoma characterised by a predominantly 
nested pattern of melanoma but may sometimes contain a 
dermal nodule with a lateral intraepidermal component 
extending more than 3 rete ridges beyond the vertical growth 
phase melanoma. Pagetoid spread is common in this subtype. 
(Please see Table 2.1). 
T cell exhaustion 
A state of T cell dysfunction, characterised by poor T cell 
effector function, which may occur in cancer. 
Targeted DNA 
sequencing 
A technique that involves sequencing a specific region of DNA 
at a high resolution. 
Telomerase 
A protein that adds telomere sequences to the 3’ end of the 
telomere. 
Telomere 
Repetitive nucleotide sequences at the ends of chromosomes 
that protect them from fusion with other chromosomes. 
Tertile Any of 3 equal groups. 
Time-to-event 
analysis 
Pertaining to survival analyses, considering the time to the 
event (either melanoma relapse or melanoma-specific death) 
or the time to the censoring point for participants not having 
the event or not known to have had the event. 
Transcription 
A process whereby part of the DNA of a gene is copied into 
RNA. 
Transcriptome The messenger RNA expressed by the genes of an organism. 
Tumour implant The insertion of tumour into a host (e.g. a mouse). 
Tumour-infiltrating 
lymphocytes (TILs) 
Lymphocytes in the vertical growth phase that surround and 
disrupt melanoma cells [181]. 
 Absent TILs: no lymphocytes or if present, they do not 
infiltrate the vertical growth phase melanoma [60]. 
 Non-brisk TILs: lymphocytes infiltrate the invasive 
melanoma but only focally [60]. 
 Brisk TILs: lymphocytes diffusely infiltrate the entire base 
or the entire invasive component [60]. 
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Term Definition 
Tumour-infiltrating 
melanophages 
Macrophages/melanophages that infiltrate or are closely 
apposed to the VGP melanoma. 
Tumour loss 
A clear deficit within the silhouette of the melanoma at 4x 
magnification and composed of a variable presence of 
lymphocytes, melanophages and/or fibrous tissue. 
Ubiquitin A small regulatory protein. 
Univariable 
Involving one predictor variable in a statistical model with one 
outcome. 
Unsupervised 
hierarchical 
clustering 
A computerised method of grouping objects that are similar 
together in a cluster, without any pre-conditions. 
UV signature 
A distinct pattern of somatic mutations that develops as a 
consequence of exposure to ultraviolet radiation and typically 
leads to the formation of pyrimidine dimers involving cytosine-
thymine or cytosine-cytosine to thymine-thymine [378].  
Variant 
A difference in the DNA between an individual and most 
people. 
Vector 
An organism that does not cause disease but transfers a 
pathogen to another host. 
Vertical growth 
phase (VGP) 
melanoma 
Melanoma that invades the dermis and dermal melanoma 
nests show a growth advantage over intraepidermal nests, or 
are >15 cells and/or dermal mitoses are present [5]. 
Virtual pathology 
The use of digitised pathology images and computerised 
techniques for the assessment of histological sections. 
Visceral Relating to an internal organ. 
Wilcoxon rank-sum 
(Mann Whitney U) 
test 
A non-parametric test to assess whether two variables come 
from two different distributions or from the same distribution; 
the extension to 3 or more variables is termed the Mann 
Whitney U test. 
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 : Prof. Cook Protocol 
B.1 Prof. Cook Protocol 
Review data were recorded in a FileMaker Pro® Database designed and implemented 
by the Section of Epidemiology and Biostatistics. Below are a series of screen shots 
showing the data fields used in accordance with the protocol developed by Professor 
M. Cook. 
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B.2 Descriptive statistics of 158 cases of primary 
melanoma 
The table below summarises the scoring of variables used in the Prof. Cook protocol 
for 158 cases of primary melanoma.  
  
303 
Measure Feature N Statistic Value 
Number of H&E slides 158 Median (range) 1 (1-4) 
Histological subtype 
Superficial spreading 158 N (%) 115 (72.78) 
Nodular   14 (8.86) 
Lentigo maligna (melanoma)   1 (0.63) 
Acral lentiginous   3 (1.9) 
Naevoid melanoma minimal 
deviation 
  6 (3.8) 
Spitzoid   1 (0.63) 
Subungual   1 (0.63) 
Lentigo maligna (in situ)   2 (1.27) 
Melanoma in situ   1 (0.63) 
Metastasis   1 (0.63) 
Other   8 (5.06) 
Unknown   5 (3.16) 
Maximum diameter (mm) 158 Median (range) 7 (1.7-23.8) 
Growth phase 
Radial growth phase (in situ) 158 N (%) 5 (3.16) 
Radial growth phase 
(microinvasive) 
  7 (4.43) 
Vertical growth phase   146 (92.41) 
Clark’s level 
I 158 N (%) 4 (2.53) 
II   7 (4.43) 
III   11 (6.96) 
IV   121 (76.58) 
V   4 (2.53) 
Base absent   7 (4.43) 
Unknown   4 (2.53) 
Breslow thickness (mm) 158 Median (range) 1.37 (0-9) 
Ulceration  
Yes 158 N (%) 30 (18.99) 
No   128 (81.01) 
Diameter of ulceration (mm) 29 Median (range) 1.6 (0.1-15) 
Percentage ulceration (%) 29 Median (range) 20 (1.38-87.5) 
Traumatic ulceration 
Yes 158 N (%) 22 (13.92) 
No   32 (20.25) 
Unknown   104 (65.82) 
Erosion only 
Yes 158 N (%) 3 (1.9) 
No   29 (18.35) 
Unknown   126 (79.75) 
Epidermis absent 
Yes 158 N (%) 1 (0.63) 
No   41 (25.95) 
Unknown   116 (73.42) 
304 
Measure Feature N Statistic Value 
Mitotic rate/mm2  
0 158 N (%) 39 (24.68) 
1-5   87 (55.06) 
≥6   31 (19.62) 
Unknown   1 (0.63) 
TILs 
Absent 158 N (%) 8 (5.06) 
Non-brisk   100 (63.29) 
Brisk   30 (18.99) 
Non-evaluable   19 (12.03) 
Unknown   1 (0.63) 
TILs location 
Central 158 N (%) 2 (1.27) 
Peripheral   3 (1.9) 
Both   125 (79.11) 
Unknown   28 (17.72) 
TILs intensity 
Scanty 158 N (%) 76 (48.1) 
Moderate   40 (25.32) 
Dense   14 (8.86) 
Unknown   28 (17.72) 
TILs distribution 
Focal 158 N (%) 2 (1.27) 
Multifocal   96 (60.76) 
Segmental   30 (18.99) 
Unknown   30 (18.99) 
Dominant nodule 
infiltrated by TILs 
Yes 158 N (%) 70 (44.3) 
No   3 (1.9) 
Unknown   85 (53.8) 
Regression 
Yes 158 N (%) 6 (3.8) 
No   144 (91.14) 
Uncertain   8 (5.06) 
Stage of regression 
No regression 158 N (%) 144 (91.14) 
Stage 1   7 (4.43) 
Stage 2   5 (3.16) 
Stage 3   1 (0.63) 
Unknown stage   1 (0.63) 
Thickness of regression (mm) 13 Median (range) 0.72 (0.2-1.4) 
Microsatellites 
Yes 158 N (%) 2 (1.27) 
No   155 (98.1) 
Unknown   1 (0.63) 
Lymphovascular 
invasion 
Yes 158 N (%) 12 (7.59) 
No   142 (89.87) 
Uncertain   4 (2.53) 
305 
Measure Feature N Statistic Value 
Perineural invasion 
Yes 158 N (%) 2 (1.27) 
No   154 (97.47) 
Uncertain   2 (1.27) 
Distance to peripheral margin (mm) 158 Median (range) 1.71 (0-19) 
Distance to deep margin (mm) 158 Median (range) 4 (0-18) 
Coexistent naevus 
Yes 158 N (%) 23 (14.56) 
No   117 (74.05) 
Uncertain   18 (11.39) 
Naevus type 
Compound 158 N (%) 2 (1.27) 
Intradermal   36 (22.78) 
Dysplastic   1 (0.63) 
Congenital   1 (0.63) 
Unknown   118 (74.68) 
Main cell type 
Epithelioid 158 N (%) 94 (59.49) 
Small/ Naevoid   31 (19.62) 
Spindle   15 (9.49) 
Spitzoid   4 (2.53) 
Balloon   1 (0.63) 
Other   6 (3.8) 
Unknown   7 (4.43) 
Giant tumour cells 
Yes 158 N (%) 15 (9.49) 
No   59 (37.34) 
Unknown   84 (53.16) 
Intercellular clefting 
Yes 158 N (%) 24 (15.19) 
No   50 (31.65) 
Unknown   84 (53.16) 
Spitzoid features 
Yes 158 N (%) 20 (12.66) 
No   55 (34.81) 
Unknown   83 (52.53) 
 
  
306 
 : Virtual Pathology Protocol 
C.1 Virtual pathology protocol 
Review data were recorded in a FileMaker Pro® Database designed and implemented 
by the Section of Epidemiology and Biostatistics. On the following two pages are a 
series of screen shots showing the data fields used in accordance with the virtual 
pathology protocol (Figure B1.1). 
C.2 Pilot work to quantify stromal content in primary 
melanomas using virtual pathology imaging 
The average proportion of stromal content in each tumour and matching core was 
plotted after the addition of each scored arrow to give a moving average plot. This was 
done in order to assess the variance across the scored arrow count and to evaluate the 
optimum number of arrows that would give a meaningful estimation of the proportion of 
stroma (Figure B1.2). 
A)            B) 
  
Figure B1.1 The moving average for the proportion of stroma by arrow count 
A) The moving average for the proportion of stroma by arrow count across a 
representative area of tumour for sample 272204. The graph shows the 
proportion of stroma, beginning with the first arrow and then increasing in 
number. The “true” proportion of stroma is approximately 0.5, over 300 arrows. 
The proportion of stroma varies a lot when the sample is small, reflected by 
fluctuations in the graph. The graph reaches a steady state after 145 arrows. 
After 50 arrows, the proportion of stroma is approximately 0.55 which reflects 
about 10% error. B) The moving average for the proportion of stroma by arrow 
count in core 1 of sample 272204. The estimated proportion of stroma is 
approximately 0.3. 
  
3
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C.3 Comparison of representative tumour with tumour 
core 
The table below gives the mean and standard deviation of the proportion of stroma in 
the representative tumours compared with the cores, by sample number, and the 
corresponding p-values from two-tailed T-tests. The results show that for some cases 
(e.g. 272254 and 272309), the estimated proportion of stroma within the core was 
similar to the estimated proportion of stroma within the representative tumours. 
However, for others (e.g. 272204 and 272279), the estimated proportion of stroma 
within the core appeared to differ from the estimated proportion of stroma within the 
representative tumour. 
 
Proportion of stroma in 
representative tumours 
Proportion of stroma 
in cores 
 
Sample 
number 
Median (range) Mean (s.d) Median (range) Mean (s.d) 
T-test 
p-value 
272204 0.50 (0.43-1) 0.53 (0.05) 0.31 (0.17-1) 0.33 (0.15) <0.00005 
272254 0.18 (0.15-1) 0.21 (0.11) 0.22 (0-0.28) 0.20 (0.07) 0.3419 
272279 0.25 (0-0.5) 0.24 (0.08) 0.57 (0.46-1) 0.57 (0.09) <0.00005 
272288 0.36 (0-0.5) 0.35 (0.04) 0.17 (0-0.32) 0.19 (0.06) <0.00005 
272305 0.41 (0.39-1) 0.43 (0.06) 0.32 (0-0.42) 0.32 (0.06) <0.00005 
272308 0.29 (0-0.31) 0.27 (0.04) 0.27 (0-0.31) 0.24 (0.06) <0.00005 
272309 0.52 (0-0.58) 0.51 (0.06) 0.5 (0.41-1) 0.52 (0.10) 0.5196 
272314 0.27 (0-0.31) 0.25 (0.07) 0.27 (0-0.35) 0.25 (0.07) 0.6458 
272318 0.33 (0-0.75) 0.34(0.08) 0.33 (0-0.4) 0.32(0.07) 0.0495 
272320 0.43 (0.3-1) 0.43 (0.04) 0.46 (0-0.53) 0.45 (0.07) 0.0218 
C.4 Comparison of percentage stroma by eyeball 
estimate versus arrow count 
% agreement for percentage stroma by estimate vs. arrow count was 57.89% (11/19). 
 Stroma % arrow count 
Stroma % estimate 0 1-24% 25-49% 50-74% ≥75% Total 
0 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
1-24% 0 (0) 4 (66.67) 4 (36.36) 1 (50.00) 0 (0) 9 (47.37) 
25-49% 0 (0) 2 (33.33) 7 (63.64) 1 (50.00) 0 (0) 10 (52.63) 
50-74% 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
≥75% 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
Total 0 (0) 6 (100) 11 (100) 2 (100) 0 (0) 19 (100) 
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C.5 Comparison of percentage of stroma by eyeball 
estimate versus an eyeball estimate using categories 
% agreement for percentage stroma by estimate vs. stroma category was 73.68% 
(14/19). 
 Stroma category 
Stroma % estimate None Some Moderate Lots Total 
0 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
1-24% 0 (0) 5 (100) 4 (30.77) 0 (0) 9 (47.37) 
25-49% 0 (0) 0 (0) 9 (69.23) 1 (100) 10 (52.63) 
50-74% 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
≥75% 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
Total 0 (0) 5 (100) 13 (100) 1 (100) 19 (100) 
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 : Core Comparisons 
D.1 Comparison of Core 1 and Core 2 
The table below summarises the results comparing core 1 and core 2. 
The Spearman correlation coefficient (rho), percentage (%) agreement, kappa statistic, 
95% confidence intervals (95%CI), p-value and the strength of agreement are shown 
for factors recorded using the virtual pathology protocol within the first and second 
cored regions. Missing values were excluded from the calculation of the percentage 
agreement. NA=not applicable. NC=not calculable. 
Cored region measures 
 Analysis of core 1 versus core 2 
Factor 
Spearman 
rho 
% 
Agreement 
Kappa 
(95%CI) 
p-value 
Strength of 
agreement 
Percentage of stroma 0.7   2x10-58 NA 
Quality of the stroma  92 
0.41 
(0.25-0.57) 
<1x10-16 Moderate 
Melanoma cell shape  89 
0.61 
(0.5-0.69) 
<1x10-16 Substantial 
Melanoma cell structure  74 
0.58 
(0.51-0.64) 
<1x10-16 Moderate 
Melanoma cell 
pigmentation 
 88 
0.64 
(0.55-0.72) 
<1x10-16 Substantial 
Presence or absence of 
immune cell infiltrate 
 93 
0.47 
(0.31-0.64) 
<1x10-16 Moderate 
Extent of immune cell 
infiltrate 
 61 
0.39 
(0.31-0.45) 
<1x10-16 Fair 
Location of immune cell 
infiltrate 
 61 
0.42 
(0.36-0.49) 
<1x10-16 Moderate 
Presence or absence of 
lymphocytic infiltrate 
 67 
0.47 
(0.39-0.54) 
<1x10-16 Moderate 
Extent of lymphocytic 
infiltrate 
 57 
0.36 
(0.3-0.44) 
<1x10-16 Fair 
Presence or absence of 
plasma cell infiltrate 
 75 
0.54 
(0.46-0.62) 
<1x10-16 Moderate 
Extent of plasma cell 
infiltrate 
 75 
0.53 
(0.45-0.61) 
<1x10-16 Moderate 
Presence or absence of 
macrophage/melanophage 
infiltrate 
 73 
0.56 
(0.49-0.62) 
<1x10-16 Moderate 
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Cored region measures 
 Analysis of core 1 versus core 2 
Factor 
Spearman 
rho 
% 
Agreement 
Kappa 
(95%CI) 
p-value 
Strength of 
agreement 
Extent of 
macrophage/melanophage 
infiltrate 
 63 
0.46 
(0.39-0.52) 
<1x10-16 Moderate 
Presence or absence of 
neutrophilic infiltrate 
 75 
0.51 
(0.43-0.58) 
<1x10-16 Moderate 
Extent of neutrophilic 
infiltrate 
 75 
0.51 
(0.43-0.59) 
<1x10-16 Moderate 
Presence or absence of 
eosinophilic infiltrate 
 76 
0.52 
(0.45-0.6) 
<1x10-16 Moderate 
Core mitoses (tertiles)  55 
0.32 
(0.26-0.41) 
<1x10-16 Fair 
Core blood vessels  55 
0.28 
(0.22-0.36) 
2x10-15 Fair 
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